<PAGE> 1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 10-K
<TABLE>
<S> <C> <C>
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER: 0-10521
</TABLE>
------------------------
QUEST MEDICAL, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
TEXAS 75-1646002
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
201 ALLENTOWN PARKWAY,
ALLEN, TEXAS 75002
(Address of principal executive offices) (Zip Code)
</TABLE>
Registrant's telephone number, including area code: (972) 390-9800
SECURITIES REGISTERED UNDER SECTION 12(B) OF THE EXCHANGE ACT:
<TABLE>
<CAPTION>
TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED
------------------- -----------------------------------------
<C> <C>
NONE NONE
</TABLE>
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE EXCHANGE ACT:
TITLE OF CLASS
-----------
Common Stock, $.05 Par Value
------------------------
Indicate by checkmark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of the S-K is not contained herein, and will not be contained, to the best
of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
Aggregate market value of the registrant's Common Stock held by
non-affiliates of the registrant as of March 21, 1997:$51,514,600.
Number of shares outstanding of the registrant's Common Stock as of March
21, 1997: 8,353,938
------------------------
DOCUMENTS INCORPORATED BY REFERENCE
PORTIONS OF THE REGISTRANT'S DEFINITIVE PROXY STATEMENT FOR THE
REGISTRANT'S ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 25, 1997, ARE
INCORPORATED BY REFERENCE INTO PART III.
================================================================================
<PAGE> 2
QUEST MEDICAL, INC.
ANNUAL REPORT
FORM 10-K
YEAR ENDED DECEMBER 31, 1996
PART I
ITEM 1. BUSINESS
GENERAL
Quest Medical, Inc., a Texas corporation ("Quest" or the "Company"),
designs, develops, manufactures and markets a variety of healthcare products
used primarily in cardiovascular surgery, neurostimulation and intravenous fluid
delivery applications. The Company operates several stable product lines,
including cardiovascular products (such as pressure control valves, filters and
surgical retracting tapes), specialized intravenous fluid delivery tubing sets
and accessories and pressure monitoring kits used primarily in labor and
delivery. The Company has levered these product lines, its existing corporate
infrastructure and its core competencies in manufacturing, engineering and
regulatory affairs to develop the Quest MPS(R) myocardial protection system, an
innovative and sophisticated system designed to manage the delivery of solutions
to the heart during open-heart surgery. In addition, the Company, during 1995,
entered the neurostimulation market by acquiring Neuromed, Inc. ("Neuromed"),
which designs, develops, manufactures and markets a line of electronic spinal
cord stimulation ("SCS") devices used to manage chronic severe pain. In November
1996, the Company merged Neuromed into a newly formed subsidiary, Advanced
Neuromodulation Systems, Inc., a Texas corporation ("ANS"). References to
"Quest" or the "Company" in this Form 10-K include ANS, unless otherwise
indicated.
In 1991, Quest acquired two companies that manufactured and marketed
various cardiovascular products, enhancing the Company's presence in the
cardiovascular products marketplace. In 1992, Quest identified a need in this
marketplace for an automated and integrated myocardial protection system that
would be versatile, easy to use, efficient to monitor and cost-effective.
Myocardial protection is the process of arresting and caring for the heart
during open-heart surgery. The Quest MPS system is designed to integrate key
functions relating to the delivery of solutions to the heart such as varying the
rate and ratio of oxygenated blood, crystalloid, potassium and other additives,
and controlling temperature, pressure and other variables to allow simpler, more
flexible and cost-effective management of this process. The MPS system employs
advanced pump, temperature control and microprocessor technologies and includes
a line of captive and noncaptive disposable products. The Company received
510(k) market clearance for its MPS system from the FDA in March 1996, and
shortly thereafter began clinical validation of the system, which was completed
during July 1996. The Company began commercial shipment of MPS in the U.S.
during September 1996.
In its continuing effort to expand into potentially high growth niche
markets in the medical device industry, the Company acquired Neuromed in March
1995. SCS is gaining acceptance as a viable, efficacious and cost-effective
treatment alternative to repeat back surgeries for relieving chronic severe back
pain. The Company believes that its CompuStim products, which are powered by
radio frequency transmitters external to the body, are the technological leaders
in the field. The Company in 1996 test marketed PainDoc, a pen-based computer
system that works in tandem with the Company's CompuStim devices to assist
physicians and their patients in optimizing the performance of the Company's SCS
devices both pre- and post-operatively. The Company anticipates full U.S. market
release of PainDoc in 1997.
Since its founding in 1979, the Company has developed, manufactured and
marketed specialized intravenous fluid delivery tubing sets and accessories sold
primarily to major hospitals in the United States. Over the last several years,
the revenues generated by this product line, a substantial component of the
Company's historical base business, have significantly aided the funding of the
Company's research and development efforts. The Company manufactures and markets
about 50 distinct models of specialized intravenous fluid delivery tubing sets.
1
<PAGE> 3
PRODUCTS
The following table summarizes certain information with respect to the
Company's principal products in commercial distribution.
<TABLE>
<CAPTION>
PRODUCTS DESCRIPTION/USE
-------- ---------------
<S> <C>
Neuromodulation
SCS CompuStim Devices Neurostimulation devices used to relieve
chronic pain
PainDoc(R) Pen-based computer system used to
optimize the performance of the
Company's implanted SCS devices both
pre- and post-operatively
Cardiovascular
Pressure Control Valves Pressure control valves used during
open-heart surgery
Arterial Line Filters and Bubble Traps Filters and traps used to remove
potentially dangerous air and other
matter from the blood during open-heart
surgery
Retract-O-Tape(R) Surgical tubes used to retract and
occlude blood vessels during open-heart
surgery
MPS System and Related Disposables Cardioplegia delivery system and related
fluid delivery catheters and delivery
sets
Intravenous Fluid Delivery
Multiport(R) Sets Intravenous administration sets that
allow multiple drug infusions
Anesthesia Sets Intravenous administration sets that
allow needleless "port" administration
Other
Intrauterine Pressure Catheters and transducers used to assess
Catheters/Transducers the frequency, duration and intensity of
contractions during high risk labor
</TABLE>
NEUROMODULATION
Background. SCS devices employ neurostimulation, the process of
electrically stimulating the spinal cord to reduce chronic severe neuropathic
(as opposed to acute) pain by "masking" the pain signals sent to the brain.
Neuropathic pain usually arises from nerve damage. SCS device implantation
manages the pain associated with failed back syndrome (resulting from certain
spinal disorders or unsuccessful spinal cord surgery), peripheral neuropathy,
phantom limb or stump pain, ischemic pain and reflex sympathetic dystrophy.
The market for SCS devices is currently divided between RF-coupled devices,
which use an external power source, and fully implantable systems known as
internal pulse generator ("IPG") devices. The Company believes that lPG devices
currently account for a substantial majority of the number of SCS procedures
performed, with RF-coupled devices accounting for the remainder. The Company
designs, develops, manufactures and markets RF-coupled SCS devices. The primary
advantages of the RF-coupled device include the simple replacement or recharge
of the external battery pack, and relatively lower overall cost. IPG devices
provide the convenience of a completely internalized system, but involve added
cost, complexity and risk because repeat surgeries are required to replace the
IPG power source. Moreover, the latest generation SCS devices generally include
more electrodes and dual channel receivers, both of which
2
<PAGE> 4
consume more electrical energy than an implanted power source can practically
deliver over an extended period of time.
SCS Devices. The Company's SCS systems consist of three primary components:
leads, a receiver and a transmitter. The leads are most commonly placed through
the skin into the spinal column's epidural space. This procedure is similar to
that employed by physicians to administer drugs for anesthesia and other common
medical applications. Typically, one or two leads are inserted, each of which
has multiple electrodes that can be used to stimulate the targeted nerve roots
of the spinal cord. Each lead is then connected to the receiver, which is
implanted under the skin on the side of the abdomen. The receiver contains
electronics that receive RF energy and data from a source (the transmitter)
outside the body, and delivers the prescribed electrical pulses to the leads.
The transmitter is approximately the size of a pager, and is typically worn on a
belt. Since it is external to the body, the transmitter can be easily programmed
and serviced as needed, and its battery can be simply recharged or replaced.
Neuromed introduced its first product, the Multiprogrammable Spinal Cord
Stimulator, or Multistim@, in 1979. Since that time, Neuromed has played a
significant role in the development of SCS products. Multistim incorporated a
quadrapolar electrode system within a single lead, and was considered a major
innovation in the field of neurostimulation because it significantly reduced
surgical time, cost and risk. Since the launch of Multistim, Neuromed has
developed and introduced a wide range of RF-coupled SCS systems with a variety
of options to accommodate different applications and degrees of pain.
The Company's recently introduced CompuStim systems include four, eight and
sixteen electrode leads; specialty leads for peripheral applications; single and
dual channel receivers; and rechargeable transmitters and antennae. The Company
believes that the CompuStim product line's multi-electrode leads and
multiprogrammable electronics technology have changed the manner in which
neurostimulation is performed worldwide. For example, Neuromed's "Dual Octrode"
device, a system of dual leads with eight electrodes each introduced in 1995,
creates a targeted current density that appears to be especially effective in
relieving chronic axial (or body trunk) pain. Previously, quadrapolar SCS
systems only relieved the leg pain associated with failed back syndrome.
Industry sources support the view that the Dual Octrode device provides improved
pain relief to both the legs and the back. Consequently, although the Dual
Octrode device has only been on the United States market since February 1995, it
now accounts for approximately 59 percent of Neuromed's current product revenue
and, in the Company's judgment, is the technological leader in the SCS field.
The Company believes that the long term results of SCS in the treatment of pain
have improved as a result of the flexibility of Neuromed's designs, epitomized
by the Dual Octrode product. Moreover, the ease of use of the system has
expanded the potential market for these products.
Use of the Company's current SCS products in certain operating modes
consumes relatively greater amounts of electrical current, reducing the
operating time of the rechargeable, externally worn battery packs. In addition,
certain of the Company's current SCS products have experienced switch failures
attributable in significant part to a specific brand of switches. These switches
were replaced by a new switch in April 1996 that have not exhibited the same
problems. Patient misuse has also contributed to the switch failures. Finally,
the Company's SCS products have exhibited some intermittent stimulation, which
the Company believes is attributable to several factors including improper
antenna placement, physicians or patients adjusting stimulation below
perceptible levels, improper receiver implant placement techniques and lead
movement. During 1996, the Company devoted significant engineering resources to
refining and enhancing its SCS products to address these matters. While most of
these enhancements were implemented during the second half of 1996, a few
enhancements are being implemented during the first quarter of 1997. The Company
believes these efforts have significantly improved the product quality,
reliability and performance of its current SCS products. In addition, during
1996, the Company began designing and implementing improved patient and
physician communications and training programs to address certain user problems.
The Company expects these efforts to continue throughout 1997.
The Company believes its RF-coupled SCS devices represent a strong base for
penetration of the broader neuromodulation market. The Company has begun
development of an IPG system and a constant rate implantable drug pump to better
serve the broad needs of the pain management market. By offering an IPG
3
<PAGE> 5
and implantable drug pump, the Company can serve the largest segment of the
neuromodulation market, leverage its sales and marketing capabilities and
address a number of new indications such as angina, various motor disorders, and
Alzheimer's and Parkinson's disease.
PainDoc. In addition to its current array of SCS devices, the Company is
developing and testing PainDoc, a pen-based computer system that is designed to
assist physicians and their patients in optimizing the performance of the
Company's SCS devices both pre- and post-operatively. PainDoc interfaces with
the Company's CompuStim transmitters to optimize SCS therapy and document
treatment outcomes. PainDoc allows the physician to input information regarding
the patient's description of the location and intensity of the patient's pain.
The resulting "pain map" is then analyzed by the computer to assess and select
the most effective stimulation sets, or combination of multi-electrode
stimulation arrays, to treat the pain. The selected arrays are uploaded into the
patient's CompuStim transmitter. After a trial period, the patient reports to
the physician the location and level of pain relief. These trial results are
uploaded back into PainDoc for the physician's objective review and analysis.
The physician can visually compare the patient's pain map against a stimulation
map and assess whether desired levels of pain relief have been obtained and
whether excess stimulation has been delivered. This process can be effective in
targeting the location of desired pain relief, reducing the patchiness of pain
relief delivered by many SCS devices and reducing or eliminating
overstimulation.
PainDoc enables the physician to program up to 24 different stimulation
sets delivering electrical stimulation every 50 milliseconds to expand pain area
coverage and relief. The Company believes that PainDoc should also allow
physicians to create a broad based database tool that, by using a standardized
methodology, will enable physicians to share and compare outcomes data, which
can then be used to deliver more efficacious pain relief to individual patients.
The Company believes that PainDoc and CompuStim devices used in tandem should
significantly enhance the effectiveness, flexibility and precision of managing
chronic neuropathic pain. The Company expects PainDoc to promote the selection
of the Company's CompuStim devices for SCS procedures, especially as SCS devices
become more complex and the pain management process becomes more refined. In
October 1995, the Company received 510(k) approval from the FDA to market
PainDoc as an interactive medical treatment device. See Item 1:
"Business -- Other Business Matters -- Government Regulation." The Company test
marketed the product during 1996 and expects full U.S. market release during
1997.
During the year ended December 31, 1996 and 1995, the Company's SCS
products accounted for $11.4 million and $10.4 million, respectively, of total
net revenue. The 1995 period includes revenue for nine months from the date of
acquisition of March 31, 1995.
CARDIOVASCULAR
Valves, Filters and Traps. The Company manufactures and markets a line of
proprietary specialized pressure control valves, pre-bypass and arterial line
filters and bubble traps, which are used by the perfusionist during
cardiopulmonary bypass surgery. Pressure control valves are placed in the
suction line to "vent," or decompress, the heart. These valves serve a number of
functions, including the maintenance of vacuum at a safe and consistent level to
minimize heart muscle tissue damage, as well as the prevention of inadvertent
and potentially catastrophic retrograde air flow into the heart. In 1993 and
1994, respectively, the Company introduced to the market two extensions of its
pressure control valve technology, the RetroGuard valve and the PlegiaGuard
valve. The RetroGuard valve is used with centrifugal pumps to prevent potential
retrograde blood flow and possible air embolism. The PlegiaGuard valve is used
to relieve overpressure in the cardioplegia line in the event that the line
becomes inadvertently clamped or occluded. The Company's arterial line filters
and bubble traps are used in the bypass circuit to remove air and other
potentially dangerous matter from the blood prior to the blood's return to the
patient. The Company's pre-bypass filters are used to flush the circuit external
to the patient's body prior to the initiation of the bypass procedure to
eliminate man-made debris within the lines. During the years ended December 31,
1996, 1995, and 1994, the Company's valves, filters and traps accounted for $5.4
million, $5.2 million, and $4.2 million, respectively, of total net revenue.
4
<PAGE> 6
Surgical Tapes and Other Products. The Company manufactures and markets
surgical retracting tapes under the trademark Retract-O-Tape, a product line of
silicone elastomer surgical tubing used to apply traction to and occlude blood
vessels during surgical procedures. The Company's surgical tapes are hollow
tubes, sealed at both ends to trap air, which resist collapsing when they come
into contact with a body structure. The Company's ACTester product line consists
of instrumentation and associated disposables used to measure the activated
clotting time of blood. During the years ended December 31, 1996, 1995, and
1994, the Company's surgical tapes and ACTester products accounted for $2.1
million, $1.8 million, and $1.6 million, respectively, of total net revenue.
MPS System. In 1992, based on discussions with perfusionists and
cardiovascular surgeons regarding the logistical limitations of existing
cardioplegia delivery systems, the Company identified a need for an automated
and integrated myocardial protection system that would be versatile, easy to
use, efficient and cost-effective. Over the past several years, cardiovascular
surgeons have developed advanced myocardial protection protocols for open-heart
surgery that significantly complicate the safe and efficient administration of
cardioplegia delivery using existing systems. Protocols now call for warm or
cold cardioplegia, various levels of potassium, retrograde or antegrade
cardioplegia flow, and a number of other variables. Existing cardioplegia
delivery systems are limited in their ability to accommodate these evolving
protocols, and are also difficult to control and monitor due to the number of
different components and protocol variables. Based on its reengineering of the
conceptual approach to cardioplegia delivery, the Company designed the MPS
system to address the limitations of existing cardioplegia delivery systems. The
Company then commissioned an independent research firm to survey over 150
surgeons and perfusionists to confirm the market demand for an automated and
integrated approach to managing cardioplegia delivery.
The Company subsequently developed, and in August 1995 filed a 510(k) with
the FDA for, the MPS system. In March 1996, the Company received clearance from
the FDA to market MPS and shortly thereafter began clinical testing of the
system. Clinical testing was completed during July 1996 and commercial shipment
of MPS began during September 1996.
The MPS system, which employs advanced pump, temperature control and
microprocessor technologies, is designed to enable the perfusionist to vary the
blood/crystalloid ratio and potassium concentration, maintain a constant blood
temperature, and maintain a constant delivery pressure through an automated and
integrated device. The MPS instrument is designed to provide this flexibility
through the simple setting of dials on its control panel. The Company believes
that the MPS system will simplify the cardioplegia delivery process and thus
improve the safety of this process by reducing the risk of human error.
As a part of the MPS system, the Company has designed and developed a
"captive" disposable delivery set, which fits into the instrument and is
necessary to the operation of the instrument. The Company has also designed and
developed additional "non-captive" disposable tubing and other accessories for
use with the MPS system. These non-captive disposables are not integral to the
operation of the instrument and can be purchased from other manufacturers. The
Company has received FDA clearance to market certain of its non-captive
disposables through the submission and approval of 510(k)s, and began marketing
such products during the fourth quarter of 1996. During the year ended December
31, 1996, the Company's MPS system and related products accounted for $443,000
of total net revenue.
INTRAVENOUS FLUID DELIVERY
Since its founding in 1979, the Company has developed, manufactured and
marketed specialized intravenous fluid delivery tubing sets and accessories sold
primarily to major hospitals in the United States. Over the last several years
the revenues generated by this product line, a substantial component of the
Company's historical base business, have significantly aided the funding of the
Company's research and development efforts. The Company's core competencies in
medical device manufacturing, engineering and regulatory affairs have largely
been developed as a consequence of its experience with intravenous fluid
delivery products, including the electronic intravenous pump and associated
disposables business that was sold in 1987.
5
<PAGE> 7
The Company manufactures and markets about 50 distinct models of
specialized intravenous fluid delivery tubing sets, which can be broken down
into two major product categories -- Multiport(R) sets and anesthesia sets.
Hospitals frequently require specialized disposable intravenous tubing sets for
more complex therapy procedures employed in anesthesia administration,
intravenous feeding, intensive care and cancer therapy. The Company's
intravenous tubing sets generally consist of specialized tubing and connector
variations that distinguish them from standard intravenous sets. The Company
also manufactures and markets injection sites used in heparin and other
medication administrations.
The Company has one patented specialized tubing set, purchased primarily by
the University of Texas System Cancer Center (M.D. Anderson Hospital), which is
used to deliver multiple drugs for complex chemotherapy applications. See Item
1: "Business -- Other Business Matters -- Marketing and Major Customer." During
the years ended December 31, 1996, 1995, and 1994 the Company's intravenous
fluid delivery products accounted for $5.2 million, $6.0 million, and $6.3
million, respectively, of total net revenue.
OTHER PRODUCTS
The Company also designs, manufactures and markets other products for the
healthcare industry, including pressure monitoring kits used in labor and
delivery procedures and various critical care applications. The Company's
intrauterine pressure monitoring devices are used to determine pressure within
the mother's uterus primarily during high risk labor and delivery. Approximately
25 percent of the nearly four million births occurring annually in the United
States are categorized as "high risk" due to factors such as obesity, drug use,
disease, age or low fetus weight. During these procedures, a catheter is
inserted into the mother's uterus to measure uterine fluid pressure. This
information allows the clinician to monitor the progression of labor and to
determine whether intervention is necessary or advisable. The Company's
intrauterine pressure monitoring devices are marketed as kits containing all of
the components required to measure uterine fluid pressure. During the years
ended December 31, 1996, 1995, and 1994 the Company's other products (primarily
pressure monitoring kits) accounted for $1.6 million, $1.8 million, and $1.9
million, respectively, of total net revenue.
OTHER BUSINESS MATTERS
MARKETING AND MAJOR CUSTOMER
ANS has historically relied on specialty distributors to market its SCS
devices. During 1996, however, the Company made the strategic decision to
replace certain distributors in specified geographic markets with commissioned
sales agents. Currently, the Company has 11 specialty distributors who employ 34
personnel to market the SCS devices. In addition, the Company has eight
commissioned sales agents who sell the Company's SCS devices. The Company
employs three regional sales managers who oversee these specialty distributors
and commissioned sales agents. The primary medical specialists the Company
targets in its marketing efforts are anesthesiologists, neurosurgeons, and
orthopedic surgeons. Although neurosurgeons were the first practitioners to use
SCS applications, anesthesiologists now account for a greater percentage of
sales as the relative number of these practitioners has grown and as the
understanding and acceptance of SCS treatment has increased. The Company derives
85 percent of net revenues attributable to its SCS devices from domestic sales
and approximately 15 percent from European and Australian sales.
The Company markets its MPS system and related disposables domestically
through a direct sales force operating on a sales team approach. This team
consists of nine members who have been involved with the MPS through its final
development and clinical validation. The team consists of five regional sales
managers, two field clinical specialists, and two inside account
representatives. The Company does not plan to add additional sales personnel
during 1997. The inside account representatives qualify accounts and assist the
regional managers while the clinical specialists in-service and train surgeons,
perfusionists, and other personnel on the MPS system. The Company plans to
market the MPS system internationally through specialty distributors, although
it does not anticipate international market introduction until 1998.
Clinical evaluations since the commercial introduction of the MPS in
September 1996 have, in management's view, validated that the MPS provides
simpler, more flexible and cost-effective management of
6
<PAGE> 8
myocardial protection. As a consequence of the current hospital consolidation
trend, coupled with the intense pressure hospitals are under to minimize capital
expenditures, however, hospitals have been reluctant to make timely purchase
decisions on new capital equipment. Therefore, to accelerate the adoption of MPS
and shorten the selling process, the Company in early 1997 decided to offer MPS
on a one-year rental basis and on a lease/purchase basis. This strategy will
decrease short-term revenues because the rental agreement does not qualify as a
sale, but should, in management's opinion, accelerate placement of MPS systems
and related disposable revenues. The Company believes that once a surgeon
changes the cardioplegia protocol using features of MPS, it will be very
difficult to return to the old, make-shift system. There can be no assurance
that such rental strategy will accelerate placement of MPS systems.
The Company markets most of its other cardiovascular products, pressure
monitoring kits for labor, and delivery and intravenous fluid delivery tubing
sets through direct contact with hospitals, telemarketing, independent sales
representatives, marketing arrangements with certain distributors and, to a
lesser extent, through direct mail. The Company employs one direct sales manager
who oversees the distributors who sell the Company's pressure monitoring kits
and three inside sales representatives who primarily sell the Company's
intravenous fluid delivery tubing set products through telemarketing. The
Company derives approximately 87 percent of net revenues attributable to
cardiovascular products, pressure monitoring kits, and intravenous fluid
delivery tubing sets from domestic sales and approximately 13 percent from
European, Australian and Japanese sales.
During 1996, the Company had one major customer that accounted for 10
percent or more of its net revenues. Sun Medical, Inc., a specialty distributor
of ANS products, accounted for $2.6 million, or 10 percent, of the Company's net
revenues for the year ended December 31, 1996. In addition, the University of
Texas Cancer Center (M. D. Anderson Hospital) accounted for $2.3 million, $2.6
million and $2.7 million, or 9 percent, 10 percent and 19 percent of the
Company's net revenues for the years ended December 31, 1996, 1995 and 1994,
respectively. The Company supplies a patented specialized intravenous tubing set
used by M. D. Anderson Hospital for oncology applications. While the Company
believes its relations with Sun Medical and M. D. Anderson Hospital are good,
the loss of one or both of these customers could have a material adverse effect
on the Company's business, financial condition and results of operations.
RESEARCH AND DEVELOPMENT
Since 1992, the Company has focused a majority of its research and
development efforts on designing and developing the MPS system and related
products. The Company has spent $11.5 million on the research and development of
its MPS system and related products, representing about 80 percent of the
Company's research and development expense since 1992. Although the Company
plans to continue engaging in ongoing research and development to introduce new
products, enhance the effectiveness, ease of use, safety and reliability of
existing products and expand the applications for which its products are
appropriate, particularly in the cardiovascular and neuromodulation fields, the
Company expects research and development expense to decline from peak levels
during 1995, as a result of completing development of the MPS system and certain
related products. Research and development expense was $3.3 million, $4.6
million and $3.5 million for the years ended December 31, 1996, 1995 and 1994,
respectively. The Company has budgeted $2.8 million for research and development
during 1997. Management expects about half of such expenditures to be directed
to refining current ANS SCS products and designing and developing next
generation ANS SCS products, with the other half directed primarily to MPS. As
of March 21, 1997, the Company had an in-house research and development staff of
18 engineers, technicians and designers, down from 24 at March 1996.
MANUFACTURING
The Company manufactures and packages certain ANS SCS products,
cardiovascular products (such as pressure control valves, filters, traps, MPS
and surgical retracting tapes), pressure monitoring kits, and intravenous fluid
delivery products at its primary manufacturing facility in Allen, Texas. This
facility received ISO 9001 certification (for design and manufacturing
processes) in July 1995. See Item 1. "Business -- Other Business
Matters -- Government Regulations." Until the first quarter of 1996, when such
operations were moved to the Allen, Texas facility, the Company manufactured its
line of SCS devices and related products at
7
<PAGE> 9
an ISO 9002 certified (manufacturing only) facility in Fort Lauderdale, FL.
Finally, the Company manufactures certain cardiovascular products at a facility
in Orange County, California and will continue to do so for the foreseeable
future.
The Company's manufacturing processes consist of the assembly of standard
and custom component parts and the testing of completed products. The Company
subcontracts with various suppliers to provide it with the quantity of component
parts necessary to assemble its products. Almost all of these components are
available from a number of different suppliers, although certain components are
purchased from single sources, who manufacture these components from the
Company's toolings. For example, the Company relies on single suppliers for two
separate components of the specialized oncology intravenous tubing set that the
Company supplies to the University of Texas System Cancer Center (M.D. Anderson
Hospital), the Company's largest customer. The Company believes that there are
alternative and satisfactory sources for single-sourced components, although a
sudden disruption in supply from one of these suppliers could adversely affect
the Company's ability to deliver the finished product on time. The Company owns
its own molds for production of a majority of the components used in specialized
tubing sets and cardiovascular products. Consequently, in the event of supply
disruption, the Company would be able to fabricate its own components or
subcontract with another supplier, albeit after a delay in the production
process.
The Company devotes significant attention to quality control. Its quality
control measures begin at the manufacturing level where components are assembled
in a "clean room" environment designed and maintained to reduce product exposure
to particulate matter. Products are tested throughout the manufacturing process
for adherence to specifications. Finished components are shipped to outside
processors for sterilization through radiation or treatment with ethylene oxide
gas. After sterilization, the products are quarantined and tested before they
are shipped to customers.
Skills of assembly workers required for the manufacture of medical products
are similar to those required in typical assembly operations. The Company
believes that workers with these skills are readily available in the Dallas and
Orange County areas.
COMPETITION
In marketing its products, the Company competes with numerous companies
that have substantially greater financial resources and engage in substantially
greater research and development efforts than the Company. ANS competes in the
market for SCS devices with one other significant supplier, Medtronic, Inc.
Medtronic holds a substantial majority share of the market and sells both
RF-coupled systems and IPG devices.
Numerous competitors exist for the Company's cardiovascular products,
specialized tubing sets and pressure monitoring kits. These markets are
dominated by established manufacturers that have broader product lines, greater
distribution capabilities, substantially greater capital resources and larger
marketing, research and development staffs and facilities than the Company. Many
of these competitors offer broader product lines within the specific product
market and/or in the general field of medical devices and supplies. Broad
product lines give many of the Company's competitors the ability to negotiate
exclusive, long-term medical device supply contracts and, consequently, the
ability to offer comprehensive pricing of their competing products. By offering
a broader product line in the general field of medical devices and supplies,
competitors may also have a significant advantage in marketing competing
products to group purchasing organizations, HMOs and other managed care
organizations that are increasingly seeking to reduce costs through
centralization of purchasing functions. In addition, the Company's competitors
may use price reductions to preserve market share in their product markets.
The Company is aware of at least two cardioplegia delivery systems
currently being marketed that compete with the MPS system. While these products
represent improvements over cardioplegia delivery systems currently in use in
that they have partially integrated some of the cardioplegia equipment
components, the Company believes that the MPS system will offer a greater range
of functionality, flexibility and ease-of-use. In addition, innovations in
surgical techniques or medical practices could have the effect of reducing or
eliminating market demand for one or more of the Company's products. For
example, some cardiovascular
8
<PAGE> 10
surgeons and medical device companies are developing techniques, procedures and
devices for performing coronary artery bypass surgery without stopping the
heart, both through open-heart surgery and minimally invasive procedures,
thereby eliminating the need for myocardial protection in these cases and
potentially reducing the market for the MPS system. While these techniques,
procedures and devices have not to date attained widespread use, there can be no
assurance that they will not gain broader market acceptance. While these and
other surgical techniques, procedures and devices may reduce the number of
coronary artery bypass procedures that require myocardial protection, the
Company believes that most, if not all, surgical suites will need to be equipped
with a myocardial protection system.
The Company believes that the principal competitive factors in the
neurostimulation, cardiovascular and intravenous fluid delivery markets are
cost-effectiveness, impact on patient outcomes, product performance, quality and
ease of use, technical innovation and customer service. The Company intends to
continue to compete on the basis of its high performance products, innovative
technologies, manufacturing capability, close customer relations and support and
its strategy to increase its offerings of products within these markets.
PATENTS, TRADEMARKS AND PROPRIETARY INFORMATION
The Company owns twenty United States patents relating to products that the
Company currently markets. Although one of the Company's patents expired in
February 1996, the Company does not believe that such expiration will have a
material adverse effect on the Company or its ability to sell the applicable
product.
ANS currently owns four of the United States patents referred to above and
also owns one foreign patent. In management's view, these patents offer
reasonable coverage of its SCS devices' electrode, receiver and transmitter
technology. These patents cover both RF-coupled devices and IPG systems,
although the Company currently manufactures only RF-coupled devices. Pending
patent applications concern ANS' PainDoc computer system and its innovative
Multistim technology.
Twelve of the twenty patents cover the Company's cardiovascular products.
From 1993 through 1996, the Company filed five applications for patents relating
to the MPS system and related products. Three applications resulted in patents
and the remaining two are pending issuance. In the Company's opinion, the MPS
related patents broadly cover key elements of the MPS system, including the MPS
system's innovative methods of pumping, mixing and heating fluids. Management
believes that the issued patents should provide significant protection for its
MPS system. The Company also filed various applications regarding its unique
line of retrograde catheters which may be used with the MPS system or other
cardioplegia delivery systems.
The Company also owns three patents relating to its intravenous fluid
delivery tubing sets and accessories and other products.
The validity of any patents issued to the Company may be challenged by
others and the Company could encounter legal and financial difficulties in
enforcing its patent rights against infringers. In addition, there can be no
assurance that other technologies cannot or will not be developed or that
patents will not be obtained by others which would render the Company's patents
obsolete. With the possible exception of the patent relating to the specialized
tubing sets manufactured for the University of Texas System Cancer Center (M.D.
Anderson Hospital), the loss of any one patent would not have a material adverse
effect on the Company's current revenue base. Although the Company does not
believe that patents are the sole determinant in the commercial success of its
products, the loss of a significant percentage of its patents or its patents
relating to a specific product line, particularly the MPS system or ANS' SCS
product line, could have a material adverse effect on the Company's business,
financial condition and results of operations.
The Company has developed technical knowledge which, although
non-patentable, is considered by the Company to be significant in enabling it to
compete. However, the proprietary nature of such knowledge may be difficult to
protect. The Company has entered into an agreement with each key employee
prohibiting such employee from disclosing any confidential information or trade
secrets of the Company and prohibiting that employee from engaging in any
competitive business while the employee is working for the Company and for a
period of one year thereafter. In addition, these agreements also provide that
any inventions or discoveries
9
<PAGE> 11
relating to the business of the Company by these individuals will be assigned to
the Company and become the Company's sole property.
Claims by competitors and other third parties that the Company's products
allegedly infringe the patent rights of others could have a material adverse
effect on the Company. The medical device industry is characterized by frequent
and substantial intellectual property litigation. The cardiovascular device
market and the interventional pain management markets are maturing and, as such,
are characterized by extensive patent and other intellectual property claims,
which can create greater potential than in less developed markets for possible
allegations of infringement, particularly with respect to newly developed
technology. Intellectual property litigation is complex and expensive and the
outcome of this litigation is difficult to predict. Any future litigation,
regardless of outcome, could result in substantial expense to the Company and
significant diversion of the efforts of the Company's technical and management
personnel. An adverse determination in any such proceeding could subject the
Company to significant liabilities to third parties, or require the Company to
seek licenses from third parties or pay royalties that may be substantial.
Furthermore, there can be no assurance that necessary licenses would be
available to the Company on satisfactory terms or at all. Accordingly, an
adverse determination in a judicial or administrative proceeding or failure to
obtain necessary licenses could prevent the Company from manufacturing or
selling certain of its products, which could have a material adverse effect on
the Company's business, financial condition and results of operations.
QUEST, MULTIPORT, RETROGUARD, RETRACT-O-TAPE, ACTest, MPS, DUO-TUBE and
PainDoc are among the Company's registered trademarks and COMPUSTIM and ACTester
are among its nonregistered trademarks. Registration applications are pending
for various trademarks the Company believes have value in the marketplace.
GOVERNMENT REGULATION
The manufacture and sale of the Company's products are subject to
regulation by numerous governmental authorities, principally the FDA and
corresponding foreign agencies. The research and development, manufacturing,
promotion, marketing and distribution of the Company's products in the United
States are governed by the Federal Food, Drug and Cosmetic Act and the
regulations promulgated thereunder (the "FDC Act and Regulations"). The Company
is subject to inspection by the FDA for compliance with such regulations and
procedures.
The FDA has traditionally pursued a rigorous enforcement program to ensure
that regulated entities such as the Company comply with the FDC Act and
Regulations. A company not in compliance may face a variety of regulatory
actions, including warning letters, product detentions, device alerts, mandatory
recalls or field corrections, product seizures, injunctive actions or civil
penalties and criminal prosecutions of the company or responsible employees,
officers and directors. The Company was inspected in the summer of 1996 with no
major violations found.
Under the FDA's requirements, if a manufacturer can establish that a newly
developed device is "substantially equivalent" to a legally marketed device, the
manufacturer may seek marketing clearance from the FDA to market the device by
filing a 510(k) premarket notification with the FDA. The 510(k) premarket
notification must be supported by data establishing the claim of substantial
equivalence to the satisfaction of the FDA. The process of obtaining a 510(k)
clearance typically can take several months to a year or longer. If substantial
equivalence cannot be established, or if the FDA determines that the device
requires a more rigorous review, the FDA will require that the manufacturer
submit a PMA that must be carefully reviewed and approved by the FDA prior to
sale and marketing of the device in the United States. The process of obtaining
a PMA can be expensive, uncertain and lengthy, frequently requiring anywhere
from one to several or more years from the date of FDA submission. Both a 510(k)
and a PMA, if granted, may include significant limitations on the indicated uses
for which a product may be marketed. FDA enforcement policy strictly prohibits
the promotion of approved medical devices for unapproved uses. In addition,
product approvals can be withdrawn for failure to comply with regulatory
requirements or the occurrence of unforeseen problems following initial
marketing. Although all of the Company's currently marketed products have been
the subject of successful 510(k) submissions and the Company believes that most
of its products currently in
10
<PAGE> 12
development will also be eligible for the 510(k) submission process, there can
be no assurance that the FDA will agree with this view.
The Company is also subject to regulation in each of the foreign countries
in which it sells its products with regard to product standards, packaging
requirements, labeling requirements, import restrictions, tariff regulations,
duties and tax requirements. Many of the regulations applicable to the Company's
products in such countries are similar to those of the FDA. The national health
or social security organizations of certain countries require the Company's
products to be qualified before they can be marketed in those countries. To
date, the Company has not experienced significant difficulty in complying with
these regulations.
To position itself for access to European and other international markets,
Quest sought and obtained certification under the ISO 9000 Series of Standards.
ISO 9000 is a set of integrated requirements, which when implemented, form the
foundation and framework for an effective quality management system. These
standards were developed and published by the ISO, a worldwide federation of
national standard bodies, founded in Geneva, Switzerland in 1946. ISO has over
92 member countries. ISO certification is widely regarded as essential to enter
Western European markets.
The Company obtained certification and was registered as an ISO 9001
compliant company on July 1, 1995. The ISO 9001 registration is the most
stringent standard in the ISO series and lasts for three years. The German
notified body, Landesgewerbeanstalt Bayern ("LGA") issued the certificate. The
ISO 9001 standards cover design, production, installation and servicing of
products. The Company will be subject to an annual audit by the notified body to
maintain the registration. The Company was then certified to be in compliance
with the Medical Device Directive ("MDD") as well as ISO 9001 by the notified
body TUV Rheinland ("TUV") in July 1996. Subsequently, in December 1996, the
Company's ANS implantable products were certified to be in compliance with the
Active Implantable Medical Directive ("AIMD") by TUV product services, another
notified body. These certifications were sought and obtained for the purpose of
getting the CE mark which represents product approval throughout the European
Union. As a result, the CE mark was maintained on all ANS products. The Company
also received CE mark certification on its line of retrograde and antegrade
catheters.
The financial arrangements through which the Company markets, sells and
distributes its products may be subject to certain federal and state laws and
regulations in the United States with respect to the provision of services or
products to patients who are Medicare or Medicaid beneficiaries. The "fraud and
abuse" laws and regulations prohibit the knowing and willful offer, payment or
receipt of anything of value to induce the referral of Medicare or Medicaid
patients for services or goods. In addition, the physician anti-referral laws
prohibit the referral of Medicare or Medicaid patients for certain "Designated
Health Services" to entities in which the referring physician has an ownership
or compensation interest. Violations of these laws and regulations may result in
civil and criminal penalties, including substantial fines and imprisonment. In a
number of states, the scope of fraud and abuse or physician anti-referral laws
and regulations, or both, have been extended to include the provision of
services or products to all patients, regardless of the source of payment,
although there is variation from state to state as to the exact provisions of
such laws or regulations. In other states, and on a national level, several
health care reform initiatives have been proposed which would have a similar
impact. The Company believes that its operations and its marketing, sales and
distribution practices currently comply in all respects with all current fraud
and abuse and physician anti-referral laws and regulations, to the extent they
are applicable. Although the Company does not believe that it will need to
undertake any significant expense or modification to its operations or its
marketing, sales and distribution practices to comply with federal and state
fraud and abuse and physician anti-referral regulations currently in effect or
proposed, financial arrangements between manufacturers of medical devices and
other health care providers may be subject to increasing regulation in the
future. Compliance with such regulation could adversely affect the Company's
marketing, sales and distribution practices, and may affect the Company in other
respects not presently foreseeable, but which could have an adverse impact on
the Company's business, financial condition and results of operations.
11
<PAGE> 13
THIRD PARTY REIMBURSEMENT AND COST CONTAINMENT
The Company's products are purchased primarily by hospitals and other
users, which then bill various third party payors for the services provided to
the patients. These payors, which include Medicare, Medicaid, private insurance
companies and managed care organizations, reimburse part or all of the costs and
fees associated with the procedures performed with these devices.
Medicare and Medicaid reimbursement for hospitals is based on a fixed
amount for admitting a patient with a specific diagnosis. Because of this fixed
reimbursement method, hospitals have incentives to use less costly methods in
treating Medicare and Medicaid patients, and will frequently make capital
expenditures to take advantage of less costly treatment technologies.
Frequently, reimbursement is reduced to reflect the availability of a new
procedure or technique, and as a result hospitals are generally willing to
implement new cost saving technologies before these downward adjustments take
effect. Likewise, because the rate of reimbursement for certain physicians who
perform certain procedures has been and may in the future be reduced in the
event of further changes in the resource-based relative value scale method of
payment calculation, physicians may seek greater cost efficiency in treatment to
minimize any negative impact of reduced reimbursement. Any amendments to
existing reimbursement rules and regulations which restrict or terminate the
reimbursement eligibility (or the extent or amount of coverage) of medical
procedures using the Company's products or the eligibility (or the extent or
amount of coverage) of the Company's products could have an adverse impact on
the Company's business, financial condition and results of operations. Third
party payors are increasingly challenging the prices charged for medical
products and services and may deny reimbursement if they determine that a device
was not used in accordance with cost-effective treatment methods as determined
by the payor, was experimental or was used for an unapproved application.
The Company's SCS devices, for example, while cost-effective compared to
repeat back surgeries, have encountered some resistance to third party
reimbursement. Although Medicare, Medicaid and many private insurers reimburse
for the SCS device and procedure, especially after repeat back surgeries have
failed to relieve the chronic pain, certain payors refuse to reimburse for SCS
devices and others, including the Veterans Administration, restrict
reimbursement. There can be no assurance that in the future, third party payors
will continue to reimburse for the Company's products, or that their
reimbursement levels will not adversely affect the profitability of the
Company's products. In addition, the cost of health care has risen significantly
over the past decade, and there have been and may continue to be proposals by
legislators and regulators to curb these costs. Legislative action limiting
reimbursement for certain procedures could have a material adverse effect on the
Company's business, financial condition and results of operations.
In response to the focus of national attention on rising health care costs,
a number of changes to reduce costs have been proposed or have begun to emerge.
There have been, and may continue to be, proposals by legislators and regulators
and third party payors to curb these costs. There has also been a significant
increase in the number of Americans enrolling in some form of managed care plan.
It has become a typical practice for hospitals to affiliate themselves with as
many managed care plans as possible. Higher managed care penetration typically
drives down the prices of health care procedures, which in turn places pressure
on medical supply prices. This causes hospitals to implement tighter vendor
selection and certification processes, by reducing the number of vendors used,
purchasing more products from fewer vendors and trading discounts on price for
guaranteed higher volumes to vendors. Hospitals have also sought to control and
reduce costs over the last decade by joining group purchasing organizations or
purchasing alliances. The Company cannot predict what continuing or future
impact existing or proposed legislation, regulation or such third party payor
measures may have on its future business, financial condition or results of
operations.
Changes in reimbursement policies and practices of third party payors could
have a substantial and material impact on sales of certain of the Company's
products. The development or increased use of more cost-effective treatments
could cause such payors to decrease or deny reimbursement to favor these other
treatments.
12
<PAGE> 14
EMPLOYEES
As of March 21, 1997, the Company employed 247 full-time employees, 18 in
research and development, 43 in sales and marketing, 153 in manufacturing and
related operations, and the remainder in executive and administrative positions.
None of the Company's employees is represented by a labor union and the Company
considers its employee relations to be good.
ADVISORY BOARDS
The Company has established two Boards of Clinical Advisors (the "Advisory
Boards"). The Advanced Neuromodulation Systems Advisory Board (the "ANSAB") is
comprised of individuals with substantial expertise in neurostimulation and pain
management. Members of the Company's management and scientific and technical
staff consult closely with the ANSAB to identify specific areas where techniques
are changing and where existing products do not adequately fulfill the needs of
the pain physician. The ANSAB helps management evaluate new product ideas and
concepts and once a product is approved for development, its subsequent design
and development. The ANSAB may also participate in the clinical testing of
products developed.
The Quest Advisory Board (the "QAB") is comprised of individuals with
substantial expertise in the field of myocardial protection who have played
instrumental roles in the identification of the market need for MPS system and
its subsequent design and development. Members of the Company's management and
scientific and technical staff consult closely with the QAB to better understand
the technical and clinical requirements of the cardiovascular surgical team and
product functionality needed to meet those requirements. The Company anticipates
that the QAB will continue to play a similar role with respect to other
products, and may assist the Company in educating other physicians in the use of
the MPS and related products.
Certain members of the Advisory Boards are employed by academic
institutions and may have commitments to or consulting or advisory agreements
with other entities that may limit their availability to the Company. The
members of the Advisory Boards may also serve as consultants to other medical
device companies. No members of the ANSAB or QAB are expected to devote more
than a small portion of their time to the Company.
ITEM 2. PROPERTIES
In December 1993, the Company moved into its new manufacturing facility and
executive offices in Allen, Texas (located north of Dallas). The facility covers
approximately 107,000 square feet and was constructed during 1993 on a 19.2 acre
tract that the Company acquired in 1985. The Company borrowed $4.4 million from
MetLife Capital Corporation to construct and outfit this facility. This
financing is collateralized by the Allen land, the Allen facility and certain
equipment of the Company. See Note 5 of the Notes to Consolidated Financial
Statements. Management expects the current facility to serve its manufacturing,
storage and executive office needs in the Dallas area for the foreseeable
future.
The Company also currently leases approximately 4,600 square feet of office
and manufacturing space in Orange County, California on a month-to-month basis.
The Company plans to continue manufacturing certain cardiovascular surgery
products at this facility for the foreseeable future.
Until February 1996, ANS leased approximately 18,000 square feet of office
and manufacturing space in Fort Lauderdale, Florida, where it manufactured and
marketed its SCS devices. During late 1995 and early 1996, the Company relocated
the ANS operations to the Company's facility in Allen, Texas.
ITEM 3. LEGAL PROCEEDINGS
As a consequence of the Neuromed Acquisition in March 1995, the Company is
a party to product liability claims related to SCS devices sold by Neuromed
prior to the acquisition. Product liability insurers have assumed responsibility
for defending the Company against these claims, subject to reservation of rights
in certain cases. While historically product liability claims against Neuromed
have not resulted in significant
13
<PAGE> 15
monetary liability for Neuromed beyond its insurance coverage, there can be no
assurances that the Company will not incur significant monetary liability to the
claimants if such insurance is unavailable or inadequate for any reason, or that
the Company's SCS business and new SCS product lines will not be adversely
affected by these product liability claims. While the Company seeks to maintain
appropriate levels of product liability insurance with coverage that the Company
believes is comparable to that maintained by companies similar in size and
serving similar markets, there can be no assurance that the Company will avoid
significant future product liability claims relating to its SCS, cardiovascular,
intravenous fluid delivery or other products.
Except for such product liability claims and other ordinary routine
litigation incidental or immaterial to its business, the Company is not
currently a party to any other pending legal proceeding. The Company maintains
general liability insurance against risks arising out of the normal course of
business.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Inapplicable.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The Company's common stock is quoted on the Nasdaq National Market under
the symbol "QMED." On March 21, 1997, there were approximately 831 holders of
record of the Company's common stock. The following table sets forth the
quarterly high and low closing sales prices for the Company's common stock.
These prices do not include adjustments for retail mark-ups, mark-downs or
commissions.
<TABLE>
<CAPTION>
HIGH LOW
1995: ------ ------
<S> <C> <C>
First Quarter............................................... $ 8.75 $ 4.88
Second Quarter.............................................. $12.50 $ 7.13
Third Quarter............................................... $14.50 $11.75
Fourth Quarter.............................................. $12.00 $ 9.75
</TABLE>
<TABLE>
<CAPTION>
HIGH LOW
1996: ------ ------
<S> <C> <C>
First Quarter............................................... $14.50 $10.25
Second Quarter.............................................. $14.38 $ 6.00
Third Quarter............................................... $ 9.13 $ 5.63
Fourth Quarter.............................................. $ 8.25 $ 5.75
</TABLE>
<TABLE>
<CAPTION>
HIGH LOW
1997: ------ ------
<S> <C> <C>
First Quarter............................................... $ 8.13 $ 6.00
(through March 21, 1997)
</TABLE>
To date, the Company has not declared or paid any cash dividends on its
common stock, and the present policy of the Board of Directors is to retain any
earnings to provide for the Company's growth. Any future determination to pay
dividends will be at the discretion of the Board of Directors, and dependent
upon the Company's financial condition, results of operations, capital
requirements and such other factors as the Board of Directors deems relevant. In
addition, the Company's current credit arrangement with NationsBank of Texas,
N.A. ("NationsBank") prohibits the payment of cash dividends.
On August 26, 1996, the Board of Directors voted to redeem the Company's
then outstanding stock purchase rights at $0.01 per share. The redemption price
for the outstanding rights was paid on September 27,
14
<PAGE> 16
1996 to shareholders of record as of September 12, 1996. See Note 7 of the Notes
to Consolidated Financial Statements.
Subsequent to December 31, 1996, in connection with borrowing $2.0 million
from a stockholder, the Company issued the stockholder five-year warrants to
purchase 100,000 shares at an exercise price of $6.50 per share, the closing
sales price on the date the indebtedness was incurred. See Item 7. "Management's
Discussion and Analysis of Financial Condition and Results of
Operations -- Liquidity and Capital Resources" and Note 5 of the Notes to
Consolidated Financial Statements. The Company relied on the private placement
exemptions provided by Regulation D under the Securities Act of 1933, as
amended, in issuing the warrants.
ITEM 6. SELECTED FINANCIAL DATA
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31
----------------------------------------------------
1992 1993 1994 1995(1) 1996
------- ------- ------- -------- -------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net revenue............................. $13,612 $13,643 $13,999 $ 25,321 $26,074
Gross profit............................ 6,553 6,591 6,381 14,697 15,069
Research and development expense........ 1,387 1,910 3,542 4,583 3,343
Nonrecurring charges(2)................. 1,247 -- -- 10,500 --
Marketing and general and administrative
expense.............................. 4,141 4,400 4,977 8,395 11,626
Earnings (loss) from operations,
excluding nonrecurring charges....... 1,025 281 (2,138) 1,719 100
Earnings (loss) from operations......... (222) 281 (2,138) (8,781) 100
Other income (expense), net............. 473 667 419 (1,168) (429)
Earnings (loss) from continuing
operations before income taxes,
extraordinary item and cumulative
effect of change in accounting
principle............................ 251 948 (1,719) (9,950) (329)
Net earnings (loss) 194 816(3) (1,719) (10,374)(4) (412)
Net earnings (loss) per share........... $ .03 $ .15 $ (.33) $ (1.56) $ (.05)
Weighted average common and common
equivalent shares outstanding........ 5,594 5,559 5,257 6,642 8,531(5)
</TABLE>
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31
----------------------------------------------------
1992 1993 1994 1995 1996
------- ------- ------- -------- -------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Balance Sheet Data:
Cash, cash equivalents and marketable
securities........................... $ 6,693 $ 6,594 $ 5,262 $ 3,914 $ 2,062
Working capital......................... 10,847 9,566 7,411 12,183 11,088
Total assets............................ 20,448 26,739 24,235 44,496 48,992
Short-term notes payable and current
maturities of long-term notes
payable.............................. 799 2,297 2,759 1,616 2,084
Notes payable, excluding current
maturities........................... 242 4,101 4,124 8,558 11,912
Stockholders' equity.................... $17,639 $18,252 $15,931 $ 30,870 $30,993
</TABLE>
- ---------------
(1) Includes results of Neuromed from April 1, 1995.
(2) Nonrecurring charge in 1992 relates to the write-off of assets of a
discontinued business and in 1995 relates to purchased research and
development incurred in connection with the Neuromed acquisition.
(3) Includes an increase in net income of $169, or $.03 per share, relating to
the cumulative effect of a change in accounting principle.
(4) Includes a decrease in net income of $269 (net of income tax benefit of
$139), or $(.03) per share, from the write-off of capitalized debt issuance
costs due to early repayment of bank debt.
15
<PAGE> 17
(5) The Company completed a public offering of 1,676,667 shares for net proceeds
of $15.2 million in the fourth quarter of 1995.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion of the financial condition and results of
operations of the Company should be read in conjunction with the Consolidated
Financial Statements of the Company and the related Notes thereto.
RESULTS OF OPERATIONS
Comparison of the Years Ended December 31, 1996 and 1995
Revenues. Net revenue of $26.1 million for the year ended December 31,
1996, was $800,000 above the level for the comparable 1995 period of $25.3
million. This increase during 1996 compared to 1995 was primarily attributable
to including a full twelve months of revenue generated by ANS, formerly
Neuromed, Inc., which was acquired on March 31, 1995. Revenue of ANS products
for 1996 was $11.4 million compared to $10.4 million for the last nine months of
1995. In addition, the Company introduced the next generation of multi-electrode
leads in 1996, which prompted delays in purchase commitments. The Company made
the strategic decision in 1996 to market its ANS products through commissioned
sales agents rather than distributors in certain geographical areas of the
United States. This decision resulted in a decrease of approximately $300,000 in
ANS revenue during 1996 due to the return of inventories from those distributors
whom the Company decided to replace with sales agents. During early 1996,
management announced plans to re-build the infrastructure at ANS to transform
ANS into an industry leader and compete effectively in the SCS market.
Management believes it has taken major steps in improving the current products
of ANS and is continuing these efforts into the first quarter of 1997.
Management believes that these efforts should return ANS to sustained and
profitable revenue growth during 1997.
During the third quarter of 1996, the Company completed clinical validation
of the MPS system for cardioplegia delivery and began commercial shipments
during September 1996, a quarter later than management had expected. Revenue
from the MPS system and related disposable products during 1996 was $443,000,
significantly below management's expectations. Clinical evaluations since the
commercial introduction of the MPS have validated that the MPS provides simpler,
more flexible and cost-effective management of myocardial protection. As a
consequence of the current hospital consolidation trend, coupled with the
intense pressure hospitals are under to minimize capital expenditures, however,
hospitals have been reluctant to make timely purchase decisions on new capital
equipment. Therefore, to accelerate the adoption of MPS and shorten the selling
process, the Company, in early 1997, decided to offer MPS on a one-year rental
basis and on a lease/purchase basis. This strategy will decrease short-term
revenues because the rental agreement does not qualify as a sale, but should, in
management's opinion, accelerate placement of MPS systems and related disposable
revenues. The Company believes that once a surgeon changes the cardioplegia
protocol using features of MPS, it will be very difficult to return to the old,
make-shift system. There can be no assurance that such rental strategy will
accelerate placement of MPS systems.
Net revenue from sales of the Company's other cardiovascular products,
pressure monitoring kits used in labor and delivery and specialized intravenous
fluid delivery tubing sets decreased from $14.9 million in 1995 to $14.2 during
1996 due to lower unit sales volume from the Company's specialized intravenous
fluid delivery tubing sets.
Gross Profit. Gross profit during 1996 increased to $15.1 million compared
to $14.7 million in 1995. As a percentage of net revenue, gross profit decreased
slightly to 57.7 percent in 1996 compared to 58.0 percent during 1995. This
slight decrease in gross profit margin was principally the result of higher
manufacturing overhead expense related to the Company's ANS products.
Operating Expenses. Research and development expense decreased to $3.34
million in 1996 compared to $4.58 million in 1995, and as a percentage of net
revenue, decreased to 12.8 percent in 1996 from 18.1 percent
16
<PAGE> 18
during 1995. This decrease was the result of a reduction in salary and contract
labor expense from staffing reductions due to the completion of the development
of the MPS system. Separately, the Company devoted significant engineering
resources and took major steps to improve ANS products during 1996. This effort
is continuing into the first quarter of 1997. The Company has budgeted $2.8
million for research and development during 1997. Management expects about half
of such expenditures to be directed to refining current ANS products and
designing and developing next generation ANS products for market introduction
during 1998. The other half of 1997 budgeted expenditures will be directed to
continued developments in the MPS system. Management expects that most of its
research and development activities during 1997 will continue to be financed
through internally-generated funds.
Marketing, general and administrative expenses as a percentage of net
revenue increased to 44.6 percent during 1996 compared to 33.2 percent during
1995, and the dollar amount increased by $3.23 million. The largest increase
occurred in marketing expense with expenditures in 1996 increasing by $2.4
million over the comparable period a year ago and as a percentage of net
revenue, increased to 25.3 percent in 1996 compared to 16.6 percent in 1995. Of
such increase, $1.6 million was additional marketing expense of ANS related to
additional salary, benefit, commission, travel, samples and promotional expense.
The 1995 period included only nine months of expense. During 1996, the Company
reorganized part of its ANS distribution network for ANS products and replaced
several distributors in certain areas of the United States with eight
commissioned sales agents and three direct regional managers. Also during 1996,
the Company has designed ANS training, customer support and sales and marketing
materials and videos and will continue those efforts in early 1997. The Company
has also reestablished relationships with key implanters who had discontinued
using the ANS products prior to the Company's acquisition. The remainder of the
increase in marketing expense of $800,000 in 1996 compared to 1995 was primarily
the result of additional salary, benefit and travel expense from four additional
direct salespersons hired during the fourth quarter of 1995 in preparation of
the commercial introduction of the MPS system. As previously mentioned, the
Company began commercial shipments of MPS during September 1996, about a quarter
later than it had anticipated at the beginning of 1996. Currently, the Company
has five direct salespersons marketing the MPS system and does not anticipate
adding additional salespersons during 1997. In early 1997, the Company decided
to offer MPS on a one-year rental basis and on a lease/purchase basis to
accelerate the adoption of MPS and shorten the selling process. If this strategy
is successful, the Company would reevaluate adding salespersons during 1997, as
circumstances warrant. Management has decided to focus most of its efforts for
MPS during 1997 on the U.S. and Canadian markets, and does not anticipate
introduction of the MPS internationally until fiscal 1998.
General and administrative expense increased $800,000 during 1996 compared
to 1995, and as a percentage of net revenue, increased from 16.6 percent in 1995
to 19.3 percent in 1996. Of such increase, $335,000 was attributable to higher
amortization expense of ANS intangibles. In addition, the 1996 period includes
$256,000 of expense related to a writeoff of a receivable due from a former ANS
distributor who filed bankruptcy and an increase to the Company's reserves for
bad debt ($60,000). The remainder of the increase in expense during 1996
compared to 1995 was primarily the result of higher recruiting, relocation and
401(k) Company match expenses.
Earnings (Loss) From Operations. Earnings from operations for 1996 totaled
$100,000 compared to a net loss from operations in 1995 of $8.78 million. In
connection with the Neuromed acquisition, $10.5 million of the aggregate
purchase price was identified as purchased in-process research and development,
and in accordance with generally accepted accounting principles, was charged to
expense with no related tax benefit during 1995. Excluding the 1995 expense for
purchased research and development, earnings from operations decreased from
$1.72 million in 1995 to $100,000 in 1996, reflecting higher levels of
marketing, general and administrative expense discussed above.
Other Expense. Other expense decreased to $429,000 in 1996 compared to
$1.17 million in 1995 due to lower interest expense. The 1995 period reflects
interest expense on $15 million of bank debt incurred in March 1995 in
connection with the Neuromed acquisition, which was repaid in November of 1995
from the proceeds of a public offering. Interest income decreased $260,000 from
1995 levels due to reduced funds available for investment. This decrease in
interest income was partially offset, however, by a $108,000 increase in gains
on the sale of marketable securities.
17
<PAGE> 19
Income Taxes. Despite the Company's loss before income tax expense of
$329,000 in 1996, the Company recorded income tax expense of $83,000 as a
consequence of the nondeductibility of amortization costs in excess of net
assets acquired (goodwill). During 1995, the Company similarly recorded income
tax expense of $155,000 despite a loss before income tax expense of $9.95
million as a consequence of the nondeductibility of the $10.5 million expense
for purchased research and development and amortization costs in excess of net
assets acquired.
Net Loss. The net loss decreased from $10.4 million in 1995 to $412,000 in
1996 primarily due to the $10.5 million expense during 1995 for purchased
in-process research and development incurred in connection with the Neuromed
acquisition. Excluding this $10.5 million expense, the Company's net loss of
$412,000 in 1996 compared to net earnings of $126,000 in 1995 and resulted from
increased operating expenditures, particularly in general and administrative and
marketing.
Comparison of the Years Ended December 31, 1995 and 1994
Revenues. Net revenue of $25.3 million for the year ended December 31,
1995, was $11.3 million, or 80.7 percent above the level for the comparable 1994
period of $14.0 million. This increase during 1995 compared to 1994 was
primarily attributable to revenue generated by Neuromed, which was acquired on
March 31, 1995. Net revenue from sales of the Company's other products increased
6.3 percent during 1995 compared to 1994 primarily due to higher unit sales
volume from the Company's cardiovascular products.
Gross Profit. Gross profit during 1995 increased to $14.7 million compared
to $6.4 million in 1994, an increase of 130 percent. As a percentage of net
revenue, gross profit increased to 58.0 percent in 1995 compared to 45.6 percent
during 1994. This increase in gross profit and gross profit margin during 1995
compared to 1994 was primarily attributable to the revenue generated by
Neuromed, since Neuromed's products contribute higher gross profit margins than
the Company's other product lines.
Operating Expenses. Research and development expense increased to
approximately $4.6 million during 1995 compared to the 1994 level of $3.5
million, although such expense decreased as a percentage of net revenue from
25.3 percent during 1994 to 18.1 percent during 1995. These expenditures during
1995 were $2.1 million more than originally budgeted at the beginning of fiscal
1995. Of such overage, $650,000 were expenditures directed toward Neuromed while
the remainder represented additional expenditures directed at continued
development of the Company's MPS(TM) brand of myocardial protection system. As
previously noted, the Company filed for FDA market clearance under a 510(k)
during August 1995 and on March 8, 1996 received clearance to commercially
market the MPS system, which occurred during the third quarter of 1996.
Increased expenditures during 1995 compared to 1994 were primarily the result of
additional salary and contract labor expense from staff additions and increased
consulting expense.
Marketing, general and administrative expenses as a percent of net revenue
decreased to 33.2 percent during 1995 compared to 35.6 percent during 1994,
while the dollar amount increased $3.4 million. Marketing expense as a
percentage of net revenue increased to 16.6 percent in 1995 from 13.7 percent
during 1994, and the dollar amount increased by $2.3 million. Of such increase,
$1.7 million was Neuromed marketing expense. The remainder of the increase in
marketing expense was primarily the result of additional salary and benefit
expense from personnel additions, and increased travel, commission, convention
and recruiting expense. During the fourth quarter of 1995, the Company hired
four additional direct salespersons in anticipation of the 510(k) clearance of
its MPS system. General and administrative expense increased $1.1 million during
1995 compared to 1994, but as a percentage of net revenue, decreased from 21.9
percent during 1994 to 16.6 percent during 1995. This increase in expense during
1995 compared to 1994 was attributable to general and administrative expense of
Neuromed, including amortization expense of Neuromed intangibles.
Loss from Operations. On March 31, 1995, the Company acquired all of the
capital stock of Neuromed, Inc. Of the aggregate purchase price for Neuromed,
$10.5 million was identified as purchased in-process research and development
and in accordance with generally accepted accounting principles was charged to
expense, with no related tax benefit, during 1995. As a result, the loss from
operations increased from $2.1 million in 1994 to $8.8 million during 1995.
Excluding the charge for purchased research and
18
<PAGE> 20
development, the Company generated earnings from operations of $1.7 million
compared to the $2.1 million loss for the 1994 period, reflecting the positive
impact of the Neuromed acquisition.
Other Income (Expense). Other income (expense) decreased to an expense of
$1.2 million during 1995 compared to income of $419,000 during 1994. This
decrease was primarily the result of higher interest expense which increased
$1.1 million during 1995 from 1994. The Company incurred $15.0 million of
long-term bank debt on March 31, 1995, which was used to fund most of the cash
payment of the Neuromed acquisition. Higher overall interest rates on borrowed
money also contributed to the increase in interest expense during 1995 compared
to 1994. In addition, gains recognized on the sale of the Company's investments
was $29,000 for 1995 compared to $464,000 for 1994, also contributing to the
decrease in other income.
Income Taxes. The Company recorded income tax expense of $155,000 during
1995 as a consequence of the nondeductibility of the $10.5 million expense for
purchased research and development and amortization expense of costs in excess
of net assets acquired. No income tax benefit was recognized for the Company's
1994 net operating loss.
Net Loss. The net loss increased from $1.7 million in 1994 to $10.4 million
during 1995 primarily as a result of the aforementioned $10.5 million expense
for purchased in-process research and development incurred in connection with
the Neuromed acquisition. In addition, the net loss for 1995 reflects an
extraordinary charge of $269,000 for the writeoff of capitalized debt issuance
costs due to early repayment of the long-term bank debt.
LIQUIDITY AND CAPITAL RESOURCES
The Company's working capital decreased from $12.2 million at year-end 1995
to $11.1 million at year-end 1996 principally due to an increase of $1.1 million
in accounts payable. The ratio of current assets to current liabilities was
3.0:1 at December 31, 1996, compared to 3.7:1 at December 31, 1995. Cash, cash
equivalents and marketable securities totaled $2.1 million, a decrease of $1.8
million from year-end 1995.
The Company increased its investment in inventories during 1996 by $2.26
million, substantially all of which relates to the MPS system and its related
disposables. The Company anticipates a decrease in its investment in inventories
of approximately $1.0 million by year-end 1997.
During 1996, the Company invested $2.0 million in capital expenditures for
additional manufacturing tooling and equipment and an upgraded management
information system. The Company expects capital expenditures for fiscal 1997 to
decrease to $1.5 million. These capital expenditures, during 1997, are
principally for manufacturing tooling and equipment for the Company's current
ANS SCS products and next generation neuromodulation products.
In connection with the Neuromed acquisition in March 1995, the Company
agreed to pay contingent earn-out consideration in January 1996 and January
1997, depending on Neuromed's attainment of certain sales objectives. At yearend
1995, the Company had a note payable in connection with the 1995 earn-out
consideration in the amount of $1.5 million, payable in January 1996. The
Company withheld payment of the $1.5 million obligation pending arbitration of
certain disputes between the Company and Neuromed's former owner. In October
1996, the sales objectives for the 1996 earn-out were reached and the Company
recorded a note payable in the amount of $3.37 million which was due and payable
in January 1997. The Company similarly withheld payment of this note pending
arbitration. In addition, the Company had a short-term note payable to the
former owner of Neuromed at December 31, 1996, in the amount of $972,000 due in
January 1997, related to certain purchase price adjustments (principally tax
refunds and future tax credits) awarded through an arbitration. The Company paid
the $972,000 obligation during January 1997 utilizing a portion of its cash
reserves. On February 6, 1997, the Company and the former owner of Neuromed
reached a settlement (the "Settlement") of all issues between them. Under terms
of the Settlement, the Company agreed to pay $500,000 on March 3, 1997, and
deliver a promissory note in the amount of $1.0 million payable on February 6,
1998, for full settlement of the contingent earn-out considerations. The
promissory note bears interest at the rate of 10 percent per annum with interest
due and payable monthly. The Company also agreed to pay $3.0 million on March 3,
1997, to purchase certain patent rights from Neuromed's former owner. On
19
<PAGE> 21
March 3, 1997, the Company made payment of the $3.5 million pursuant to the
Settlement with borrowed funds discussed below. See Notes 3 and 5 of the Notes
to Consolidated Financial Statements.
On February 21, 1997, the Company borrowed $2.0 million from a shareholder
pursuant to a promissory note. The promissory note is due and payable on
February 21, 1998, and bears interest at the rate of 6 percent per annum. In
addition, the Company issued the shareholder five-year warrants to purchase
100,000 shares of common stock at an exercise price of $6.50 per share, the
closing sales price on the date the indebtedness was incurred. The Company
utilized proceeds from the loan to pay a portion of the Settlement discussed
above. See Note 5 of the Notes to Consolidated Financial Statements.
On March 3, 1997, the Company amended its $5.0 million working capital line
of credit with NationsBank of Texas, N.A. Under the third amended agreement, the
working capital line of credit was increased to $5.65 million and a $350,000
term loan facility was added. Both facilities expire on January 31, 1998.
Borrowings under the working capital line of credit bear interest at prime plus
100 basis points, or at the Company's option, LIBOR plus 275 basis points.
Borrowings under the term loan facility bear interest at prime plus 100 basis
points, or at the Company's option, LIBOR plus 225 basis points. The facilities
are collateralized by all of the Company's assets with the exception of the real
property, building, and equipment that collateralize the long-term financing on
the Company's facility in Allen, Texas. Under the working capital line, the
Company is required to make monthly principal payments of $90,000, with interest
payable quarterly. Under the term loan facility, no principal payments are due
until maturity and interest is payable quarterly. On March 3, 1997, the Company
increased its borrowings under the working capital line of credit by $1.1
million and borrowed $350,000 under the term loan facility. These additional
borrowings were utilized to pay a portion of the debt under the Settlement
described above. See Note 5 of the Notes to Consolidated Financial Statements.
Management believes that its current cash, cash equivalents and marketable
securities and funds generated from operations will be sufficient to satisfy
normal cash operating requirements, debt service and capital requirements during
the remainder of 1997. During the first quarter of 1998, however, $8.1 million
of debt will become due and payable. The Company is exploring various means to
either refinance or payoff the debt entirely, including without limitation, a
new loan facility, alternative debt or equity financing, asset or division sale,
technology transfer or other arrangements.
CASH FLOWS
Net cash used in operating activities in 1996 decreased to $446,000
compared to $1.53 million in 1995. The primary use of cash during 1996 was an
increase in the Company's investment in inventories, which increased by $2.26
million, primarily related to building MPS units and manufacturing supplies of
related disposables. The Company anticipates that its operating activities
during 1997 will provide cash and anticipates a decrease in its investment in
inventories of approximately $1.0 million by year-end 1997. During 1995, the net
cash used in operating activities of $1.5 million was primarily due to an
increase in net working capital, principally in the areas of accounts
receivable, inventory and prepaid expenses.
Investing activities in 1996 resulted in a net use of cash of $3.5 million
compared to a net use of cash during 1995 of $14.1 million. Primary uses of cash
in investing activities during 1996 were capital expenditures of $2.0 million
for additional manufacturing equipment and office equipment and $3.0 million for
the purchase of certain patent rights from the former owner of Neuromed, Inc.
See "-- Liquidity and Capital Resources" and Notes 3 and 5 of the Notes to
Consolidated Financial Statements. The primary source of cash from investing
activities in 1996 was from the sale of certain of the Company's investments in
marketable securities, which provided $1.5 million. Primary uses of cash in
investing activities during 1995 were $16.0 million utilized to consummate the
Neuromed acquisition and capital expenditures of $1.5 million. The primary
source of cash from investing activities in 1995 was from the sale of certain of
the Company's investments in marketable securities, which provided $3.3 million.
Financing activities in 1996 provided $3.3 million of net cash compared to
$16.9 million in 1995. Primary sources of cash from financing activities in 1996
consisted of a net increase in notes payable of $3.0 million to fund the
purchase of certain patent rights from the former owner of Neuromed and $559,000
from the exercise
20
<PAGE> 22
of stock options. The $3.0 million obligation was paid during March 1997. See
Note 5 of the Notes to Consolidated Financial Statements. Primary uses of cash
in financing activities during 1996 were $151,000 of principal payments for
long-term notes payable and $103,000 utilized in the redemption of the Company's
shareholder rights plan. Primary sources of cash from financing activities in
1995 consisted of $15.0 million provided from borrowings under a senior-term
bank facility which was utilized to fund most of the cash portion of the
Neuromed acquisition purchase price, $1.9 million of additional borrowings under
the Company's working capital line of credit, and $15.2 million of net proceeds
provided by a public offering. In addition, the exercise of stock options in
1995 provided $369,000. Primary uses of cash in financing activities during 1995
were repayment of the $15.0 million senior-term bank indebtedness and $108,000
of principal payments for long-term notes payable.
RECENT EVENTS
On March 10, 1997, the Company announced that the Company's Board of
Directors has engaged Smith Barney and Rauscher Pierce Refsnes to seek strategic
alternatives to enhance shareholder value. These strategic alternatives may
include a merger, sale of assets, other business combination, or a joint venture
or strategic alliance.
OUTLOOK AND UNCERTAINTIES
Quest does not provide forecasts of potential future financial performance.
While Quest management is optimistic about Quest's long-term prospects, the
following issues and uncertainties, among others, should be considered in
evaluating its growth outlook.
Liquidity. The Company's liquidity has been substantially reduced over the
course of the preceding year, and in the first quarter of 1998, $8.1 million in
debt will become due. The Company's management believes that it will be able to
refinance or repay the debt through a new loan facility, alternative debt or
equity financing, asset or division sale, technology transfer or other
arrangement, but there can be no assurance to this effect. The Company's
leverage and debt service requirements could affect its ability to grow and its
level of profitability.
Search for Strategic Alternatives. The Company has engaged Smith Barney and
Rauscher Pierce Refsnes to seek strategic alternatives to enhance shareholder
value. Although management is optimistic that it will identify an alternative to
pursue, there are many risks and uncertainties inherent in such a process and
there can be no assurance that a strategic alternative will be identified or, if
identified, will be implemented successfully.
Product Development and Market Acceptance. The Company's growth depends in
part on the development and market acceptance of new products, including the MPS
system and related products and next generation ANS products. There is no
assurance that the Company will continue to develop successful products, that
delays in product introduction will not be experienced, or that once such
products are introduced, the market will accept them. In addition, while
management believes that offering the MPS system on a one-year rental basis and
a lease/purchase basis should accelerate the placement of MPS units and related
disposables, there can be no assurance to this effect.
Government Regulation. The Company's business is subject to extensive
government regulation, principally by the FDA. The regulatory process,
especially as it relates to product approvals, can be lengthy, expensive and
uncertain.
Competition and Technological Change. The medical device market is highly
competitive. The Company competes with many larger companies that have access to
greater capital, research and development, marketing, distribution and other
resources than the Company. In addition, this market is characterized by
extensive research efforts and rapid product development and technological
change, which could render the Company's products obsolete or noncompetitive.
Intellectual Property Rights. The Company relies in part on patents, trade
secrets and proprietary technology to remain competitive. It may be necessary to
defend these rights or to defend against claims that
21
<PAGE> 23
the Company is infringing the rights of others. Intellectual property litigation
and controversies are disruptive and expensive.
Cost Pressures on Medical Technology. The overall escalating cost of
medical products and healthcare results in significant cost pressure. Third
party payors are under intense pressure to challenge the prices charged for
medical products and services.
Potential Product Liability. The testing, manufacturing, marketing and sale
of medical devices entail substantial risks of liability claims or product
recalls.
Other Uncertainties. Other operating, financial or legal risks or
uncertainties are discussed in this Form 10-K in specific contexts and in the
Company's other periodic SEC filings. The Company is, of course, also subject to
general economic risks, the risk of interruption in the source of supply, the
risk of loss of a major customer, dependence on key personnel and other risks
and uncertainties.
CURRENCY FLUCTUATIONS
Substantially all of the Company's international sales are denominated in
U.S. dollars. Fluctuations in currency exchange rates in other countries could
reduce the demand for the Company's products by increasing the price of the
Company's products in the currency of the countries in which the products are
sold, although management does not believe currency fluctuations have had a
material effect on the Company's results of operations to date.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information required by this item is set forth in Appendices A and C.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information required by this item is contained under the captions
"Election of Directors" and "Executive Officers" in the definitive proxy
material of the Company to be filed in connection with its 1997 annual meeting
of stockholders, which information is incorporated herein by reference.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item is contained under the captions
"Compensation and Committees of the Board of Directors" and "Compensation of
Executive Officers" in the definitive proxy material of the Company to be filed
in connection with its 1997 annual meeting of stockholders, which information is
incorporated herein by reference. Information under the caption titled "Report
of the Board of Directors on Annual Compensation" and "Performance Graph" is not
incorporated by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT
The information required by this item is contained under the caption
"Security Ownership of Management and Principal Shareholders" in the definitive
proxy material of the Company to be filed in connection with its 1997 annual
meeting of stockholders, which information is incorporated herein by reference.
22
<PAGE> 24
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this item is contained under the caption
"Certain Relationships and Related Transactions" in the definitive proxy
material of the Company to be filed in connection with its 1997 annual meeting
of stockholders, which information is incorporated herein by reference.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) 1. Financial Statements:
See Index to Financial Statements on the second page of Appendix A.
2. Financial Statement Schedules:*
Schedule II -- Valuation and Qualifying Accounts.
See Appendix B.
* Those schedules not listed above are omitted as not applicable or
not required.
3. Exhibits: See (c) below.
(b) Reports on Form 8-K:
None
(c) Exhibits:
<TABLE>
<C> <S>
2.1 -- Agreement for the Purchase and Sale of All of the Issued
Capital Stock of Neuromed, Inc. dated February 10, 1995,
between Quest Medical, Inc. and William N. Borkan(5)
2.2 -- Amendment Agreement dated March 17, 1995, between Quest
Medical, Inc. and William N. Borkan(5)
2.3 -- Letter Agreement dated as of September 23, 1995, by and
between Quest Medical, Inc. and William N. Borkan(6)
3.1 -- Articles of Incorporation, as amended(6)
3.2 -- Bylaws(1)
4.1 -- Rights Agreement dated as of August 30, 1996, between
Quest Medical, Inc. and KeyCorp Shareholder Services,
Inc. as Rights Agent(7)
10.1 -- Quest Medical, Inc. 1979 Amended and Restated Employees
Stock Option Plan(2)
10.2 -- Form of 1979 Employees Stock Option Agreement(3)
10.3 -- Quest Medical, Inc. Directors Stock Option Plan (as
amended)(2)
10.4 -- Form of Directors Stock Option Agreement(1)
10.5 -- Quest Medical, Inc. 1987 Stock Option Plan(6)
10.6 -- Form of 1987 Employee Stock Option Agreement(6)
10.7 -- Quest Medical, Inc. 1995 Stock Option Plan(6)
10.8 -- Form of 1995 Employee Stock Option Agreement(6)
10.9 -- Form of Employment Agreement and Covenant Not to Compete,
between the Company and key employees(1)
10.10 -- Promissory Note dated December 28, 1993, between Quest
Medical, Inc. and MetLife Capital Financial
Corporation(4)
10.11 -- Commercial Deed of Trust, Security Agreement and
Assignment of Leases and Rents and Fixture Filing dated
December 28, 1993, between Quest Medical, Inc. and
MetLife Capital Financial Corporation(4)
</TABLE>
23
<PAGE> 25
<TABLE>
<S> <C>
10.12 -- Term Promissory Note dated December 28, 1993, between
Quest Medical, Inc. and MetLife Capital Corporation(4)
10.13 -- Loan and Security Agreement dated December 28, 1993,
between Quest Medical, Inc. and MetLife Capital
Corporation(4)
10.14 -- Supplemental Security Agreement Number One dated December
28, 1993, between Quest Medical, Inc. and MetLife Capital
Corporation(4)
10.15 -- Third Amended and Restated Credit Agreement dated as of
March 3, 1997, between Quest Medical, Inc. and
NationsBank of Texas, N.A.(8)
10.16 -- Promissory Note (Facility A. Note) in the original
principal amount of $5,650,000 dated March 3, 1997(8)
10.17 -- Promissory Note (Facility B. Note) in the original
principal amount of $350,000 dated March 3, 1997(8)
10.18 -- First Amended and Restated Security Agreement dated March
3, 1997, between Quest Medical, Inc. and NationsBank of
Texas, N.A.(8)
10.19 -- First Amended and Restated Security Agreement dated March
3, 1997, between Advanced Neuromodulation Systems, Inc.
and NationsBank of Texas, N.A.(8)
10.20 -- First Amended and Restated Intellectual Property Security
Agreement and Assignment dated as of March 3, 1997,
between Quest Medical, Inc. and NationsBank of Texas
N.A.(8)
10.21 -- First Amended and Restated Intellectual Property Security
Agreement and Assignment dated as of March 3, 1997,
between Advanced Neuromodulation Systems, Inc. and
NationsBank of Texas, N.A.(8)
10.22 -- First Amended and Restated License Agreement dated as of
March 3, 1997, between Quest Medical, Inc. and
NationsBank of Texas, N.A.(8)
10.23 -- First Amended and Restated License Agreement dated as of
March 3, 1997, between Advanced Neuromodulation Systems,
Inc. and NationsBank of Texas, N.A.(8)
10.24 -- Guaranty of Advanced Neuromodulation Systems, Inc. in
favor of NationsBank of Texas, N.A. under the Third
Amended and Restated Credit Agreement dated as of March
3, 1997(8)
11.1 -- Computation of Earnings Per Share(8)
21.1 -- Subsidiaries(8)
23.1 -- Consent of Independent Auditors(8)
</TABLE>
- ---------------
(1) Filed as an Exhibit to the Company's Registration Statement on Form S-18,
Registration No. 2-71198-FW, and incorporated herein by reference.
(2) Filed as an Exhibit to the report of the Company on Form 10-K for the year
ended December 31, 1987, and incorporated herein by reference.
(3) Filed as an Exhibit to the Company's Registration Statement on Form S-1,
Registration No. 2-78186, and incorporated herein by reference.
(4) Filed as an Exhibit to the report of the Company on Form 10-KSB for the year
ended December 31, 1993, and incorporated herein by reference.
(5) Filed as an Exhibit to the report of the Company on Form 10-KSB for the year
ended December 31, 1994, and incorporated herein by reference.
(6) Filed as an Exhibit to the Company's Registration Statement on Form SB-2,
Registration No. 33-62991, and incorporated herein by reference.
(7) Filed as an Exhibit to the report of the Company on Form 8-K dated September
3, 1996, and incorporated herein by reference.
(8) Filed herewith.
24
<PAGE> 26
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Company has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Date: March 28, 1997
QUEST MEDICAL, INC.
By: /s/ THOMAS C. THOMPSON
----------------------------------
Thomas C. Thompson,
President
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed by the following persons on behalf of the Company and in
the capacities and on the dates indicated:
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<C> <S> <C>
/s/ THOMAS C. THOMPSON President and Director of Quest March 28, 1997
- ----------------------------------------------------- Medical, Inc. (Principal
Thomas C. Thompson Executive Officer)
/s/ F. ROBERT MERRILL III Senior Vice March 28, 1997
- ----------------------------------------------------- President -- Finance,
F. Robert Merrill III Secretary and Treasurer of
Quest Medical, Inc.
(Principal Financial and
Accounting Officer)
Director of Quest Medical, Inc. March 28, 1997
- -----------------------------------------------------
Linton E. Barbee
Director of Quest Medical, Inc. March 28, 1997
- -----------------------------------------------------
Robert C. Eberhart
/s/ HUGH M. MORRISON Director of Quest Medical, Inc. March 28, 1997
- -----------------------------------------------------
Hugh M. Morrison
/s/ RICHARD D. NIKOLAEV Director of Quest Medical, Inc. March 28, 1997
- -----------------------------------------------------
Richard D. Nikolaev
/s/ MICHAEL J. TORMA Director of Quest Medical, Inc. March 28, 1997
- -----------------------------------------------------
Michael J. Torma
</TABLE>
25
<PAGE> 27
APPENDIX A
CONSOLIDATED FINANCIAL STATEMENTS
INDEPENDENT AUDITORS' REPORT
THREE YEARS ENDED DECEMBER 31, 1996
FORMING A PART OF THE ANNUAL REPORT
FORM 10-K
ITEM 8
OF
QUEST MEDICAL, INC. AND SUBSIDIARIES
(NAME OF ISSUER)
FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
UNDER
THE SECURITIES AND EXCHANGE ACT OF 1934
<PAGE> 28
QUEST MEDICAL, INC. AND SUBSIDIARIES
TABLE OF CONTENTS
TO
CONSOLIDATED FINANCIAL STATEMENTS
FORM 10-K -- ITEM 8
<TABLE>
<S> <C>
INDEPENDENT AUDITORS' REPORT................................
CONSOLIDATED FINANCIAL STATEMENTS:
Consolidated Balance Sheets -- December 31, 1996 and 1995...
Consolidated Statements of Operations -- Three years ended
December 31, 1996.........................................
Consolidated Statements of Stockholders' Equity -- Three
years ended December 31, 1996.............................
Consolidated Statements of Cash Flows -- Three years ended
December 31, 1996.........................................
Notes to Consolidated Financial Statements..................
</TABLE>
A-1
<PAGE> 29
REPORT OF INDEPENDENT AUDITORS
The Board of Directors
Quest Medical, Inc.
We have audited the accompanying consolidated balance sheets of Quest
Medical, Inc. and subsidiaries (the Company) as of December 31, 1996 and 1995,
and the related consolidated statements of operations, stockholders' equity, and
cash flows for each of the three years in the period ended December 31, 1996.
Our audit also included the financial statement schedule listed in the Index at
Item 14A. These consolidated financial statements and schedule are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements and schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of Quest Medical,
Inc. and subsidiaries at December 31, 1996 and 1995, and the consolidated
results of their operations and their cash flows for each of the three years in
the period ended December 31, 1996, in conformity with generally accepted
accounting principles. Also, in our opinion, the related financial statement
schedule, when considered in relation to the basic financial statements taken as
a whole, presents fairly in all material respects the information set forth
therein.
/s/ ERNST & YOUNG LLP
------------------------------------
ERNST & YOUNG LLP
Dallas, Texas
March 14, 1997
A-2
<PAGE> 30
QUEST MEDICAL INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 1996 AND 1995
ASSETS
<TABLE>
<CAPTION>
1996 1995
----------- -----------
<S> <C> <C>
Current assets:
Cash and cash equivalents................................. $ 696,196 $ 1,325,630
Marketable securities..................................... 1,366,089 2,588,547
Receivables:
Trade accounts, less allowance for doubtful accounts of
$174,337 in 1996 and $114,337 in 1995................. 4,829,827 4,955,235
Net investment in sales-type leases.................... 176,875 --
Interest and other..................................... 134,162 128,492
----------- -----------
Total receivables...................................... 5,140,864 5,083,727
----------- -----------
Inventories:
Raw materials.......................................... 3,931,282 2,743,702
Work-in-process........................................ 1,400,712 1,077,529
Finished goods......................................... 3,032,600 2,285,961
----------- -----------
Total inventories...................................... 8,364,594 6,107,192
----------- -----------
Deferred income taxes..................................... 317,276 356,703
Prepaid expenses and other current assets................. 668,808 1,226,268
----------- -----------
Total current assets................................... 16,553,827 16,688,067
----------- -----------
Property, plant and equipment:
Land...................................................... 1,930,289 1,930,289
Building and improvements................................. 5,296,125 5,271,718
Furniture and fixtures.................................... 3,827,738 2,964,471
Machinery and equipment................................... 4,962,846 3,879,802
----------- -----------
16,016,998 14,046,280
Less accumulated depreciation and amortization............ 4,832,468 3,784,510
----------- -----------
Net property, plant and equipment...................... 11,184,530 10,261,770
----------- -----------
Cost in excess of net assets acquired, net of accumulated
amortization of $817,784 in 1996 and $340,300 in 1995..... 10,931,849 9,546,298
Patents, net of accumulated amortization of $1,311,556 in
1996 and $1,086,433 in 1995............................... 4,063,843 1,288,966
Purchased technology from acquisitions, net of accumulated
amortization of $730,775 in 1996 and $413,558 in 1995..... 3,967,225 4,284,442
Tradenames, net of accumulated amortization of $218,750 in
1996 and $93,750 in 1995.................................. 2,281,250 2,406,250
Other assets, net of accumulated amortization of $190,000 in
1996 and $178,667 in 1995................................. 9,931 19,964
----------- -----------
$48,992,455 $44,495,757
=========== ===========
</TABLE>
See accompanying notes to consolidated financial statements.
A-3
<PAGE> 31
QUEST MEDICAL INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 1996 AND 1995
LIABILITIES AND STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
1996 1995
----------- -----------
<S> <C> <C>
Current liabilities:
Accounts payable.......................................... $ 2,269,269 $ 1,210,265
Short-term notes payable and current maturities of
long-term notes payable................................ 2,084,122 1,616,311
Accrued salary and employee benefit costs................. 924,309 630,908
Accrued relocation costs.................................. -- 291,370
Other accrued expenses.................................... 188,605 755,976
----------- -----------
Total current liabilities......................... 5,466,305 4,504,830
----------- -----------
Notes payable............................................... 11,912,036 8,558,297
Deferred income taxes....................................... 620,631 562,580
Commitments and contingencies
Stockholders' equity:
Common stock, $.05 par value.
Authorized 25,000,000 shares in 1996 and 10,000,000
shares in 1995; issued 8,338,510 shares in 1996 and
8,147,349 shares in 1995.............................. 416,926 407,367
Additional capital........................................ 38,699,517 38,253,670
Retained earnings (deficit)............................... (7,992,082) (7,579,925)
Unrealized loss on marketable securities net of tax
benefit of $67,423 in 1996 and $108,729 in 1995........ (130,878) (211,062)
----------- -----------
Total stockholders' equity........................ 30,993,483 30,870,050
----------- -----------
$48,992,455 $44,495,757
=========== ===========
</TABLE>
See accompanying notes to consolidated financial statements.
A-4
<PAGE> 32
QUEST MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31
<TABLE>
<CAPTION>
1996 1995 1994
----------- ------------ -----------
<S> <C> <C> <C>
Net revenue......................................... $26,073,808 $ 25,320,990 $13,999,165
Cost of revenue..................................... 11,005,260 10,624,215 7,617,932
----------- ------------ -----------
Gross profit.............................. 15,068,548 14,696,775 6,381,233
----------- ------------ -----------
Operating expenses:
General and administrative........................ 5,027,749 4,199,398 3,063,296
Research and development.......................... 3,342,626 4,582,868 3,542,193
Purchased research and development................ -- 10,500,000 --
Marketing......................................... 6,597,983 4,195,972 1,913,793
----------- ------------ -----------
14,968,358 23,478,238 8,519,282
----------- ------------ -----------
Earnings (loss) from operations........... 100,190 (8,781,463) (2,138,049)
Other income (expense):
Gain on sale of marketable securities............. 136,975 29,115 464,113
Interest expense.................................. (766,769) (1,657,818) (569,428)
Investment and other income, net.................. 200,322 460,282 524,171
----------- ------------ -----------
(429,472) (1,168,421) 418,856
----------- ------------ -----------
Loss before income taxes and extraordinary
item.................................... (329,282) (9,949,884) (1,719,193)
Income taxes........................................ 82,875 155,114 --
----------- ------------ -----------
Loss before extraordinary item............ (412,157) (10,104,998) (1,719,193)
Extraordinary item -- loss on early extinguishment
of debt, net of income tax benefit of $138,599.... -- (269,045) --
----------- ------------ -----------
Net loss.................................. $ (412,157) $(10,374,043) $(1,719,193)
=========== ============ ===========
Per common and common equivalent share:
Loss before extraordinary item.................... $ (.05) $ (1.52) $ (.33)
=========== ============ ===========
Extraordinary item................................ $ -- $ (.04) $ --
=========== ============ ===========
Net loss.......................................... $ (.05) $ (1.56) $ (.33)
=========== ============ ===========
</TABLE>
See accompanying notes to consolidated financial statements.
A-5
<PAGE> 33
QUEST MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31
<TABLE>
<CAPTION>
1996 1995 1994
----------- ------------ -----------
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss......................................... $ (412,157) $(10,374,043) $(1,719,193)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation.................................. 1,047,958 952,935 761,174
Amortization.................................. 1,156,157 922,454 362,771
Extraordinary item: write off of debt issuance
costs....................................... -- 407,644 --
Deferred income taxes......................... 97,478 200,002 --
Non-operating gains included in net loss...... (139,030) (137,898) (464,113)
Purchased research and development............ -- 10,500,000 --
Changes in assets and liabilities, net of
effects of acquisition:
Receivables................................. (57,137) (2,020,213) 387,347
Inventories................................. (2,257,402) (557,095) 22,471
Prepaid expenses............................ 415,289 (750,284) (128,770)
Accounts payable............................ 700,679 (346,134) (325,167)
Accrued expenses............................ (998,289) (340,966) (304,894)
Other....................................... -- 9,720 (39,701)
----------- ------------ -----------
Net cash used in operating activities.... (446,454) (1,533,878) (1,448,075)
----------- ------------ -----------
Cash flows from investing activities:
Net proceeds from marketable securities
transactions.................................. 1,480,924 3,317,881 1,346,903
Additions to property, plant and equipment....... (1,972,300) (1,468,732) (1,076,871)
Additions to patents............................. (3,000,000) -- --
Acquisition, net of cash acquired................ -- (15,996,910) --
Other............................................ 3,637 6,550 19,510
----------- ------------ -----------
Net cash provided by (used in) investing
activities............................. (3,487,739) (14,141,211) 319,542
----------- ------------ -----------
Cash flows from financing activities:
Net increase (decrease) in short-term notes
payable....................................... (1,450,000) -- 500,000
Proceeds of long-term notes payable, net of debt
issuance costs................................ 4,450,000 16,431,233 106,978
Payment of long-term notes payable............... (150,647) (15,108,486) (121,977)
Exercise of stock options........................ 558,552 369,449 137,047
Net proceeds from public offering of common
stock......................................... -- 15,218,815 --
Redemption of rights plan........................ (103,146) -- --
Issuance (purchase) of treasury stock, net....... -- 1,745 --
----------- ------------ -----------
Net cash provided by financing
activities............................. 3,304,759 16,912,756 622,048
----------- ------------ -----------
Net increase (decrease) in cash and cash
equivalents...................................... (629,434) 1,237,667 (506,485)
Cash and cash equivalents at beginning of year..... 1,325,630 87,963 594,448
----------- ------------ -----------
Cash and cash equivalents at end of year........... $ 696,196 $ 1,325,630 $ 87,963
=========== ============ ===========
Supplemental cash flow information is presented
below:
Income taxes paid.................................. $ -- $ -- $ --
=========== ============ ===========
Interest paid (net of amounts capitalized)......... $ 668,049 $ 1,571,553 $ 558,337
=========== ============ ===========
</TABLE>
See accompanying notes to consolidated financial statements.
A-6
<PAGE> 34
QUEST MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
THREE YEARS ENDED DECEMBER 31, 1996
<TABLE>
<CAPTION>
UNREALIZED
COMMON STOCK RETAINED LOSS ON TOTAL
-------------------- ADDITIONAL EARNINGS MARKETABLE TREASURY STOCKHOLDERS'
SHARES AMOUNT CAPITAL (DEFICIT) SECURITIES STOCK EQUITY
--------- -------- ----------- ------------ ---------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1993....... 7,939,441 $396,972 $18,787,628 $ 5,430,286 $(169,308) $(6,193,796) $ 18,251,782
Shares issued upon exercise of
stock options.................. 43,057 2,153 134,894 -- -- -- 137,047
Issuance of 1,882 common shares
from treasury.................. -- -- 5,595 -- -- 4,075 9,670
Stock dividend................... -- -- 586,054 (916,975) -- 330,921 --
Adjustment to unrealized losses
on marketable securities....... -- -- -- -- (748,326) -- (748,326)
Net loss......................... -- -- -- (1,719,193) -- -- (1,719,193)
--------- -------- ----------- ------------ --------- ----------- ------------
Balance at December 31, 1994....... 7,982,498 399,125 19,514,171 2,794,118 (917,634) (5,858,800) 15,930,980
Shares issued upon exercise of
stock options.................. 160,422 8,021 361,429 -- -- -- 369,450
Issuance of 245 common shares
from treasury.................. -- -- 1,216 -- -- 529 1,745
Adjustment to unrealized losses
on marketable securities....... -- -- -- -- 706,572 -- 706,572
Issuance of 1,033,333 common
shares from treasury for
acquisition.................... -- -- 6,779,285 -- -- 2,237,246 9,016,531
Sale of treasury and new common
shares in public offering, net
of offering costs.............. 4,429 221 11,597,569 -- -- 3,621,025 15,218,815
Net loss......................... -- -- -- (10,374,043) -- -- (10,374,043)
--------- -------- ----------- ------------ --------- ----------- ------------
Balance at December 31, 1995....... 8,147,349 407,367 38,253,670 (7,579,925) (211,062) -- 30,870,050
Shares issued upon exercise of
stock options.................. 159,178 7.959 479,207 -- -- -- 487,166
Adjustment to unrealized losses
on marketable securities....... -- -- -- -- 80,184 -- 80,184
Issuance of 31,983 new common
shares for employee bonuses and
cancellation of a stock
option......................... 31,983 1,600 69,786 -- -- -- 71,386
Redemption of rights plan
dividend....................... -- -- (103,146) -- -- -- (103,146)
Net loss......................... -- -- -- (412,157) -- -- (412,157)
--------- -------- ----------- ------------ --------- ----------- ------------
Balance at December 31, 1996....... 8,338,510 $416,926 $38,699,517 $ (7,992,082) $(130,878) -- $ 30,993,483
========= ======== =========== ============ ========= =========== ============
</TABLE>
See accompanying notes to consolidated financial statements.
A-7
<PAGE> 35
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996
(1) BUSINESS
Quest Medical, Inc. and its subsidiaries (the "Company") design, develop,
manufacture and market a variety of healthcare products used primarily in
cardiovascular surgery, interventional pain management and intravenous fluid
delivery applications. The Company's revenues are derived primarily from sales
throughout the United States, Europe and Australia.
The research and development, manufacture, sale and distribution of medical
devices is subject to extensive regulation by various public agencies,
principally the Food and Drug Administration and corresponding state, local and
foreign agencies. Product approvals and clearances can be delayed or withdrawn
for failure to comply with regulatory requirements or the occurrence of
unforeseen problems following initial marketing.
In addition, the Company's products are purchased primarily by hospitals
and other users which then bill various third party payors including Medicare,
Medicaid, private insurance companies and managed care organizations. These
third party payors reimburse fixed amounts for services based on a specific
diagnosis. The impact of changes in third party payor reimbursement policies and
any amendments to existing reimbursement rules and regulations which restrict or
terminate the eligibility of the Company's products could have an adverse impact
on the Company's financial condition and results of operations.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The consolidated financial statements include the accounts of Quest
Medical, Inc. and subsidiaries. All significant intercompany balances and
transactions have been eliminated in consolidation. The preparation of financial
statements in conformity with generally accepted accounting principles requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from these
estimates.
Revenue from product sales is recognized at the time the product is
shipped.
The Company leases the Quest MPS myocardial protection system to customers
under noncancellable leases with terms of five years. The present value of the
minimum rentals to be received under such leases is recorded as net sales. The
difference between the gross rentals to be received and the present value of the
rentals is recorded as unearned finance income and is amortized into income on
the interest method over the lease term. The cost of the leased equipment is
charged to cost of sales at the time the sale is recorded. The present value of
the rentals to be received under such leases is recorded as net investment in
sales-type leases. At December 31, 1996, the balance in the net investment in
sales-type leases was $176,875.
Cash equivalents include certificates of deposit and short-term, highly
liquid debt instruments with original maturities of three months or less.
The Company's marketable equity and debt securities are classified as
available-for-sale and are carried at fair value, with the unrealized gains and
losses reported in a separate component of stockholders' equity. The amortized
cost of debt securities in this category is adjusted for amortization of
premiums and accretion of discounts to maturity. Such amortization is included
in investment income. Realized gains and losses and declines in value judged to
be other-than-temporary are included in other income. The cost of securities
sold is based on the specific identification method. Interest and dividends are
included in investment income.
Inventories are recorded at the lower of standard cost or market. Standard
cost approximates actual cost determined on the first-in, first-out (FIFO)
basis.
A-8
<PAGE> 36
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Property, plant and equipment are stated at cost. Major renewals and
betterments are capitalized; maintenance and repairs are charged to operations
as incurred. Provisions for depreciation and amortization of property, plant and
equipment are computed using the straight-line method using estimated useful
lives of 3 to 30 years.
The excess of costs over the net assets of businesses acquired is amortized
on a straight line basis over the estimated useful lives of 20 to 25 years. The
Company assesses the recoverability of this intangible asset, as well as other
intangible assets, primarily based on its current and anticipated future
undiscounted cash flows. At December 31, 1996, the Company does not believe
there has been any impairment of its intangible assets.
Cost of purchased patents is amortized on a straight-line basis over the
estimated useful lives (4 to 17 years) of such patents. Costs of patents which
are the result of internal development are charged to current operations.
The cost of purchased technology related to acquisitions is based on
appraised values at the date of acquisition and is amortized on a straight-line
basis over the estimated useful lives (10 to 15 years) of such technology.
The cost of purchased tradenames is based on appraised values at the date
of acquisition and is amortized on a straight-line basis over the estimated
useful life (20 years) of such tradenames.
Product development costs including start-up, research and development,
advertising and promotional costs are charged to operations in the year in which
such costs are incurred. Total advertising expense included in marketing was
$25,914, $84,978 and $61,388 at December 1996, 1995 and 1994, respectively.
Loss per share for 1996, 1995, and 1994 is based upon 8,531,499, 6,642,082
and 5,256,683 common and common equivalent shares outstanding, respectively.
Common stock equivalents are outstanding stock options and are included in
average common and common equivalent shares outstanding using the treasury stock
method except during periods where their effect would be antidilutive. During
1994, the Board of Directors approved a 3 percent stock dividend. The weighted
average number of common and common equivalent shares outstanding used in
computing loss per share were increased to retroactively reflect the stock
dividend.
Deferred income taxes are recorded based on the liability method and
represent the tax effect of the differences between the financial and tax basis
of assets and liabilities other than costs in excess of the net assets of
businesses acquired.
The Company has elected to follow APB No. 25, "Accounting for Stock Issued
to Employees" and related Interpretations in the primary financial statements
and to provide supplementary disclosures required by FASB Statement No. 123,
"Accounting for Stock-Based Compensation." (See Note 7.)
Certain prior period amounts have been reclassified to conform to current
year presentation.
(3) ACQUISITION
On March 31, 1995, the Company acquired for $15,403,263 cash (excluding
$1,062,414 of related acquisition and financing costs) and 833,333 shares of
Quest common stock valued at $6,458,331, all of the capital stock of Neuromed,
Inc. ("Neuromed"). The transaction also provided for contingent consideration
over the following two years, payable in a combination of cash and additional
shares of Quest common stock in January 1996 and January 1997, depending on
sales of Neuromed's products reaching certain objectives. Financing for the cash
portion of the purchase price was provided by a bank. (See Note 5.)
In July 1995, the sales objectives for 1995 were reached which triggered a
liability for the 1995 contingent consideration payments with regard to the
Neuromed acquisition. The Company recorded the additional "earn-out"
consideration of 200,000 shares of Quest common stock valued at $2,558,200 and a
$1,500,000 liability (payable in cash in January 1996). In addition, in
September 1995, the Company amended certain
A-9
<PAGE> 37
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
terms of the acquisition agreement whereby the Company agreed to accelerate
issuance of the 200,000 shares for the 1995 earn-out and the seller relinquished
certain rights from the previous agreement. The amended agreement set the 1996
contingent consideration, payable in January 1997, at a cash payment equal to
$3,370,000, if earned.
In January 1996, the Company withheld payment of the $1,500,000 pursuant to
the 1995 contingent consideration obligation pending arbitration of certain
disputes between the Company and Neuromed's former owner. In October 1996, the
sales objectives for the 1996 earn-out were reached and the Company recorded a
note payable in the amount of $3,370,000 which was due in January 1997. The
Company similarly withheld payment of this note pending arbitration. In
addition, the Company had a short-term note payable to the former owner of
Neuromed at December 31, 1996, in the amount of $972,000 due in January 1997,
related to certain purchase price adjustments (principally tax refunds and
future tax credits) awarded through an arbitration. The Company paid the
$972,000 obligation during January 1997. On February 6, 1997, the Company and
the former owner of Neuromed reached a settlement (the "Settlement") of all
issues between them. Under the terms of the Settlement, the Company agreed to
pay $500,000 in cash on March 3, 1997, and deliver a promissory note in the
amount of $1,000,000 payable on February 6, 1998, for full settlement of the
contingent considerations. The Company also agreed to pay $3,000,000 in cash on
March 3, 1997, to purchase certain patent rights from Neuromed's former owner.
(See Note 5.)
The acquisition was accounted for by the purchase method of accounting. The
allocation of the purchase price among identifiable tangible and intangible
assets was based upon a risk adjusted income approach. The cost in excess of net
assets acquired is being amortized on a straight line basis over twenty years.
Purchased in-process research and development was identified and valued
through extensive interviews and analysis of data concerning Neuromed's products
under development. Expected future cash flows for products under development
were discounted taking into account economic risks associated with the inherent
difficulties and uncertainty in completing the products, and thereby achieving
technological feasibility, and risks related to the viability of and potential
changes in future target markets. This resulted in $10,500,000 of purchased
research and development which had not yet achieved technological feasibility
and does not have alternative uses. Therefore, in accordance with generally
accepted accounting principles, the $10,500,000, with no related tax benefit,
was charged to expense during the year ended December 31, 1995.
The purchase price allocation for the acquisition of Neuromed, as of
December 31, 1996, is summarized below:
<TABLE>
<S> <C>
Tradenames.................................................. $ 2,500,000
Purchased technology........................................ 4,000,000
Cost in excess of net assets acquired....................... 10,736,427
Purchased research and development.......................... 10,500,000
Excess of liabilities over tangible assets acquired......... (1,222,986)
Deferred financing costs.................................... 468,767
-----------
$26,982,208
===========
</TABLE>
In connection with the purchase, the Company determined that the operations
of Neuromed would be relocated to the Company's facility in Allen, Texas by the
end of the first quarter of 1996. The relocation was completed during the first
quarter of 1996 and the Company incurred $1,234,335 of relocation costs which
were recorded as an adjustment to cost in excess of net assets acquired.
A-10
<PAGE> 38
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The following unaudited pro forma summary presents the results of
operations as if the acquisition had occurred on January 1, 1994. This summary
does not purport to be indicative of what would have occurred had the
acquisition been made as of this date or of results which may occur in the
future. This method of combining the companies is for the presentation of
unaudited pro forma summary results of operations. Actual statements of
operations of Quest Medical and of Neuromed have been combined from the
effective date of the acquisition forward.
<TABLE>
<CAPTION>
YEAR ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31,
1995 1994
------------ ------------
<S> <C> <C>
Pro forma revenue......................................... $27,728,289 $22,043,518
Pro forma earnings (loss) from operations................. 2,634,499 (86,467)
----------- -----------
Pro forma net earnings (loss) before extraordinary item in
1995.................................................... 584,986 (1,220,055)
----------- -----------
Pro forma net earnings (loss) per common and equivalent
share before extraordinary item in 1995................. $ .08 $ (0.20)
=========== ===========
</TABLE>
The pro forma operations information excludes the charge of $10,500,000
($1.72 per share) related to purchased in-process research and development which
was expensed at the date of acquisition.
(4) MARKETABLE SECURITIES
The following is a summary of available-for-sale securities at December 31,
1996:
<TABLE>
<CAPTION>
GROSS GROSS
UNREALIZED UNREALIZED ESTIMATED
COST GAINS LOSSES FAIR VALUE
---------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
Investment grade preferred securities... $ 622,596 $4,503 $ 45,817 $ 581,282
Publicly traded limited partnerships.... 263,004 -- 44,019 218,985
Real estate investment trusts........... 297,695 3,498 41,688 259,505
Other................................... 381,095 10 74,788 306,317
---------- ------ -------- ----------
$1,564,390 $8,011 $206,312 $1,366,089
========== ====== ======== ==========
</TABLE>
At December 31, 1996, no individual security represented more than 20
percent of the total portfolio or 1 percent of total assets. The Company did not
have any investments in derivative financial instruments at December 31, 1996.
The following is a summary of available-for-sale securities at December 31,
1995:
<TABLE>
<CAPTION>
GROSS GROSS
UNREALIZED UNREALIZED ESTIMATED
COST GAINS LOSSES FAIR VALUE
---------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
Investment grade preferred securities... $ 993,241 $ 252 $135,928 $ 857,565
Publicly traded limited partnerships.... 506,447 -- 39,697 466,750
Real estate investment trusts........... 1,031,417 11,899 96,816 946,500
Other................................... 377,233 3,884 63,385 317,732
---------- ------- -------- ----------
$2,908,338 $16,035 $335,826 $2,588,547
========== ======= ======== ==========
</TABLE>
At December 31, 1995, no individual security represented more than 15
percent of the total portfolio or 2 percent of total assets. The Company did not
have any investments in derivative financial instruments at December 31, 1995.
A-11
<PAGE> 39
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(5) CURRENT AND LONG-TERM DEBT
On March 31, 1995, the Company entered into a loan agreement (the "Loan
Agreement") with a bank providing for $15 million in senior term financing,
which was utilized to pay substantially all of the cash portion of the Neuromed
purchase price and a working capital line of up to $5 million. Borrowings under
both facilities bore interest at prime plus 125 basis points, or at the
Company's option, LIBOR plus 300 basis points. During December 1995, the Company
repaid in its entirety the senior term loan utilizing net proceeds it received
from a public offering. (See Note 7.)
At December 31, 1996 and 1995, the Company had advances in the amount of
$4,550,000 outstanding under its working capital line with a weighted average
interest rate of 7.19 percent and 7.69 percent for 1996 and 1995, respectively.
At December 31, 1996, the Company was not in compliance with certain financial
covenants in its loan agreement, but has cured the noncompliance through an
amended loan agreement described below.
On March 3, 1997, the Company amended the $5 million working capital line
of credit. Under the amended agreement, the working capital line of credit was
increased to $5,650,000 and a $350,000 term loan facility was added. Borrowings
under the working capital line of credit bear interest at prime plus 100 basis
points, or at the Company's option, LIBOR plus 275 basis points. Borrowings
under the term loan bear interest at prime plus 100 basis points, or at the
Company's option, LIBOR plus 225 basis points. The facilities are collateralized
by all of the Company's assets with the exception of the real property,
building, and equipment that collateralize the long-term financing on the Allen
facility described below. The Company is subject to certain covenants related to
the loan agreement including the maintenance of a minimum fixed charge ratio, a
maximum total liabilities to tangible net worth ratio, and a maximum margin
ratio (as defined). Under the amended agreement, the Company is prohibited from
paying cash dividends. Under the working capital line of credit, the Company is
required to make monthly payments of $90,000 with interest payable quarterly.
Under the term loan, no principal payments are due until maturity and interest
is payable quarterly. These facilities will expire on January 31, 1998. On March
3, 1997, the Company increased its borrowings under the working capital line of
credit by $1,100,000 and borrowed $350,000 under the term loan facility. These
additional borrowings were utilized to pay a portion of the debt under the
February 6, 1997 Settlement discussed below.
On February 21, 1997, the Company borrowed $2,000,000 from a shareholder
pursuant to a promissory note. The promissory note bears interest at the rate of
6 percent per annum. Under the terms of the promissory note, the Company is
required to make quarterly interest payments with a principal payment of
$2,000,000 due and payable at the maturity of the note on February 21, 1998. In
conjunction with the promissory note, the Company issued the shareholder
five-year warrants to purchase 100,000 shares of common stock at an exercise
price of $6.50 per share, the closing sales price on the date the indebtedness
was incurred. Under the warrant agreement, the shareholder has the right to one
demand registration in addition to piggyback registration rights. The loan is
subordinated to the bank debt described above and the shareholder has a second
lien on all of the assets collateralizing the bank debt. Proceeds of the loan
were utilized to pay a portion of the debt under the Settlement described below.
At December 31, 1996, the Company had a short-term, noninterest-bearing
note payable in the amount of $972,197 due in connection with certain purchase
price adjustments (primarily tax refunds and tax credits) awarded through an
arbitration to the former owner of Neuromed, Inc. The note was paid during
January 1997 from cash reserves. In addition, on February 6, 1997, the Company
reached a Settlement (the "Settlement") on all outstanding issues with the
former owner of Neuromed relating to the Neuromed acquisition. Under the
Settlement, the Company agreed to pay $4.5 million in settlement of the earn-out
provisions of the purchase agreement and the purchase of certain patent rights.
Of the Settlement, $3.5 million is an interest bearing note at 10.25 percent per
annum from February 6, 1997, and is due and payable on March 3, 1997. The
Company paid such note on March 3, 1997, utilizing proceeds from the bank debt
and shareholder debt described above. In addition, the Company issued the former
owner a promissory note in the
A-12
<PAGE> 40
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
amount of $1,000,000. The promissory note bears interest at the rate of 10
percent per annum with interest due and payable monthly and a principal payment
of $1,000,000 due and payable on February 6, 1998. The loan is subordinated to
the bank debt described above and is collateralized with a second lien that is
pari passu with the shareholder's lien.
The Company classified short-term notes payable of $8,100,000 at December
31, 1996, as long-term notes payable due to refinancings that took place during
February and March of 1997. Of such amount, $3,650,000 (excluding current
maturities of $900,000) relates to borrowings under the Company's working
capital line of credit which was amended in March 1997, and the remaining
$4,450,000 relates to the February 1997 Settlement with the former owner of
Neuromed which was financed through the amended bank agreement which provided
funds of $1,450,000, the shareholder promissory note of $2,000,000, and the
promissory note due to Neuromed's former owner of $1,000,000, all of which are
discussed above.
On December 28, 1993, the Company entered into two agreements for long-term
financing of its principal office and manufacturing facility in the amount of
$4,355,071. The first agreement, in the amount of $3,000,000, is related to the
building. This loan bore interest through 1995 at an adjustable rate based on
the 30-day commercial paper rate plus 300 basis points. Effective January 1996,
the Company fixed the rate of interest for the remainder of the term of the loan
at 8.59 percent. This note has a 25-year amortization. The Company has the
option of prepaying this note during years 6-10, subject to certain provisions.
The loan is collateralized by the Allen facility building and land and has an
unpaid balance of $2,923,260 at December 31, 1996. The second agreement, in the
amount of $1,355,071, is related to certain equipment and furnishings. This loan
bore interest through 1995 at an adjustable rate based on the 30-day commercial
paper rate plus 250 basis points. Effective January 1996, the Company fixed the
rate of interest for the remainder of the term of the loan at 7.94 percent. This
note has a 10-year amortization. This loan is collateralized by the equipment
and furnishings purchased with the proceeds and has an unpaid balance of
$1,050,702 at December 31, 1996.
Scheduled payments of current and long-term debt are as follows:
<TABLE>
<S> <C>
1997..................................................... $2,084,122
1998..................................................... $8,278,566
1999..................................................... $ 192,082
2000..................................................... $ 208,336
2001..................................................... $ 225,824
Thereafter............................................... $3,007,228
==========
</TABLE>
The carrying value of the Company's debt approximates its fair value.
A-13
<PAGE> 41
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(6) FEDERAL INCOME TAXES
The significant components of the net deferred tax liability at December
31, were as follows:
<TABLE>
<CAPTION>
1996 1995
----------- -----------
<S> <C> <C>
Deferred tax assets:
Tax credit and net operating loss carry forwards........ $ 2,631,362 $ 2,119,781
Accrued expenses and reserves........................... 344,915 377,302
Unrealized loss on marketable securities................ 67,422 108,729
Valuation allowance..................................... (858,835) (271,767)
----------- -----------
Total deferred tax asset........................ 2,184,864 2,334,045
Deferred tax liabilities:
Purchased intangible assets............................. (1,976,958) (2,110,125)
Excess of tax over book depreciation.................... (335,368) (259,361)
Other................................................... (175,893) (170,436)
----------- -----------
Total deferred tax liability.................... (2,488,219) (2,539,922)
----------- -----------
Net deferred tax liability...................... $ (303,355) $ (205,877)
=========== ===========
</TABLE>
At December 31, 1996 and 1995, $688,895 and $271,767, respectively, of the
total valuation allowance is attributable to stock option deductions which, when
realized, will be credited to additional capital. The additional valuation
allowance at December 31, 1996, is for certain tax credit carryforwards related
to the Neuromed acquisition. During 1996, the valuation allowance increased by
$587,068. During 1995, the valuation allowance decreased by $1,473,323 which was
recorded as a reduction of costs in excess of net assets acquired because the
decrease resulted from deferred tax liabilities recorded in connection with the
acquisition of Neuromed.
The provision for income taxes for the years ended December 31 consists of
the following amounts:
<TABLE>
<CAPTION>
1996 1995 1994
-------- -------- --------
<S> <C> <C> <C>
Current.............................................. $(14,603) $(44,888) $ --
Deferred............................................. 97,478 200,002 --
-------- -------- --------
$ 82,875 $155,114 $ --
======== ======== ========
</TABLE>
A reconciliation of the provision for taxes on the loss before
extraordinary item, to the benefit calculated at the U.S. statutory rate
follows:
<TABLE>
<CAPTION>
1996 1995 1994
--------- ----------- ---------
<S> <C> <C> <C>
Federal income tax benefit at statutory rate... $(111,956) $(3,382,961) $(584,526)
Tax effect of:
Tax exempt interest.......................... (11,734) (19,949) (52,862)
Nondeductible amortization of goodwill....... 163,258 81,855 13,856
Recognition of research and development tax
credit benefit............................ -- (109,135) --
Nondeductible writeoff of purchased
in-process research and development....... -- 3,570,000 --
Benefit of net operating loss not
recognized................................ -- -- 637,308
Other........................................ 43,307 15,304 (13,776)
--------- ----------- ---------
Income tax expense................... $ 82,875 $ 155,114 $ --
========= =========== =========
</TABLE>
A-14
<PAGE> 42
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
At December 31, 1996, general business credits of $1,008,523 and
alternative minimum tax credits of $152,620 are available to offset future tax
liabilities. If unused, the general business credits expire in various amounts
beginning in 1997 through 2010.
(7) STOCKHOLDERS' EQUITY
On August 26, 1996, the Board of Directors voted to redeem the Company's
then outstanding stock purchase rights at $0.01 per share. The redemption price
for the outstanding rights was paid on September 27, 1996 to shareholders of
record as of September 12, 1996.
Also on August 26, 1996, the Board of Directors adopted a new Shareholder's
Rights Plan in which rights to purchase shares of the Company's common stock
were distributed as a dividend, one right per share, to shareholders of record
as of September 12, 1996. The rights are not exercisable or transferable apart
from the common stock until ten business days following the date that a person
or group acquires more than 15 percent of the Company's common stock or
announces a tender or exchange offer for more than 20 percent of the Company's
common stock. Upon becoming exercisable, each right entitles the holders to
purchase one share of common stock for $30.00. If the rights become exercisable
because a person or group acquires more than 15 percent of the common stock (an
"Acquiring Person"), however, the purchase price and number of shares
purchasable will be adjusted so that the holder will have the right to receive,
upon the exercise of the right at the applicable exercise price, that number of
shares of the Company's common stock having a market value equal to two times
the applicable exercise price of the right. If the Company is acquired in a
merger or other business combination transaction, or 50 percent or more of its
consolidated assets or earning power are sold, provision will be made so that
each holder of a right will have the right to receive, upon the exercise of the
right at the applicable exercise price, that number of shares of the acquiring
company's common stock having a market value of two times the applicable
exercise price of the right. Until a right is exercised, the holder of a right,
as such, will have no rights as a stockholder of the Company, including, without
limitation, the right to vote as a stockholder or receive dividends. Under the
Rights Plan, the number of shares issuable upon exercise of the rights is
subject to adjustment by the Company to prevent dilution. After a person becomes
an Acquiring Person, the Company's board of directors may exchange the rights,
other than those owned by the Acquiring Person, in whole or in part, at an
exchange ratio of one share of common stock per right, subject to adjustment.
The rights may be redeemed in whole by the Company at a price of $0.01 per right
at any time prior to their expiration on September 12, 2006, or prior to the
point at which they become exercisable.
The Company has various stock option plans pursuant to which stock options
may be granted to key employees and officers (the "Employees' Plans") and one
plan under which directors and advisory directors of the Company may be granted
options (the "Directors' Plan"). The most recent of the Employees' Plans was
adopted and approved by shareholders of the Company during 1995 (the "1995
Plan") which reserved for issuance 250,000 shares of Common Stock; provided,
however, that on January 1 of each year (commencing in 1996), the aggregate
number of shares of Common Stock reserved for issuance under the 1995 Plan shall
be increased by the same percentage that the total number of issued and
outstanding shares of Common Stock increased from the preceding January 1 to the
following December 31 (if such percentage is positive). On January 1, 1996,
pursuant to this provision, the Company added 136,000 shares to the 1995 Plan.
All options outstanding under the Employees' Plans and Directors' Plan are
nonqualified stock options, however, the 1995 Plan allows for the grant of
incentive stock options intended to qualify for preferential tax treatment under
Section 422 of the Internal Revenue Code of 1986. Under all of the Company's
plans, the exercise price of all options granted must equal or exceed the fair
market value of the Common Stock at the time of the grant. Options granted under
the Employees' Plans expire ten years from the date of grant and for the most
part are exercisable one-fourth each year over a four-year period of continuous
service. Options under the Directors' Plan expire six years from the date of
grant and for the most part are exercisable one-fourth each year over a
four-year period of continuous service. Certain options under both the
Employees' Plans and Directors' Plan,
A-15
<PAGE> 43
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
however, have a special two-year vesting schedule. These options are exercisable
one-half each year over a two-year period.
At December 31, 1996, under all of the Company's stock option plans,
1,175,188 shares have been granted and are outstanding, 1,091,715 shares of
Common Stock have been issued upon exercise, and 55,409 shares were reserved for
future grants.
Data with respect to stock option plans of the Company are as follows:
<TABLE>
<CAPTION>
EXERCISABLE
OPTIONS OUTSTANDING OPTIONS
- ----------------------------------------------------------------------- -------------------
WEIGHTED WEIGHTED
AVERAGE AVERAGE
EXERCISE EXERCISE
SHARES PRICE SHARES PRICE
--------- -------- ------- --------
<S> <C> <C> <C> <C>
January 1, 1994................................. 894,455 $2.90
Granted......................................... 252,444 $4.68
3% stock dividend............................... 31,709 --
Exercised....................................... (43,057) $3.18
Rescinded....................................... (47,548) $3.23
--------- -----
December 31, 1994............................... 1,088,003 $3.25 488,590 $2.50
------- -----
Granted......................................... 239,520 $8.11
Exercised....................................... (160,422) $2.30
Rescinded....................................... (40,540) $4.11
--------- -----
December 31, 1995............................... 1,126,561 $4.33 622,226 $2.84
------- -----
Granted......................................... 323,000 $8.12
Exercised....................................... (159,178) $3.06
Rescinded....................................... (115,195) $8.36
--------- -----
December 31, 1996 1,175,188 $5.16 663,459 $3.51
--------- ----- ------- -----
</TABLE>
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING AT EXERCISABLE OPTIONS AT
DECEMBER 31, 1996 DECEMBER 31, 1996
- ------------------------------------------------------------------------- ---------------------------
WEIGHTED
AVERAGE WEIGHTED AVERAGE WEIGHTED AVERAGE
RANGE OF REMAINING LIFE EXERCISE EXERCISE
EXERCISE PRICE SHARES (YEARS) PRICE SHARES PRICE
-------------- --------- -------------- ---------------- ------- ----------------
<S> <C> <C> <C> <C> <C>
$1.45 -- 2.25........ 223,831 2.41 $1.78 223,831 $ 1.78
$2.25 -- 3.50........ 78,893 4.46 $3.17 78,893 $ 3.17
$3.50 -- 5.25........ 411,064 5.27 $4.11 297,910 $ 3.97
$5.25 -- 8.00........ 303,400 7.28 $6.63 47,200 $ 6.71
$8.00 -- 12.25........ 158,000 8.44 $10.74 15,625 $11.27
--------- ---- ------ ------- -------
1,175,188 5.62 $5.15 663,459 $ 3.51
========= ==== ====== ======= =======
</TABLE>
A-16
<PAGE> 44
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
In accordance with APB No. 25, the Company records no compensation expense
for its stock option awards. As required by SFAS No. 123, the Company provides
the following disclosure of hypothetical values for these awards. The
weighted-average fair value of an option granted in 1996 and 1995, was $3.09 and
$3.01, respectively. For purposes of fair market value disclosures, the fair
market value of an option grant was estimated using the Black-Scholes option
pricing model with the following assumptions:
<TABLE>
<CAPTION>
1996 1995
---- ----
<S> <C> <C>
Risk-free interest rate..................................... 6.0% 6.2%
Average life of options (years)............................. 3.0 3.0
Volatility.................................................. 48.4% 48.4%
Dividend Yield.............................................. -- --
</TABLE>
Had the compensation expense been recorded based on these hypothetical
values, pro forma net loss for 1996 and 1995 would have been $(541,855) and
$(10,466,956), respectively, and pro forma net loss per common share for 1996
and 1995 would have been $(.06) and $(1.58), respectively.
In the fourth quarter of 1995, the Company sold 1,676,667 shares in a
public offering. Net proceeds to the Company were $15.2 million, of which $13.9
million was used to repay the senior-term bank debt incurred in connection with
the Neuromed acquisition. Net loss per share would have been ($1.28) if this
transaction had occurred on March 31, 1995, the date at which the debt incurred
in connection with the Neuromed acquisition was first outstanding.
(8) COMMITMENTS AND CONTINGENCIES
The Company has no material commitments under noncancellable operating
leases. Total rent expense under operating leases for the years ended December
31, 1996, 1995, and 1994 was $47,476, $127,113 and $24,930, respectively.
As a consequence of the Neuromed Acquisition in March 1995, the Company is
a party to product liability claims related to SCS devices sold by Neuromed
prior to the acquisition. Product liability insurers have assumed responsibility
for defending the Company against these claims, subject to reservation of rights
in certain cases. While historically product liability claims against Neuromed
have not resulted in significant monetary liability for Neuromed beyond its
insurance coverage, there can be no assurances that the Company will not incur
significant monetary liability to the claimants if such insurance is unavailable
or inadequate for any reason, or that the Company's SCS business and new SCS
product lines will not be adversely affected by these product liability claims.
Except for such product liability claims and other ordinary routine
litigation incidental or immaterial to its business, the Company is not
currently a party to any other pending legal proceeding. The Company maintains
general liability insurance against risks arising out of the normal course of
business.
(9) FINANCIAL INSTRUMENTS, RISK CONCENTRATION, AND MAJOR CUSTOMERS
In the United States, the Company's accounts receivable are due primarily
from hospitals and distributors located throughout the country. Internationally,
the Company's accounts receivable are due primarily from distributors located in
Europe and Australia. The Company generally does not require collateral for
trade receivables. The Company maintains an allowance for doubtful accounts
based upon expected collectibility. Any losses from bad debts have historically
been within management's expectations.
Net sales to a major customer for each of the years ended December 31, as a
percentage of total net revenues were as follows: 1996 -- 10 percent, 1995 -- 10
percent, and 1994 -- 19 percent. Foreign sales, primarily in Europe and
Australia, for the years ended December 31, 1996 and 1995 were approximately 14
percent and 12 percent of total net revenue, respectively.
A-17
<PAGE> 45
QUEST MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(10) EMPLOYEE BENEFIT PLANS
The Company has a defined contribution retirement savings plan (the "Plan")
available to substantially all employees. The Plan permits employees to elect
salary deferral contributions of up to 15 percent of their compensation and
requires the Company to make matching contributions equal to 50 percent of the
participants' contributions, to a maximum of 6 percent of the participants'
compensation. The expense of the Company's contribution was $176,858 in 1996,
$142,485 in 1995, and $102,961 in 1994.
(11) SUBSEQUENT EVENT
On March 10, 1997, the Company announced that the Company's Board of
Directors has engaged Smith Barney and Rauscher Pierce Refsnes to seek strategic
alternatives to enhance shareholder value. These strategic alternatives may
include a merger, sale of assets, other business combination, or a joint venture
or strategic alliance.
A-18
<PAGE> 46
APPENDIX B
SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS
FORMING A PART OF THE ANNUAL REPORT
FORM 10-K
ITEM 14
OF
QUEST MEDICAL, INC. AND SUBSIDIARIES
(NAME OF ISSUER)
FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
UNDER
THE SECURITIES AND EXCHANGE ACT OF 1934
<PAGE> 47
SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS
QUEST MEDICAL, INC. AND SUBSIDIARIES
DECEMBER 31, 1996
<TABLE>
<CAPTION>
BALANCE AT CHARGED BALANCE
BEGINNING CHARGED TO TO OTHER AT END OF
DESCRIPTION OF PERIOD EXPENSES ACCOUNTS DEDUCTIONS PERIOD
----------- ---------- ---------- -------- ---------- ---------
<S> <C> <C> <C> <C> <C>
Year ended December 31, 1996:
Allowance for doubtful accounts.... $114,337 $ 60,000 $ -- $ -- $174,337
Reserve for obsolete inventory..... 238,679 12,100 -- 20,307(1) 230,472
-------- -------- -------- ------- --------
Total...................... $353,016 $ 72,100 $ -- $20,307 $404,809
======== ======== ======== ======= ========
Year ended December 31, 1995:
Allowance for doubtful accounts.... $ 14,337 $ -- $100,000(2) $ -- $114,337
Reserve for obsolete inventory..... -- 238,679 -- -- 238,679
-------- -------- -------- ------- --------
Total...................... $ 14,337 $238,679 $100,000 $ -- $353,016
======== ======== ======== ======= ========
Year ended December 31, 1994:
Allowance for doubtful accounts.... $ 14,337 $ -- $ -- $ -- $ 14,337
Reserve for obsolete inventory..... 53,927 29,197 -- 83,124(1) --
-------- -------- -------- ------- --------
Total...................... $ 68,264 $ 29,197 $ -- $83,124 $ 14,337
======== ======== ======== ======= ========
</TABLE>
- ---------------
(1) Obsolete inventory written off, net of recoveries.
(2) Addition to reserve is result of purchase of Neuromed, Inc.
B-1
<PAGE> 48
APPENDIX C
QUARTERLY FINANCIAL DATA
(UNAUDITED)
FORMING A PART OF THE ANNUAL REPORT
FORM 10-K
ITEM 8
OF
QUEST MEDICAL, INC. AND SUBSIDIARIES
(NAME OF ISSUER)
FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
UNDER
THE SECURITIES AND EXCHANGE ACT OF 1934
<PAGE> 49
<TABLE>
<CAPTION>
1ST 2ND 3RD 4TH
---------- ------------ ---------- ----------
<S> <C> <C> <C> <C>
1996
Net revenue............................. $6,149,126 $ 6,669,619 $6,486,521 $6,768,542
Gross profit............................ 3,496,976 3,931,915 3,786,638 3,853,019
Earnings (loss) from operations......... 24,796 217,978 124,249 (266,833)
Earnings (loss) before income taxes..... (76,225) 122,675 35,564 (411,296)
Net earnings (loss)..................... $ (94,572) $ 114,323 $ 6,748 $ (438,656)
---------- ------------ ---------- ----------
Net earnings (loss) per common and
common equivalent share............... $ (.01) $ .01 $ -- $ (.05)
</TABLE>
<TABLE>
<CAPTION>
1ST 2ND(1)(2) 3RD 4TH(3)
---------- ------------ ---------- ----------
<S> <C> <C> <C> <C>
1995
Net revenue............................. $4,071,640 $ 7,231,494 $6,818,923 $7,198,933
Gross profit............................ 2,044,288 4,348,356 3,968,885 4,335,246
Earnings (loss) from operations......... (336,944) (9,775,378) 543,507 787,352
Earnings (loss) before income taxes..... (364,598) (10,248,708) 90,541 572,881
Earnings (loss) before extraordinary
item.................................. (364,598) (10,248,708) 90,541 417,767
Extraordinary item -- loss on early
extinguishment of debt................ -- -- -- (269,045)
Net earnings (loss)..................... $ (364,598) $(10,248,708) $ 90,541 $ 148,722
---------- ------------ ---------- ----------
Per common and common equivalent share:
Net earnings (loss) before extraordinary
item.................................. $ (.07) $ (1.66) $ .01 $ .05
Extraordinary item...................... -- -- -- (.03)
---------- ------------ ---------- ----------
Net earnings (loss)..................... $ (.07) $ (1.66) $ .01 $ .02
========== ============ ========== ==========
</TABLE>
- ---------------
(1) Includes results of Neuromed, Inc. from April 1, 1995 (See Note 3)
(2) Includes a charge of $10,500,000 for purchased in-process research and
development incurred in connection with the acquisition of Neuromed, Inc.
(See Note 3)
(3) Extraordinary item of $269,045 (net of income tax benefit of $138,599) from
write-off of capitalized debt issuance costs due to repayment of bank debt.
C-1
<PAGE> 50
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<C> <S>
2.1 -- Agreement for the Purchase and Sale of All of the Issued
Capital Stock of Neuromed, Inc. dated February 10, 1995,
between Quest Medical, Inc. and William N. Borkan(5)
2.2 -- Amendment Agreement dated March 17, 1995, between Quest
Medical, Inc. and William N. Borkan(5)
2.3 -- Letter Agreement dated as of September 23, 1995, by and
between Quest Medical, Inc. and William N. Borkan(6)
3.1 -- Articles of Incorporation, as amended(6)
3.2 -- Bylaws(1)
4.1 -- Rights Agreement dated as of August 30, 1996, between
Quest Medical, Inc. and KeyCorp Shareholder Services,
Inc. as Rights Agent(7)
10.1 -- Quest Medical, Inc. 1979 Amended and Restated Employees
Stock Option Plan(2)
10.2 -- Form of 1979 Employees Stock Option Agreement(3)
10.3 -- Quest Medical, Inc. Directors Stock Option Plan (as
amended)(2)
10.4 -- Form of Directors Stock Option Agreement(1)
10.5 -- Quest Medical, Inc. 1987 Stock Option Plan(6)
10.6 -- Form of 1987 Employee Stock Option Agreement(6)
10.7 -- Quest Medical, Inc. 1995 Stock Option Plan(6)
10.8 -- Form of 1995 Employee Stock Option Agreement(6)
10.9 -- Form of Employment Agreement and Covenant Not to Compete,
between the Company and key employees(1)
10.10 -- Promissory Note dated December 28,1993, between Quest
Medical, Inc. and MetLife Capital Financial
Corporation(4)
10.11 -- Commercial Deed of Trust, Security Agreement and
Assignment of Leases and Rents and Fixture Filing dated
December 28,1993, between Quest Medical, Inc. and MetLife
Capital Financial Corporation(4)
10.12 -- Term Promissory Note dated December 28,1993, between
Quest Medical, Inc. and MetLife Capital Corporation(4)
10.13 -- Loan and Security Agreement dated December 28,1993,
between Quest Medical, Inc. and MetLife Capital
Corporation(4)
10.14 -- Supplemental Security Agreement Number One dated December
28,1993, between Quest Medical, Inc. and MetLife Capital
Corporation(4)
10.15 -- Third Amended and Restated Credit Agreement dated as of
March 3, 1997, between Quest Medical, Inc. and
NationsBank of Texas, N.A.(8)
10.16 -- Promissory Note (Facility A. Note) in the original
principal amount of $5,650,000 dated March 3, 1997(8)
10.17 -- Promissory Note (Facility B. Note) in the original
principal amount of $350,000 dated March 3, 1997(8)
10.18 -- First Amended and Restated Security Agreement dated March
3, 1997, between Quest Medical, Inc. and NationsBank of
Texas, N.A.(8)
10.19 -- First Amended and Restated Security Agreement dated March
3, 1997, between Advanced Neuromodulation Systems, Inc.
and NationsBank of Texas, N.A.(8)
</TABLE>
<PAGE> 51
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<C> <S>
10.20 -- First Amended and Restated Intellectual Property Security
Agreement and Assignment dated as of March 3, 1997,
between Quest Medical, Inc. and NationsBank of Texas
N.A.(8)
10.21 -- First Amended and Restated Intellectual Property Security
Agreement and Assignment dated as of March 3, 1997,
between Advanced Neuromodulation Systems, Inc. and
NationsBank of Texas, N.A.(8)
10.22 -- First Amended and Restated License Agreement dated as of
March 3, 1997, between Quest Medical, Inc. and
NationsBank of Texas, N.A.(8)
10.23 -- First Amended and Restated License Agreement dated as of
March 3, 1997, between Advanced Neuromodulation Systems,
Inc. and NationsBank of Texas, N.A.(8)
10.24 -- Guaranty of Advanced Neuromodulation Systems, Inc. in
favor of NationsBank of Texas, N.A. under the Third
Amended and Restated Credit Agreement dated as of March
3, 1997(8)
11.1 -- Computation of Earnings Per Share(8)
21.1 -- Subsidiaries(8)
23.1 -- Consent of Independent Auditors(8)
</TABLE>
- ---------------
(1) Filed as an Exhibit to the Company's Registration Statement on Form S-18,
Registration No. 2-71198-FW, and incorporated herein by reference.
(2) Filed as an Exhibit to the report of the Company on Form 10-K for the year
ended December 31, 1987, and incorporated herein by reference.
(3) Filed as an Exhibit to the Company's Registration Statement on Form S-1,
Registration No. 2-78186, and incorporated herein by reference.
(4) Filed as an Exhibit to the report of the Company on Form 10-KSB for the year
ended December 31, 1993, and incorporated herein by reference.
(5) Filed as an Exhibit to the report of the Company on Form 10-KSB for the year
ended December 31, 1994, and incorporated herein by reference.
(6) Filed as an Exhibit to the Company's Registration Statement on Form SB-2,
Registration No. 33-62991, and incorporated herein by reference.
(7) Filed as an Exhibit to the report of the Company on Form 8-K dated September
3, 1996, and incorporated herein by reference.
(8) Filed herewith.
<PAGE> 1
EXHIBIT 10.15
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
THIRD AMENDED AND RESTATED
CREDIT AGREEMENT
BETWEEN
QUEST MEDICAL, INC.
AND
NATIONSBANK OF TEXAS, N.A.
Dated as of March 3, 1997
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
TABLE OF CONTENTS
ARTICLE I. DEFINITIONS
<TABLE>
<S> <C> <C>
1.1 Definitions ................................. 1
1.2 Accounting and Other Terms .................. 16
ARTICLE II. ADVANCES
2.1 (a) Facility A Advances ................... 17
2.2 Manner of Borrowing ......................... 17
2.3 Evidence of Indebtedness .................... 18
2.4 Fees ........................................ 18
2.5 Prepayments ................................. 19
2.6 Repayment ................................... 19
2.7 Reduction of Commitments .................... 20
2.8 Interest .................................... 20
2.9 Default Interest ............................ 21
2.10 Continuation and Conversion Elections ....... 21
2.11 Maximum Amount of Interest .................. 22
2.12 Computations ................................ 23
2.13 Taxes ....................................... 23
2.14 Capital Adequacy; Increased Costs ........... 23
ARTICLE III. CONDITIONS PRECEDENT TO ADVANCES.
3.1 Conditions Precedent to Advances ............ 25
3.2 Conditions Precedent to All Advances ........ 28
3.3 Legal Details ............................... 28
ARTICLE IV. AFFIRMATIVE COVENANTS
4.1 Books, Records and Properties ............... 28
4.2 Financial Statements and Reports ............ 28
4.3 Maintenance of Existence .................... 30
4.4 Insurance ................................... 30
4.5 Compliance with Applicable Laws ............. 30
4.6 Other Information and Documents ............. 30
4.7 Default ..................................... 30
4.8 Taxes ....................................... 30
</TABLE>
(i)
<PAGE> 3
<TABLE>
<S> <C> <C>
4.9 Further Assurances .......................... 30
4.10 Filings ..................................... 31
4.11 Maintenance ................................. 31
4.12 ERISA Compliance ............................ 31
4.13 Indemnity by Borrower ....................... 31
ARTICLE V. NEGATIVE COVENANTS
5.1 Liens ....................................... 32
5.2 Transfer of Assets .......................... 32
5.3 New Industry ................................ 32
5.4 Restricted Investments ...................... 33
5.5 Transactions with Affiliates ................ 33
5.6 Fixed Charges Coverage Ratio ................ 33
5.7 Margin Ratio ................................ 33
5.8 Total Liabilities to Tangible Worth Ratio ... 33
5.9 Capital Expenditures ........................ 33
5.10 Merger and Consolidation .................... 33
5.11 Debt ........................................ 33
5.12 Distributions ............................... 34
ARTICLE VI. REPRESENTATIONS AND WARRANTIES
6.1 Organization; Qualification; Authority ...... 34
6.2 Financial Statements ........................ 34
6.3 Conflicting Agreements and Other Matters .... 34
6.4 Governmental Consent ........................ 35
6.5 Enforceability .............................. 35
6.6 Actions Pending ............................. 35
6.7 Outstanding Debt ............................ 35
6.8 Title to Properties ......................... 35
6.9 Taxes ....................................... 36
6.10 Regulation G, etc ........................... 36
6.11 ERISA ....................................... 36
6.12 Disclosure .................................. 36
6.13 Environmental Matters ....................... 36
6.14 Sufficiency of Capital ...................... 37
6.15 Affiliates .................................. 37
6.16 Intellectual Property ....................... 37
</TABLE>
ARTICLE VII. DEFAULT
(ii)
<PAGE> 4
<TABLE>
<S> <C> <C>
7.1 Events of Default ........................... 37
7.2 Remedies Upon Default ....................... 39
7.3 Performance by Lender ....................... 40
7.4 Lender Not in Control ....................... 40
7.5 Waivers ..................................... 40
7.6 Cumulative Rights ........................... 41
7.7 Expenditures by Lender ...................... 41
ARTICLE VIII. MISCELLANEOUS
8.1 Money ....................................... 41
8.2 Headings .................................... 41
8.3 Articles, Sections, and Exhibits ............ 41
8.4 Notices and Deliveries ...................... 41
8.5 Place of Payment ............................ 43
8.6 Survival of Agreements ...................... 43
8.7 Parties in Interest ......................... 43
8.8 Expenses .................................... 43
8.9 Governing Law ............................... 43
8.10 MANDATORY ARBITRATION ....................... 43
8.11 WAIVER OF JURY TRIAL ........................ 44
8.12 Maximum Amount Limitation ................... 45
8.13 Severability ................................ 45
8.14 Amendment ................................... 45
8.15 Exceptions to Covenants ..................... 46
8.16 Counterparts ................................ 46
8.17 Restatement ................................. 46
8.18 ENTIRE AGREEMENT ............................ 46
</TABLE>
(iii)
<PAGE> 5
EXHIBITS
Exhibit A Facility A Note
Exhibit B Facility B Note
Exhibit C Intentionally Deleted
Exhibit D Security Agreement
Exhibit E Intellectual Property Security Agreement
Exhibit F License Agreement
Exhibit G Compliance Certificate
Exhibit H Guaranty Agreement
Exhibit I Borrowing Notice
Exhibit J Conversion or Continuation Notice
Exhibit K Borrowing Base Certificate
Exhibit L Pledge Agreement
Exhibit M Deed of Trust
Exhibit N Subordination Agreement
SCHEDULES
Schedule 1 Affiliates
Schedule 2 Allen Property
Schedule 3 Litigation
Schedule 4 Intellectual Property
(iv)
<PAGE> 6
THIRD AMENDED AND RESTATED CREDIT AGREEMENT
THIRD AMENDED AND RESTATED CREDIT AGREEMENT (this "Agreement") dated as of
March 3, 1997, between QUEST MEDICAL, INC., a Texas corporation, having its
principal office at One Allentown Parkway, Allen, Texas 75002 ("Borrower"), and
NATIONSBANK OF TEXAS, N.A., a national banking association, having its
principal office at 901 Main Street, Dallas, Texas 75202 ("Lender").
BACKGROUND
Borrower and Lender have entered into (1) the Credit Agreement dated as of
October 22, 1993, (2) the First Amended and Restated Credit Agreement dated as
of March 31, 1995 (as amended, the "First Restated Credit Agreement") providing
for a line of credit in the maximum principal amount of $5,000,000 ("Existing
Facility A"), the proceeds of which are to be used for working capital
purposes, and a $15,000,000 term facility ("Existing Facility B"), the proceeds
of which were used to acquire all capital stock of Neuromed, Inc., a Florida
corporation and (3) the Second Amended and Restated Credit Agreement dated as
of February 9, 1996 (as amended, the "Second Restated Credit Agreement") which
renewed Existing Facility A and restated Existing Facility B. Borrower has
requested that Lender renew Existing Facility A and provide a new term
facility, the proceeds of which will be used to provide for the working capital
needs of Borrower and to make certain arbitration payments, subject to the
terms of this Agreement.
In consideration of the mutual covenants and agreements contained herein,
and other good and valuable consideration, receipt of which is acknowledged by
all parties hereto, the parties agree as follows:
AGREEMENT.
ARTICLE I. DEFINITIONS
1.1 Definitions. The terms defined in this Article I (except as otherwise
expressly provided in this Agreement) for all purposes shall have the following
meanings:
"Account" has the meaning assigned to such term in the UCC.
"Additional Costs" has the meaning set forth in Section 2.14.
"Advance" means an advance by Lender to Borrower pursuant to Article II,
and refers to a Facility A Advance or a Facility B Advance.
"Affiliate" means any Person that directly or indirectly through one or
more Persons Controls, or is Controlled By or Under Common Control with,
Borrower or a Person who Controls or is Controlled by, Borrower.
<PAGE> 7
"Allen Property" means the real property described on Schedule 2, together
with all improvements and equipment located thereon.
"ANS" means Advanced Neuromodulation Systems, Inc., a Texas corporation.
"Applicable Law" means the Laws of the United States of America applicable
to contracts made or performed in the State of Texas, including, without
limitation, 12 USC Section Section 85 and 86 as amended to the date hereof and
as the same may be amended at any time and from time to time hereafter and any
other statute of the United States of America now or at any time hereafter
prescribing maximum rates of interest on loans and extensions of credit, and
the Laws of the State of Texas, including, without limitation, Articles
5069-l.04 and 5069-l.07 (a), Title 79, Revised Civil Statutes of Texas, 1925,
as amended at any time and from time to time hereafter and any other statute of
the State of Texas now or at any time hereafter prescribing maximum rates of
interest on loans and extensions of credit ("Art. l.04").
"Applicable Margin" means (a) with respect to Prime Advances, 1.00% per
annum, (b) with respect to LIBOR Advances, 2.75% per annum, and with respect to
the Facility B Advance, 2.25% per annum.
"Art. 1.04" has the meaning given to such term in the definition of
Applicable Law in Article I.
"Borkan Debt" means the "Subordinated Obligations", as defined in the
Borkan Subordination Agreement.
"Borkan Subordination Agreement" means the Subordination Agreement date
March 3, 1997, among William Borkan, Borrower and Lender.
"Borrowing" means a borrowing under Facility A or Facility B of the same
Type made on the same day.
"Borrowing Base" means, at the time in question, an amount equal to the
sum of (a) 80% of Eligible Accounts, plus (b) 25% of Eligible Inventory
composed of raw materials and MPS finished goods, plus (c) 50% of Eligible
Inventory composed of non-MPS finished goods.
"Borrowing Base Certificate" means a certificate, signed by a duly
authorized officer of Borrower, in the form of Exhibit K, appropriately
completed.
"Borrowing Notice" has the meaning set forth in Section 2.2(a).
"Business Day" means a day on which banks are open for the transaction of
business as required by this Agreement in Dallas, Texas and New York, New York
and, with respect to any LIBOR Advance, a domestic business day in London,
England and a day on which commercial
-2-
<PAGE> 8
banks are open for international business in London, England (including
dealings in United States dollar deposits), and as otherwise relevant to the
determination to be made or the action to be taken.
"Capital Leases" means capital leases and subleases, as defined in the
Financial Accounting Standards Board Statement of Financial Accounting
Standards No. 13, dated November 1976, as amended.
"Code" means the Internal Revenue Code of 1986, as amended.
"Collateral" means that property of Borrower or any other Person in which
Lender shall have Liens to secure payment and performance of the Obligation.
"Collateral Documents" means all security agreements, pledge agreements
and any other agreements or documents executed or delivered to secure repayment
of the Obligation or part thereof.
"Compliance Certificate" means a certificate, signed by a duly authorized
officer of Borrower, in the form of Exhibit G, appropriately completed.
"Consequential Loss" means with respect to (a) Borrower's payment of all
or any portion of the then-outstanding principal amount of a LIBOR Advance on a
day other than the last day of the related Interest Period, including, without
limitation, payments made as a result of the acceleration of the maturity of a
Note pursuant to Section 7.2, and (b) any of the circumstances specified in
Sections 2.2(e), 2.5, 2.7 and 2.14 on which a Consequential Loss may be
incurred, any loss, cost or expense incurred by Lender as a result of the
timing of the payment of the Advance or in liquidating, redepositing,
redeploying or reinvesting the principal amount so paid or affected by the
timing of the Advance or the circumstances described in Sections 2.2(e), 2.5,
2.7 and 2.14, which amount shall be the sum of (i) the interest that, but for
the timing of the payment of the Advance, Lender would have earned in respect
of that principal amount, reduced, if Lender is able to redeposit, redeploy, or
reinvest the principal amount, by the interest earned by Lender as a result of
redepositing, redeploying or reinvesting the principal amount plus (ii) any
expense or penalty incurred by such Lender by reason of liquidating,
redepositing, redeploying or reinvesting the principal amount. Each
determination by Lender of any Consequential Loss is, in the absence of
manifest error, conclusive and binding.
"Continue," "Continuation" and "Continued" each refer to the continuation
pursuant to Section 2.10 of a LIBOR Advance from one Interest Period to the
next Interest Period.
"Control" or "Controlled By" or "Under Common Control" mean possession,
direct or indirect, of power to direct or cause the direction of management or
policies (whether through ownership of voting securities, by contract or
otherwise); provided that, in any event (a) any Person which beneficially owns
20% or more (in number of votes) of the securities having
-3-
<PAGE> 9
ordinary voting power for the election of directors of a corporation shall
be presumed to control such corporation, and (b) no Person shall be deemed to
be an Affiliate of a corporation solely by reason of his being an officer or
director of such corporation.
"Conversion or Continuance Notice" has the meaning set forth in Section
2.10.
"Debt" means, with respect to any Person, all debt, obligations and
liabilities of such Person, including without limitation, (a) all "liabilities"
which would be reflected on a balance sheet of such Person, prepared in
accordance with GAAP, (b) all obligations of such Person in respect of any
Guaranty, (c) all obligations of such Person in respect of any Capital Lease,
(d) all obligations, debt and liabilities secured by any Lien on any property
or assets of such Person and (e) all obligations of such Person in respect of
letters of credit, acceptances or similar obligations issued or created for the
account of such Person.
"Debt for Borrowed Money" means, as to any Person, at any date, without
duplication, (a) all obligations of such Person for borrowed money, (b) all
obligations of such Person evidenced by bonds, debentures, notes or other
similar instruments, (c) all obligations of such Person to pay the deferred
purchase price of property or services, except trade accounts payable arising
in the ordinary course of business, (d) all obligations of such Person in
respect of any Guaranty, (e) all obligations of such Person in respect of any
Capital Lease, and (f) all obligations, debt and liabilities secured by any
Lien on any property or assets of such Person.
"Debtor Relief Laws" means any applicable liquidation, conservatorship,
bankruptcy, moratorium, rearrangement, fraudulent conveyance, insolvency,
reorganization or similar debtor relief Laws relating to the enforcement of
creditors' rights generally from time to time in effect.
"Default" means any of the events specified in Section 7.1, whether or not
there has been satisfied any requirement in connection with such event for the
giving of notice, or the lapse of time, or the happening of any further
condition, event or act.
"Device" has the meaning set forth in the FDA Act.
"Distribution" means, as to any Person, (a) any declaration or payment of
any distribution or dividend (other than a stock dividend) on, or the making of
any pro rata distribution, loan, advance, or investment to or in any holder (in
its capacity as a partner, shareholder or other equity holder) of, any
partnership interest or shares of capital stock or other equity interest of
such Person, or (b) any purchase, redemption, or other acquisition or
retirement for value of any shares of partnership interest or capital stock or
other equity interest of such Person.
"Dollars" and the sign "$" mean lawful money of the United States of
America.
"Drug" has the meaning set forth in the FDA Act.
-4-
<PAGE> 10
"EBITDA" means, as of any date of determination, the sum of Borrower's and
its Subsidiaries' (a) pre-tax income or deficit, as the case may be (excluding
extraordinary items and income from the sale of assets other than in the
ordinary course of business), plus (b) cash interest expense paid; amortization
of Debt discounts; any payments or fees with respect to letters of credit,
bankers' acceptances or similar facilities; fees and expenses with respect to
interest rate swap or similar agreements or foreign currency hedge, exchange or
similar agreements, plus (c) consolidated depreciation and amortization
expense, all calculated on a consolidated basis in accordance with GAAP,
determined for the four fiscal quarters preceding the date of calculation.
"Effective Date" means March 3, 1997.
"Eligible Accounts" means at the time of any determination thereof, the
lesser of (a) $3,000,000 and (b) each Account as to which the following
requirements have been fulfilled to the satisfaction of Lender:
(a) Borrower or a Subsidiary of Borrower has lawful and absolute
title to such Account;
(b) Such Account is a valid, legally enforceable obligation of the
Person who is obligated under such Account (the "account debtor") for
goods or services delivered or rendered to such Person;
(c) There has been excluded from such Account any portion that is
subject to any dispute, offset, counterclaim or other claim or defense on
the part of the account debtor or to any claim on the part of the account
debtor denying liability under such Account;
(d) Borrower or a Subsidiary of Borrower has full and unqualified
right to assign and grant a security interest in such Account to Lender
as security for the Obligation;
(e) Such Account is payable in Dollars and is evidenced by an
invoice rendered to the account debtor and such Account is not evidenced
by any chattel paper, promissory note or other instrument;
(f) Such Account is subject to a fully perfected first priority
security interest in favor of Lender pursuant to the Loan Papers, prior
to the rights of, and enforceable as such against, any other Person
(including holders of a purchase money security interest);
(g) If the account debtor in respect of such Account is either
located outside the United States of America or primarily conducts
business in a jurisdiction outside the
-5-
<PAGE> 11
United States of America, or if the goods or services sold giving rise to
such Account are to be delivered or performed outside of the United
States of America, (i) the account debtor is located in a province of the
Dominion of Canada in which all actions necessary to perfect a first
priority security interest in all Collateral in favor of Lender have
occurred, (ii) the entire amount of the payment obligation represented by
such Account is secured by either (A) an irrevocable Dollar-denominated
commercial letter of credit issued or confirmed by a financial
institution (1) the short-term debt obligations of which have the same or
higher rating, as established by either Standard & Poor's Corporation or
Moody's Investors Service, Inc., as comparable obligations of Lender, (2)
the short-term obligations of the holding company of such financial
institution have the same or higher rating, as established by Standard &
Poor's Corporation or Moody's Investors Service, Inc., as comparable
obligations of NationsBank Corporation (if either or both of such
financial institution and Lender do not have outstanding comparable
short-term obligations or such obligations are not rated), or (3)
acceptable to Lender (if (A) either or both of such financial institution
and Lender and (B) either or both of the holding company of such
financial institution and NationsBank Corporation do not have outstanding
comparable short-term obligations or such obligations are not rated), the
proceeds of which letter of credit have been assigned to Lender or which
letter of credit shall specifically provide that payment thereunder shall
be made solely to an account maintained by Borrower at Lender (which
account and all property on deposit therein has been assigned to Lender),
or (B) a receivables insurance policy issued by ExImBank or a private
insurance company acceptable to Lender and ExImBank, in either case, the
proceeds of which policy have been assigned to Lender;
(h) Such Account is not subject to any Lien in favor of any Person
other than the Lien of Lender pursuant to the Loan Papers;
(i) Such Account has not been due and payable for more than 90 days
from the invoice date; and
(j) No account debtor in respect of such Account is (i) any
Tribunal, domestic or foreign; provided, for purposes of determining
"Eligible Account", "Tribunal" shall not include any government or
university, medical department of any government or university or
hospital associated with any government or university located in the
United States of America, (ii) the subject of a proceeding under any
Debtor Relief Laws, or (iii) the United States of America or any state;
provided, that, unless Lender agrees otherwise, no Accounts payable by an
account debtor shall constitute Eligible Accounts if 10% or more of the
aggregate dollar amount of all Accounts owed to Borrower by such account debtor
have been due and payable for 91 days or more from their respective invoice
dates.
-6-
<PAGE> 12
"Eligible Inventory" means, at the time of any determination thereof, the
lesser of (a) $2,650,000, reduced by $90,000 each calendar month commencing
April 1, 1997, and (b) each item of Inventory (excluding work-in-progress)
valued at the lower of cost or market value, as to which the following
requirements have been fulfilled to the satisfaction of Lender:
(i) Borrower or a Subsidiary of Borrower has lawful and absolute
title to such Inventory;
(ii) Such Inventory is subject to a fully perfected first priority
security interest in favor of Lender pursuant to the Loan Papers, prior
to the rights of, and enforceable as such against, any other Person
(including holders of a purchase money security interest);
(iii) Such Inventory is (A) neither adulterated nor misbranded, (B)
not the subject of any pending or threatened proceeding or action by FDA
or other Tribunal seeking the recall, seizure or condemnation or the
prohibition of the sale, use or distribution of such Inventory, (C)
properly registered with FDA (if such registration is required), (D)
produced at an Establishment registered with FDA (if such registration is
required), (E) not subject to any restriction on the distribution, sale
or use by Lender or any purchaser at any foreclosure sale or other
realization on the Collateral and (F) not a Drug;
(iv) Such Inventory was produced in compliance with the FDA Act and
the Fair Labor Standards Act and related rules and regulations;
(v) Such Inventory is located at 2930-G and 2930-H Grace Lane, Costa
Mesa, California or One Allentown Parkway, Allen, Texas.
"ERISA" means the Employee Retirement Income Security Act of 1974, as
amended from time to time.
"Establishment" has the meaning set forth in 21 CFR Section 807.3.
"Event of Default" means the occurrence of any of the events specified in
Section 7.1, provided there has been satisfied any requirement in connection
with such event for the giving of notice, or the lapse of time, or the
happening of any further condition, event or act.
"ExImBank" means Export-Import Bank of the United States, an agency of the
United States of America, and any successor entity.
"Existing Facility A" has the meaning set forth in the Background section.
"Existing Facility B" has the meaning set forth in the Background section.
-7-
<PAGE> 13
"Facility A Advance" means an Advance described in Section 2.1(a) to be
made from time to time by Lender to Borrower.
"Facility A Commitment" means $5,650,000, as the same may be reduced or
terminated pursuant to Sections 2.7.
"Facility A Commitment Fee" has the meaning set forth in Section 2.4(a).
"Facility A Note" means the promissory note of Borrower payable to the
order of Lender, in substantially the form of Exhibit A, and any and all
renewals, extensions, modifications and amendments thereof and substitutions
therefor.
"Facility A Termination Date" means January 31, 1998, or such earlier date
that the Facility A Commitment is terminated.
"Facility B Advance" means the Advance described in Section 2.1(b) to be
made on the Effective Date by Lender to Borrower.
"Facility B Commitment" means $350,000.
"Facility B Interest Rate" means, with respect to the Facility B Advance,
a rate per annum equal to the lesser of (a) the sum of (i) the LIBOR Rate, plus
(ii) the Applicable Margin and (b) the Highest Lawful Rate.
"Facility B Note" means the promissory note of Borrower payable to the
order of Lender, in substantially the form of Exhibit B, and any and all
renewals, extensions, modifications and amendments thereof and substitutions
therefor.
"Facility B Termination Date" means January 31, 1998, or such earlier date
that the Facility B Commitment is terminated.
"FDA" means the Food and Drug Administration and any successor.
"FDA Act" means the Federal Food, Drug and Cosmetic Act, 21 USC Section
301, et seq, and all amendments and successors thereto.
"Financial Statements" means with respect to Borrower and its
Subsidiaries, consolidated and consolidating balance sheets, consolidated and
consolidating profit and loss statements, reconciliation of capital and surplus
(prepared as to fiscal quarters and fiscal years, only), and statements of cash
flow.
"First Restated Credit Agreement" has the meaning specified in the
Background section.
-8-
<PAGE> 14
"Fixed Charges" means the sum of, for Borrower and its Subsidiaries,
determined in accordance with GAAP on a consolidated basis, (a) interest
expense (including interest expense pursuant to Capital Leases), plus (b) lease
expense payable for Operating Leases, determined for the four fiscal quarters
preceding the date of calculation.
"Fixed Charges Coverage Ratio" means the ratio of Net Earnings Available
for Fixed Charges to Fixed Charges.
"GAAP" means generally accepted accounting principles applied on a
consistent basis, set forth in the Opinions of the Accounting Principles Board
of the American Institute of Certified Public Accountants and/or in statements
of the Financial Accounting Standards Board, which are applicable in the
circumstances as of the date in question, and the requirement that such
principles be applied on a consistent basis shall mean that the accounting
principles observed in a current period are comparable in all material respects
to those applied in a preceding period. Unless otherwise indicated herein, all
accounting terms will be defined according to GAAP.
"Government Securities" means direct obligations of the United States of
America or any agency thereof, or obligations fully guaranteed by the United
States of America or any agency thereof.
"Guaranty" of any Person means any contract, agreement or understanding of
such Person pursuant to which such Person guarantees, or in effect guarantees,
any Debt of any other Person in any manner, whether directly or indirectly;
except that "Guaranty" shall not include the endorsement by such Person in the
ordinary course of business of negotiable instruments or documents for deposit
or collection.
"Guaranty Agreement" means a Guaranty Agreement in the form of Exhibit H,
or, if executed in connection with the First Restated Credit Agreement or the
Second Restated Credit Agreement, a Guaranty Agreement (as that term is defined
in the such credit agreement).
"hereof", "hereto", "hereunder" and similar terms refer to this Agreement
and not to any particular section or provision of this Agreement.
"Highest Lawful Rate" means at the particular time in question the maximum
rate of interest which, under Applicable Law, Lender is then permitted to
charge on the Obligation. If the maximum rate of interest which, under
Applicable Law, Lender is permitted to charge on the Obligation shall change
after the date hereof, the Highest Lawful Rate shall be automatically increased
or decreased, as the case may be, from time to time as of the effective time of
each change in the Highest Lawful Rate without notice to Borrower. For purposes
of determining the Highest Lawful Rate under the Applicable Law of the State of
Texas, the applicable rate ceiling shall be (a) the indicated rate ceiling
described in and computed in accordance with the provisions of Section (a)(l)
of Art. l.04; or (b) provided notice is given as required in Section (h)(1) of
said Art. l.04, the quarterly ceiling computed pursuant to Section (d) of said
Art. l.04;
-9-
<PAGE> 15
provided, however, that at any time the indicated rate ceiling, the
annualized ceiling or the quarterly ceiling, as applicable, shall be less than
18% per annum or more than 24% per annum, the provisions of Sections (b)(1) and
(2) of said Art. l.04 shall control for purposes of such determination, as
applicable.
"Indemnitee" has the meaning set forth in Section 4.13.
"Interest Period" means, with respect to any LIBOR Advance, the period
beginning on the date the Advance is made or continued as a LIBOR Advance and
ending one, two, three or six months thereafter (as Borrower shall select);
provided, however, that:
(a) Borrower may not select any Interest Period that ends after any
principal repayment date (including the Facility A Termination Date and
the Facility B Termination Date) unless, after giving effect to such
selection, the aggregate principal amount of LIBOR Advances having
Interest Periods that end on or prior to such principal repayment date,
shall be at least equal to the principal amount of Advances due and
payable on and prior to such date;
(b) whenever the last day of any Interest Period would otherwise
occur on a day other than a Business Day, the last day of such Interest
Period shall be extended to occur on the next succeeding Business Day;
provided, however, that if such extension would cause the last day of
such Interest Period to occur in the next following calendar month, the
last day of such Interest Period shall occur on the next preceding
Business Day;
(c) no Interest Period for a Facility A Advance may extend beyond
the Facility A Termination Date; and
(d) no Interest Period for the Facility B Advance may extend beyond
the Facility B Termination Date.
"Inventory" has the meaning assigned to such term in the UCC.
"Investment" in any Person means any investment, whether by means of share
purchase, loan, advance, extension of credit, capital contribution or
otherwise, in or to such Person, the Guaranty of Debt of such Person or the
subordination of any claim against such Person to other Debt of such Person.
"Laws" means all statutes, laws, ordinances, regulations, orders, writs,
injunctions, or decrees of the United States, any state or commonwealth, any
municipality, any foreign country, any territory or possession, or any
Tribunal.
-10-
<PAGE> 16
"Lending Office" means, with respect to Lender, its branch or affiliate,
(i) initially, the office of Lender, branch or affiliate identified as such in
Section 8.4(b), and (ii) subsequently, such other office of Lender, branch or
affiliate as Lender may designate to Borrower as the office from which the
Advances of Lender will be made and maintained and for the account of which all
payments of principal and interest on the Advances and the Commitment Fee will
thereafter be made. Lender may have more than one Lending Office for the
purpose of making Prime Advances and LIBOR Advances.
"LIBOR Advance" means an Advance bearing interest at the LIBOR Rate.
"LIBOR Rate" means a simple per annum interest rate equal to the lesser of
(a) the Highest Lawful Rate, and (b) sum of the Applicable Margin plus the
LIBOR Rate Basis. The LIBOR Rate shall, with respect to LIBOR Advances subject
to reserve or deposit requirements under any Law, be subject to premiums
assessed therefor by each Lender, which are payable directly to each Lender in
an amount sufficient to compensate such Lender for any increased cost or
reduced rate of return attributable to such reserve deposit requirements. Any
calculation by a Lender of such increased cost or reduced rate of return which
is in reasonable detail and submitted to Borrower shall, in the absence of
manifest error, be presumptive evidence of the validity of such claim. Once
determined for any LIBOR Advance, the LIBOR Rate shall remain unchanged during
the applicable Interest Period.
"LIBOR Rate Basis" shall mean, for any LIBOR Advance for any Interest
Period therefore, the rate per annum (rounded upwards, if necessary, to the
nearest one-one hundredth (1/100th) of one percent (1%)) appearing on Telerate
Page 3750 (or any successor page) as the London interbank offered rate for
deposits in United States dollars at approximately 11:00 a.m. (London time) two
Business Days prior to the first day of such Interest Period. If for any
reason such rate is not available, the term "LIBOR Rate" shall mean, for any
LIBOR Advance for any Interest Period therefor, the rate per annum (rounded
upwards, if necessary, to the nearest one-one hundredth (1/100th) of one
percent (1%)) appearing on Reuters Screen LIBO page as the London interbank
offered rate for deposits in United States dollars at approximately 11:00 a.m.
(London time) two Business Days prior to the first day of such Interest Period
for a term comparable to such Interest Period; provided, however, if more than
one rate is specified on Reuters Screen LIBO Page, the applicable rate shall be
the arithmetic mean of all such rates.
"Lien" means any mortgage, pledge, security interest, encumbrance, lien or
charge of any kind (including any agreement to give or not to give any of the
foregoing), any conditional sale or other title retention agreement, any lease
in the nature thereof, and the filing of or agreement to give any financing
statement.
"Listed Debt" means any debt security (the issuer of which is a
corporation organized under the laws of any of the United States of America)
rated, at any date of determination, any one of the three highest ratings by
Standard & Poor's Corporation or Moody's Investors Service, Inc., each
regularly traded on the New York Stock Exchange or the American Stock Exchange.
-11-
<PAGE> 17
"Listed Securities" means any equity security regularly traded on the New
York Stock Exchange or the American Stock Exchange.
"Litigation" means any proceeding, claim, lawsuit and/or investigation
conducted or, to the knowledge of Borrower, threatened by or before any
Tribunal, including, but not limited to, proceedings, claims, lawsuits, and/or
investigations under or pursuant to any environmental, occupational, safety and
health, antitrust, unfair competition, securities, Tax, or other Law, or under
or pursuant to any contract, agreement or other instrument.
"Loan Papers" means this Agreement, the Notes, the Borkan Subordination
Agreement, the Swisher Subordination Agreement, any agreement securing or
assuring performance of the Obligation and all other agreements, certificates
and documents delivered by Borrower hereunder or any other Person pursuant
hereto.
"Margin Ratio" means the ratio, as at any date of determination, of (a)
the sum of the aggregate unpaid principal of all outstanding Advances, plus all
accrued, unpaid interest on all Advances, plus the amount of all other
Obligations, to (b) EBITDA.
"Material Adverse Change or Effect" means any act or circumstance which
(a) would be material and adverse to the combined financial condition, business
operations or prospects of Borrower and its Subsidiaries or any other Obligor,
(b) in any material manner whatsoever would adversely affect the validity or
enforceability of any of the Loan Papers or (c) in any material manner impairs
the value of any material portion of the Collateral.
"Maximum Amount" means the maximum amount of interest which, under
Applicable Law, Lender is permitted to charge on the Obligation.
"NationsBank" means NationsBank of Texas, N.A., a national banking
association.
"Net Earnings Available for Fixed Charges" means, for Borrower and its
Subsidiaries, determined in accordance with GAAP on a consolidated basis, (a)
Net Income before Taxes, plus (b) extraordinary non-cash charges, plus (c)
interest expense (including interest expense pursuant to Capital Leases), plus
(d) lease expense pursuant to Operating Leases, determined for the fiscal
quarter preceding the date of calculation.
"Net Income" means, for Borrower and its Subsidiaries, determined in
accordance with GAAP on a consolidated basis, net profit or loss.
"Neuromed" means Neuromed, Inc., a Florida corporation.
-12-
<PAGE> 18
"Neuromed Agreement" means the Agreement for the Purchase and Sale of All
of the Issued Capital Stock of Neuromed, Inc. dated February 10, 1995, between
Borrower and William Borkan.
"Note" or "Notes" means the Facility A Note and the Facility B Note.
"Obligations" means all present and future obligations, indebtedness and
liabilities, and all renewals and extensions of all or any part thereof, of
Borrower and each Obligor to Lender arising from, by virtue of, or pursuant to
this Agreement, any of the other Loan Papers and any and all renewals and
extensions thereof or any part thereof, or future amendments thereto, all
interest accruing on all or any part thereof and reasonable attorneys' fees
incurred by Lender for the administration, execution of waivers, amendments and
consents, and in connection with any restructuring, workouts or in the
enforcement or the collection of all or any part thereof, whether such
obligations, indebtedness and liabilities are direct, indirect, fixed,
contingent, joint, several or joint and several. Without limiting the
generality of the foregoing, "Obligations" includes all amounts would be owed
by Borrower, each other Obligor and any other Person (other than Lender) to
Lender under any Loan Paper, but for the fact that they are unenforceable or
not allowable due to the existence of a bankruptcy, reorganization or similar
proceeding involving Borrower, any other Obligor or any other Person (including
all such amounts which would become due or would be secured but for the filing
of any petition in bankruptcy, or the commencement of any insolvency,
reorganization or like proceeding of Borrower, any other Obligor or any other
Person under any Debtor Relief Law).
"Obligor" means (a) Borrower, (b) each other Person (other than Lender)
liable for performance of any of the obligations under the Loan Papers and (c)
each other Person the property of which secures the performance of any of the
obligations under the Loan Papers.
"Operating Leases" means operating leases, as defined in the Financial
Accounting Standards Board Statement of Financial Accounting Standards No. 13,
dated November 1976, as amended.
"PBGC" means the Pension Benefit Guaranty Corporation, and any successor
to all or any of the Pension Benefit Guaranty Corporation's functions under
ERISA.
"Permitted Investments" means Government Securities, Listed Debt, Listed
Securities and State Securities; provided Investments in Listed Securities of a
single issuer shall not exceed 25% of the outstanding equity having voting
rights of such issuer.
"Permitted Liens" means: (a) Liens granted to Lender to secure the
Obligation, (b) Liens in assets of Borrower or a Subsidiary of Borrower which
assets are not required by the Loan Papers to be subject to a Lien in favor of
Lender or which are not required by the Loan Papers to not be subject to a Lien
in favor of any Person, (c) Liens in the Allen Property to the extent such
Liens do not cover or purport to cover any asset of Borrower which is subject
to a Lien in
-13-
<PAGE> 19
favor of Lender, (d) pledges or deposits made to secure payment of worker's
compensation or occupational injury insurance (or to participate in any fund in
connection with worker's compensation or occupational injury insurance),
unemployment insurance, pensions or social security programs or to secure
performance of bids, tenders, contracts or leases, or to secure statutory
obligations, surety or appeal bonds, or indemnity, performance or similar bonds
in the ordinary course of business, (e) Liens imposed by mandatory provisions
of law such as for materialmen's, mechanics', warehousemen's and other like
Liens arising in the ordinary course of business, securing indebtedness whose
payment is not yet due or which are being contested in good faith and as to
which adequate cash reserves established in accordance with GAAP have been
provided, (f) Liens for taxes, assessments and governmental charges or levies
imposed upon a Person or upon such Person's income or profits or property, if
the same are not yet due and payable or if the same are being contested in good
faith and as to which adequate cash reserves have been provided, (g) Liens in
favor of MetLife Capital Corporation or its affiliates upon the Allen Property
in existence and of record on March 31, 1995, provided such Liens do not secure
Debt in excess of the amount of such Debt on March 31, 1995, as reduced by
payments on and after March 31, 1995, (h) Liens to secure Borrower's or any
Subsidiary's of Borrower obligations under lease agreements related to the real
property and improvements located at 2930-G and 2930-H Grace Lane, Costa Mesa,
California, or any reasonably comparable lease agreements entered into as
replacements for or expansion of such lease agreements, or (i) Liens permitted
by and subject to the Borkan Subordination Agreement and the Swisher
Subordination Agreement.
"Person" means and includes an individual, a partnership, a joint venture,
a corporation, a limited liability company, a trust, an unincorporated
organization, and a government or any department, Tribunal, agency or political
subdivision thereof.
"Plan" means an employee benefit plan or other plan maintained by Borrower
for employees of Borrower covered by Title IV of ERISA, or subject to the
minimum funding standards under Section 412 of the Internal Revenue Code of
1986, as amended ("Code").
"Prime Advance" means an Advance bearing interest at the Prime Rate.
"Prime Base Rate" means the prime interest rate charged by NationsBank as
announced or published by NationsBank from time to time as its prime rate, and
which may not be the lowest interest rate charged by NationsBank.
"Prime Rate" means, with respect to each Prime Advance, a rate per annum
equal to the lesser of (a) the sum of (i) the Prime Base Rate, plus (ii) the
Applicable Margin and (b) the Highest Lawful Rate.
"Principal Office" means the principal office of Lender located at 901
Main Street, Dallas, Texas 75202.
-14-
<PAGE> 20
"Quarterly Date" means March 31, June 30, September 30 and December 31.
"Refinancing Advance" means an Advance which is used to pay the principal
of an existing Advance at the end of its Interest Period and which, after
giving effect to such application, does not result in an increase in the
aggregate outstanding amount of Advances.
"Regulatory Modification" has the meaning set forth in Section 2.14.
"Reportable Event" has the meaning specified in Title IV of ERISA.
"Rights" means rights, remedies, powers and privileges.
"Second Restated Credit Agreement" has the meaning specified in the
Background section.
"Solvent" means, with respect to a particular date, that on such date (a)
the fair value of the property of a Person is greater than the total amount of
liabilities, including, without limitation, contingent liabilities, of such
Person, (b) the present fair salable value of the assets of such Person is not
less than the amount that will be required to pay the probable liability of
such Person on its debts as they become absolute and matured, (c) such Person
is able to realize upon its assets and pay its debts and other liabilities,
contingent obligations and other commitments as they mature in the normal
course of business, (d) such Person does not intend to, or believe that it
will, incur debts or liabilities beyond such Person's ability to pay as such
debts and liabilities mature, and (e) such Person is not engaged in business or
a transaction, and is not about to engage in business or a transaction, for
which such Person's property would constitute unreasonably small capital after
giving due consideration to the prevailing practice in the industry in which
such Person is engaged. In computing the amount of contingent liabilities at
any time, it is intended that such liabilities will be computed at the amount
which, in light of all the facts and circumstances existing at such time,
represents the amount that can reasonably be expected to become an actual or
material liability.
"Special Counsel" means the law firm of Donohoe, Jameson & Carroll, P.C.,
Dallas, Texas, Special Counsel to Lender, and each other attorney or law firm
representing Lender.
"State Securities" means direct obligations of any state or political
subdivision thereof, rated, at any date of determination, A-1 or P-1 by
Standard & Poor's Corporation or Moody's Investors Service, Inc.
"Subsidiary" of any Person means any corporation, limited liability
company, partnership, joint venture, trust or estate of which (or in which)
more than 50% of: (a) the outstanding capital stock having voting power to
elect a majority of the Board of Directors of such corporation (irrespective of
whether at the time capital stock of any other class or classes of such
corporation shall or might have voting power upon the occurrence of any
contingency), (b)
-15-
<PAGE> 21
the interest in the capital or profits of such partnership or joint venture, or
(c) the beneficial interest of such trust or estate, is at the time directly or
indirectly owned by such Person, by such Person and one or more of its
Subsidiaries or by one or more of such Person's Subsidiaries.
"Swisher Debt" means the "Subordinated Obligations", as defined in the
Swisher Subordination Agreement.
"Swisher Subordination Agreement" means the Subordination Agreement date
March 3, 1997, among Robert Swisher, Borrower and Lender.
"Tangible Net Worth" means, with respect to Borrower, shareholders'
equity, as shown on a balance sheet prepared in accordance with GAAP on a
consolidated basis, less the aggregate book value of intangible assets shown on
such balance sheet (provided, goodwill shall not be used in any determination
of "Tangible Net Worth" if goodwill is shown on the balance sheet as a negative
number, provided further that goodwill shown on the balance sheet as a positive
number shall be deducted in determining "Tangible Net Worth").
"Taxes" means all taxes, assessments, fees or other charges from time to
time or at any time imposed by any Laws or by any Tribunal.
"Term Debt" means debt for borrowed money the original scheduled maturity
of the last installment of which was more than twelve months after the date
borrowed.
"Total Liabilities" means all liabilities of Borrower which would be
classified as total liabilities on a balance sheet prepared in accordance with
GAAP on a consolidated basis.
"Tribunal" means any state, commonwealth, federal, foreign, territorial,
or other court or governmental department, commission, board, bureau, agency or
instrumentality.
"Type" refers to the distinction between Advances bearing interest at the
Prime Rate and LIBOR Rate.
"UCC" means the Uniform Commercial Code of Texas, as amended.
"Unrestricted Cash" means all cash, Government Securities, Listed Debt,
Listed Securities and State Securities owned by Borrower which are not subject
to any Lien.
1.2 Accounting and Other Terms. All accounting terms used in this
Agreement which are not otherwise defined herein shall be construed in
accordance with GAAP consistently applied on a consolidated basis for Borrower
and its Subsidiaries, unless otherwise expressly stated herein. If after the
Effective Date any change in GAAP applicable to Borrower or its Subsidiaries
results in a change in the manner of any calculation under the Loan Papers,
Borrower and Lender shall negotiate amendments to the Loan Papers to
accommodate such
-16-
<PAGE> 22
changes in GAAP. References herein to one gender shall be deemed to include all
other genders. Except where the context otherwise requires, (a) definitions
imparting the singular shall include the plural and vice versa and (b) all
references to time are deemed to refer to Dallas time.
ARTICLE II. ADVANCES
2.1 (a) Facility A Advances. Lender agrees, upon the terms and subject
to the conditions of this Agreement, to make Facility A Advances to Borrower
from time to time from the Effective Date to the Facility A Termination Date;
provided, however, that immediately after giving effect to each Facility A
Advance pursuant to this Section 2.1(a), the aggregate principal amount of the
Facility A Advances shall at no time exceed the lesser of (a) the Facility A
Commitment and (b) the Borrowing Base.
(b) Facility B Advance. Lender agrees, upon the terms and subject
to the conditions of this Agreement, to make the Facility B Advance to Borrower
on the Effective Date.
2.2 Manner of Borrowing.
(a) Each Borrowing of Advances shall be made upon the written notice of
Borrower, received by Lender (i) not later than 12:00 noon three Business Days
prior to the date of the proposed Borrowing, in the case of LIBOR Advances; and
(ii) not later than 11:00 a.m. on the date of such Borrowing, in the case of
Prime Advances. Each such notice of a Borrowing (a "Borrowing Notice") shall
be by telecopy or telex, promptly confirmed by letter, in substantially the
form of Exhibit I specifying therein:
(i) the date of such proposed Borrowing, which shall be a Business
Day;
(ii) the amount of such proposed Borrowing which, (A) shall not
exceed the unused portion of the Facility A Commitment, (B) shall not,
when added to the aggregate principal of outstanding Facility A Advances,
exceed the Borrowing Base, (C) shall, in the case of a Borrowing of LIBOR
Advances, be in an amount of not less than $50,000 or an integral
multiple of $50,000 in excess thereof and (D) in the case of a Borrowing
of Prime Advances, be in an amount of not less than $50,000 or an
integral multiple of $10,000 in excess thereof;
(iii) the Type of Advances of which the Borrowing is to be
comprised; and
(iv) if the Borrowing is to be comprised of LIBOR Advances, the
duration of the initial Interest Period applicable to such Advances.
-17-
<PAGE> 23
If the Borrowing Notice fails to specify the duration of the initial
Interest Period for any Borrowing comprised of LIBOR Advances, such Interest
Period shall be one month.
(b) Provided that all conditions precedent to the making of such Advance
have been satisfied, Lender shall on the date of such Advance (other than a
Refinancing Advance) deposit the funds so requested in the deposit account no.
1291792407 of Borrower with Lender.
(c) After giving effect to any Borrowing, there shall not be more than
five different Interest Periods in effect.
(d) No Interest Period for a Borrowing under Facility A or Facility B
shall extend beyond the Facility A Termination Date or Facility B Termination
Date, respectively.
(e) Borrower shall indemnify Lender against any Consequential Loss
incurred by Lender as a result of (i) any failure to fulfill, on or before the
date specified for the Advance, the conditions to the Advance set forth herein
or (ii) Borrower's requesting that an Advance not be made on the date specified
in the Borrowing Notice.
2.3 Evidence of Indebtedness.
(a) Facility A Advances shall be evidenced by the Facility A Note in the
amount of the Facility A Commitment in effect on the Effective Date. The
Facility B Advance shall be evidenced by the Facility B Note in the amount of
the Facility B Commitment in effect on the Effective Date.
(b) Absent manifest error, Lender's records shall be prima facie evidence
as to amounts owed Lender under the Notes and this Agreement.
2.4 Fees.
(a) Facility A Commitment Fee. Subject to the provisions of Section 8.12,
Borrower shall pay to Lender a commitment fee ("Facility A Commitment Fee") at
the rate of 3/8% per annum on the average daily unused portion of the Facility
A Commitment. The Facility A Commitment Fee shall be payable in arrears (i) on
each Quarterly Date, commencing March 31, 1997 and (ii) on the Facility A
Termination Date.
(b) Origination Fee. Subject to the provisions of Section 8.12, Borrower
shall pay to Lender an origination fee of $10,000 with respect to the Facility
A Commitment and Facility B Commitment.
-18-
<PAGE> 24
2.5 Prepayments.
(a) Borrower may, upon at least three Business Days prior written notice
to Lender stating the proposed date and aggregate principal amount of the
prepayment, prepay the outstanding principal amount of any Advances in whole or
in part, together with accrued interest to the date of such prepayment on the
principal amount prepaid without premium or penalty other than any
Consequential Loss; provided, however, that in the case of a prepayment of a
Prime Advance, the notice of prepayment may be given by telephone by 11:00 a.m.
on the date of prepayment. Each partial prepayment shall, in the case of LIBOR
Advances, be in an aggregate principal amount of not less than $50,000 or an
integral multiple of $50,000 in excess thereof and, in the case of Prime
Advances, be in an aggregate principal amount of not less than $50,000 or an
integral multiple of $10,000 in excess thereof. No prepayment of the Facility
B Advance can reduce the outstanding principal of the Facility B Advance to
less than $50,000 unless the entire outstanding principal of the Facility B
Advance is prepaid. If any notice of prepayment is given, the principal amount
stated therein, together with accrued interest on the amount prepaid and the
amount, if any, due under Section 2.14, shall be due and payable on the date
specified in such notice.
(b) If at any time the aggregate principal of outstanding Facility A
Advances exceeds the lesser of (a) the Facility A Commitment and (b) the
Borrowing Base, Borrower shall immediately prepay Facility A Advances then
outstanding in the aggregate amount equal to such excess, together with accrued
interest to the date of such prepayment on the principal amount prepaid without
premium or penalty other than any Consequential Loss. If at any time the
aggregate principal of outstanding Facility B Advances exceeds the Facility B
Commitment, Borrower shall immediately prepay the Facility B Advance then
outstanding in the aggregate amount equal to such excess, together with accrued
interest to the date of such prepayment on the principal amount prepaid without
premium or penalty other than any Consequential Loss.
(c) Unless otherwise specified by Borrower, any prepayment of Advances
pursuant to this Section 2.5 shall be applied first to Prime Advances, if any,
then outstanding, and second to LIBOR Advances with the shortest remaining
Interest Periods outstanding.
(d) No prepayments of Facility A Advances made solely pursuant to this
Section 2.5 shall cause the Facility A Commitment to be reduced.
(e) Any prepayments of the Facility B Advance made solely pursuant to this
Section 2.5 shall cause the Facility B Commitment to be reduced by the amount
of such prepayment.
2.6 Repayment.
(a) Facility A. Borrower shall repay to Lender the outstanding principal
amount of the Facility A Advances on the Facility A Termination Date.
-19-
<PAGE> 25
(b) Facility B. Borrower shall repay to Lender the outstanding principal
amount of the Facility B Advance on the Facility B Termination Date.
(c) General. The principal amount of each LIBOR Advance is due and
payable on the last day of the applicable Interest Period, which principal
payment may be made by means of a Refinancing Advance (subject to the other
provisions of this Agreement). On the date of a reduction of the Facility A
Commitment or Facility B Commitment pursuant to Section 2.7, the aggregate
amount of the applicable Advances outstanding on the date of reduction in
excess of the Facility A Commitment or Facility B Commitment as reduced shall
be due and payable, which principal payment may not be made by means of a
Refinancing Advance.
2.7 Reduction of Commitments.
(a) Mandatory. The Facility A Commitment shall reduce by $90,000 on
the first day of each calendar month, commencing on April 1, 1997.
(b) Optional. Borrower shall have the right at any time and from
time to time upon not less than three Business Days' notice to Lender not
later than 12:00 noon (if telephonic, to be confirmed by telex or in
writing on or before the date of reduction or termination), to terminate
or reduce the Facility A Commitment or the Facility B Commitment, in whole
or in part, provided that each partial termination shall be in an
aggregate amount which is an integral multiple of $50,000; provided, any
reduction of the Facility B Commitment to less than $50,000 must reduce
the Facility B Commitment to zero. Once reduced or terminated, neither
the Facility A Commitment nor the Facility B Commitment may be increased
or reinstated. On the date of any such reduction, Borrower shall repay
such principal amount (together with accrued interest thereon and any
Consequential Loss) of outstanding Advances as may be necessary so that
after such repayment, the aggregate unpaid principal amount of Advances
does not exceed the amount of the Facility A Commitment or the Facility B
Commitment, as appropriate, as then reduced.
2.8 Interest. Subject to Sections 2.09 and 8.12, Borrower shall pay
interest on the unpaid principal amount of each Advance from the date of such
Advance until such principal shall be paid in full, at the following rates per
annum:
(a) Prime Advances. Prime Advances shall bear interest at a rate
per annum equal to the Prime Rate as in effect from time to time. The
Facility B Advance may not be a Prime Advance.
(b) LIBOR Advances. LIBOR Advances shall bear interest at the rate
per annum equal to the LIBOR Rate applicable to such Advance, which at no
time shall exceed the Highest Lawful Rate.
-20-
<PAGE> 26
(c) Payment Dates. Accrued and unpaid interest on Prime Advances
shall be paid in arrears on each Quarterly Date, on the Facility A
Termination Date. Accrued and unpaid interest in respect of each LIBOR
Advance shall be paid on the last day of the appropriate Interest Period
and on the date of any prepayment or repayment of such Advance; provided,
however, that if any Interest Period for a LIBOR Advance exceeds three
months, interest shall also be paid on the date which falls three months
after the beginning of such Interest Period.
(d) Index. Reference to any particular index or reference rate for
determining any applicable interest rate under this Agreement is for
purposes of calculating the interest due and is not intended as and shall
not be construed as requiring Lender to actually obtain its funds used to
make any Advance at any particular index or reference rate.
2.9 Default Interest. During the continuation of any Event of Default,
Borrower shall pay, on demand, interest (after as well as before judgment to
the extent permitted by Law) on the principal amount of all Advances
outstanding and on all other Obligations due and unpaid hereunder for each
Advance equal to the Highest Lawful Rate.
2.10 Continuation and Conversion Elections
(a) Borrower may upon irrevocable written notice to Lender and subject to
the terms of this Agreement:
(i) elect to convert, on any Business Day, all or any portion of
outstanding Prime Advances (in an aggregate amount not less than $50,000
or an integral multiple of $50,000 in excess thereof) into LIBOR
Advances; or
(ii) elect to convert, at the end of any Interest Period therefor,
all or any portion of outstanding LIBOR Advances comprised in the same
Borrowing (in an aggregate amount not less than $50,000 or an integral
multiple of $10,000 in excess thereof), into Prime Advances; or
(iii) elect to continue, at the end of any Interest Period
therefor, any LIBOR Advances;
provided, however, that if the aggregate amount of outstanding LIBOR
Advances comprised in the same Borrowing shall have been reduced as a result of
any payment, prepayment or conversion of part thereof to an amount less than
$50,000, the LIBOR Advances comprised in such Borrowing shall automatically
convert into Prime Advances at the end of each respective Interest Period;
provided, further, that if the aggregate amount of outstanding LIBOR Advances
outstanding under Facility B shall have been reduced as a result of any
payment, prepayment or conversion of part thereof to an amount less than
$50,000, all outstanding
-21-
<PAGE> 27
principal of the Facility B Advance shall be due and payable at the end of each
respective Interest Period and the Facility B Commitment shall terminate on the
end of the last Interest Period.
(b) Borrower shall deliver a notice of conversion or continuation (a
"Conversion or Continuation Notice"), in substantially the form of Exhibit J,
to Lender not later than (i) 12:00 noon three Business Days prior to the
proposed date of conversion or continuation, if the Advances or any portion
thereof are to be converted into or continued as LIBOR Advances; and (ii) 10:00
a.m. on the Business Day of the proposed conversion, if the Advances or any
portion thereof are to be converted into Prime Advances.
Each such Conversion or Continuation Notice shall be by telecopy or telex,
promptly confirmed by letter, specifying therein:
(i) the Note to which the proposed conversion or continuation
relates;
(ii) the proposed date of conversion or continuation;
(iii) the aggregate amount of Advances to be converted or
continued;
(iv) the nature of the proposed conversion or continuation; and
(v) the duration of the applicable Interest Period.
(c) If, upon the expiration of any Interest Period applicable to LIBOR
Advances, Borrower shall have failed to select a new Interest Period to be
applicable to such LIBOR Advances or if an Event of Default shall then have
occurred and be continuing, Borrower shall be deemed to have elected to convert
such LIBOR Advances into Prime Advances effective as of the expiration date of
such current Interest Period.
(d) Notwithstanding any other provision contained in this Agreement, after
giving effect to any conversion or continuation of any Advances, there shall
not be outstanding Advances with more than five different Interest Periods.
2.11 Maximum Amount of Interest. In no event shall any interest rate
charged hereunder exceed the Highest Lawful Rate. If the amount of interest
payable for the account of Lender on any Quarterly Date in respect of the
immediately preceding interest computation period would exceed the Maximum
Amount, the amount of interest payable on such Quarterly Date shall be
automatically reduced to the Maximum Amount. If the amount of interest payable
for the account of Lender in respect of any interest computation period is
reduced pursuant to the immediately preceding sentence and the amount of
interest payable for its account in respect of any subsequent interest
computation period would be less than the Maximum Amount, then the amount of
interest payable for its account in respect of such subsequent interest
computation period shall be automatically increased to such Maximum Amount;
provided that at no time shall
-22-
<PAGE> 28
the aggregate amount by which interest paid for the account of Lender has been
increased pursuant to this sentence exceed the aggregate amount by which
interest paid for its account has theretofore been reduced pursuant to the
immediately preceding sentence.
2.12 Computations. Subject to the provisions of Section 8.12 of this
Agreement, interest on all Advances as well as computation of the Facility A
Commitment Fee shall be calculated on the basis of actual days elapsed, but
computed as if each year consisted of 360 days. All LIBOR Advances shall bear
interest from and including the first day of the applicable Interest Period to
(but not including) the last day of such Interest Period. All Prime Advances
shall bear interest from and including each Quarterly Date to (but not
including) the next Quarterly Date.
2.13 Taxes. All payments made by Borrower under this Agreement shall be
made free and clear of and without deduction for or on account of any present
or future income, stamp or other Taxes (excluding, however, Taxes imposed on
the overall net income of Lender or any franchise Taxes).
2.14 Capital Adequacy; Increased Costs.
(a) If Lender shall have determined that any change after the Effective
Date in any applicable Law or guideline regarding capital adequacy, capital
maintenance or similar requirements against loan commitments made by Lender
(including any such applicable Law or guideline which may be adopted before the
date of this Agreement but which requirements are phased in over a period of
time), or any change therein, or any change in the interpretation or
administration thereof by any Tribunal, central bank or comparable agency
charged with the interpretation or administration thereof, or compliance by
Lender (or any Lending Office of Lender) or any corporation controlling Lender
with any request or directive regarding capital adequacy, capital maintenance
or similar requirements against loan commitments, whether or not having the
force of law (each such adoptions or modification and each interpretation or
administration being herein called a "Regulatory Modification"), has or would
have the effect of increasing the cost of Lender with respect to this Agreement
as a result of reducing the rate of return on Lender's or such corporation's
capital as a consequence of its obligations hereunder ("Additional Costs") to a
level below that which Lender or such corporation could have achieved but for
such adoption, change or compliance (taking into consideration Lender's or such
corporation's policies with respect to such capital impositions) by an amount
deemed by Lender to be material, then from time to time, Borrower shall pay to
Lender such Additional Costs as will compensate Lender for such reduction. No
failure by Lender to immediately demand payment of Additional Costs payable
hereunder shall constitute a waiver of Lender's right to demand payment of such
Additional Costs at any subsequent time. Determinations by Lender for purposes
of this Section 2.14 shall be presumed correct, provided that such
determinations are made reasonably and in good faith. Nothing contained herein
shall be construed or so operate as to require Borrower to pay any interest,
fees, costs or charges greater than as permitted by Applicable Law.
-23-
<PAGE> 29
(b) If, after the date hereof, any Tribunal, central bank or other
comparable authority, shall at any time impose, modify or deem applicable any
reserve (including, without limitation, any imposed by the Board of Governors
of the Federal Reserve System), special deposit or similar requirement against
assets of, deposits with or for the account of, or credit extended by, Lender,
or shall impose on Lender other conditions affecting a LIBOR Advance, the
Notes, or its obligation to make a LIBOR Advance; and the result of any of the
foregoing is to increase the cost to Lender of making or maintaining LIBOR
Advances, or to reduce the amount of any sum received or receivable by Lender
under this Agreement or under the Notes by an amount deemed by Lender to be
material, then, within five days after demand by Lender, Borrower shall pay to
Lender the additional amount or amounts as will compensate Lender for the
increased cost or reduction. A certificate of Lender claiming compensation
under this Section 2.14 and setting forth in reasonable detail the calculation
of the additional amount or amounts to be paid to it hereunder shall be
conclusive in the absence of manifest error. If Lender demands compensation
under this Section 2.14, Borrower may at any time, upon at least five Business
Days' prior notice to Lender either (i) repay in full the then outstanding
principal amount of LIBOR Advances, together with accrued interest thereon, or
(ii) convert such LIBOR Advances to Prime Advances in accordance with the
provisions of this Agreement; provided, however, that Borrower shall be liable
for any Consequential Loss arising pursuant to such actions.
(c) Notwithstanding any other provision of this Agreement, if the
introduction of or any change in or in the interpretation or administration of
any Law shall make it unlawful, or any central bank or other Tribunal shall
assert that it is unlawful, for Lender to perform its obligations hereunder to
make LIBOR Advances or to continue to fund or maintain LIBOR Advances
hereunder, then, on notice thereof and demand therefor by Lender to Borrower,
(i) each LIBOR Advance will automatically, upon such demand, convert into a
Prime Advance and (ii) the obligation of Lender to make, or to convert into or
Continue Advances as, LIBOR Advances shall be suspended until Lender notifies
Borrower that Lender has determined that the circumstances causing such
suspension no longer exist.
(d) Upon the occurrence and during the continuance of any Default or Event
of Default, (i) each LIBOR Advance will automatically, on the last day of the
then existing Interest Period therefor, convert into a Prime Advance and (ii)
the obligation of Lender to make, or to convert into or Continue Advance as,
LIBOR Advances shall be suspended.
(e) Failure on the part of Lender to demand compensation for any increased
costs, increased capital or reduction in amounts received or receivable or
reduction in return on capital pursuant to this Section 2.14 with respect to
any period shall not constitute a waiver of Lender's right to demand
compensation with respect to such period or any other period.
(f) The obligations of Borrower under this Section 2.14 shall survive any
termination of this Agreement; provided that at no time may Lender demand any
compensation under Sections 2.14(a) or (b) for any amount with respect to any
period prior to the date which is six
-24-
<PAGE> 30
months prior to the date of the notice or certificate delivered by Lender
pursuant to either Section 2.14(a) or (b); provided further that Lender shall
not demand any compensation under Section 2.14(a) or (b) except in accordance
with Lender's normal policies for administering loans with similar provisions.
(g) Determinations by Lender for purposes of this Section 2.14 shall be
conclusive, absent manifest error. Any certificate delivered to Borrower by
Lender pursuant to this Section 2.14 shall include in reasonable detail the
basis for Lender's demand for additional compensation.
ARTICLE III. CONDITIONS PRECEDENT TO ADVANCES.
3.1 Conditions Precedent to Advances. The obligation of Lender to make
the first Advance to be made by it hereunder is subject to the satisfaction of
the following conditions:
(a) Laws. The making of the Facility A Commitment and the Facility B
Commitment shall not contravene any Law applicable to Lender.
(b) No Default. (i) No Material Adverse Change, as determined by Lender,
shall have occurred and be continuing since September 30, 1996, and (ii) there
shall not be a Default or Event of Default existing.
(c) Representations and Warranties. The representations and warranties
in Article VI and the other Loan Papers shall be true and correct in all
material respects.
(d) Certificate. Borrower shall have delivered to Lender an officer's
certificate for each Obligor, executed by authorized officers of such Obligor,
dated the Effective Date, certifying (A) that attached thereto is a copy of its
certificate or articles of incorporation certified by the Secretary of State
(or other appropriate officer) of the jurisdiction of its incorporation, which
is true and complete, and in full force and effect, without amendment except as
shown, (B) that attached thereto is a copy of its bylaws, which is true and
complete, and in full force and effect, without amendment except as shown, (C)
that attached thereto is a copy of the resolutions of the board of directors of
such Obligor authorizing execution, delivery and performance of this Agreement
and all other Loan Papers, which are true and complete, are in full force and
effect, were duly adopted, have not been amended, modified, or revoked, and
constitute all resolutions of such Obligor adopted with respect to this loan
transaction, (D) that attached thereto are certificates of good standing and
certificates of existence for such Obligor issued not more than ten days prior
to the Effective Date, issued by the appropriate officer of the jurisdiction of
organization of such Obligor and of each jurisdiction in which the nature of
such Obligor's business or properties require such qualification, (E) with
respect to Borrower, that the pledged interests in ANS have been issued and are
outstanding and a description of the ownership of the pledged interests in ANS,
(F) with respect to each Obligor other than Borrower, a description of the
ownership of all authorized, issued and outstanding equity interests of such
Obligor and
-25-
<PAGE> 31
(G) to the incumbency, name, and signature of each officer authorized to sign
this Agreement and any other Loan Paper on its behalf. Lender may conclusively
rely on each certificate delivered pursuant to this Section 3.1(d) until it
receives notice from Borrower in writing to the contrary.
(e) Proceedings. All corporate proceedings of each Obligor taken in
connection with the transactions contemplated by this Agreement and all
documents incidental thereto shall be satisfactory in form and substance to
Lender and Special Counsel; and Lender shall have received, as of the Effective
Date, copies of all documents or other evidence which Lender or Special Counsel
may reasonably request in connection with said transactions.
(f) Loan Papers. Each Obligor shall have delivered to Lender the Loan
Papers to be executed by such Obligor, dated as of the Effective Date,
appropriately completed.
(g) Existing Facility A. Borrower shall have paid to Lender and Lender
shall have received all accrued unpaid interest on and fees (including
commitment fees) in respect of advances under Existing Facility A. All
outstanding, unpaid principal of advances under Existing Facility A shall be
renewed and restated and evidenced by the Facility A Note.
(h) Origination Fee. Borrower shall have paid to Lender and Lender shall
have received the fee described in Section 2.4(b).
(i) Documents. Borrower shall have delivered to Lender the following (in
the number of counterpart requested by Lender), all in form and substance
satisfactory to Lender:
(i) The results of UCC and other Lien searches against the assets
of each Obligor, and evidence satisfactory to Lender that all Liens
(other than Permitted Liens) in favor of any Person against assets of any
Obligor shall have been released and any credit facility related to any
of the above shall have been terminated.
(ii) Evidence satisfactory to Lender of the perfection and
priority of the Liens in the Collateral.
(iii) If requested by Lender, reasonable evidence that any
Obligor is the rightful owner and has good title to its Collateral, as
applicable.
(iv) A certificate computed after giving effect to the Initial
Advance, but demonstrating compliance on the Effective Date with all
financial ratios described in Sections 5.6, 5.7, 5.8 and 5.9 (determined
on a pro forma basis as of the Effective Date, based on the unaudited
financial statements of Borrower as of December 31, 1996).
(v) Copies of insurance binders or certificates covering the
assets of each Obligor indicating Lender as a loss payee.
-26-
<PAGE> 32
(vi) Payment of all fees (including attorneys' fees) incurred by
Lender.
(vii) Copies of all documentation relating to debt owed by
Borrower and each other Obligor to any Person, including without
limitation, all credit agreements, notes, collateral documents, bonds,
instruments and other documentation in connection with any extension of
credit.
(viii) Certificates for all of the outstanding capital stock of
each Subsidiary of Borrower and stop transfer and Article 8 letters in
favor of Lender.
(ix) Stock and other powers for all shares of the outstanding
capital stock of each Subsidiary of Borrower.
(x) Executed UCC financing statements with respect to all
furniture, equipment, inventory and stock certificates with respect to
the Borrower and each Subsidiary of Borrower.
(xi) Executed Pledge Agreement in the form of Exhibit L with
respect to all capital stock of Borrower's Subsidiaries, all marketable
securities and a $350,000 certificate of deposit or time deposit at
NationsBank together with the delivery of such capital stock, securities
(excluding certificates evidencing marketable securities), certificate of
deposit or time deposit.
(xii) The Borkan Subordination Agreement and the Borkan
Subordination Agreement, together with copies of each agreement
evidencing or securing the Subordinated Obligations (as that term is
defined in each such Subordination Agreement).
(j) Financial Condition Certificate. Lender shall have received a
certificate of each Obligor to the effect that: (i) the fair and saleable value
of the assets of such Obligor, after giving effect to this Agreement, the Notes
and the other Loan Papers, will exceed amounts that will be required to be paid
by such Obligor on or in respect of its existing debts (including contingent
liabilities) as they mature; (ii) such Obligor will not have unreasonably small
capital to carry out its business as now conducted or as proposed to be
conducted, and (iii) such Obligor has not incurred debts beyond its ability to
pay such debts as they mature.
(k) Opinion of Counsel. Lender shall have received an opinion of Hughes &
Luce L.L.P. acceptable to Lender and Special Counsel.
(l) Further Documents. As of the Effective Date, Lender shall have
received, in form and substance satisfactory to Lender and Special Counsel,
such other documents
-27-
<PAGE> 33
and instruments as Lender may reasonably require to evidence the status,
organization or authority of Borrower, and to evidence payment of the
Obligation.
3.2 Conditions Precedent to All Advances. Lender shall not be obligated
to make any Advance, if (a) there is in existence at such time a Default under
Section 4.2, 5.6, 5.7, 5.8, or 5.9; (b) an Event of Default has occurred and is
continuing; (c) if any representations and warranties contained in Article VI
of this Agreement shall be false or untrue in any material respect on the date
of such Advance, as if made on such date except for representations and
warranties that are by their express terms limited to a specific date; or (d)
any Subsidiary of Borrower has not executed and delivered to Lender a Guaranty
Agreement. Each request by Borrower for an Advance shall constitute a
representation by Borrower that it is in compliance with the provisions of this
Section 3.2.
3.3 Legal Details. All documents executed or submitted pursuant hereto
by Borrower shall be satisfactory in form and substance to Lender and Special
Counsel. Lender and Special Counsel shall receive all information, and such
counterpart originals or certified or other copies of and such materials, as
Lender or Special Counsel may reasonably request. All legal matters incident
to the transactions contemplated by this Agreement (including, without
limitation, matters arising from time to time as a result of changes occurring
with respect to any Laws) shall be satisfactory to Special Counsel.
ARTICLE IV. AFFIRMATIVE COVENANTS
From the date hereof, and so long as this Agreement is in effect and until
final payment in full of the Obligation and the performance of all other
obligations of Borrower under this Agreement and the other Loan Papers,
Borrower agrees and covenants that it shall, and shall cause each Subsidiary of
Borrower to, observe, perform, comply and fulfill each and every covenant, term
and provision set forth below:
4.1 Books, Records and Properties. Borrower shall, and shall cause each
Subsidiary of Borrower to, maintain its books and records in accordance with
GAAP. Borrower during normal business hours and after reasonable notice by
Lender shall, and shall cause each Subsidiary of Borrower to, permit any of
Lender's agents or representatives to have access to and examine its books and
records, including statements and schedules with respect to the Collateral, and
to copy and make abstracts therefrom, and to inspect any of the properties of
Borrower and each Subsidiaries of Borrower to, at any time(s) hereafter during
normal business hours; provided, that any such access or inspection shall not
disrupt Borrower's operations.
4.2 Financial Statements and Reports. Borrower shall furnish or cause
to be furnished to Lender the following Financial Statements and reports:
(a) Accounting Period Statements. As soon as practicable after the end
of each fiscal quarter of Borrower and in any event within 45 days after the
end of each fiscal quarter of
-28-
<PAGE> 34
Borrower, copies of Financial Statements as of the end of such quarter, all in
reasonable detail and certified as complete and correct in all material
respects, subject to changes resulting from year-end adjustment, by a financial
officer of Borrower or any other Person acceptable to Lender;
(b) Annual Statements. As soon as practicable after the end of each
fiscal year of Borrower and in any event within 90 days thereafter, copies of
annual Financial Statements, setting forth in each case in comparative form the
figures for the previous fiscal year, all in reasonable detail and accompanied
by an unqualified opinion of independent certified public accountants approved
by Borrower's board of directors, which opinion shall state that the Financial
Statements have been prepared in accordance with GAAP, that their examination
has been made in accordance with generally accepted auditing standards and that
said financial statements present fairly the consolidated financial position of
Borrower and its Subsidiaries and their results of operations;
(c) Compliance Certificate and related reports. Within 45 days after the
end of each fiscal quarter, the Compliance Certificate for the last day of such
quarter.
(d) Borrowing Base Certificate and related reports. Within 15 days after
the end of each month:
(i) The Borrowing Base Certificate for the last day of such month;
(ii) A schedule showing for such month an aging of Accounts of
Borrower in categories of current, 30 days past due, 60 days past due and
91 or more days past due; and
(iii) A schedule showing for such month Accounts payable by each
account debtor of which 10% or more of the aggregate dollar amount of all
Accounts owed to Borrower by such account debtor have been due and
payable for 91 days or more from their respective invoice dates;
(e) Contingent Liabilities Report. Promptly upon becoming aware, written
notice of any actual or potential contingent liabilities, including Litigation,
against Borrower or any Subsidiary of Borrower involving liability in an amount
which must be disclosed in either Borrower's financial statements or filings
with the Securities and Exchange Commission.
(f) FDA Reports. Promptly upon receipt from FDA, a copy of each
inspection report received from FDA and responses from and to FDA.
(g) SEC Filings. As soon as filed with the Securities and Exchange
Commission, copies of each of Borrower's forms 10-Q, 10-K and 8-K.
-29-
<PAGE> 35
4.3 Maintenance of Existence. Borrower shall cause to be done all
things necessary to preserve and keep in full force and effect Borrower's and
each of Borrower's Subsidiaries' existence as a corporation; provided, (a) any
Subsidiary of Borrower may merge with and into Borrower if Borrower is the
surviving entity and (b) any Subsidiary of Borrower may merge with and into
another Subsidiary of Borrower.
4.4 Insurance. Borrower shall maintain, and shall cause each Subsidiary
of Borrower to, in force with financially sound and reputable insurers, the
insurance policies required pursuant to the Loan Papers in accordance with the
provisions thereof and such other policies with respect to its respective
property and business against such casualties and contingencies (including
fire, worker's compensation or occupational injury insurance, business
interruption and public liability) and in such amounts as is customary in the
lines of business of comparable size and financial strength, with a loss payee
endorsement for casualty insurance in favor of Lender and noncancelable without
30 days prior notice to Lender. Borrower shall supply evidence of such
insurance to Lender.
4.5 Compliance with Applicable Laws. Borrower shall, and shall cause
each Subsidiary of Borrower to, comply with the requirements of all applicable
Laws and orders (including but not limited to the FDA Act, ERISA and
environmental laws) of Tribunals or other governmental authorizations necessary
to the ownership of Borrower's and each of Subsidiary's of Borrower properties
or to the conduct of its business if the result of failure to so comply would
have a Material Adverse Effect.
4.6 Other Information and Documents. Borrower shall, and shall cause
each Subsidiary of Borrower to, promptly deliver to Lender such information,
certificates and documents in addition to those herein mentioned as Lender may
from time to time reasonably request.
4.7 Default. Borrower shall report to Lender immediately any Default or
Event of Default, and any notice of any claimed default under any other Debt
agreement, specifying the default and steps taken or to be taken to cure.
4.8 Taxes. Borrower shall pay any stamp, loan, transaction or similar
taxes that may be imposed on this Agreement, the Advances hereunder, the Notes,
or any of the transactions hereunder, and shall pay, and shall cause each
Subsidiary of Borrower to, all income, ad valorem, and other taxes of Borrower
or such Subsidiary before they become delinquent except taxes being contested
by appropriate means and in good faith and the levy and execution of which have
been stayed and continued to be stayed. Any such taxes must be paid before
their nonpayment causes a Lien (other than a Permitted Lien) to be filed on any
of the Collateral.
4.9 Further Assurances. Borrower will, and will cause each other
Obligor to, on request of Lender, promptly correct any defect, error or
omission which may be discovered in the contents of any of the Loan Papers or
in the execution or acknowledgment thereof, and will
-30-
<PAGE> 36
execute, acknowledge and deliver such further instruments and do such further
acts as may be necessary or as may be requested by Lender to carry out more
effectively the purposes of this Agreement and the Loan Papers and to subject
to the Liens any of Borrower's or any other Obligor's properties, rights or
interests covered or intended to be covered thereby, and to perfect and
maintain all Liens at any time securing all or any part of the debt hereunder.
4.10 Filings. Borrower will pay all expenses incurred in connection with
the filing of any of the Loan Papers and every other instrument in addition or
supplemental to any thereof that shall be required by Law in order to perfect
and maintain the validity and effectiveness of Liens at any time securing all
or any part of the debt hereunder.
4.11 Maintenance. Borrower will, and shall cause each Subsidiary of
Borrower to, maintain all of Borrower's and such Subsidiary's material property
in good condition and repair (wear and tear excepted) and make all necessary
replacements thereof, and preserve and maintain all material leases, licenses,
privileges, franchises, certificates and the like used in the operation of
Borrower's and such Subsidiary's business (other than with respect to any such
lease, license, privilege, franchise and certificate which the Board of
Directors of Borrower or such Subsidiary of Borrower has determined that the
expiration or termination of which is in the best interest of Borrower or such
Subsidiary of Borrower, respectively).
4.12 ERISA Compliance. Borrower shall, and shall cause each Subsidiary of
Borrower to, (a) at all times, make prompt payment of all contributions
required under all Plans and required to meet the minimum funding standard set
forth in ERISA with respect to its Plans, (b) notify Lender immediately of any
fact, including, but not limited to, any Reportable Event arising in connection
with any of its Plans, which might constitute grounds for termination thereof
by the PBGC or for the appointment by the appropriate United States District
Court of a trustee to administer such Plan, together with a statement, if
requested by Lender as to the reason therefor and the action, if any, proposed
to be taken with respect thereto, and (c) furnish to Lender, upon its request,
such additional information concerning any of its Plans as may be reasonably
requested.
4.13 Indemnity by Borrower. Borrower shall indemnify, save, and hold
harmless Lender and its shareholders, directors, officers, agents, attorneys,
and employees (collectively, the "Indemnitees") from and against: (a) any and
all claims, demands, actions, or causes of action that are asserted by any
Person other than Borrower, its shareholders, directors, officers, agents,
attorneys, and employees against any Indemnitee if the claim, demand, action or
cause of action relates to the Obligations, the use of proceeds of any Advance,
or the relationship of Borrower and Lender under this Agreement or any
transaction contemplated pursuant to this Agreement or any other Loan Paper,
(b) any proceeding or any administrative, investigative or arbitration
proceeding by or before any Tribunal or arbitral directly or indirectly related
to (i) a claim, demand, action or cause of action described in clause (a) above
or (ii) any claim, demand, proceeding, action or cause of action involving
Borrower or any Affiliate (including any shareholder) of Borrower in which any
Indemnitee incurs costs and expenses as a result of any
-31-
<PAGE> 37
requirement that such Indemnitee testify or produce records therein (other than
as a result of any Litigation commenced by an Indemnitee or Borrower in which
such Indemnitee is not a prevailing party), and (c) any and all liabilities,
losses, costs, or expenses (including attorneys' fees and disbursements) that
any Indemnitee suffers or incurs as a result of any of the foregoing (other
than as a result of any Litigation commenced by an Indemnitee or Borrower in
which such Indemnitee is not the prevailing party); provided, however, that
Borrower shall not have any obligation under this Section 4.13 to a particular
Indemnitee or with respect to any of the foregoing arising out of the
negligence or willful misconduct of such Indemnitee. If any claim, demand,
action or cause of action is asserted against any Indemnitee, such Indemnitee
shall promptly notify Borrower, but the failure to so promptly notify Borrower
shall not affect Borrower's obligations under this Section 4.13 except to the
extent such failure materially impairs Borrower's ability to defend any such
claim, demand, action or cause of action. Any obligation or liability of
Borrower to any Indemnitee under this Section 4.13 shall survive the expiration
or termination of this Agreement and the repayment of the Obligation.
ARTICLE V. NEGATIVE COVENANTS
From the date hereof and so long as this Agreement is in effect and until
final payment in full of the Obligation, and the performance of all other
obligations of Borrower under this Agreement and the other Loan Papers,
Borrower agrees and covenants that it shall, and shall cause each of its
Subsidiaries to, observe, perform, comply and fulfill each and every covenant,
term and provision set forth below:
5.1 Liens. Borrower shall not, and shall not permit any Subsidiary of
Borrower to, grant, permit or suffer to exist any Lien on any of its property
or assets, except (a) Permitted Liens, and (b) Liens granted under the Loan
Papers.
5.2 Transfer of Assets. Borrower shall not, and shall not permit any
Subsidiary of Borrower to, sell, lease, transfer, or otherwise dispose of
assets of Borrower or such Subsidiary, except (a) payments of business expenses
of Borrower or such Subsidiary in the ordinary course of business, (b)
Inventory and Investments in the ordinary course of business and for full and
fair consideration, (c) assets which Borrower or such Subsidiary determines in
good faith are worthless or obsolete, (d) assets not subject to a Lien or
license in favor of Lender the value of which, individually and in the
aggregate, does not exceed 5% of the gross revenue of Borrower and its
Subsidiaries (determined on or consolidated basis) during the preceding fiscal
year from operations, or (e) in connection with Investments permitted pursuant
to Section 5.4.
5.3 New Industry. Borrower shall not, and shall not permit any
Subsidiary of Borrower to, enter any industry or type of business which is not
directly related to the research, design, development, manufacture and/or
marketing of Devices.
-32-
<PAGE> 38
5.4 Restricted Investments. Borrower shall not make or have outstanding
any Investments, except for Permitted Investments.
5.5 Transactions with Affiliates. Borrower shall not, and shall not
permit any Subsidiary of Borrower to, enter into any transaction with any
Affiliate, except in the ordinary course of the business of Borrower or such
Subsidiary, and on fair and reasonable terms no less favorable to Borrower or
such Subsidiary than it would obtain in a comparable arm's length transaction
with a Person not an Affiliate.
5.6 Fixed Charges Coverage Ratio. Borrower shall not permit the Fixed
Charges Coverage Ratio to be less than the following ratios for the fiscal
quarters ending as follows:
December 31, 1996 0.70 to 1.00
March 31, 1997 1.00 to 1.00
June 30, 1997 1.20 to 1.00
September 30, 1997 1.50 to 1.00
December 31, 1997 1.75 to 1.00
5.7 Margin Ratio. Borrower shall not permit the Margin Ratio to be
greater than the following ratios for the fiscal quarters ending as follows:
March 31, 1997 2.00 to 1.00
June 30, 1997 1.85 to 1.00
September 30, 1997 1.75 to 1.00
December 31, 1997 1.65 to 1.00
5.8 Total Liabilities to Tangible Worth Ratio. Borrower shall not
permit the ratio of Total Liabilities to Tangible Net Worth to be greater than
as indicated below, (a) as at the end of each fiscal quarter of Borrower,
ending during the period indicated or (b) on the date indicated:
Effective Date through December 31, 1996 2.50 to 1.00
March 31, 1997 and thereafter 1.75 to 1.00
5.9 Capital Expenditures. Borrower shall not permit the aggregate
amount of Capital Expenditures incurred or paid during calendar year 1997 to
exceed $1,500,000.
5.10 Merger and Consolidation. Borrower shall not, and shall not permit
any Subsidiary of Borrower to, merge or consolidate with any other Person or
allow any other Person to merge or consolidate with it.
5.11 Debt. Borrower shall not, and shall not permit any Subsidiary of
Borrower to, create, incur, assume, become or be liable in any manner in
respect of, or suffer to exist, any Debt for Borrowed Money, except (a) Debt
under the Loan Papers, (b) obligations in respect of
-33-
<PAGE> 39
trade payables (i) incurred by Borrower or a Subsidiary of Borrower in the
ordinary course of business, and (ii) not in excess of $250,000 in the
aggregate, (c) Debt the proceeds of which was used solely for the acquisition
and construction of the Allen Property not in excess of the amount of such Debt
on the Effective Date, as reduced by payments on and after the Effective Date,
(d) Debt payable to William Borkan pursuant to Section 1.2(iii) of the Neuromed
Agreement and the Borkan Debt, and (e) the Swisher Debt; provided, the
aggregate amount of the Borkan Debt and the Swisher Debt shall not exceed
$3,000,000.
5.12 Distributions. Borrower shall not declare, pay, make or become
liable for any Distribution.
ARTICLE VI. REPRESENTATIONS AND WARRANTIES
Borrower represents and warrants as follows:
6.1 Organization; Qualification; Authority. Borrower and each
Subsidiary of Borrower is a corporation duly organized, validly existing and in
good standing under the laws of the state indicated on Schedule 1. Borrower
and each Subsidiary of Borrower has the power to own its properties and to
carry on its businesses as now being conducted. The Board of Directors of
Borrower has duly authorized the execution, delivery and performance of the
Loan Papers to be executed by Borrower. No consent of the shareholders of
Borrower is required as a prerequisite to the validity and enforceability of
any Loan Papers or any other document contemplated hereby. Borrower has full
legal right and corporate power, and authority to execute, deliver, and perform
its obligations under the Loan Papers to be executed and delivered by it.
6.2 Financial Statements. The unaudited financial statements for the
fiscal year ended December 31, 1996 and the unaudited financial statements for
the nine months ended September 30, 1996 and for the most recent fiscal quarter
(including any related schedules and/or notes) are true and correct in all
material respects (subject, as to interim statements, to charges resulting from
audits and year-end adjustments) have been prepared in accordance with GAAP
(except, as to interim statements, for notes and year-end adjustments)
consistently followed throughout the periods specified, and fairly present in
accordance with GAAP the financial condition and results of operations of
Borrower as at the dates thereof and for the periods indicated. There has been
no material adverse change in the business, condition or operations (financial
or otherwise) of Borrower since September 30, 1996.
6.3 Conflicting Agreements and Other Matters. Neither Borrower nor any
Subsidiary of Borrower is a party to any contract or agreement or subject to
any restriction which materially and adversely affects the ability of Borrower
to perform its obligations under the Loan Papers. Neither the execution nor
delivery of this Agreement, the Notes, or the other Loan Papers, nor
fulfillment of nor compliance with the terms and provisions of this Agreement,
the Notes or the other Loan Papers will conflict with, or result in a breach of
the terms, conditions or provisions
-34-
<PAGE> 40
of, or constitute a default under, or result in any violation of, or result in
the creation of any Lien (except for Liens created by the Loan Papers) upon any
of the properties or assets of Borrower or any Subsidiary of Borrower pursuant
to the articles of incorporation of Borrower or such Subsidiary, any award of
any arbitrator or any agreement, instrument, order, judgment, decree, statute,
law, rule or regulation to which Borrower or such Subsidiary is subject.
Neither Borrower nor any Subsidiary of Borrower is a party to, or otherwise
subject to any provision contained in, any instrument evidencing indebtedness
of Borrower or such Subsidiary, any agreement relating thereto or any other
contract or agreement which limits the amount of, or otherwise imposes
restrictions on the incurring of, Debt of Borrower of the type to be evidenced
by the Notes.
6.4 Governmental Consent. Neither the nature of Borrower or any
Subsidiary of Borrower, its businesses or properties, nor any relationship
between Borrower, any Subsidiary of Borrower and any other Person, nor any
circumstance in connection with the execution, delivery and performance of this
Agreement, the Loan Papers or the Notes is such as to require any
authorization, consent, approval, exemption of other action by or notice to or
filing with any court or Tribunal (other than routine filings and recordings to
perfect Liens) in connection with the execution and delivery of this Agreement,
the Notes, the other Loan Papers, or fulfillment of or compliance with the
terms and provisions hereof, of the Notes or of the other Loan Papers.
6.5 Enforceability. This Agreement is, the other Loan Papers are and
the Notes when delivered will be legal, valid and binding obligations of
Borrower enforceable against Borrower in accordance with their terms, except as
limited by Debtor Relief Laws.
6.6 Actions Pending. Other than as described on Schedule 3, there is no
Litigation pending or, to the knowledge of Borrower, threatened against
Borrower or any Subsidiary of Borrower, or any properties or rights of Borrower
or any Subsidiary of Borrower, by or before any court, arbitrator or Tribunal
which may reasonably be expected to result in any Material Adverse Effect.
There is no Litigation pending or, to the knowledge of Borrower, threatened
against Borrower or any Subsidiary of Borrower which purports to affect the
validity or enforceability of this Agreement, either Note or any of the other
Loan Papers.
6.7 Outstanding Debt. Neither Borrower nor any Subsidiary of Borrower
has any outstanding Debt except (a) as described on the balance sheet of
Borrower for the nine months ended September 30, 1996, (b) trade payables
incurred in the ordinary course of business, (c) Debt for Borrowed Money owed
to Lender, (d) Debt of Borrower to William Borkan as described in and subject
to the Borkan Security Agreement, and (e) Debt of Borrower to Robert Swisher as
described in and subject to the Swisher Security Agreement. There exists no
default under the provisions of any instrument evidencing such Debt or of any
material agreement relating thereto.
6.8 Title to Properties. Borrower and each Subsidiary of Borrower has
good and indefeasible title to its respective real properties (other than
properties which it leases) and good
-35-
<PAGE> 41
title to all of its other material properties and assets used in the operations
of its business, subject to no Lien of any kind except Liens permitted by
Section 5.1. All leases necessary in any material respect for the conduct of
the respective businesses of Borrower are valid and subsisting and are in full
force and effect.
6.9 Taxes. Borrower and each Subsidiary of Borrower has paid all taxes
and assessments owed by it to the extent that such taxes and assessments have
become due, except such taxes as are being contested in good faith by
appropriate proceedings for which adequate reserves have been established in
accordance with GAAP.
6.10 Regulation G, etc. Neither Borrower nor any Subsidiary of Borrower
owns or has any present intention of acquiring any "margin stock" as defined in
Regulation G (12 CFR Part 207) of the Board of Governors of the Federal Reserve
System (herein called "margin stock"). None of the proceeds of any Advance
will be used, directly or indirectly, for the purpose, whether immediate,
incidental or ultimate, of purchasing or carrying any margin stock or for the
purpose of maintaining, reducing or retiring any indebtedness which was
originally incurred to purchase or carry any stock that is currently a margin
stock or for any other purpose which might constitute this transaction a
"purpose credit" within the meaning of such Regulation G. Neither Borrower
nor any agent acting on its behalf has taken or will take any action which
might cause this Agreement or the Notes to violate Regulation G, Regulation T,
Regulation X or any other regulation of the Board of Governors of the Federal
Reserve System or to violate the Securities Exchange Act of 1934, as amended,
in each case as in effect now or as the same may hereafter be in effect.
6.11 ERISA. No accumulated funding deficiency (as defined in section 302
of ERISA and section 412 of the Code), whether or not waived, exists with
respect to any Plan. No liability to the PBGC has been or is expected by
Borrower or any Subsidiary of Borrower to be incurred with respect to any Plan
by Borrower or any Subsidiary of Borrower which is or would be materially
adverse to Borrower or any Subsidiary of Borrower. Neither Borrower nor any
Subsidiary of Borrower has incurred or presently expects to incur any
withdrawal liability under Title IV of ERISA with respect to any Multiemployer
Plan which is or would be materially adverse to Borrower.
6.12 Disclosure. Neither this Agreement or any other document,
certificate or statement furnished, or to be furnished, to Lender by or on
behalf of Borrower or any other Obligor in connection herewith or therewith
contains any untrue statement of a material fact or omits to state a material
fact necessary in order to make the statements contained herein and therein not
misleading in any material respect.
6.13 Environmental Matters. Borrower, each Subsidiary of Borrower, the
plants and sites each owns, and to the best of Borrower's knowledge after due
inquiry of the owners of leased property the plants and sites which each leases
have complied with all federal, state, local and regional statutes, ordinances,
orders, judgments, rulings and regulations relating to any
-36-
<PAGE> 42
matters of pollution or of environmental regulation or control except, in any
such case, where such failure to comply would not result in a Material Adverse
Effect. Without limiting the generality of the preceding sentence, neither
Borrower nor any Subsidiary of Borrower has received notice of and does not
have actual knowledge of any actual or claimed or asserted failure so to comply
which alone or together with any other such failure is material and would
result in a Material Adverse Effect. During periods of use, ownership,
occupancy or operation by Borrower and each Subsidiary of Borrower, none of
Borrower, any Subsidiary of Borrower, or their respective plants or sites have
managed, generated, released or disposed of, any hazardous wastes, hazardous
substances, hazardous materials, toxic substances or toxic pollutants, as those
terms are used or defined in the Resource Conservation and Recovery Act, the
Comprehensive Environmental Response Compensation and Liability Act, the
Hazardous Materials Transportation Act, the Toxic Substance Control Act, the
Clean Air Act and the Clean Water Act, in material violation of or in a manner
which would result in liability under such statutes or any regulations
promulgated pursuant thereto or any other applicable law, except where such
noncompliance or liability would not result in a Material Adverse Effect.
6.14 Sufficiency of Capital. Borrower and each Subsidiary of Borrower
are, and after consummation of this Agreement and after giving effect to the
Obligation incurred and Liens created by Borrower and each Subsidiary of
Borrower in connection herewith will be, Solvent.
6.15 Affiliates. No Affiliate of Borrower exists, except as identified
on Schedule 1.
6.16 Intellectual Property. Except as identified on Schedule 4 hereto or
patents, trademarks or copyrights for which neither the Borrower nor any
Affiliate of Borrower has applied for a copyright registration, trademark
registration or patent and no copyright, trademark or patent has been issued or
registered on behalf of Borrower or an Affiliate of Borrower, neither Borrower
nor any Affiliate of Borrower owns or has any right or interest in any
intellectual property, including but not limited to patents, trademarks and
copyrights.
ARTICLE VII. DEFAULT
7.1 Events of Default. The term "Event of Default" as used herein,
means the occurrence and continuance of any one or more of the following events
(including the passage of time, if any, specified therefor):
(a) Borrower shall fail to pay any amount, whether principal, interest or
other amounts, payable hereunder or under the Notes when due and such failure
shall continue for three days from the date due; or
(b) (i) Any representation or warranty made by Borrower or any other
Obligor under or in connection with any Loan Paper shall prove to have been
incorrect in any material respect when made or (ii) (A) a breach of any
representation or warranty made by any party thereto (other than Borrower)
under or in connection with any Acquisition Document is discovered, (B)
-37-
<PAGE> 43
Lender makes a determination that such breach has caused or will cause a
Material Adverse Change or Effect and gives notice thereof to Borrower, and (C)
such breach has not already been cured or paid for by such party, or,
alternatively, Borrower or such party does not cure such breach or the
situation giving rise thereto to the complete satisfaction of Lender within 30
days after receipt of such notice from Lender; or
(c) Borrower shall fail to perform or observe any term, covenant or
agreement contained in Sections 5.6, 5.7, 5.8, or 5.9 and such failure shall
continue for two consecutive months or any other provision of Article V of this
Agreement; or
(d) Borrower or any other Obligor shall fail to perform or observe any
term, covenant or agreement contained in any Loan Paper on its part to be
performed or observed, other than described in Section 7.1(a), (b), or (c), and
such default has continued for a period of 30 days; or
(e) Borrower, any Subsidiary of Borrower or any other Obligor shall fail
to pay any Debt (other than under the Loan Papers) which is, singly or in the
aggregate, in an amount equal to or greater than $100,000, or any interest or
premium thereon, when due (whether by scheduled maturity, required prepayment,
acceleration, demand or otherwise) and such failure shall continue after the
applicable grace period, if any, specified in the agreement or instrument
relating to such Debt; or any other default under any agreement or instrument
relating to any such Debt, or any other event, shall occur and shall continue
after the applicable grace or cure period, if any, specified in such agreement
or instrument, if the effect of such default or event is to accelerate, or to
permit the acceleration of, the maturity of such Debt; or any such Debt shall
be declared to be due and payable, or required to be prepaid (other than by a
regularly scheduled required prepayment), prior to the stated maturity thereof;
or
(f) Borrower, any Subsidiary of Borrower or any other Obligor shall
generally not pay its debts as such debts become due, or shall admit in writing
its inability to pay its debts generally, or shall make a general assignment
for the benefit of creditors; or any proceeding shall be instituted by or
against Borrower, any Subsidiary of Borrower or any other Obligor seeking to
adjudicate it a bankrupt or insolvent, or seeking liquidation, winding-up,
reorganization, arrangement, adjustment, protection, relief, or composition of
it or its debts under any Debtor Relief Laws, or seeking the entry of an order
for relief or the appointment of a receiver, trustee, or other similar official
for it or for any substantial part of its property; or Borrower, any Subsidiary
of Borrower or any other Obligor shall take any action to authorize any of the
actions set forth above in this Section 7.1(f); or
(g) Any judgment or order for the payment of money in excess of 10% of
Unrestricted Cash (calculated as at the date of entry of the judgment or order)
shall be rendered against Borrower, any Subsidiary of Borrower or any other
Obligor and either (i) enforcement proceedings shall have been commenced by any
creditor upon such judgment or order or (ii)
-38-
<PAGE> 44
there shall be any period of 30 consecutive days during which a stay of
enforcement of such judgment or order, by reason of a pending appeal or
otherwise, shall not be in effect; or
(h) Lender for any reason shall cease to have a valid and perfected first
priority security interest in any material portion (as reasonably determined by
Lender) of the Collateral purported to be covered thereby; or
(i) FDA or any Tribunal shall issue any order resulting in the banning,
recall or seizure of any Device of Borrower or any Subsidiary of Borrower the
sales of which Device constituted 5% or more of gross sales revenue of Borrower
(determined on a consolidated basis) for the twelve months preceding the date
such order is issued; or
(j) Any Inventory of Borrower or any Subsidiary of Borrower produced in
the United States of America is not produced in compliance with the Fair Labor
Standards Act and such failure results in the banning, recall or seizure of
Inventory constituting 5% or more of the value (valued at the greater of market
or book value without giving effect to such ban, recall or seizure or any other
write down is the value of such Inventory) of all Inventory of Borrower or such
Subsidiary, respectively; or
(k) Any material provision of the Loan Papers shall at any time for any
reason cease to be valid and binding on Borrower or any other Obligor or shall
be declared to be null and void, or the validity or enforceability thereof
shall be contested by Borrower or any other Obligor, or a proceeding shall be
commenced by any Tribunal having jurisdiction over Borrower, any other Obligor
or any Collateral, seeking to establish the invalidity or unenforceability
thereof and such proceeding (if commenced by a Person other than Borrower or
any other Obligor) shall remain undismissed or unstayed for a period of 30
days, or Borrower or any other Obligor shall deny that it has any or further
liability or obligation thereunder; or
(l) The occurrence of a default or event of default (howsoever
designated) contained in any other Loan Paper and such default or event of
default shall continue beyond any applicable grace or cure period.
7.2 Remedies Upon Default. If an Event of Default specified in Section
7.1(f) shall occur and be continuing, the aggregate unpaid principal balance of
and accrued interest on the Obligation shall thereupon become due and payable
and the Facility A Commitment shall immediately terminate concurrently
therewith, without any action by Lender and without diligence, presentment,
demand, protest, notice of protest or intent to accelerate, or notice of any
other kind, all of which are hereby expressly waived. Should any other Event
of Default occur and be continuing, Lender may do any one or more of the
following:
(a) Acceleration. Declare the entire unpaid balance of the Obligation,
or any part thereof, immediately due and payable, whereupon it shall be due and
payable without any action
-39-
<PAGE> 45
by Lender and without diligence, presentment, demand, protest, notice of
protest or intent to accelerate or notice of any other kind, all of which are
hereby expressly waived.
(b) Termination. Terminate the Facility A Commitment.
(c) Judgment. Reduce any claim to judgment.
(d) Rights. Exercise any and all Rights afforded by the Laws of the
State of Texas or any other jurisdiction, including, but not limited to, the
UCC, or by any other Loan Papers, or by Law or equity, or otherwise.
(e) Offset. Exercise the Rights of offset and/or banker's Lien against
the interest of Borrower and each other Obligor in and to every account and
other property of Borrower and each other Obligor which is in the possession of
Lender, to the extent of the full amount of the Obligation.
7.3 Performance by Lender. Should any covenant, duty or agreement of
Borrower fail to be performed in all material respects in accordance with the
terms of this Agreement or the Collateral Documents, Lender may, at its option,
perform, or attempt to perform, such covenant, duty or agreement on behalf of
Borrower. In such event, Borrower shall, at the request of Lender, promptly pay
any amount expended by Lender in such performance or attempted performance to
Lender at Lender's Principal Office, together with interest thereon at the
lesser of (a) the Prime Rate plus 3% and (b) the Highest Lawful Rate from the
date of such expenditure by Lender until paid. Notwithstanding the foregoing,
it is expressly understood that Lender shall not have any liability or
responsibility for the performance of any duties of Borrower hereunder.
7.4 Lender Not in Control. None of the covenants or other provisions
contained in this Agreement shall, or shall be deemed to, give Lender the
Rights or power to exercise control over the affairs management of Borrower,
the power of Lender being limited to the Right to exercise the remedies
provided in this Article VII; provided that, if Lender becomes the owner of any
interest in Borrower, whether through foreclosure or otherwise, Lender shall be
entitled to exercise such legal Rights as it may have by being an owner of such
interest in Borrower.
7.5 Waivers. The acceptance by Lender at any time and from time to time
of part payment on the Obligation shall not be deemed to be a waiver of any
Event of Default or Default then existing. No waiver by Lender of any
particular Event of Default or Default shall be deemed to be a waiver of any
Event of Default or Default other than said particular Event of Default or
Default. No delay or omission by Lender in exercising any Right under any Loan
Papers shall impair such Right or be construed as a waiver thereof or an
acquiescence therein, nor shall any single or partial exercise of any such
Right preclude other or further exercise thereof, or the exercise of any other
Right under the Loan Papers or otherwise.
-40-
<PAGE> 46
7.6 Cumulative Rights. All Rights available to Lender under the Loan
Papers shall be cumulative of and in addition to all other Rights granted to
Lender at Law or in equity, whether or not the Obligation be due and payable
and whether or not Lender shall have instituted any suit for collection or
other action in connection with any Loan Paper.
7.7 Expenditures by Lender. Any sums, including reasonable attorneys'
fees, spent by Lender pursuant to the exercise of any Right provided in this
Article VII shall become part of the Obligation and shall bear interest at a
rate per annum equal to the lesser of (a) the Prime Rate plus 3% and (b) the
Highest Lawful Rate from the date spent until the date repaid by Borrower.
ARTICLE VIII. MISCELLANEOUS
8.1 Money. Unless stipulated otherwise, all references herein to
"Dollars", "money", "payments", or other similar financial or monetary terms,
are references to currency of the United States of America.
8.2 Headings. The headings, captions and arrangements used in this
Agreement and the other Loan Papers are, unless specified otherwise, for
convenience only and shall not be deemed to limit, amplify or modify the terms
of any Loan Paper, nor affect the meaning thereof.
8.3 Articles, Sections, and Exhibits. All references to "Article",
"Sections", "subparagraphs" or "subsections" contained herein are, unless
specifically indicated otherwise, references to articles, sections,
subparagraphs and subsections of this Agreement. All references to "Exhibits"
and "Schedules" contained herein are references to exhibits and schedules
attached hereto, all of which are made a part hereof for all purposes, the same
as if set forth herein verbatim. If any exhibit or schedule attached hereto
which is to be executed and delivered contains blanks or is otherwise required
to be updated from time to time, it shall be completed correctly and in
accordance with the terms and provisions contained and as contemplated herein
prior to, at the time of or after the execution and delivery thereof.
8.4 Notices and Deliveries.
(a) Manner of Delivery. All notices, communications and materials
(including all Information) to be given or delivered pursuant to this Agreement
shall, except in those cases where giving notice by telephone is expressly
permitted, be given or delivered in writing. All written notices,
communications and materials shall be sent by registered or certified mail,
postage prepaid, return receipt requested, by telecopier, or delivered by hand.
In the event of a discrepancy between any telephonic notice and any written
confirmation thereof, such written confirmation shall be deemed the effective
notice except to the extent Lender or Borrower has acted in reliance on such
telephonic notice.
-41-
<PAGE> 47
(b) Addresses. All notices, communications and materials to be given or
delivered pursuant to this Agreement shall be given or delivered at the
following respective addresses and telecopier and telephone numbers and to the
attention of the following individuals or departments:
(i) if to Borrower, to it at:
Quest Medical, Inc.
One Allentown Parkway
Allen, Texas 75002
Telephone No: (972) 390-9800
Telecopier No: (972) 390-9687
Attention: F. Robert Merrill III
(ii) if to Lender, to it at:
NationsBank of Texas, N.A.
NationsBank Plaza
901 Main Street
7th Floor
Dallas, Texas 75202
Telephone No: (214) 508-0365
Telecopier No: (214) 508-3140
Attention: Commercial Banking
or at such other address, telecopier or telephone number or to the attention of
such other individual or department as the party to which such information
pertains may hereafter specify for the purpose in a notice to the other
specifically captioned "Notice of Change of Address".
(c) Effectiveness. Each notice, communication and any material to be
given or delivered to Lender or Borrower pursuant to this Agreement shall be
effective or deemed delivered or furnished (i) if sent by certified mail,
return receipt requested, on the fifth Business Day after such notice,
communication or material is deposited in the mail, addressed as above
provided, (ii) if sent by telecopier, when such notice, communication or
material is transmitted to the appropriate number determined as above provided
in this Section 8.4 and the appropriate receipt is received or acknowledged,
(iii) if sent by hand delivery or overnight courier, when left at the address
of the addressee addressed as above provided and the appropriate receipt is
received or acknowledged, and (iv) if given by telephone, when communicated to
the individual or any member of the department specified as the individual or
department to whose attention
-42-
<PAGE> 48
notices, communications and materials are to be given or delivered except that
notices of a change of address, telecopier or telephone number or individual or
department to whose attention notices, communications and materials are to be
given or delivered shall not be effective until received.
8.5 Place of Payment. All sums payable to Lender hereunder shall be
paid to Lender at either Lender's Principal Office or at a branch of Lender
within Dallas or Collin Counties, Texas, not later than noon, Dallas time, on
the date due, in immediately available funds. Except as provided in Article
II, if any payment falls due on other than a Business Day, then such due date
shall be extended to the next succeeding Business Day, and interest on such
amount (if applicable) shall be payable in respect to such extension.
8.6 Survival of Agreements. All covenants, agreements, representations
and warranties made herein shall survive the execution and the delivery of this
Agreement, the Notes and the other Loan Papers.
8.7 Parties in Interest. All covenants and agreements contained in the
Loan Papers shall bind and inure to the benefit of the respective successors
and assigns of the parties hereto, except that Borrower may not assign its
rights hereunder without the prior written consent of Lender.
8.8 Expenses. Borrower agrees (a) to pay all out-of-pocket expenses of
Lender in connection with the negotiation and preparation of this Agreement,
including exhibits and amendments, consents and waivers to any of the other
Loan Papers as may from time to time hereafter be requested or required, and
the reasonable fees and expenses of Special Counsel from time to time in
connection with the negotiation, preparation and execution of the Loan Papers,
and (b) to pay or reimburse Lender for all reasonable costs and expenses,
including reasonable fees and expenses of counsel to Lender, incurred in
connection with the enforcement or preservation of any rights under or the
collection of any amounts due pursuant to any of the Loan Papers. The
obligations of Borrower under this Section 8.8 shall survive any termination of
this Agreement.
8.9 Governing Law. This Agreement and all other Loan Papers shall be
deemed contracts made under the Laws of Texas and shall be construed and
enforced in accordance with and governed by the Laws of Texas, except to the
extent federal Laws govern the validity, construction, enforcement and
interpretation of all or any part of the Loan Papers. Without excluding any
other jurisdiction, Borrower agrees that the courts of Texas will have
jurisdiction over proceedings in connection herewith. Borrower and Lender
hereby agree that the provisions of Art. 5069-15.01 et seq. of the Revised
Civil Statutes of Texas, 1925, as amended, shall not apply to this Agreement
and the Notes.
8.10 MANDATORY ARBITRATION. (A) ANY CONTROVERSY OR CLAIM BETWEEN OR
AMONG THE PARTIES HERETO INCLUDING BUT NOT LIMITED
-43-
<PAGE> 49
TO THOSE ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY RELATED AGREEMENTS
OR INSTRUMENTS, INCLUDING ANY CLAIM BASED ON OR ARISING FROM AN ALLEGED TORT,
SHALL BE DETERMINED BY BINDING ARBITRATION IN ACCORDANCE WITH THE FEDERAL
ARBITRATION ACT (OR IF NOT APPLICABLE, THE APPLICABLE STATE LAW), THE RULES OF
PRACTICE AND PROCEDURE FOR THE ARBITRATION OF COMMERCIAL DISPUTES OF JUDICIAL
ARBITRATION AND MEDIATION SERVICES, INC. ("JAMS"), AND THE "SPECIAL RULES" SET
FORTH BELOW. IN THE EVENT OF ANY INCONSISTENCY, THE SPECIAL RULES SHALL
CONTROL. JUDGMENT UPON ANY ARBITRATION AWARD MAY BE ENTERED IN ANY COURT HAVING
JURISDICTION. ANY PARTY TO THIS AGREEMENT MAY BRING AN ACTION, INCLUDING A
SUMMARY OR EXPEDITED PROCEEDING, TO COMPEL ARBITRATION OF ANY CONTROVERSY OR
CLAIM TO WHICH THIS AGREEMENT APPLIES IN ANY COURT HAVING JURISDICTION OVER
SUCH ACTION.
(a) Special Rules. The arbitration shall be conducted in Dallas, Texas
and administered by JAMS who will appoint an arbitrator; if JAMS is unable or
legally precluded from administering the arbitration, then the American
Arbitration Association will serve. All arbitration hearings will be commenced
within ninety days of the demand for arbitration; further, the arbitrator shall
only, upon a showing of cause, be permitted to extend the commencement of such
hearing for up to an additional sixty days.
(b) Reservations of Rights. Nothing in this Agreement or any other Loan
Paper shall be deemed to (i) limit the applicability of any otherwise
applicable statutes of limitation or repose and any waivers contained in this
Agreement; or (ii) be a waiver by Lender of the protection afforded to it by 12
U.S.C. Section 91 or any substantially equivalent state law; or (iii) limit
the right of Lender hereto (A) to exercise self help remedies such as (but not
limited to) setoff, or (B) to foreclose against any real or personal property
collateral, or (C) to obtain from a court provisional or ancillary remedies
such as (but not limited to) injunctive relief or the appointment of a
receiver. Lender may exercise such self help rights, foreclose upon such
property, or obtain such provisional or ancillary remedies before, during or
after the pendency of any arbitration proceeding brought pursuant to this
Agreement. At Lender's option, foreclosure under a deed of trust or mortgage
may be accomplished by any of the following: the exercise of a power of sale
under the deed of trust or mortgage, or by judicial sale under the deed of
trust or mortgage, or by judicial foreclosure. Neither this exercise of self
help remedies nor the institution or maintenance of an action for foreclosure
or provisional or ancillary remedies shall constitute a waiver of the right of
any party, including the claimant in any such action, to arbitrate the merits
of the controversy or claim occasioning resort to such remedies.
8.11 WAIVER OF JURY TRIAL. TO THE MAXIMUM EXTENT PERMITTED BY LAW,
BORROWER HEREBY WAIVES ANY RIGHT THAT IT MAY HAVE TO A TRIAL BY JURY OF ANY
DISPUTE (WHETHER A CLAIM IN TORT, CONTRACT,
-44-
<PAGE> 50
EQUITY, OR OTHERWISE) ARISING UNDER OR RELATING TO THIS AGREEMENT, THE OTHER
LOAN PAPERS, OR ANY RELATED MATTERS, AND AGREES THAT ANY SUCH DISPUTE SHALL BE
TRIED BEFORE A JUDGE SITTING WITHOUT A JURY.
8.12 Maximum Amount Limitation. It is not the intention of any of the
parties to this Agreement to make an agreement violative of the Laws of any
applicable jurisdiction relating to usury. Regardless of any provision in this
Agreement, the Notes or any other Loan Paper, Lender shall never be entitled to
receive, collect or apply, as interest on the Obligation, any amount in excess
of the Maximum Amount. If Lender ever receives, collects or applies, as
interest, any such excess, such amount which would be excessive interest shall
be deemed a partial repayment of principal and treated hereunder as such; and
if principal is paid in full, any remaining excess shall be paid to Borrower.
In determining whether or not the interest paid or payable, under any specific
contingency, exceeds the Maximum Amount, Borrower and Lender shall, to the
maximum extent permitted under Applicable Laws, (a) characterize any
nonprincipal payment as an expense, fee or premium rather than as interest, (b)
exclude voluntary prepayments and the effect thereof, and (c) amortize,
prorate, allocate and spread in equal parts, the total amount of interest
throughout the entire contemplated term of the Obligation so that the interest
rate is uniform throughout the entire term of the Obligation; provided that if
the Obligation is paid and performed in full prior to the end of the full
contemplated term thereof, and if the interest received for the actual period
of existence thereof exceeds the Maximum Amount, Lender shall refund to
Borrower the amount of such excess or credit the amount of such excess against
the total principal amount owing, and, in such event, Lender shall not be
subject to any penalties provided by any Laws for contracting for, charging or
receiving interest in excess of the Maximum Amount. This Section 8.12 shall
control every other provision of all agreements among the parties to this
Agreement pertaining to the transactions contemplated by or contained in the
Notes and the other Loan Papers.
8.13 Severability. If any provision of this Agreement or any other Loan
Paper is held to be illegal, invalid or unenforceable under present or future
Laws during the term thereof, such provision shall be fully severable, the
appropriate agreement or instrument shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part thereof,
and the remaining provisions thereof shall remain in full force and effect and
shall not be affected by the illegal, invalid or unenforceable provision or by
its severance therefrom. Furthermore, in lieu of such illegal, invalid or
unenforceable provision there shall be added automatically as a part of such
agreement or instrument a provision as similar in terms to the illegal, invalid
or unenforceable provision as may be possible and legal, valid and enforceable.
8.14 Amendment. The provisions of this Agreement and each other Loan
Paper may not be amended, modified or waived except by the written agreement of
Borrower and Lender. This Agreement embodies the entire agreement among the
parties, supersedes all prior agreements and understandings, if any, relating
to the subject matter hereof, and may be amended only as provided above.
-45-
<PAGE> 51
8.15 Exceptions to Covenants. Borrower shall not be deemed to be
permitted to take any action or fail to take any action which is permitted as
an exception to any of the covenants contained herein or which is within the
permissible limits of any of the covenants contained herein if such action or
omission would result in the breach of any other covenant contained herein.
8.16 Counterparts. This Agreement may be executed in any number of
counterparts, all of which taken together shall constitute one and the same
instrument, but in making proof of this Agreement, it shall not be necessary to
produce or account for more than one such counterpart.
8.17 Restatement. This Agreement restates in its entirety the Second
Restated Credit Agreement. All obligations of each Obligor pursuant to the
Second Restated Credit Agreement are amended and restated by this Agreement,
which is not intended as a release or novation of any such obligation.
8.18 ENTIRE AGREEMENT. THIS AGREEMENT AND THE LOAN PAPERS REPRESENT THE
FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF
PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS BY THE PARTIES. THERE
ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.
==========================================
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
==========================================
-46-
<PAGE> 52
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written.
QUEST MEDICAL, INC.
By: /s/ F. ROBERT MERRILL III
F. Robert Merrill III, Vice President
NATIONSBANK OF TEXAS, N.A.
By: /s/ BRIAN K. SCHNEIDER
Brian K. Schneider, Vice President
-47-
<PAGE> 1
EXHIBIT 10.16
PROMISSORY NOTE
(Facility A Note)
$5,650,000.00 Dallas, Texas March 3, 1997
QUEST MEDICAL, INC., a Texas corporation, with its principal office
located at One Allentown Parkway, Allen, Texas 75002 ("Borrower"), for value
received, promises to pay to the order of NATIONSBANK OF TEXAS, N.A.
("Lender"), at its Dallas Banking Center at 901 Main Street, Dallas, Texas
75202, in immediately available funds and in lawful money of the United States
of America, the principal sum of Five Million Six Hundred and Fifty Thousand
and 00/100 Dollars ($5,650,000.00), or such lesser sum as shall be due and
payable from time to time hereunder, on January 31, 1998, or sooner, as
provided in the Credit Agreement referred to below. Borrower promises to pay
interest on the unpaid principal amount of the Facility A Advances (as defined
in the Credit Agreement) from the date made until such principal amount is paid
in full, at such interest rates, and payable at such times, as are specified in
the Credit Agreement.
For the purposes of this Note, the following terms have the respective
meanings assigned to them below:
"Applicable Law" means the laws of the United States of America
applicable to contracts made or performed in the State of Texas,
including, without limitation, 12 USC 86, as amended to the date hereof
and as the same may be amended at any time and from time to time
hereafter and any other statute of the United States of America now or at
any time hereafter prescribing maximum rates of interest on loans and
extensions of credit, and the laws of the State of Texas, including,
without limitation, Article 1.04, Title 79, Revised Civil Statutes of
Texas, 1925, as the same may be amended at any time and from time to time
hereafter ("Article 1.04") and any other statute of the State of Texas
now or at any time hereafter prescribing maximum rates of interest on
loans and extensions of credit provided that pursuant to Article
5069-15.10(b), Title 79, Revised Civil Statues, 1925, as amended,
Borrower agrees that the provisions of Chapter 15, Title 79, Revised
Civil Statutes of Texas, 1925, as amended, shall not apply to this Note.
"Highest Lawful Rate" means at the particular time in question the
maximum rate of interest which, under Applicable Law, Lender is then
permitted to charge on the obligation hereunder. If the maximum rate of
interest which, under Applicable Law, Lender is permitted to charge on
the obligation hereunder shall change after the date hereof, the Highest
Lawful Rate shall be automatically increased or decreased, as the case
may be, from time to time as of the effective time of each change in the
Highest Lawful Rate without notice to Borrower. For purposes of
determining the Highest Lawful Rate under the Applicable Law of the State
of Texas, the applicable rate ceiling shall be (i) the indicated rate
ceiling described in and computed in accordance with the provisions of
Section (a)(1) of Article 1.04, Title 79, Revised Civil Statues of Texas
1925, as amended, or (ii) if the parties subsequently contract as allowed
by Applicable Law, the quarterly
<PAGE> 2
ceiling or the annualized ceiling computed pursuant to Section (d) of
said Article 1.04; provided, however, that if at any time the indicated
rate ceiling, the quarterly ceiling or the annualized ceiling, as
applicable, shall be less than 18% per annum or more than 24% per annum,
the provisions of Sections (b)(1) and (2) of said Article 1.04 shall
control for purposes of such determination, as applicable.
Notwithstanding the foregoing and all other provisions of this Note and
any documents and instruments executed in connection with this Note, in no
event shall the interest payable hereon, whether before or after maturity,
exceed the Highest Lawful Rate of interest which, under Applicable Law, Lender
is permitted to charge to Borrower.
All agreements between Borrower and Lender, or any subsequent holder of
this Note, whether now existing or hereafter arising and whether written or
oral, are expressly limited so that in no contingency or event whatsoever,
whether by reason of acceleration of the maturity of this Note or otherwise,
shall the amount paid or agreed to be paid to the holder of this Note for the
use, forbearance, or detention of the funds advanced pursuant to this Note or
for the performance or payment of any covenant or obligation contained herein
or in any other document evidencing, securing or pertaining to this Note,
exceed the maximum amount permissible under Applicable Law. If from any
circumstance whatsoever fulfillment of any provision hereof or of any such
other document, at the time performance of such provision shall be due, shall
involve transcending the limit of validity prescribed by Applicable Law, then
ipso facto, the obligation to be fulfilled shall be reduced to the limit of
such validity, and if from any circumstance the holder hereof shall ever
receive anything of value deemed excess interest by Applicable Law, an amount
equal to any such excess interest shall be applied to the reduction of the
principal amount owing under this Note, and not to the payment of interest, or
if such excess interest exceeds the unpaid principal balance of this Note, such
excess interest shall be refunded to Borrower. All sums paid or agreed to be
paid to any holder of this Note for the use, forbearance or detention of any
funds advanced pursuant to this Note shall, to the extent permitted by
Applicable Law, be amortized, prorated, allocated and spread throughout the
full term of this Note until payment in full so that the rate of interest on
account of the indebtedness evidenced by this Note is uniform throughout the
term hereof. The terms and provisions of this paragraph shall control and
supersede every other provision of all agreements between Borrower and any
holder of this Note.
This Note is issued pursuant to the Third Amended and Restated Credit
Agreement between Borrower and Lender dated as of March 3, 1997 (such
agreement, together with all amendments and restatements, the "Credit
Agreement"), to which reference is made for a statement of the rights and
obligations of Lender and the duties and obligations of Borrower in relation
thereto; but neither this reference to the Credit Agreement nor any provision
thereof shall affect or impair the absolute and unconditional obligation of
Borrower to pay unpaid principal of and interest on this Note when due. The
Credit Agreement among other things, contains provisions for acceleration of
the maturity hereof upon the happening of certain stated events and also for
prepayments on account of principal hereof prior to the maturity hereof upon
the terms and conditions therein specified. If a breach of or default under
the Credit Agreement or any other Loan Paper (as defined in the Credit
Agreement) shall occur, unpaid principal of and
-2-
<PAGE> 3
interest on this Note may be declared due and payable without notice, at the
option of the holder of this Note, in the manner and with the effect provided
thereunder. Failure to exercise this option shall not constitute a waiver of
the right to exercise the same in the event of any subsequent default or event
of default. This Note is a renewal and restatement of the promissory note
(Facility A Note) dated February 9, 1996 made by Borrower and payable to the
order of Lender in the principal amount of $5,000,000.00, and is not a novation
or impairment of such note.
If this Note is placed in the hands of an attorney for collection after
default, or if all or any part of the indebtedness represented hereby is
proved, established or collected in any court or in any bankruptcy,
receivership, debtor relief, probate or other court proceedings, Borrower and
all endorsers, sureties and guarantors of this Note jointly and severally agree
to pay reasonable attorneys' fees and collection costs to the holder hereof in
addition to the principal and interest payable hereunder.
Borrower and all endorsers, sureties and guarantors of this Note hereby
severally waive demand, presentment for payment, protest, notice of protest,
notice of acceleration of and notice of intention to accelerate the maturity of
this Note, diligence in collecting, the bringing of any suit against any party
and any notice of or defense on account of any extensions, renewals, partial
payments or changes in any manner of or in this Note or in any of its terms,
provisions and covenants, or any releases or substitutions of any security, or
any delay, indulgence or other act of any trustee or any holder hereof, whether
before or after maturity.
THIS NOTE AND THE RIGHTS AND DUTIES OF THE PARTIES HEREUNDER SHALL BE
GOVERNED BY THE LAWS OF THE STATE OF TEXAS, EXCEPT TO THE EXTENT THE SAME ARE
GOVERNED BY THE FEDERAL LAWS OF THE UNITED STATES OF AMERICA APPLICABLE TO
NATIONAL BANKS. THE BOOKS AND RECORDS OF LENDER SHALL CONSTITUTE PRIMA FACIE
EVIDENCE OF ALL SUMS DUE LENDER HEREUNDER.
==========================================
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
==========================================
-3-
<PAGE> 4
QUEST MEDICAL, INC.
By: /s/ F. ROBERT MERRILL III
------------------------------------
F. Robert Merrill III, Vice President
-4-
<PAGE> 5
N O T I C E O F F I N A L A G R E E M E N T
THIS NOTE AND THE OTHER WRITTEN LOAN PAPERS EXECUTED CONTEMPORANEOUSLY WITH
THIS NOTE REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE
CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES.
THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.
BORROWER REPRESENTS THAT IT TODAY RECEIVED A COPY OF THIS NOTICE.
Borrower Lender
QUEST MEDICAL, INC. NATIONSBANK OF TEXAS, N.A.
By: /s/ F. ROBERT MERRILL III By: /s/ BRIAN K. SCHNEIDER
------------------------------------ -----------------------------------
F. Robert Merrill III, Vice President Brian K. Schneider, Vice President
-5-
<PAGE> 1
EXHIBIT 10.17
PROMISSORY NOTE
(Facility B Advance Note)
$350,000.00 Dallas, Texas March 3, 1997
QUEST MEDICAL, INC., a Texas corporation, with its principal office
located at One Allentown Parkway, Allen, Texas 75002 ("Borrower"), for value
received, promises to pay to the order of NATIONSBANK OF TEXAS, N.A.
("Lender"), at its Dallas Banking Center at 901 Main Street, Dallas, Texas
75202, in immediately available funds and in lawful money of the United States
of America, the principal sum of Three Hundred and Fifty Thousand and 00/100
Dollars ($350,000.00), or such lesser sum as shall be due and payable from time
to time hereunder, on January 31, 1998, or sooner, as provided in the Credit
Agreement referred to below. Borrower promises to pay interest on the unpaid
principal amount of the Facility B Advances (as defined in the Credit
Agreement) from the date made until such principal amount is paid in full, at
such interest rates, and payable at such times, as are specified in the Credit
Agreement.
For the purposes of this Note, the following terms have the respective
meanings assigned to them below:
"Applicable Law" means the laws of the United States of America
applicable to contracts made or performed in the State of Texas,
including, without limitation, 12 USC 86, as amended to the date hereof
and as the same may be amended at any time and from time to time
hereafter and any other statute of the United States of America now or at
any time hereafter prescribing maximum rates of interest on loans and
extensions of credit, and the laws of the State of Texas, including,
without limitation, Article 1.04, Title 79, Revised Civil Statutes of
Texas, 1925, as the same may be amended at any time and from time to time
hereafter ("Article 1.04") and any other statute of the State of Texas
now or at any time hereafter prescribing maximum rates of interest on
loans and extensions of credit provided that pursuant to Article
5069-15.10(b), Title 79, Revised Civil Statues, 1925, as amended,
Borrower agrees that the provisions of Chapter 15, Title 79, Revised
Civil Statutes of Texas, 1925, as amended, shall not apply to this Note.
"Highest Lawful Rate" means at the particular time in question the
maximum rate of interest which, under Applicable Law, Lender is then
permitted to charge on the obligation hereunder. If the maximum rate of
interest which, under Applicable Law, Lender is permitted to charge on
the obligation hereunder shall change after the date hereof, the Highest
Lawful Rate shall be automatically increased or decreased, as the case
may be, from time to time as of the effective time of each change in the
Highest Lawful Rate without notice to Borrower. For purposes of
determining the Highest Lawful Rate under the Applicable Law of the State
of Texas, the applicable rate ceiling shall be (i) the indicated rate
ceiling described in and computed in accordance with the provisions of
Section (a)(1) of Article 1.04, Title 79, Revised Civil Statues of Texas
1925, as amended,
<PAGE> 2
or (ii) if the parties subsequently contract as allowed by Applicable
Law, the quarterly ceiling or the annualized ceiling computed pursuant to
Section (d) of said Article 1.04; provided, however, that if at any time
the indicated rate ceiling, the quarterly ceiling or the annualized
ceiling, as applicable, shall be less than 18% per annum or more than 24%
per annum, the provisions of Sections (b)(1) and (2) of said Article 1.04
shall control for purposes of such determination, as applicable.
Notwithstanding the foregoing and all other provisions of this Note and
any documents and instruments executed in connection with this Note, in no
event shall the interest payable hereon, whether before or after maturity,
exceed the Highest Lawful Rate of interest which, under Applicable Law, Lender
is permitted to charge to Borrower.
All agreements between Borrower and Lender, or any subsequent holder of
this Note, whether now existing or hereafter arising and whether written or
oral, are expressly limited so that in no contingency or event whatsoever,
whether by reason of acceleration of the maturity of this Note or otherwise,
shall the amount paid or agreed to be paid to the holder of this Note for the
use, forbearance, or detention of the funds advanced pursuant to this Note or
for the performance or payment of any covenant or obligation contained herein
or in any other document evidencing, securing or pertaining to this Note,
exceed the maximum amount permissible under Applicable Law. If from any
circumstance whatsoever fulfillment of any provision hereof or of any such
other document, at the time performance of such provision shall be due, shall
involve transcending the limit of validity prescribed by Applicable Law, then
ipso facto, the obligation to be fulfilled shall be reduced to the limit of
such validity, and if from any circumstance the holder hereof shall ever
receive anything of value deemed excess interest by Applicable Law, an amount
equal to any such excess interest shall be applied to the reduction of the
principal amount owing under this Note, and not to the payment of interest, or
if such excess interest exceeds the unpaid principal balance of this Note, such
excess interest shall be refunded to Borrower. All sums paid or agreed to be
paid to any holder of this Note for the use, forbearance or detention of any
funds advanced pursuant to this Note shall, to the extent permitted by
Applicable Law, be amortized, prorated, allocated and spread throughout the
full term of this Note until payment in full so that the rate of interest on
account of the indebtedness evidenced by this Note is uniform throughout the
term hereof. The terms and provisions of this paragraph shall control and
supersede every other provision of all agreements between Borrower and any
holder of this Note.
This Note is issued pursuant to the Second Amended and Restated Credit
Agreement between Borrower and Lender dated as of March 3, 1997 (such
agreement, together with all amendments and restatements, the "Credit
Agreement"), to which reference is made for a statement of the rights and
obligations of Lender and the duties and obligations of Borrower in relation
thereto; but neither this reference to the Credit Agreement nor any provision
thereof shall affect or impair the absolute and unconditional obligation of
Borrower to pay unpaid principal of and interest on this Note when due. The
Credit Agreement among other things, contains provisions for acceleration of
the maturity hereof upon the happening of certain stated events and also for
prepayments on account of principal hereof prior to the maturity hereof upon
the terms and conditions therein specified. If a breach of or default under
the Credit Agreement or any
-2-
<PAGE> 3
other Loan Paper (as defined in the Credit Agreement) shall occur, unpaid
principal of and interest on this Note may be declared due and payable without
notice, at the option of the holder of this Note, in the manner and with the
effect provided thereunder. Failure to exercise this option shall not
constitute a waiver of the right to exercise the same in the event of any
subsequent default or event of default. This Note is a renewal and restatement
of the promissory note (Facility B Note) dated February 9, 1996 made by
Borrower and payable to the order of Lender in the principal amount of
$15,000,000.00, and is not a novation or impairment of such note.
If this Note is placed in the hands of an attorney for collection after
default, or if all or any part of the indebtedness represented hereby is
proved, established or collected in any court or in any bankruptcy,
receivership, debtor relief, probate or other court proceedings, Borrower and
all endorsers, sureties and guarantors of this Note jointly and severally agree
to pay reasonable attorneys' fees and collection costs to the holder hereof in
addition to the principal and interest payable hereunder.
Borrower and all endorsers, sureties and guarantors of this Note hereby
severally waive demand, presentment for payment, protest, notice of protest,
notice of acceleration of and notice of intention to accelerate the maturity of
this Note, diligence in collecting, the bringing of any suit against any party
and any notice of or defense on account of any extensions, renewals, partial
payments or changes in any manner of or in this Note or in any of its terms,
provisions and covenants, or any releases or substitutions of any security, or
any delay, indulgence or other act of any trustee or any holder hereof, whether
before or after maturity.
THIS NOTE AND THE RIGHTS AND DUTIES OF THE PARTIES HEREUNDER SHALL BE
GOVERNED BY THE LAWS OF THE STATE OF TEXAS, EXCEPT TO THE EXTENT THE SAME ARE
GOVERNED BY THE FEDERAL LAWS OF THE UNITED STATES OF AMERICA APPLICABLE TO
NATIONAL BANKS. THE BOOKS AND RECORDS OF LENDER SHALL CONSTITUTE PRIMA FACIE
EVIDENCE OF ALL SUMS DUE LENDER HEREUNDER.
==========================================
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
==========================================
-3-
<PAGE> 4
QUEST MEDICAL, INC.
By: /s/ F. ROBERT MERRILL III
------------------------------------
F. Robert Merrill III, Vice President
-4-
<PAGE> 5
N O T I C E O F F I N A L A G R E E M E N T
THIS NOTE AND THE OTHER WRITTEN LOAN PAPERS EXECUTED CONTEMPORANEOUSLY WITH
THIS NOTE REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE
CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES.
THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.
BORROWER REPRESENTS THAT IT TODAY RECEIVED A COPY OF THIS NOTICE.
Borrower Lender
QUEST MEDICAL, INC. NATIONSBANK OF TEXAS, N.A.
By: /s/ F. ROBERT MERRILL III By: /s/ BRIAN K. SCHNEIDER
--------------------------- -----------------------------
F. Robert Merrill III, Brian K. Schneider,
Vice President Senior Vice President
-5-
<PAGE> 1
EXHIBIT 10.18
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
FIRST AMENDED AND RESTATED SECURITY AGREEMENT
dated as of March 3, 1997
Between
QUEST MEDICAL, INC.
as Debtor
and
NATIONSBANK OF TEXAS, N.A.
as Secured Party
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
Page
----
ARTICLE I. GRANT
<S> <C> <C>
1.1 Assignment and Grant of Security ............... 2
1.2 Description of Obligations ..................... 5
1.3 Debtor Remains Liable .......................... 6
1.4 Delivery of Security Collateral ................ 6
ARTICLE II. REPRESENTATIONS AND WARRANTIES
2.1 Representations and Warranties ................. 6
ARTICLE III. COVENANTS
3.1 Further Assurances ............................. 8
3.2 Equipment, Fixtures and Inventory .............. 10
3.3 Insurance ...................................... 11
3.4 Place of Perfection; Records; Collection of
Receivables, Chattel Paper and Instruments ..... 11
3.5 Transfers and Other Liens ...................... 12
3.6 Brokerage Agreements ........................... 13
3.7 Rights to Dividends and Distributions .......... 14
3.8 Right of Secured Party to Notify Issuers ....... 14
3.9 Secured Party Appointed Attorney-in-Fact ....... 14
ARTICLE IV. RIGHTS AND POWERS OF SECURED PARTY
4.1 Secured Party May Perform ...................... 15
4.2 Secured Party's Duties ......................... 15
4.3 Remedies ....................................... 16
4.4 Further Approvals Required ..................... 17
4.5 INDEMNITY AND EXPENSES ......................... 18
ARTICLE V. MISCELLANEOUS
5.1 Cumulative Rights .............................. 18
5.2 Modifications; Amendments; Schedules; Etc ...... 18
5.3 Continuing Security Interest ................... 19
5.4 MANDATORY ARBITRATION .......................... 19
5.5 GOVERNING LAW; TERMS ........................... 20
5.6 WAIVER OF JURY TRIAL ........................... 20
5.7 Secured Party's Right to Use Agents ............ 20
</TABLE>
i
<PAGE> 3
<TABLE>
<S> <C> ............................................ <C>
5.8 No Interference, Compensation or Expense ....... 20
5.9 Waivers of Rights Inhibiting Enforcement ....... 20
5.10 Notices and Deliveries ......................... 21
(a) Manner of Delivery........................ 21
(b) Addresses ................................ 21
(c) Effectiveness ............................ 22
5.11 Successors and Assigns ......................... 22
5.12 Loan Paper ..................................... 22
5.13 Definitions .................................... 22
5.14 Severability ................................... 23
5.15 Obligations Not Affected ....................... 23
5.16 Prior Security Agreements ...................... 23
5.17 Counterparts ................................... 23
5.18 ENTIRE AGREEMENT ............................... 23
</TABLE>
ii
<PAGE> 4
SCHEDULES:
<TABLE>
<S> <C>
Schedule 1 - Inventory Locations
Schedule 2 - Required Consents
Schedule 3 - Bank Accounts
Schedule 4 - Insurance
Schedule 5 - Vendor Agreements
Schedule 6 - Excluded Equipment and Furnishings
Schedule 7 - Brokerage Agreements
Schedule 8 - Filing Locations
Schedule 9 - Permits
</TABLE>
iii
<PAGE> 5
FIRST AMENDED AND RESTATED SECURITY AGREEMENT
FIRST AMENDED AND RESTATED SECURITY AGREEMENT, dated as of March 3, 1997
(this "Agreement"), made by Quest Medical, Inc., a Texas corporation
("Debtor"), in favor of NationsBank of Texas, N.A., a national banking
association ("Secured Party").
BACKGROUND.
(1) Secured Party and Debtor have entered into the Credit Agreement
dated as of October 22, 1993 (as amended, the "Original Credit Agreement"), the
Security Agreement dated May 28, 1993 ("Facility A Security Agreement") as
amended and restated from time to time, the Security Agreement dated as of
October 22, 1993 ("Existing Security Agreement") as amended and restated from
time to time and related agreements.
(2) Secured Party and Debtor have entered into the First Amended and
Restated Credit Agreement dated as of March 31, 1995 (such agreement, together
with all amendments and restatements thereof, the "1995 Credit Agreement")
which restates in its entirety the Original Credit Agreement.
(3) Secured Party and Debtor have entered into the Second Amended and
Restated Credit Agreement dated as of February 9, 1996 (such agreement,
together with all amendments and restatements thereof, the "Existing Credit
Agreement") which restates in its entirety the 1995 Credit Agreement.
(4) Secured Party and Debtor have entered into the Third Amended and
Restated Credit Agreement dated as of March 3, 1997 (such agreement, together
with all amendments and restatements thereof, the "Credit Agreement") which
restates in its entirety the Existing Credit Agreement.
(5) It is the intention of the parties hereto that this Agreement
create a first priority security interest securing the payment of the
obligations set forth in Section 1.2.
(6) It is a condition precedent to the effectiveness of the Credit
Agreement that Debtor shall have executed and delivered this Security
Agreement.
AGREEMENT.
NOW, THEREFORE, in consideration of the premises set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, and in order to induce Secured Party to make the Advances
under the Credit Agreement, Debtor hereby agrees with Secured Party as follows:
<PAGE> 6
ARTICLE I. GRANT
1.1 Assignment and Grant of Security. Subject to the last paragraph
of this Section 1.1, Debtor hereby assigns and pledges to Secured Party and
hereby grants to Secured Party a security interest in, the entire right, title
and interest of Debtor, in and to the following assets of Debtor, whether now
owned or hereafter acquired ("Collateral"):
(a) all inventory in all of its forms, wherever located, now or
hereafter existing, including, but not limited to, (i) all raw materials and
work in process therefor, finished goods thereof, and materials used or
consumed in the manufacture or production thereof, (ii) goods in which Debtor
has an interest in mass or a joint or other interest or right of any kind
(including, without limitation, goods in which Debtor has an interest or right
as consignee), and (iii) goods which are returned to or repossessed by Debtor,
and all accessions thereto and products thereof and documents therefor (any and
all such inventory, accessions, products and documents being the "Inventory");
(b) other than equipment described in the last paragraph of this
Section 1.1, all equipment (as defined in the Uniform Commercial Code) and
(whether or not included in such definition), all vehicles, machinery,
chattels, tools, parts, furniture, furnishings and supplies, of every nature,
wherever located, all additions, accessories and improvements thereto and
substitutions therefor and all accessories, parts and equipment which may be
attached to or which are necessary for the operation and use of such personal
property, together with all accessions thereto, and all rights under or arising
out of present or future contracts relating to the foregoing ("Equipment");
(c) all property so related to particular real estate that an
interest in it arises under the real estate law of the jurisdiction in which
such Collateral is located, including all equipment, fixtures and articles of
personal property now or hereafter attached to or used in or about any building
or buildings now erected or hereafter to be erected on any real property now or
hereafter owned or leased by Debtor (the "Property"), which are necessary to
the complete and comfortable use and occupancy of such building or buildings
for the purposes for which they were or are to be erected; all materials to be
delivered to the Property and used or to be used in connection with the
construction of any building to be constructed on the Property, including, but
not limited to, all masonry, siding, roof shingles, flooring, doors, windows,
tile, shutters, stoves, ovens, awnings, screens, cabinets, shades, blinds,
carpets, draperies, furniture, furnishings, plumbing, heating, air
conditioning, lighting, ventilating, refrigerating, cooking, laundry and
incinerating equipment and all fixtures and appurtenances thereto, and such
other goods and chattels and personal property as are ever used or furnished in
operating such buildings or the activities conducted therein, and all building
materials and equipment now or hereafter delivered to the Property and intended
to be installed thereon ("Fixtures");
2
<PAGE> 7
(d) all general intangibles (as defined in the Uniform Commercial
Code), and (whether or not included in such definition) all contract rights
other than Receivables; all inventions, processes, production methods,
proprietary information and know-how; and all licenses or other agreements
granted to Debtor with respect to any of the foregoing; all information,
customer lists, advertising lists, advertising contracts, identification of
suppliers, data, plans, blueprints, specifications, designs, drawings, recorded
knowledge, surveys, engineering reports, test reports, manuals, materials
standards, processing standards, performance standards, telephone numbers and
telephone listings, catalogs, books, records, computer and automatic machinery
software and programs, and the like pertaining to operations by or the business
of Debtor; all field accounting information and all media in which or on which
any of the information or knowledge or data or records may be recorded or
stored and all computer programs used for the compilation or printout of such
information, knowledge, records or data; all licenses, consents, permits,
variances, certifications and approvals of all Tribunals now or hereafter held
by Debtor pertaining to operations or business now or hereafter conducted; all
rights to receive return of deposits and trust payments; all rights to payment
under letters of credit and similar agreements; all tax refunds (including,
without limitation, all federal and state income tax refunds and benefits of
net operating loss carry forwards); and all causes of action, rights, claims
and warranties now or hereafter owned or acquired by Debtor ("General
Intangibles");
(e) all of the following, to the extent that not included in "General
Intangibles": trade secrets, all know-how, inventions, processes, methods,
information, data, plans, blueprints, specifications, designs, drawings,
engineering reports, test reports, materials standards, processing standards
and performance standards, and all computer and automatic machinery software
and programs directly related thereto, and all licenses or other agreements to
which Debtor is a party with respect to any of the foregoing ("Trade Secrets");
(f) all instruments and letters of credit (each as defined in the
Uniform Commercial Code), and (whether or not included in such definitions) all
promissory notes, drafts, bills of exchange and trade acceptances
("Instruments");
(g) all writings which evidence both a monetary obligation and a
security interest in or a lease of specific goods ("Chattel Paper");
(h) all documents, warehouse receipts, bills of lading, including,
without limitation, documents of title (as defined in the Uniform Commercial
Code) or other receipts covering, evidencing or representing any property
described in this Section 1.1 ("Documents");
(i) all accounts, contract rights, Chattel Paper, Documents,
Instruments, deposit accounts, General Intangibles, tax refunds and other
obligations of any kind owing to Debtor, now or hereafter existing, arising out
of or in connection with the sale or lease of goods or the
3
<PAGE> 8
rendering of services, and all rights now or hereafter existing in and to
all security agreements, leases, and other contracts securing or otherwise
relating to any such accounts, contract rights, Chattel Paper, Documents,
Instruments, deposit accounts, General Intangibles, tax refunds or obligations
(any and all such accounts, contract rights, Chattel Paper, Documents,
Instruments, deposit accounts, General Intangibles, tax refunds and obligations
being the "Receivables");
(j) all licenses, permits and other similar rights now or hereafter
owned by Debtor (including but not limited to all licenses, permits and similar
rights issued by the FDA) and necessary to the operation of its business,
including but not limited to all licenses, permits and other rights listed on
Schedule 9;
(k) all agreements and accounts of Debtor described on Schedule 7,
all interest in any security subject to such agreement or account (including
but not limited to all interest in any equity or debt security, option,
warrant, put, call, futures agreements, commodity agreements, margin accounts,
short positions and partnership interests), all property subject to or
maintained in each such account or pursuant to such agreement, each deposit
account (time, demand or other) in which any proceeds of or income from the
foregoing may be on deposit, all cash maintained with each Person pursuant to
any such agreement or account, all general intangibles consisting of the
foregoing and each agreement, document or Instrument governing or evidencing
any of the foregoing and all amendments and restatements thereof, and all
claims of Debtor against any Person with respect to any of the foregoing (all
of the foregoing being herein collectively called the "Brokerage Agreements");
(l) all rights, claims and benefits of Debtor against any Person
arising out of, relating to or in connection with any property described in
this Section 1.1 purchased by Debtor, including, without limitation, any such
rights, claims or benefits against any Person storing or transporting any
property described in this Section 1.1;
(m) the balance of every deposit account of Debtor under control of
Secured Party and each of its Affiliates and any other claim of Debtor against
Secured Party, now or hereafter existing, liquidated or unliquidated, and all
money, Instruments, securities, Documents, Chattel Paper, credits, claims,
demands, income, and any other property, rights and interests of Debtor which
at any time shall come into the possession or custody or under the control of
Secured Party or any of its agents, affiliates or correspondents, for any
purpose, and the proceeds of any thereof (Secured Party shall be deemed to have
possession of any of the Collateral in transit to or set apart for it or any of
its agents, affiliates or correspondents. The holder of any participation in
the Obligations shall have a right of setoff with respect to any obligation of
such holder to Debtor to satisfy the Obligations);
(n) all Acquisition Documents;
4
<PAGE> 9
(o) all agreements with vendors and other distributors of Inventory,
including but not limited to those described in Schedule 5;
(p) all insurance policies and bonds and claims and payments
thereunder;
(q) all property similar to the above hereafter acquired by Debtor;
and
(r) all accessions to, substitutions for and replacements, proceeds
and products of any and all of the foregoing Collateral (including, without
limitation, proceeds which constitute property of the types described in this
Section 1.1) and, to the extent not otherwise included, all (i) payments under
insurance (whether or not Secured Party is the loss payee thereof), or any
indemnity, warranty or guaranty, payable by reason of loss or damage to or
otherwise with respect to any of the foregoing Collateral and (ii) cash.
Nothing in this Section 1.1 or otherwise in any Loan Paper is intended as
a grant of a security interest in any of the following property of Debtor:
(i) heating, ventilation or air conditioning systems now or
hereafter located on the Allen Property,
(ii) the furniture and equipment described on Schedule 6, whether
now owned or hereafter acquired, and all accessions to,
substitutions for and replacements, proceeds and products of
such office furniture and equipment, and
(iii) the computer systems described on Schedule 6, whether now
owned or hereafter acquired, and all accessions to, substitutions
for and replacements, proceeds and products of such computer
systems.
The assets described in clauses (i) through (iii) of this paragraph shall not
constitute Collateral for purposes of this Agreement. Secured Party agrees
that, upon request of Debtor, it will execute and deliver to Debtor and MetLife
Capital Corporation or its affiliates (collectively, "MetLife") any documents
reasonably requested by Debtor or MetLife to evidence that Secured Party does
not have a security interest in the assets described in clauses (i) through
(iii) of this paragraph.
1.2 Description of Obligations. This Agreement creates a first
priority security interest securing the payment and performance of the
Obligations, including, but not limited to any and all obligations now or
hereafter existing of Debtor and each other Obligor under the Credit Agreement
and other Loan Papers, including any extensions, modifications, substitutions,
amendments and renewals thereof, whether for principal, interest, fees,
premium, expenses, indemnification or otherwise (all such obligations of Debtor
and each other Obligor being the "Obligations"). Without limiting the
generality of the foregoing, this Agreement secures the
5
<PAGE> 10
payment of all amounts which constitute part of the Obligations and would be
owed by Debtor and each other Obligor to Secured Party under any Loan Paper,
but for the fact that they are unenforceable or not allowable due to the
existence of a bankruptcy, reorganization or similar proceeding involving
Debtor or any other Person (including all after, or that would have secured but
for, the filing of any petition in bankruptcy, or the commencement of any
insolvency, reorganization or like proceeding of Debtor or any other Obligor).
1.3 Debtor Remains Liable. Anything herein to the contrary
notwithstanding, (a) Debtor shall remain liable under the contracts and
agreements included in the Collateral to the extent set forth therein to
perform all of its duties and obligations thereunder to the same extent as if
this Agreement had not been executed, (b) the exercise by Secured Party of any
of the Rights hereunder shall not release Debtor from any of its duties or
obligations under the contracts and agreements included in the Collateral, and
(c) Secured Party shall not have any obligation or liability under the
contracts and agreements included in the Collateral by reason of this
Agreement, nor shall Secured Party be obligated to perform any of the
obligations or duties of Debtor thereunder or to take any action to collect or
enforce any claim for payment assigned hereunder.
1.4 Delivery of Security Collateral. All certificates or instruments
representing or evidencing the Collateral and which are issued in the name of
Debtor shall be delivered to and held by or on behalf of Secured Party pursuant
hereto and shall be in suitable form for transfer by delivery, or shall be
accompanied by duly executed instruments of transfer or assignment in blank,
all in form and substance satisfactory to Secured Party. If an Event of
Default exists, Secured Party shall have the right, at any time during such
time in its discretion and without notice to Debtor, to (a) require the
issuance in the name of Debtor and delivery to Secured Party of certificates or
instruments evidencing the interest owned by Debtor in the issuer of such
certificate or instrument (if the security is subject to a Brokerage Agreement
and the Brokerage Agreement permits such issuance) and (b) transfer to or to
register in the name of Secured Party or any of its nominees any or all of the
Collateral. In addition, Secured Party shall have the right at any time to
exchange certificates or instruments representing or evidencing Collateral for
certificates or instruments of smaller or larger denominations.
ARTICLE II. REPRESENTATIONS AND WARRANTIES
2.1 Representations and Warranties. Debtor represents and warrants,
with respect to itself and the Collateral, as follows:
(a) All of the Equipment, Fixtures and Inventory pledged by Debtor
hereunder is located at the places specified on Schedule 1 hereto (as
supplemented from time to time by Debtor by written notice to Secured Party) or
Inventory in transit to a place specified on Schedule 1 hereto (as supplemented
from time to time by Debtor by written notice to Secured
6
<PAGE> 11
Party) or Inventory in transit (i) for sale to a third-party purchaser that
upon such sale will become the obligor under a Receivable and (ii) pursuant to
a sale in the ordinary course of Debtor's business. The chief place of business
and chief executive office of Debtor and the office where Debtor keeps all of
its records concerning the Receivables, are located at One Allentown Parkway,
Allen, Texas 75002. All Chattel Paper, promissory notes or other instruments
evidencing the Receivables have been delivered and pledged to Secured Party
duly endorsed and accompanied by such duly executed instruments of transfer or
assignment as are necessary for such pledge, to be held as pledged collateral.
Debtor has possession and control of the Equipment and Inventory pledged by it
hereunder. The record owner of the real estate upon which the Equipment,
Fixtures and Inventory are located are indicated on Schedule 1.
(b) Debtor is the legal and beneficial owner of the Collateral
pledged by it free and clear of any Lien, security interest, option or other
charge or encumbrance except for the security interest created by this
Agreement and Permitted Liens. No effective financing statement or other
similar document used to perfect and preserve a security interest under the
Laws of any jurisdiction covering all or any part of the Collateral is on file
in any recording office, except (i) such as may have been filed in favor of
Secured Party relating to this Agreement and (ii) financing statements for
which Debtor will provide to Secured Party on the Closing Date proper original
executed termination statements. As of the date hereof, Debtor (including any
corporate or partnership predecessor) has no trade names and has not existed or
operated under any name other than "Quest Medical, Inc.," since March 3, 1987.
(c) This Agreement and the pledge of the Collateral pursuant hereto
creates a valid and, upon filing of financing statements in the Uniform
Commercial Code records described on Schedule 8, perfected first priority
security interest in the Collateral (other than deposit accounts in financial
institutions which are not Secured Party or subject to a Broker Agreement),
securing the payment of the Obligations, and all filings and other actions
necessary or desirable to perfect and protect such security interest and such
priority have been duly taken (or will be taken).
(d) Except as described on Schedule 2, no consent of any other Person
and no authorization, approval or other action by, and no notice to or filing
with, any Tribunal is required (i) for the pledge by Debtor of the Collateral
pledged by it hereunder, for the grant by Debtor of the security interest
granted hereby or for the execution, delivery or performance of this Agreement
by Debtor, (ii) for the perfection or maintenance of the pledge, assignment and
security interest created hereby (including the first priority nature of such
pledge, assignment and security interest) or (iii) for the exercise by Secured
Party of the Rights provided for in this Agreement or the remedies in respect
of the Collateral pursuant to this Agreement.
(e) Schedule 3 is a complete and correct list of all deposit accounts
(demand, time, special or other) maintained by or in which Debtor has an
interest and correctly describes the financial institution in which such
account is maintained (including the specific branch), the address and ABA
number of such institution, the officer of such institution having primary
7
<PAGE> 12
responsibility for Debtor's accounts, the account number and type (as
supplemented from time to time by Debtor by written notice to Secured Party).
(f) Debtor possesses all licenses and Permits, including but not
limited to all applicable certificates of occupancy, licenses and Permits, and
all health and sanitation permits, required for the operations of its business.
Schedule 9 is a complete and correct description of all of such licenses and
Permits.
(g) Schedule 4 is a complete and correct list of all insurance
policies for which Debtor is an insured or for which Debtor is a loss payee.
(h) Schedule 5 is a complete and correct list of all agreements with
each Person related to the resale and distribution of Inventory for each Person
who, during the preceding fiscal year, sold or distributed $25,000 or more of
Debtor's Inventory.
(i) All Inventory of Debtor produced by Debtor in the United States
of America has been produced in compliance with the Fair Labor Standards Act.
(j) Debtor's federal taxpayer identification number is 75-1646002.
(k) There are no conditions precedent to the effectiveness of this
Agreement that have not been satisfied or waived.
ARTICLE III. COVENANTS
3.1 Further Assurances. (a) Debtor agrees that, where any agreement
intended to be Collateral existing as of the date hereof or hereafter to which
Debtor is a party contains any restriction prohibiting Debtor from granting any
security interest under this Agreement, Debtor will use its best efforts to
obtain the necessary consent to or waiver of such restriction from any Person
so as to enable Debtor to effectively grant to Secured Party such security
interest under this Agreement.
(b) Debtor agrees that from time to time, at the expense of Debtor,
Debtor will promptly execute and deliver all further instruments and documents,
and take all further action, that may be reasonably necessary or desirable, or
that Secured Party may reasonably request, in order to perfect and protect any
pledge, assignment or security interest granted or purported to be granted
hereby, and the priority thereof, or to enable Secured Party to exercise and
enforce its rights and remedies hereunder with respect to any Collateral.
Without limiting the generality of the foregoing, upon written request by
Secured Party, Debtor will: (i) mark conspicuously each Chattel Paper included
in Receivables, and, at the request of Secured Party, each of its records
pertaining to the Collateral with the following legend:
8
<PAGE> 13
THIS INSTRUMENT IS SUBJECT TO A SECURITY INTEREST AND LIEN
PURSUANT TO A FIRST AMENDED AND RESTATED SECURITY AGREEMENT DATED
MARCH 3, 1997 (AS THE SAME MAY BE MODIFIED OR RESTATED) MADE BY
QUEST MEDICAL, INC., IN FAVOR OF NATIONSBANK OF TEXAS, N.A.
or such other legend, in form and substance satisfactory to and as specified by
Secured Party, indicating that such Chattel Paper or Collateral is subject to
the pledge, assignment and security interest granted hereby; (ii) if any
Collateral shall be evidenced by a promissory note or other Instrument or be
Chattel Paper, deliver and pledge to Secured Party hereunder such note,
Instrument or Chattel Paper duly indorsed and accompanied by duly executed
instruments of transfer or assignment, all in form and substance satisfactory
to Secured Party; and (iii) execute and file such financing or continuation
statements, or amendments thereto, and such other instruments or notices, as
may be necessary or desirable, or as Secured Party may request, in order to
perfect and preserve the pledge, assignment and security interest granted (and
the priority thereof) or purported to be granted hereby.
(c) Debtor hereby authorizes Secured Party to file one or more
financing or continuation statements, and amendments thereto, relating to all
or any part of the Collateral without the signature of Debtor where permitted
by Law. A photocopy or other reproduction of this Agreement or any financing
statement covering the Collateral or any part thereof shall be sufficient as a
financing statement where permitted by Law.
(d) Debtor will furnish to Secured Party from time to time statements
and schedules further identifying and describing the Collateral (including
information in connection with the protection, preservation, maintenance or
enforcement of the security interest) and such other reports in connection with
the Collateral as Secured Party may reasonably request, all in reasonable
detail; provided, if no Default or Event of Default exists, Secured Party will
not make more than one request in any six month period.
(e) Debtor shall not establish or maintain any deposit or similar
bank account not listed on Schedule 3 unless Secured Party receives prior
written notice thereof, Debtor executes and delivers to Secured Party
assignments of such account in such form as Secured Party may request and the
financial institution in which such account will be maintained delivers to
Secured Party acknowledgments of the assignment of such account in form and
substance satisfactory to Secured Party.
(f) In addition to such other information as shall be specifically
provided for herein, Debtor shall, if a Default or an Event of Default exists,
furnish to Secured Party such other information with respect to the Collateral
as Secured Party may reasonably request from time to time in connection with
the Collateral, including, without limitation, all documents and things in
9
<PAGE> 14
Debtor's possession, or subject to its demand for possession, related to the
production and sale by Debtor, or any subsidiary, licensee or subcontractor
thereof, of products or services sold by or under the authority of Debtor,
including by way of example, without limiting the interest granted by this
Agreement: (i) all lists and ancillary documents which identify and describe
any of Debtor's customers, advertisers, or those of its Subsidiaries or
licensees, for products sold or services rendered, including without
limitation, such existing lists and ancillary documents which contain each
customer's full name and address, the identity of the Person or Persons having
the principal responsibility on each customer's behalf for ordering products or
services of the kind supplied by Debtor, the credit, payment, discount,
delivery and other sale terms applicable to such customer, together with
detailed information setting forth the total purchases and the patterns of such
purchases; (ii) all product and service specification documents and production
and quality of services sold; (iii) all documents which reveal the names and
addresses of all sources of supply, and all terms of purchase and delivery, for
all materials and components used in the production of products or provision of
services sold; and (iv) all documents constituting or concerning the then
current or proposed advertising and promotion by Debtor or its subsidiaries,
licensees or subcontractors of products or services sold, including, by way of
example and not in limitation, all documents which reveal the media used or to
be used and the cost for all such advertising conducted within the described
period or planned for such products or services. In connection with its
enforcement of the security interest, Secured Party may use such information or
transfer it to any assignee or sublicensee permitted hereunder for such
assignee's or sublicensee's use.
3.2 Equipment, Fixtures and Inventory.
(a) Debtor shall keep the Equipment, Fixtures and Inventory pledged
by it hereunder (other than Inventory sold in the ordinary course of business)
at the places therefor specified in Section 2.1(a) or, upon thirty days' prior
written notice to Secured Party, at such other places in such jurisdiction
where all action required by Section 3.1 shall have been taken with respect to
the Equipment, Fixtures and Inventory.
(b) Debtor shall cause the Equipment and Fixtures pledged by it
hereunder to be maintained and preserved in the same condition, repair and
working order as when new, ordinary wear and tear excepted, and shall
forthwith, or in the case of any loss or damage to any of the Equipment and
Fixtures as quickly as practicable after the occurrence thereof, make or cause
to be made all repairs, replacements, and other improvements in connection
therewith which are necessary or desirable to such end (if, pursuant to Section
3.3, Secured Party releases to Debtor insurance payments in respect of the loss
or damage). Debtor shall promptly furnish to Secured Party a statement
respecting any loss or damage which singly equals or exceeds $25,000 to any of
the Equipment and Fixtures pledged by it hereunder.
(c) Debtor shall pay promptly when due or before penalty all property
and other taxes, assessments and governmental charges or levies imposed upon,
and all claims (including
10
<PAGE> 15
claims for labor, materials and supplies) against, the Collateral pledged by it
hereunder, except such taxes as are being contested in good faith by
appropriate proceedings for which adequate reserves have been established in
accordance with GAAP, except where the failure to file such returns, pay such
taxes or establish such reserves does not involve unpaid or allegedly unpaid
amounts, in aggregate, in excess of $50,000. Debtor shall comply with, and
shall cause its licensees to comply with, all requirements of the FDA Act and
the Fair Labor Standards Act.
3.3 Insurance. Debtor shall, at its own expense, maintain insurance
with respect to the Collateral in accordance with the terms set forth in
Section 4.4 of the Credit Agreement. Debtor further covenants and agrees to
keep the Collateral which is Equipment, Fixtures and Inventory and other
tangible personal property insured in such amounts, against such risks and with
such insurers as Secured Party may reasonably require. All such policies of
insurance shall be written for the benefit of Secured Party and Debtor, as
their interests may appear, and shall provide for at least thirty Business
Days' prior written notice of cancellation to Secured Party. Debtor shall
promptly furnish to Secured Party evidence of such insurance in form and
content satisfactory to Secured Party. If Debtor fails to perform or observe
any applicable covenants as to insurance on any of such Collateral, Secured
Party may at its own option obtain insurance on only Secured Party's interest
in such Collateral, any premium thereby paid by Secured Party to become part of
the Obligations, bear interest prior to the existence of an Event of Default,
at the then applicable Prime Base Rate, and during the existence of an Event of
Default, at the lesser of (a) the Prime Base Rate, plus 3% and (b) the Highest
Lawful Rate. In the event Secured Party maintains such substitute insurance,
the additional premium for such insurance shall be due on demand and payable by
Debtor to Secured Party in accordance with any notice delivered to Debtor by
Secured Party. Debtor hereby grants Secured Party a security interest in any
refunds of unearned premiums in connection with any cancellation, adjustment or
termination of any policy of insurance required by Secured Party and in all
proceeds of such insurance and hereby appoints Secured Party its
attorney-in-fact to endorse any check or draft that may be payable to Debtor in
order to collect such refunds or proceeds. Any such sums collected by Secured
Party shall be credited, except to the extent applied to the purchase by
Secured Party of similar insurance, to any amounts then owing on the
Obligations in accordance with the Credit Agreement. If no Default under
Section 4.2, 5.6, 5.7, 5.8, 5.9 or 5.11 of the Credit Agreement or an Event of
Default exists, Lender shall deliver to Debtor all insurance payments in
respect of any covered loss and any refund of any premium or other payment;
provided Debtor uses the payment in respect of an insured loss to acquire a
replacement asset of similar value.
3.4 Place of Perfection; Records; Collection of Receivables, Chattel
Paper and Instruments.
(a) Debtor shall keep its chief place of business and chief executive
office and the office where it keeps its records concerning the Receivables,
and the originals of all Chattel Paper, at the location therefor specified in
Section 2.1(a) or at such other location in the State of Texas as Debtor shall
have given written notice thereof to Secured Party no later than 30 days
11
<PAGE> 16
prior to the moving thereto. Debtor shall deliver to Secured Party all original
Brokerage Agreements to be held by Secured Party as collateral. Debtor will
hold and preserve such records and Chattel Paper and will permit
representatives of Secured Party at any time during normal business hours to
inspect and make abstracts from and copies of such records and Chattel Paper.
Debtor shall deliver to Secured Party all Instruments to be held by Secured
Party as collateral.
(b) Except as otherwise provided in this Section 3.4(b), Debtor shall
continue to collect, at its own expense, all amounts due or to become due
Debtor under the Receivables, Chattel Paper and Instruments. In connection with
such collections, Debtor may take (and, at Secured Party's direction, shall
take) such action as Debtor or Secured Party may deem reasonably necessary or
advisable to enforce collection of the Receivables, Chattel Paper and
Instruments; provided, however, that Secured Party shall have the right (if an
Event of Default exists) (without notice to Debtor) to notify the account
debtors or obligors under any Receivables, Chattel Paper and Instruments of the
assignment of such Receivables, Chattel Paper and Instruments to Secured Party
and to direct such account debtors or obligors to make payment of all amounts
due or to become due to Debtor thereunder directly to Secured Party and, at the
expense of Debtor, to enforce collection of any such Receivables, Chattel Paper
and Instruments, and to adjust, settle or compromise the amount or payment
thereof, in the same manner and to the same extent as Debtor might have done.
All amounts and proceeds (including Instruments) received by Debtor in respect
of the Receivables, Chattel Paper and Instruments shall be received in trust
for the benefit of Secured Party hereunder, shall be segregated from other
funds of Debtor and shall be forthwith paid over to Secured Party in the same
form as so received (with any necessary indorsement) to be held as cash
collateral and either (A) released to Debtor so long as no Default under
Section 4.2, 5.5, 5.7, 5.8, 5.9 or 5.11 of the Credit Agreement or Event of
Default exists or (B) if any Default under Section 4.2, 5.6, 5.7, 5.8, 5.9 or
5.11 of the Credit Agreement or Event of Default exists, applied as provided
herein. Debtor shall not adjust, settle or compromise the amount or payment of
any Receivable, Chattel Paper or Instrument, release wholly or partly any
account debtor or obligor thereof, or allow any credit or discount thereon
except in accordance with Debtor's historical operating procedure.
3.5 Transfers and Other Liens. Debtor shall not (i) sell, assign
(by operation of Law or otherwise) or otherwise dispose of, or grant any option
with respect to, any of the Collateral, except as permitted under the Credit
Agreement and this Agreement, or (ii) create or permit to exist any Lien,
security interest, option or other charge or encumbrance upon or with respect
to any of the Collateral, except for the security interest under this Agreement
(and except as provided for in the Credit Agreement). Debtor may sell Inventory
in the ordinary course of business. Debtor may sell investments subject to a
Brokerage Agreement in which Secured Party has a security interest; provided,
that the proceeds of such sale are subject to a Brokerage Agreement in which
Secured Party has a perfected, first priority security interest in favor of
Secured Party and such sale is in the ordinary course of Debtor's investment
portfolio
12
<PAGE> 17
management. Debtor shall not permit any amendment, restatement or
termination of any Brokerage Agreement without the prior written consent of
Secured Party.
3.6 Brokerage Agreements.
(a) Debtor shall, if any of the shares, securities, moneys or
property previously held by a Person other than Debtor pursuant to a Brokerage
Agreement are received by Debtor, forthwith transfer and deliver to Secured
Party such shares, securities, moneys or property so received by Debtor
(together with the certificates for any such shares and securities duly
endorsed in blank or accompanied by undated stock powers duly executed in
blank), all of which thereafter shall be held by Secured Party, pursuant to the
terms of this Agreement, as part of the Collateral; provided, that if no Event
of Default exists, Debtor may receive cash distributions and dividends (not
consisting of a distribution of or return of capital) declared and paid with
respect to any securities.
(b) (i) For the better perfection of Secured Party's Rights in and
to the Brokerage Agreements or any part thereof and to facilitate
implementation of such Rights, Debtor shall, insofar as possible, if an
Event of Default exists and upon the request of Secured Party (if Secured
Party deems such action necessary to the perfection or priority of the
Liens in the Collateral), cause the Brokerage Agreements to be
transferred, registered or otherwise put into the name or names of such
nominee or nominees of Secured Party as Secured Party shall from time to
time direct.
(ii) So long as no Event of Default exists (and after any
Event of Default until, by notice to Debtor, Secured Party elects while
the Event of Default is continuing to exercise the right to vote or
consent), Debtor shall retain the right to exercise all voting, consensual
and other power of ownership pertaining to the Brokerage Agreements owned
by it for all purposes not inconsistent with the terms of this Agreement
or any other Loan Paper; and Secured Party shall execute and deliver to
Debtor or cause to be executed and delivered to Debtor all such proxies,
powers of attorney, dividend and other orders, and all such instruments,
without recourse, as Debtor may reasonably request for the purpose of
enabling Debtor to exercise the rights and powers which it is entitled to
exercise pursuant to this Section 3.6.
(iii) If any Event of Default exists, and whether or not
Secured Party exercises any available Right to declare any Obligations due
and payable or seeks or pursues any other relief or remedy available under
applicable Laws or under any agreement relating to such Obligations, all
distributions and dividends on any securities and payments and
distributions in respect of each Brokerage Agreement shall be paid
directly to Secured Party and retained by it as part of the Collateral
subject to the terms of this Agreement, and, if Secured Party shall so
request, Debtor agrees to execute and
13
<PAGE> 18
deliver to Secured Party appropriate additional dividend, distribution
and other orders and documents to that end.
3.7 Rights to Dividends and Distributions. With respect to any
certificates, bonds, or other instruments or securities (including but not
limited to any certificate or participation issued in any proceeding under any
Debtor Relief Law) constituting a part of the Collateral, Secured Party shall
have authority if an Event of Default exists, without notice to Debtor, either
to have the same registered in Secured Party's name or in the name of a
nominee, and, with or without such registration, to demand of the issuer
thereof, and to receive and receipt for, any and all distributions (including
any stock or similar dividend or distribution) payable in respect thereof,
whether they be ordinary or extraordinary. Except for any property maintained
in a Brokerage Account, if Debtor shall become entitled to receive or shall
receive any interest in or certificate (including, without limitation, any
interest in or certificate representing a distribution in connection with any
reclassification, increase, or reduction of capital, or issued in connection
with any reorganization), or any option or rights arising from or relating to
any of the Collateral, whether as an addition to, in substitution of, as a
conversion of, or in exchange for any of the Collateral, or otherwise, Debtor
agrees to accept the same as Secured Party's agent and to hold the same in
trust on behalf of and for the benefit of Secured Party, and to deliver the
same immediately to Secured Party in the exact form received, with appropriate
undated stock or similar powers, duly executed in blank, to be held by Secured
Party, subject to the terms hereof, as Collateral. Unless an Event of Default
is in existence, Debtor shall be entitled to receive all cash dividends paid in
respect of any of the Collateral (subject to the restrictions of any other Loan
Paper).
3.8 Right of Secured Party to Notify Issuers. If an Event of Default
exists and at such other times as Secured Party is entitled to receive
dividends or distributions and other property in respect of or consisting of
Instruments and securities, Secured Party may notify each party to a Brokerage
Agreement and issuers of the Instruments and securities to make payments of all
dividends and distributions directly to Secured Party and Secured Party may
take control of all proceeds of any Instruments and securities. Until Secured
Party elects to exercise such Rights, during the continuance of an Event of
Default, Debtor, as agent of Secured Party, shall collect and segregate all
dividends and distributions and other amounts paid or distributed with respect
to the Instruments and securities.
3.9 Secured Party Appointed Attorney-in-Fact. Debtor hereby
irrevocably appoints Secured Party Debtor's attorney-in-fact, with full
authority in the place and stead of Debtor and in the name of Debtor or
otherwise to take any action and to execute any instrument which Secured Party
may deem necessary or advisable to accomplish the purposes of this Agreement,
including, without limitation (provided that the actions listed in each clause
below other than the obtainment of insurance may only be taken or exercised if
an Event of Default exists):
14
<PAGE> 19
(a) to obtain and adjust insurance required to be paid to Secured
Party pursuant to Section 3.3,
(b) to ask, demand, collect, sue for, recover, compromise, receive
and give acquittance and receipts for moneys due and to become due under or in
connection with the Collateral,
(c) to receive, indorse, and collect any drafts or other Instruments,
documents and Chattel Paper, in connection therewith, and
(d) to file any claims or take any action or institute any
proceedings which Secured Party may deem necessary or desirable for the
collection of any of the Collateral or otherwise to enforce compliance with the
terms and conditions of any Collateral or the rights of Secured Party with
respect to any of the Collateral. DEBTOR HEREBY IRREVOCABLY GRANTS TO SECURED
PARTY DEBTOR'S PROXY (EXERCISABLE IF AN EVENT OF DEFAULT EXISTS) TO VOTE ANY
SECURITIES COLLATERAL AND APPOINTS SECURED PARTY DEBTOR'S ATTORNEY-IN-FACT TO
PERFORM ALL OBLIGATIONS OF DEBTOR UNDER THIS AGREEMENT AND TO EXERCISE ALL OF
SECURED PARTY'S RIGHTS HEREUNDER. THE PROXY AND EACH POWER OF ATTORNEY HEREIN
GRANTED, AND EACH STOCK POWER AND SIMILAR POWER NOW OR THEREAFTER GRANTED
(INCLUDING ANY EVIDENCED BY A SEPARATE WRITING), ARE COUPLED WITH AN INTEREST
AND ARE IRREVOCABLE PRIOR TO FINAL PAYMENT IN FULL OF THE OBLIGATIONS.
ARTICLE IV. RIGHTS AND POWERS OF SECURED PARTY
4.1 Secured Party May Perform. If Debtor fails to perform any
agreement contained herein, Secured Party may itself perform, or cause
performance of, such agreement, and the expenses of Secured Party incurred in
connection therewith shall be payable by Debtor under Section 4.5.
4.2 Secured Party's Duties. The powers conferred on Secured Party
hereunder are solely to protect its interest in the Collateral and shall not
impose any duty upon it or any Secured Party to exercise any such powers.
Except for the safe custody of any Collateral in its possession and the
accounting for moneys actually received by it hereunder, Secured Party shall
have no duty as to any Collateral, as to ascertaining or taking action with
respect to calls, conversions, exchanges, maturities, tenders or other matters
relative to any Collateral, whether or not Secured Party has or is deemed to
have knowledge of such matters, or as to the taking of any necessary steps to
preserve rights against prior parties or any other rights pertaining to any
reasonable care in the custody and preservation of any Collateral in its
possession if such Collateral is accorded treatment substantially equal to that
which Secured Party accords its own
15
<PAGE> 20
property. Except as provided in this Section 4.2, Secured Party shall not have
any duty or liability to protect or preserve any Collateral or to preserve
rights pertaining thereto. Nothing contained in this Agreement shall be
construed as requiring or obligating Secured Party, and Secured Party shall not
be required or obligated, to (a) present or file any claim or notice or take
any action, with respect to any Collateral or in connection therewith or (b)
notify Debtor of any decline in the value of any Collateral.
4.3 Remedies. If any Event of Default exists:
(a) Secured Party may exercise in respect of the Collateral, in
addition to other rights and remedies provided for herein or otherwise
available to it, all the rights and remedies of a secured party on default
under the Uniform Commercial Code in effect in the State of Texas at that time
(the "UCC") (whether or not the Uniform Commercial Code applies to the affected
Collateral), and also may (i) require Debtor to, and Debtor hereby agrees that
it will at its expense and upon request of Secured Party forthwith, assemble
all or part of the Collateral as directed by Secured Party and make it
available to Secured Party at a place to be designated by Secured Party which
is reasonably convenient to both parties at public or private sale, at any of
Secured Party's offices or elsewhere, for cash, on credit or for future
delivery, and upon such other terms as Secured Party may deem commercially
reasonable. Debtor agrees that, to the extent notice of sale shall be required
by Law, ten days' notice to Debtor of the time and place of any public sale or
the time after which any private sale is to be made shall constitute reasonable
notification. Secured Party shall not be obligated to make any sale of
Collateral regardless of notice of sale having been given. Secured Party may
adjourn any public or private sale from time to time by announcement at the
time and place fixed therefor, and such sale may, without further notice, be
made at the time and place to which it was so adjourned.
(b) All cash proceeds received by Secured Party upon any sale of,
collection of, or other realization upon, all or any part of the Collateral
shall be applied as follows:
First: To the payment of all out-of-pocket costs and expenses incurred
in connection with the sale of, collection of or other realization upon
Collateral, including reasonable attorneys' fees and disbursements;
Second: To the payment of the Obligations in such order and in such
manner consistent with applicable Laws as Secured Party in its discretion
shall decide (with Debtor remaining liable for any deficiency); and
Third: To the extent of the balance (if any) of such proceeds, to Debtor
or other Person legally entitled thereto.
(c) All payments received by Debtor under or in connection with any
Collateral shall be received in trust for the benefit of Secured Party, shall
be segregated from other funds of
16
<PAGE> 21
Debtor and shall be forthwith paid over to Secured Party in the same form as so
received (with any necessary indorsement).
(d) Because of the FDA Act, the Securities Act of 1933, as amended
("Securities Act") and other Laws, including without limitation state blue sky
Laws, or contractual restrictions or agreements imposed by any licensor or
licensee of certain Rights, there may be legal restrictions or limitations
affecting Secured Party in any attempts to dispose of the Collateral and the
enforcement of its Rights hereunder. For these reasons, Secured Party is hereby
authorized by Debtor, but not obligated, if any Event of Default exists, to
sell or otherwise dispose of any of the Collateral at private sale, subject to
an investment letter, or in any other manner which will be in compliance with
the FDA Act, will not require the Collateral, or any part thereof, to be
registered in accordance with the Securities Act, and the rules and regulations
promulgated under the foregoing, and each other Law applicable to the
Collateral. Secured Party is also hereby authorized by Debtor, but not
obligated, to take such actions, give such notices, obtain such consents, and
do such other things as Secured Party may deem required or appropriate under
the FDA Act, Securities Act or other Laws or contractual restrictions or
agreements in the event of a sale or disposition of any Collateral. Debtor
clearly understands that Secured Party may in its discretion approach a
restricted number of potential purchasers and that a sale under such
circumstances may yield a lower price for the Collateral than would otherwise
be obtainable if same were registered and sold in the open market. No sale so
made in good faith by Secured Party shall be deemed to be not "commercially
reasonable" because so made. Debtor agrees that in the event Secured Party
shall, if an Event of Default exists, sell the Collateral or any portion
thereof at any private sale or sales, Secured Party shall have the right to
rely upon the advice and opinion of appraisers and other Persons, which
appraisers and other Persons are acceptable to Secured Party, as to the best
price reasonably obtainable upon such a private sale thereof. In the absence of
fraud, such reliance shall be conclusive evidence that Secured Party handled
such matter in a commercially reasonable manner under applicable Law.
4.4 Further Approvals Required.
(a) In connection with the exercise by Secured Party of its Rights
hereunder that effects the disposition of or use of any Collateral, it may be
necessary to obtain the prior consent or approval of Tribunals and other
Persons to a transfer or assignment of Collateral, including, without
limitation, the FDA.
(b) Debtor hereby agrees, if an Event of Default exists, to execute,
deliver, and file, and hereby appoints (to the extent permitted under
applicable Law) Secured Party as its attorney-in-fact, if an Event of Default
exists, to execute, deliver, and file on Debtor's behalf and in Debtor's name,
all applications, certificates, filings, instruments, and other documents
(including without limitation any application for an assignment or transfer of
control or ownership) that may be necessary or appropriate, in Secured Party's
opinion, to obtain such consents, waivers, or approvals. Debtor further agrees
to use its best efforts to obtain the foregoing consents, waivers,
17
<PAGE> 22
and approvals, including receipt of consents, waivers, and approvals under
applicable agreements prior to a Default or Event of Default. Debtor
acknowledges that there is no adequate remedy at Law for failure by it to
comply with the provisions of this Section 4.4(b) and that such failure would
not be adequately compensable in damages, and therefore agrees that this
Section 4.4(b) may be specifically enforced.
4.5 INDEMNITY AND EXPENSES. (A) DEBTOR AGREES TO INDEMNIFY SECURED
PARTY FROM AND AGAINST ANY AND ALL CLAIMS, LOSSES AND LIABILITIES (INCLUDING
REASONABLE ATTORNEYS' FEES) GROWING OUT OF OR RESULTING FROM THIS AGREEMENT
(INCLUDING, WITHOUT LIMITATION, ENFORCEMENT OF THIS AGREEMENT), EXCEPT CLAIMS,
LOSSES OR LIABILITIES RESULTING FROM SECURED PARTY'S GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT.
(b) Debtor will upon demand pay to Secured Party the amount of any
and all reasonable expenses, including the reasonable fees and expenses of its
counsel and of any experts and agents, which Secured Party may incur in
connection with (i) the administration of this Agreement, (ii) the custody,
preservation, use or operation of, or the sale of, collection from, or other
realization upon, any of the Collateral, (iii) the exercise or enforcement of
any of the Rights of Secured Party hereunder or (iv) the failure by Debtor to
perform or observe any of the provisions hereof. Any payments so made shall be
a part of the Obligation, shall be payable upon demand, and shall bear interest
(i) if no Event of Default exists, at the Prime Base Rate, and (ii) if an Event
of Default exists, at the lesser of (A) the Prime Base Rate plus 3% and (B) the
Highest Lawful Rate.
ARTICLE V. MISCELLANEOUS
5.1 Cumulative Rights. All Rights of Secured Party under the Loan
Papers are cumulative of each other and of every other Right which Secured
Party may otherwise have at Law or in equity or under any other contract or
other writing for the enforcement of the security interest herein or the
collection of the Obligations. The exercise of one or more Rights shall not
prejudice or impair the concurrent or subsequent exercise of other Rights.
5.2 Modifications; Amendments; Schedules; Etc. No amendment or
waiver of any provision of this Agreement, and no consent to any departure by
Debtor here from, shall in any event be effective unless the same shall be in
writing and signed by Secured Party, and then such waiver or consent shall be
effective only in the specific instance and for the specific purpose for which
given. Upon any change in any material information disclosed on any schedule,
Debtor shall promptly prepare and deliver to Secured Party a replacement
schedule, indicating its effective date, in form and substance satisfactory to
Secured Party and amendments to and
18
<PAGE> 23
additional financing statements as Secured Party may require to preserve and
perfect a first priority security interest in the Collateral.
5.3 Continuing Security Interest. This Agreement shall create a
continuing security interest in the Collateral and shall (a) remain in full
force and effect until the later of (i) the final payment in full of the
Obligations and all amounts payable under this Agreement and (ii) the
expiration or termination of the obligations of Secured Party to extend credit
to Debtor, (b) be binding upon Debtor, its successors and assigns, and (c)
inure to the benefit of, and be enforceable by, Secured Party and its
successors, transferees and assigns. Upon any such termination, Secured Party
will, at Debtor's expense, execute and deliver to Debtor such documents as such
Debtor shall reasonably request to evidence such termination.
5.4 MANDATORY ARBITRATION. (A) ANY CONTROVERSY OR CLAIM BETWEEN OR
AMONG THE PARTIES HERETO INCLUDING BUT NOT LIMITED TO THOSE ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR ANY RELATED AGREEMENTS OR INSTRUMENTS, INCLUDING
ANY CLAIM BASED ON OR ARISING FROM AN ALLEGED TORT, SHALL BE DETERMINED BY
BINDING ARBITRATION IN ACCORDANCE WITH THE FEDERAL ARBITRATION ACT (OR IF NOT
APPLICABLE, THE APPLICABLE STATE LAW), THE RULES OF PRACTICE AND PROCEDURE FOR
THE ARBITRATION OF COMMERCIAL DISPUTES OF JUDICIAL ARBITRATION AND MEDIATION
SERVICES, INC. ("JAMS"), AND THE "SPECIAL RULES" SET FORTH BELOW. IN THE EVENT
OF ANY INCONSISTENCY, THE SPECIAL RULES SHALL CONTROL. JUDGMENT UPON ANY
ARBITRATION AWARD MAY BE ENTERED IN ANY COURT HAVING JURISDICTION. ANY PARTY TO
THIS AGREEMENT MAY BRING AN ACTION, INCLUDING A SUMMARY OR EXPEDITED
PROCEEDING, TO COMPEL ARBITRATION OF ANY CONTROVERSY OR CLAIM TO WHICH THIS
AGREEMENT APPLIES IN ANY COURT HAVING JURISDICTION OVER SUCH ACTION.
(b) Special Rules. The arbitration shall be conducted in Dallas,
Texas and administered by JAMS who will appoint an arbitrator; if JAMS is
unable or legally precluded from administering the arbitration, then the
American Arbitration Association will serve. All arbitration hearings will be
commenced within ninety days of the demand for arbitration; further, the
arbitrator shall only, upon a showing of cause, be permitted to extend the
commencement of such hearing for up to an additional sixty days.
(c) Reservations of Rights. Nothing in this Agreement or any other
Loan Paper shall be deemed to (i) limit the applicability of any otherwise
applicable statutes of limitation or repose and any waivers contained in this
Agreement; or (ii) be a waiver by Secured Party of the protection afforded to
it by 12 U.S.C. Section 91 or any substantially equivalent state law; or (iii)
limit the right of Secured Party hereto (A) to exercise self help remedies such
as (but not limited to)
19
<PAGE> 24
setoff, or (B) to foreclose against any real or personal property collateral,
or (C) to obtain from a court provisional or ancillary remedies such as (but
not limited to) injunctive relief or the appointment of a receiver. Secured
Party may exercise such self help rights, foreclose upon such property, or
obtain such provisional or ancillary remedies before, during or after the
pendency of any arbitration proceeding brought pursuant to this Agreement. At
Secured Party's option, foreclosure under a deed of trust or mortgage may be
accomplished by any of the following: the exercise of a power of sale under the
deed of trust or mortgage, or by judicial sale under the deed of trust or
mortgage, or by judicial foreclosure. Neither this exercise of self help
remedies nor the institution or maintenance of an action for foreclosure or
provisional or ancillary remedies shall constitute a waiver of the right of any
party, including the claimant in any such action, to arbitrate the merits of
the controversy or claim occasioning resort to such remedies.
5.5 GOVERNING LAW; TERMS. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS, EXCEPT TO THE
EXTENT THAT THE VALIDITY OR PERFECTION OF THE SECURITY INTEREST HEREUNDER, OR
REMEDIES HEREUNDER, IN RESPECT OF ANY PARTICULAR COLLATERAL ARE GOVERNED BY THE
LAWS OF A JURISDICTION OTHER THAN THE STATE OF TEXAS. UNLESS OTHERWISE DEFINED
HEREIN OR IN THE CREDIT AGREEMENT, TERMS USED IN ARTICLE 9 OF THE UCC ARE USED
HEREIN AS THEREIN DEFINED.
5.6 WAIVER OF JURY TRIAL. SECURED PARTY AND DEBTOR HEREBY WAIVE
TRIAL BY JURY IN ANY JUDICIAL PROCEEDINGS INVOLVING, DIRECTLY OR INDIRECTLY,
ANY MATTER (WHETHER IN TORT, CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF,
RELATED TO, OR CONNECTED WITH THIS AGREEMENT OR THE RELATIONSHIP ESTABLISHED
HEREUNDER.
5.7 Secured Party's Right to Use Agents. Secured Party may exercise
its Rights under this Agreement through an agent or other designee.
5.8 No Interference, Compensation or Expense. Secured Party may
exercise its Rights under this Agreement without payment of any rent, license
fee or compensation of any kind to Debtor.
5.9 Waivers of Rights Inhibiting Enforcement. Debtor waives (a) any
claim that, as to any part of the Collateral, a public sale, should the Secured
Party elect so to proceed, is, in and of itself, not a commercially reasonable
method of sale for such Collateral, (b) except as otherwise provided in this
Agreement, TO THE EXTENT PERMITTED BY APPLICABLE LAW, NOTICE OR JUDICIAL
HEARING IN CONNECTION WITH SECURED PARTY'S DISPOSITION OF ANY OF THE COLLATERAL
INCLUDING ANY AND ALL PRIOR NOTICE AND HEARING FOR ANY PREJUDGMENT REMEDY OR
20
<PAGE> 25
REMEDIES AND ANY SUCH RIGHT THAT DEBTOR WOULD OTHERWISE HAVE UNDER THE
CONSTITUTION OR ANY STATUTE OF THE UNITED STATES OR OF ANY STATE, AND ALL OTHER
REQUIREMENTS AS TO THE TIME, PLACE AND TERMS OF SALE OR OTHER REQUIREMENTS WITH
RESPECT TO THE ENFORCEMENT OF SECURED PARTY'S RIGHTS HEREUNDER and (c) all
rights of redemption, appraisal or valuation.
5.10 Notices and Deliveries.
(a) Manner of Delivery. All notices, communications and materials to
be given or delivered pursuant to this Agreement shall, except in those cases
where giving notice by telephone is expressly permitted, be given or delivered
in writing. All written notices, communications and materials shall be sent by
registered or certified mail, postage prepaid, return receipt requested, by
telecopier, or delivered by hand. In the event of a discrepancy between any
telephonic notice and any written confirmation thereof, such written
confirmation shall be deemed the effective notice except to the extent Secured
Party or Debtor has acted in reliance on such telephonic notice.
(b) Addresses. All notices, communications and materials to be given
or delivered pursuant to this Agreement shall be given or delivered at the
following respective addresses and telecopier and telephone numbers and to the
attention of the following individuals or departments:
(i) if to Debtor, to it at:
Quest Medical, Inc.
One Allentown Parkway
Allen, Texas 75002
Telecopier No.: (972) 390-9687
Telephone No.: (972) 390-9800
Attention: F. Robert Merrill III
21
<PAGE> 26
(ii) if to Secured Party, to it at:
NationsBank of Texas, N.A.
NationsBank Plaza
901 Main Street
7th Floor
Dallas, Texas 75202
Telecopier No.: (214) 508-3140
Telephone No.: (214) 508-2825
Attention: Commercial Banking
or at such other address or, telecopier or telephone number or to the attention
of such other individual or department as the party to which such information
pertains may hereafter specify for the purpose in a notice to the other
specifically captioned "Notice of Change of Address".
(c) Effectiveness. Each notice, communication and any material to be
given or delivered to Secured Party or Debtor pursuant to this Agreement shall
be effective or deemed delivered or furnished (i) if sent by certified mail,
return receipt requested, on the fifth Business Day after such notice,
communication or material is deposited in the mail, addressed as above
provided, (ii) if sent by telecopier, when such notice, communication or
material is transmitted to the appropriate number determined as above provided
in this Section 5.10 and the appropriate receipt is received or otherwise
acknowledged, (iii) if sent by hand delivery or overnight courier, when left at
the address of the addressee addressed as above provided, and (iv) if given by
telephone, when communicated to the individual or any member of the department
specified as the individual or department to whose attention notices,
communications and materials are to be given or delivered except that notices
of a change of address, telecopier or telephone number or individual or
department to whose attention notices, communications and materials are to be
given or delivered shall not be effective until received.
5.11 Successors and Assigns. All of the provisions of this Agreement
shall be binding and inure to the benefit of the parties thereto and their
respective successors and assigns.
5.12 Loan Paper. This Agreement is a Loan Paper executed pursuant to
the Credit Agreement and shall (unless otherwise expressly indicated herein) be
construed, administered and applied in accordance with the terms and provisions
thereof.
5.13 Definitions. Capitalized terms not otherwise defined herein have
the meaning specified in the Credit Agreement and, to the extent of any
conflict, terms as defined in the Credit Agreement shall control (provided,
that a more expansive or explanatory definition shall not be deemed a
conflict).
22
<PAGE> 27
5.14 Severability. If any provision of any Loan Paper is held to be
illegal, invalid, or unenforceable under present or future Laws during the term
thereof, such provision shall be fully severable, the appropriate Loan Paper
shall be construed and enforced as if such illegal, invalid, or unenforceable
provision had never comprised a part thereof, and the remaining provisions
thereof shall remain in full force and effect and shall not be affected by the
illegal, invalid, or unenforceable provision or by its severance therefrom.
Furthermore, in lieu of such illegal, invalid, or unenforceable provision there
shall be added automatically as a part of such Loan Paper a legal, valid, and
enforceable provision as similar in terms to the illegal, invalid, or
unenforceable provision as may be possible.
5.15 Obligations Not Affected. To the fullest extent permitted by
applicable Law, the obligations of Debtor under this Agreement shall remain in
full force and effect without regard to, and shall not be impaired or affected
by:
(a) any amendment or modification or addition or supplement to any
Loan Paper, any instrument delivered in connection therewith or any assignment
or transfer thereof;
(b) any exercise, non-exercise, or waiver by Secured Party of any
Right, remedy, power or privilege under or in respect of, or any release of any
guaranty, any collateral or the Collateral or any part thereof provided
pursuant to, this Agreement or any Loan Paper;
(c) any waiver, consent, extension, indulgence or other action or
inaction in respect of this Agreement or any Loan Paper or any assignment or
transfer of any thereof; or
(d) any bankruptcy, insolvency, reorganization, arrangement,
readjustment, composition, liquidation or the like of Debtor, or any other
Person, whether or not Debtor shall have notice or knowledge of any of the
foregoing.
5.16 Prior Security Agreements. This Agreements restates in their
entirety each of the Facility A Security Agreement and the Existing Security
Agreement.
5.17 Counterparts. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be deemed an
original, but all such counterparts together shall constitute but one and the
same instrument.
5.18 ENTIRE AGREEMENT. THIS WRITTEN AGREEMENT, TOGETHER WITH THE
OTHER LOAN PAPERS, REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY
NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE
PARTIES.
23
<PAGE> 28
===============================================================================
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
===============================================================================
24
<PAGE> 29
IN WITNESS WHEREOF, Debtor and Secured Party have caused this Agreement to
be duly executed and delivered as of the date first above written.
DEBTOR:
QUEST MEDICAL, INC.
By: /s/ F. ROBERT MERRILL III
-------------------------------------
F. Robert Merrill III, Vice President
SECURED PARTY:
NATIONSBANK OF TEXAS, N.A.
By: /s/ BRIAN K. SCHNEIDER
-------------------------------------
Brian K. Schneider, Vice President
25
<PAGE> 1
EXHIBIT 10.19
================================================================================
FIRST AMENDED AND RESTATED SECURITY AGREEMENT
dated as of March 3, 1997
Between
ADVANCED NEUROMODULATION SYSTEMS, INC.
as Debtor
and
NATIONSBANK OF TEXAS, N.A.
as Secured Party
================================================================================
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
ARTICLE I. GRANT
1.1 Assignment and Grant of Security . . . . . . . . . . . . . . 2
1.2 Description of Obligations . . . . . . . . . . . . . . . . . 5
1.3 Debtor Remains Liable . . . . . . . . . . . . . . . . . . . 6
1.4 Delivery of Security Collateral . . . . . . . . . . . . . . 6
ARTICLE II. REPRESENTATIONS AND WARRANTIES
2.1 Representations and Warranties . . . . . . . . . . . . . . . 6
ARTICLE III. COVENANTS
3.1 Further Assurances . . . . . . . . . . . . . . . . . . . . . 8
3.2 Equipment, Fixtures and Inventory . . . . . . . . . . . . . 10
3.3 Insurance . . . . . . . . . . . . . . . . . . . . . . . . . 11
3.4 Place of Perfection; Records; Collection of Receivables,
Chattel Paper and Instruments . . . . . . . . . . . . . . . 12
3.5 Transfers and Other Liens . . . . . . . . . . . . . . . . . 12
3.6 Brokerage Agreements . . . . . . . . . . . . . . . . . . . . 13
3.7 Rights to Dividends and Distributions . . . . . . . . . . . 14
3.8 Right of Secured Party to Notify Issuers . . . . . . . . . . 14
3.9 Secured Party Appointed Attorney-in-Fact . . . . . . . . . . 14
ARTICLE IV. RIGHTS AND POWERS OF SECURED PARTY
4.1 Secured Party May Perform . . . . . . . . . . . . . . . . . 15
4.2 Secured Party's Duties . . . . . . . . . . . . . . . . . . . 15
4.3 Remedies . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.4 Further Approvals Required . . . . . . . . . . . . . . . . . 17
4.5 INDEMNITY AND EXPENSES . . . . . . . . . . . . . . . . . . . 18
ARTICLE V. MISCELLANEOUS
5.1 Cumulative Rights . . . . . . . . . . . . . . . . . . . . . 18
5.2 Modifications; Amendments; Schedules; Etc. . . . . . . . . . 18
5.3 Continuing Security Interest . . . . . . . . . . . . . . . . 19
5.4 MANDATORY ARBITRATION . . . . . . . . . . . . . . . . . . . 19
5.5 GOVERNING LAW; TERMS . . . . . . . . . . . . . . . . . . . . 20
5.6 WAIVER OF JURY TRIAL . . . . . . . . . . . . . . . . . . . . 20
5.7 Secured Party's Right to Use Agents . . . . . . . . . . . . 20
</TABLE>
i
<PAGE> 3
<TABLE>
<S> <C> <C>
5.8 No Interference, Compensation or Expense . . . . . . . . . . 20
5.9 Waivers of Rights Inhibiting Enforcement . . . . . . . . . . 20
5.10 Notices and Deliveries . . . . . . . . . . . . . . . . . . . 21
(a) Manner of Delivery . . . . . . . . . . . . . . . . . 21
(b) Addresses . . . . . . . . . . . . . . . . . . . . . . 21
(c) Effectiveness . . . . . . . . . . . . . . . . . . . . 22
5.11 Successors and Assigns . . . . . . . . . . . . . . . . . . . 22
5.12 Loan Paper . . . . . . . . . . . . . . . . . . . . . . . . . 22
5.13 Definitions . . . . . . . . . . . . . . . . . . . . . . . . 22
5.14 Severability . . . . . . . . . . . . . . . . . . . . . . . . 23
5.15 Obligations Not Affected . . . . . . . . . . . . . . . . . . 23
5.16 Prior Security Agreements . . . . . . . . . . . . . . . . . 23
5.17 Counterparts . . . . . . . . . . . . . . . . . . . . . . . . 23
5.18 ENTIRE AGREEMENT . . . . . . . . . . . . . . . . . . . . . . 23
</TABLE>
ii
<PAGE> 4
SCHEDULES:
Schedule 1 - Inventory Locations
Schedule 2 - Required Consents
Schedule 3 - Bank Accounts
Schedule 4 - Insurance
Schedule 5 - Vendor Agreements
Schedule 6 - Excluded Equipment and Furnishings
Schedule 7 - Brokerage Agreements
Schedule 8 - Filing Locations
Schedule 9 - Permits
iii
<PAGE> 5
FIRST AMENDED AND RESTATED SECURITY AGREEMENT
FIRST AMENDED AND RESTATED SECURITY AGREEMENT, dated as of March 3, 1997
(this "Agreement"), made by Advanced Neuromodulation Systems, Inc., a Texas
corporation ("Debtor"), in favor of NationsBank of Texas, N.A., a national
banking association ("Secured Party").
BACKGROUND.
(1) Secured Party and Quest Medical, Inc. ("Borrower") have entered
into the Credit Agreement dated as of October 22, 1993 (as amended, the
"Original Credit Agreement"), pursuant to which Debtor, successor by merger to
Neuromed, Inc., each a wholly-owned Subsidiary of Borrower entered in a
Security Agreement dated May 28, 1993 ("Facility A Security Agreement") as
amended and restated from time to time, the Security Agreement dated as of
October 22, 1993 ("Existing Security Agreement") as amended and restated from
time to time and related agreements.
(2) Secured Party and Borrower have entered into the First Amended
and Restated Credit Agreement dated as of March 31, 1995 (such agreement,
together with all amendments and restatements thereof, the "1995 Credit
Agreement") which restates in its entirety the Original Credit Agreement.
(3) Secured Party and Borrower have entered into the Second Amended
and Restated Credit Agreement dated as of February 9, 1996 (such agreement,
together with all amendments and restatements thereof, the "Existing Credit
Agreement") which restates in its entirety the 1995 Credit Agreement.
(4) Secured Party and Borrower have entered into the Third Amended
and Restated Credit Agreement dated as of March 3, 1997 (such agreement,
together with all amendments and restatements thereof, the "Credit Agreement")
which restates in its entirety the Existing Credit Agreement.
(5) It is the intention of the parties hereto that this Agreement
create a first priority security interest securing the payment of the
obligations set forth in Section 1.2.
(6) It is a condition precedent to the effectiveness of the Credit
Agreement that Debtor shall have executed and delivered this Security
Agreement.
<PAGE> 6
AGREEMENT.
NOW, THEREFORE, in consideration of the premises set forth herein and
for other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, and in order to induce Secured Party to make the
Advances under the Credit Agreement, Debtor hereby agrees with Secured Party as
follows:
ARTICLE I. GRANT
1.1 Assignment and Grant of Security. Subject to the last paragraph
of this Section 1.1, Debtor hereby assigns and pledges to Secured Party and
hereby grants to Secured Party a security interest in, the entire right, title
and interest of Debtor, in and to the following assets of Debtor, whether now
owned or hereafter acquired ("Collateral"):
(a) all inventory in all of its forms, wherever located, now or
hereafter existing, including, but not limited to, (i) all raw materials and
work in process therefor, finished goods thereof, and materials used or
consumed in the manufacture or production thereof, (ii) goods in which Debtor
has an interest in mass or a joint or other interest or right of any kind
(including, without limitation, goods in which Debtor has an interest or right
as consignee), and (iii) goods which are returned to or repossessed by Debtor,
and all accessions thereto and products thereof and documents therefor (any and
all such inventory, accessions, products and documents being the "Inventory");
(b) other than equipment described in the last paragraph of this
Section 1.1, all equipment (as defined in the Uniform Commercial Code) and
(whether or not included in such definition), all vehicles, machinery,
chattels, tools, parts, furniture, furnishings and supplies, of every nature,
wherever located, all additions, accessories and improvements thereto and
substitutions therefor and all accessories, parts and equipment which may be
attached to or which are necessary for the operation and use of such personal
property, together with all accessions thereto, and all rights under or arising
out of present or future contracts relating to the foregoing ("Equipment");
(c) all property so related to particular real estate that an
interest in it arises under the real estate law of the jurisdiction in which
such Collateral is located, including all equipment, fixtures and articles of
personal property now or hereafter attached to or used in or about any building
or buildings now erected or hereafter to be erected on any real property now or
hereafter owned or leased by Debtor (the "Property"), which are necessary to
the complete and comfortable use and occupancy of such building or buildings
for the purposes for which they were or are to be erected; all materials to be
delivered to the Property and used or to be used in connection with the
construction of any building to be constructed on the Property, including, but
not limited to, all masonry, siding, roof shingles, flooring, doors, windows,
tile, shutters, stoves, ovens, awnings, screens, cabinets, shades, blinds,
carpets, draperies, furniture, furnishings, plumbing, heating, air
conditioning, lighting, ventilating, refrigerating, cooking,
2
<PAGE> 7
laundry and incinerating equipment and all fixtures and appurtenances thereto,
and such other goods and chattels and personal property as are ever used or
furnished in operating such buildings or the activities conducted therein, and
all building materials and equipment now or hereafter delivered to the Property
and intended to be installed thereon ("Fixtures");
(d) all general intangibles (as defined in the Uniform Commercial
Code), and (whether or not included in such definition) all contract rights
other than Receivables; all inventions, processes, production methods,
proprietary information and know-how; and all licenses or other agreements
granted to Debtor with respect to any of the foregoing; all information,
customer lists, advertising lists, advertising contracts, identification of
suppliers, data, plans, blueprints, specifications, designs, drawings, recorded
knowledge, surveys, engineering reports, test reports, manuals, materials
standards, processing standards, performance standards, telephone numbers and
telephone listings, catalogs, books, records, computer and automatic machinery
software and programs, and the like pertaining to operations by or the business
of Debtor; all field accounting information and all media in which or on which
any of the information or knowledge or data or records may be recorded or
stored and all computer programs used for the compilation or printout of such
information, knowledge, records or data; all licenses, consents, permits,
variances, certifications and approvals of all Tribunals now or hereafter held
by Debtor pertaining to operations or business now or hereafter conducted; all
rights to receive return of deposits and trust payments; all rights to payment
under letters of credit and similar agreements; all tax refunds (including,
without limitation, all federal and state income tax refunds and benefits of
net operating loss carry forwards); and all causes of action, rights, claims
and warranties now or hereafter owned or acquired by Debtor ("General
Intangibles");
(e) all of the following, to the extent that not included in "General
Intangibles": trade secrets, all know-how, inventions, processes, methods,
information, data, plans, blueprints, specifications, designs, drawings,
engineering reports, test reports, materials standards, processing standards
and performance standards, and all computer and automatic machinery software
and programs directly related thereto, and all licenses or other agreements to
which Debtor is a party with respect to any of the foregoing ("Trade Secrets");
(f) all instruments and letters of credit (each as defined in the
Uniform Commercial Code), and (whether or not included in such definitions) all
promissory notes, drafts, bills of exchange and trade acceptances
("Instruments");
(g) all writings which evidence both a monetary obligation and a
security interest in or a lease of specific goods ("Chattel Paper");
(h) all documents, warehouse receipts, bills of lading, including,
without limitation, documents of title (as defined in the Uniform Commercial
Code) or other receipts covering, evidencing or representing any property
described in this Section 1.1 ("Documents");
3
<PAGE> 8
(i) all accounts, contract rights, Chattel Paper, Documents,
Instruments, deposit accounts, General Intangibles, tax refunds and other
obligations of any kind owing to Debtor, now or hereafter existing, arising out
of or in connection with the sale or lease of goods or the rendering of
services, and all rights now or hereafter existing in and to all security
agreements, leases, and other contracts securing or otherwise relating to any
such accounts, contract rights, Chattel Paper, Documents, Instruments, deposit
accounts, General Intangibles, tax refunds or obligations (any and all such
accounts, contract rights, Chattel Paper, Documents, Instruments, deposit
accounts, General Intangibles, tax refunds and obligations being the
"Receivables");
(j) all licenses, permits and other similar rights now or hereafter
owned by Debtor (including but not limited to all licenses, permits and similar
rights issued by the FDA) and necessary to the operation of its business,
including but not limited to all licenses, permits and other rights listed on
Schedule 9;
(k) all agreements and accounts of Debtor described on Schedule 7,
all interest in any security subject to such agreement or account (including
but not limited to all interest in any equity or debt security, option,
warrant, put, call, futures agreements, commodity agreements, margin accounts,
short positions and partnership interests), all property subject to or
maintained in each such account or pursuant to such agreement, each deposit
account (time, demand or other) in which any proceeds of or income from the
foregoing may be on deposit, all cash maintained with each Person pursuant to
any such agreement or account, all general intangibles consisting of the
foregoing and each agreement, document or Instrument governing or evidencing
any of the foregoing and all amendments and restatements thereof, and all
claims of Debtor against any Person with respect to any of the foregoing (all
of the foregoing being herein collectively called the "Brokerage Agreements");
(l) all rights, claims and benefits of Debtor against any Person
arising out of, relating to or in connection with any property described in
this Section 1.1 purchased by Debtor, including, without limitation, any such
rights, claims or benefits against any Person storing or transporting any
property described in this Section 1.1;
(m) the balance of every deposit account of Debtor under control of
Secured Party and each of its Affiliates and any other claim of Debtor against
Secured Party, now or hereafter existing, liquidated or unliquidated, and all
money, Instruments, securities, Documents, Chattel Paper, credits, claims,
demands, income, and any other property, rights and interests of Debtor which
at any time shall come into the possession or custody or under the control of
Secured Party or any of its agents, affiliates or correspondents, for any
purpose, and the proceeds of any thereof (Secured Party shall be deemed to have
possession of any of the Collateral in transit to or set apart for it or any of
its agents, affiliates or correspondents. The holder of any participation in
the Obligations shall have a right of setoff with respect to any obligation of
such holder to Debtor to satisfy the Obligations);
4
<PAGE> 9
(n) all Acquisition Documents;
(o) all agreements with vendors and other distributors of Inventory,
including but not limited to those described in Schedule 5;
(p) all insurance policies and bonds and claims and payments
thereunder;
(q) all property similar to the above hereafter acquired by Debtor;
and
(r) all accessions to, substitutions for and replacements, proceeds
and products of any and all of the foregoing Collateral (including, without
limitation, proceeds which constitute property of the types described in this
Section 1.1) and, to the extent not otherwise included, all (i) payments under
insurance (whether or not Secured Party is the loss payee thereof), or any
indemnity, warranty or guaranty, payable by reason of loss or damage to or
otherwise with respect to any of the foregoing Collateral and (ii) cash.
Nothing in this Section 1.1 or otherwise in any Loan Paper is intended
as a grant of a security interest in any of the following property of Debtor:
(i) heating, ventilation or air conditioning systems now or hereafter
located on the Allen Property,
(ii) the furniture and equipment described on Schedule 6, whether now
owned or hereafter acquired, and all accessions to, substitutions
for and replacements, proceeds and products of such office
furniture and equipment, and
(iii) the computer systems described on Schedule 6, whether now owned
or hereafter acquired, and all accessions to, substitutions for
and replacements, proceeds and products of such computer systems.
The assets described in clauses (i) through (iii) of this paragraph shall not
constitute Collateral for purposes of this Agreement. Secured Party agrees
that, upon request of Debtor, it will execute and deliver to Debtor and MetLife
Capital Corporation or its affiliates (collectively, "MetLife") any documents
reasonably requested by Debtor or MetLife to evidence that Secured Party does
not have a security interest in the assets described in clauses (i) through
(iii) of this paragraph.
1.2 Description of Obligations. This Agreement creates a first
priority security interest securing the payment and performance of the
Obligations, including, but not limited to any and all obligations now or
hereafter existing of Debtor and each other Obligor under the Credit Agreement
and other Loan Papers, including any extensions, modifications, substitutions,
5
<PAGE> 10
amendments and renewals thereof, whether for principal, interest, fees,
premium, expenses, indemnification or otherwise (all such obligations of Debtor
and each other Obligor being the "Obligations"). Without limiting the
generality of the foregoing, this Agreement secures the payment of all amounts
which constitute part of the Obligations and would be owed by Debtor and each
other Obligor to Secured Party under any Loan Paper, but for the fact that they
are unenforceable or not allowable due to the existence of a bankruptcy,
reorganization or similar proceeding involving Debtor or any other Person
(including all after, or that would have secured but for, the filing of any
petition in bankruptcy, or the commencement of any insolvency, reorganization
or like proceeding of Debtor or any other Obligor).
1.3 Debtor Remains Liable. Anything herein to the contrary
notwithstanding, (a) Debtor shall remain liable under the contracts and
agreements included in the Collateral to the extent set forth therein to
perform all of its duties and obligations thereunder to the same extent as if
this Agreement had not been executed, (b) the exercise by Secured Party of any
of the Rights hereunder shall not release Debtor from any of its duties or
obligations under the contracts and agreements included in the Collateral, and
(c) Secured Party shall not have any obligation or liability under the
contracts and agreements included in the Collateral by reason of this
Agreement, nor shall Secured Party be obligated to perform any of the
obligations or duties of Debtor thereunder or to take any action to collect or
enforce any claim for payment assigned hereunder.
1.4 Delivery of Security Collateral. All certificates or instruments
representing or evidencing the Collateral and which are issued in the name of
Debtor shall be delivered to and held by or on behalf of Secured Party pursuant
hereto and shall be in suitable form for transfer by delivery, or shall be
accompanied by duly executed instruments of transfer or assignment in blank,
all in form and substance satisfactory to Secured Party. If an Event of
Default exists, Secured Party shall have the right, at any time during such
time in its discretion and without notice to Debtor, to (a) require the
issuance in the name of Debtor and delivery to Secured Party of certificates or
instruments evidencing the interest owned by Debtor in the issuer of such
certificate or instrument (if the security is subject to a Brokerage Agreement
and the Brokerage Agreement permits such issuance) and (b) transfer to or to
register in the name of Secured Party or any of its nominees any or all of the
Collateral. In addition, Secured Party shall have the right at any time to
exchange certificates or instruments representing or evidencing Collateral for
certificates or instruments of smaller or larger denominations.
ARTICLE II. REPRESENTATIONS AND WARRANTIES
2.1 Representations and Warranties. Debtor represents and warrants,
with respect to itself and the Collateral, as follows:
6
<PAGE> 11
(a) All of the Equipment, Fixtures and Inventory pledged by Debtor
hereunder is located at the places specified on Schedule 1 hereto (as
supplemented from time to time by Debtor by written notice to Secured Party) or
Inventory in transit to a place specified on Schedule 1 hereto (as supplemented
from time to time by Debtor by written notice to Secured Party) or Inventory in
transit (i) for sale to a third-party purchaser that upon such sale will become
the obligor under a Receivable and (ii) pursuant to a sale in the ordinary
course of Debtor's business. The chief place of business and chief executive
office of Debtor and the office where Debtor keeps all of its records
concerning the Receivables, are located at One Allentown Parkway, Allen, Texas
75002. All Chattel Paper, promissory notes or other instruments evidencing the
Receivables have been delivered and pledged to Secured Party duly endorsed and
accompanied by such duly executed instruments of transfer or assignment as are
necessary for such pledge, to be held as pledged collateral. Debtor has
possession and control of the Equipment and Inventory pledged by it hereunder.
The record owner of the real estate upon which the Equipment, Fixtures and
Inventory are located are indicated on Schedule 1.
(b) Debtor is the legal and beneficial owner of the Collateral
pledged by it free and clear of any Lien, security interest, option or other
charge or encumbrance except for the security interest created by this
Agreement and Permitted Liens. No effective financing statement or other
similar document used to perfect and preserve a security interest under the
Laws of any jurisdiction covering all or any part of the Collateral is on file
in any recording office, except (i) such as may have been filed in favor of
Secured Party relating to this Agreement and (ii) financing statements for
which Debtor will provide to Secured Party on the Closing Date proper original
executed termination statements. As of the date hereof, Debtor (including any
corporate or partnership predecessor) has no trade names and has not existed or
operated under any name other than "Advanced Neuromodulation Systems, Inc." or
"Neuromed, Inc.," since March 3, 1987.
(c) This Agreement and the pledge of the Collateral pursuant hereto
creates a valid and, upon filing of financing statements in the Uniform
Commercial Code records described on Schedule 8, perfected first priority
security interest in the Collateral (other than deposit accounts in financial
institutions which are not Secured Party or subject to a Broker Agreement),
securing the payment of the Obligations, and all filings and other actions
necessary or desirable to perfect and protect such security interest and such
priority have been duly taken (or will be taken).
(d) Except as described on Schedule 2, no consent of any other Person
and no authorization, approval or other action by, and no notice to or filing
with, any Tribunal is required (i) for the pledge by Debtor of the Collateral
pledged by it hereunder, for the grant by Debtor of the security interest
granted hereby or for the execution, delivery or performance of this Agreement
by Debtor, (ii) for the perfection or maintenance of the pledge, assignment and
security interest created hereby (including the first priority nature of such
pledge, assignment and security interest) or (iii) for the exercise by Secured
Party of the Rights provided for in this Agreement or the remedies in respect
of the Collateral pursuant to this Agreement.
7
<PAGE> 12
(e) Schedule 3 is a complete and correct list of all deposit accounts
(demand, time, special or other) maintained by or in which Debtor has an
interest and correctly describes the financial institution in which such
account is maintained (including the specific branch), the address and ABA
number of such institution, the officer of such institution having primary
responsibility for Debtor's accounts, the account number and type (as
supplemented from time to time by Debtor by written notice to Secured Party).
(f) Debtor possesses all licenses and Permits, including but not
limited to all applicable certificates of occupancy, licenses and Permits, and
all health and sanitation permits, required for the operations of its business.
Schedule 9 is a complete and correct description of all of such licenses and
Permits.
(g) Schedule 4 is a complete and correct list of all insurance
policies for which Debtor is an insured or for which Debtor is a loss payee.
(h) Schedule 5 is a complete and correct list of all agreements with
each Person related to the resale and distribution of Inventory for each Person
who, during the preceding fiscal year, sold or distributed $25,000 or more of
Debtor's Inventory.
(i) All Inventory of Debtor produced by Debtor in the United States
of America has been produced in compliance with the Fair Labor Standards Act.
(j) Debtor's federal taxpayer identification number is 59-2071994.
(k) There are no conditions precedent to the effectiveness of this
Agreement that have not been satisfied or waived.
ARTICLE III. COVENANTS
3.1 Further Assurances. (a) Debtor agrees that, where any agreement
intended to be Collateral existing as of the date hereof or hereafter to which
Debtor is a party contains any restriction prohibiting Debtor from granting any
security interest under this Agreement, Debtor will use its best efforts to
obtain the necessary consent to or waiver of such restriction from any Person
so as to enable Debtor to effectively grant to Secured Party such security
interest under this Agreement.
(b) Debtor agrees that from time to time, at the expense of Debtor,
Debtor will promptly execute and deliver all further instruments and documents,
and take all further action, that may be reasonably necessary or desirable, or
that Secured Party may reasonably request, in order to perfect and protect any
pledge, assignment or security interest granted or purported to
8
<PAGE> 13
be granted hereby, and the priority thereof, or to enable Secured Party to
exercise and enforce its rights and remedies hereunder with respect to any
Collateral. Without limiting the generality of the foregoing, upon written
request by Secured Party, Debtor will: (i) mark conspicuously each Chattel
Paper included in Receivables, and, at the request of Secured Party, each of
its records pertaining to the Collateral with the following legend:
THIS INSTRUMENT IS SUBJECT TO A SECURITY INTEREST AND LIEN PURSUANT TO A
FIRST AMENDED AND RESTATED SECURITY AGREEMENT DATED MARCH 3, 1997 (AS
THE SAME MAY BE MODIFIED OR RESTATED) MADE BY ADVANCED NEUROMODULATION
SYSTEMS, INC., IN FAVOR OF NATIONSBANK OF TEXAS, N.A.
or such other legend, in form and substance satisfactory to and as specified by
Secured Party, indicating that such Chattel Paper or Collateral is subject to
the pledge, assignment and security interest granted hereby; (ii) if any
Collateral shall be evidenced by a promissory note or other Instrument or be
Chattel Paper, deliver and pledge to Secured Party hereunder such note,
Instrument or Chattel Paper duly indorsed and accompanied by duly executed
instruments of transfer or assignment, all in form and substance satisfactory
to Secured Party; and (iii) execute and file such financing or continuation
statements, or amendments thereto, and such other instruments or notices, as
may be necessary or desirable, or as Secured Party may request, in order to
perfect and preserve the pledge, assignment and security interest granted (and
the priority thereof) or purported to be granted hereby.
(c) Debtor hereby authorizes Secured Party to file one or more
financing or continuation statements, and amendments thereto, relating to all
or any part of the Collateral without the signature of Debtor where permitted
by Law. A photocopy or other reproduction of this Agreement or any financing
statement covering the Collateral or any part thereof shall be sufficient as a
financing statement where permitted by Law.
(d) Debtor will furnish to Secured Party from time to time statements
and schedules further identifying and describing the Collateral (including
information in connection with the protection, preservation, maintenance or
enforcement of the security interest) and such other reports in connection with
the Collateral as Secured Party may reasonably request, all in reasonable
detail; provided, if no Default or Event of Default exists, Secured Party will
not make more than one request in any six month period.
(e) Debtor shall not establish or maintain any deposit or similar
bank account not listed on Schedule 3 unless Secured Party receives prior
written notice thereof, Debtor executes and delivers to Secured Party
assignments of such account in such form as Secured Party may request and the
financial institution in which such account will be maintained delivers to
Secured
9
<PAGE> 14
Party acknowledgments of the assignment of such account in form and substance
satisfactory to Secured Party.
(f) In addition to such other information as shall be specifically
provided for herein, Debtor shall, if a Default or an Event of Default exists,
furnish to Secured Party such other information with respect to the Collateral
as Secured Party may reasonably request from time to time in connection with
the Collateral, including, without limitation, all documents and things in
Debtor's possession, or subject to its demand for possession, related to the
production and sale by Debtor, or any subsidiary, licensee or subcontractor
thereof, of products or services sold by or under the authority of Debtor,
including by way of example, without limiting the interest granted by this
Agreement: (i) all lists and ancillary documents which identify and describe
any of Debtor's customers, advertisers, or those of its Subsidiaries or
licensees, for products sold or services rendered, including without
limitation, such existing lists and ancillary documents which contain each
customer's full name and address, the identity of the Person or Persons having
the principal responsibility on each customer's behalf for ordering products or
services of the kind supplied by Debtor, the credit, payment, discount,
delivery and other sale terms applicable to such customer, together with
detailed information setting forth the total purchases and the patterns of such
purchases; (ii) all product and service specification documents and production
and quality of services sold; (iii) all documents which reveal the names and
addresses of all sources of supply, and all terms of purchase and delivery, for
all materials and components used in the production of products or provision of
services sold; and (iv) all documents constituting or concerning the then
current or proposed advertising and promotion by Debtor or its subsidiaries,
licensees or subcontractors of products or services sold, including, by way of
example and not in limitation, all documents which reveal the media used or to
be used and the cost for all such advertising conducted within the described
period or planned for such products or services. In connection with its
enforcement of the security interest, Secured Party may use such information or
transfer it to any assignee or sublicensee permitted hereunder for such
assignee's or sublicensee's use.
3.2 Equipment, Fixtures and Inventory.
(a) Debtor shall keep the Equipment, Fixtures and Inventory pledged
by it hereunder (other than Inventory sold in the ordinary course of business)
at the places therefor specified in Section 2.1(a) or, upon thirty days' prior
written notice to Secured Party, at such other places in such jurisdiction
where all action required by Section 3.1 shall have been taken with respect to
the Equipment, Fixtures and Inventory.
(b) Debtor shall cause the Equipment and Fixtures pledged by it
hereunder to be maintained and preserved in the same condition, repair and
working order as when new, ordinary wear and tear excepted, and shall
forthwith, or in the case of any loss or damage to any of the Equipment and
Fixtures as quickly as practicable after the occurrence thereof, make or cause
to be made all repairs, replacements, and other improvements in connection
therewith
10
<PAGE> 15
which are necessary or desirable to such end (if, pursuant to Section 3.3,
Secured Party releases to Debtor insurance payments in respect of the loss or
damage). Debtor shall promptly furnish to Secured Party a statement respecting
any loss or damage which singly equals or exceeds $25,000 to any of the
Equipment and Fixtures pledged by it hereunder.
(c) Debtor shall pay promptly when due or before penalty all property
and other taxes, assessments and governmental charges or levies imposed upon,
and all claims (including claims for labor, materials and supplies) against,
the Collateral pledged by it hereunder, except such taxes as are being
contested in good faith by appropriate proceedings for which adequate reserves
have been established in accordance with GAAP, except where the failure to file
such returns, pay such taxes or establish such reserves does not involve unpaid
or allegedly unpaid amounts, in aggregate, in excess of $50,000. Debtor shall
comply with, and shall cause its licensees to comply with, all requirements of
the FDA Act and the Fair Labor Standards Act.
3.3 Insurance. Debtor shall, at its own expense, maintain insurance
with respect to the Collateral in accordance with the terms set forth in
Section 4.4 of the Credit Agreement. Debtor further covenants and agrees to
keep the Collateral which is Equipment, Fixtures and Inventory and other
tangible personal property insured in such amounts, against such risks and with
such insurers as Secured Party may reasonably require. All such policies of
insurance shall be written for the benefit of Secured Party and Debtor, as
their interests may appear, and shall provide for at least thirty Business
Days' prior written notice of cancellation to Secured Party. Debtor shall
promptly furnish to Secured Party evidence of such insurance in form and
content satisfactory to Secured Party. If Debtor fails to perform or observe
any applicable covenants as to insurance on any of such Collateral, Secured
Party may at its own option obtain insurance on only Secured Party's interest
in such Collateral, any premium thereby paid by Secured Party to become part of
the Obligations, bear interest prior to the existence of an Event of Default,
at the then applicable Prime Base Rate, and during the existence of an Event of
Default, at the lesser of (a) the Prime Base Rate, plus 3% and (b) the Highest
Lawful Rate. In the event Secured Party maintains such substitute insurance,
the additional premium for such insurance shall be due on demand and payable by
Debtor to Secured Party in accordance with any notice delivered to Debtor by
Secured Party. Debtor hereby grants Secured Party a security interest in any
refunds of unearned premiums in connection with any cancellation, adjustment or
termination of any policy of insurance required by Secured Party and in all
proceeds of such insurance and hereby appoints Secured Party its
attorney-in-fact to endorse any check or draft that may be payable to Debtor in
order to collect such refunds or proceeds. Any such sums collected by Secured
Party shall be credited, except to the extent applied to the purchase by
Secured Party of similar insurance, to any amounts then owing on the
Obligations in accordance with the Credit Agreement. If no Default under
Section 4.2, 5.6, 5.7, 5.8, 5.9 or 5.11 of the Credit Agreement or an Event of
Default exists, Lender shall deliver to Debtor all insurance payments in
respect of any covered loss and any refund of any premium or other payment;
provided Debtor uses the payment in respect of an insured loss to acquire a
replacement asset of similar value.
11
<PAGE> 16
3.4 Place of Perfection; Records; Collection of Receivables, Chattel
Paper and Instruments.
(a) Debtor shall keep its chief place of business and chief executive
office and the office where it keeps its records concerning the Receivables,
and the originals of all Chattel Paper, at the location therefor specified in
Section 2.1(a) or at such other location in the State of Texas as Debtor shall
have given written notice thereof to Secured Party no later than 30 days prior
to the moving thereto. Debtor shall deliver to Secured Party all original
Brokerage Agreements to be held by Secured Party as collateral. Debtor will
hold and preserve such records and Chattel Paper and will permit
representatives of Secured Party at any time during normal business hours to
inspect and make abstracts from and copies of such records and Chattel Paper.
Debtor shall deliver to Secured Party all Instruments to be held by Secured
Party as collateral.
(b) Except as otherwise provided in this Section 3.4(b), Debtor shall
continue to collect, at its own expense, all amounts due or to become due
Debtor under the Receivables, Chattel Paper and Instruments. In connection
with such collections, Debtor may take (and, at Secured Party's direction,
shall take) such action as Debtor or Secured Party may deem reasonably
necessary or advisable to enforce collection of the Receivables, Chattel Paper
and Instruments; provided, however, that Secured Party shall have the right (if
an Event of Default exists) (without notice to Debtor) to notify the account
debtors or obligors under any Receivables, Chattel Paper and Instruments of the
assignment of such Receivables, Chattel Paper and Instruments to Secured Party
and to direct such account debtors or obligors to make payment of all amounts
due or to become due to Debtor thereunder directly to Secured Party and, at the
expense of Debtor, to enforce collection of any such Receivables, Chattel Paper
and Instruments, and to adjust, settle or compromise the amount or payment
thereof, in the same manner and to the same extent as Debtor might have done.
All amounts and proceeds (including Instruments) received by Debtor in respect
of the Receivables, Chattel Paper and Instruments shall be received in trust
for the benefit of Secured Party hereunder, shall be segregated from other
funds of Debtor and shall be forthwith paid over to Secured Party in the same
form as so received (with any necessary indorsement) to be held as cash
collateral and either (A) released to Debtor so long as no Default under
Section 4.2, 5.5, 5.7, 5.8, 5.9 or 5.11 of the Credit Agreement or Event of
Default exists or (B) if any Default under Section 4.2, 5.6, 5.7, 5.8, 5.9 or
5.11 of the Credit Agreement or Event of Default exists, applied as provided
herein. Debtor shall not adjust, settle or compromise the amount or payment of
any Receivable, Chattel Paper or Instrument, release wholly or partly any
account debtor or obligor thereof, or allow any credit or discount thereon
except in accordance with Debtor's historical operating procedure.
3.5 Transfers and Other Liens. Debtor shall not (i) sell, assign (by
operation of Law or otherwise) or otherwise dispose of, or grant any option
with respect to, any of the Collateral, except as permitted under the Credit
Agreement and this Agreement, or (ii) create or permit to exist any Lien,
security interest, option or other charge or encumbrance upon or with respect
to
12
<PAGE> 17
any of the Collateral, except for the security interest under this Agreement
(and except as provided for in the Credit Agreement). Debtor may sell
Inventory in the ordinary course of business. Debtor may sell investments
subject to a Brokerage Agreement in which Secured Party has a security
interest; provided, that the proceeds of such sale are subject to a Brokerage
Agreement in which Secured Party has a perfected, first priority security
interest in favor of Secured Party and such sale is in the ordinary course of
Debtor's investment portfolio management. Debtor shall not permit any
amendment, restatement or termination of any Brokerage Agreement without the
prior written consent of Secured Party.
3.6 Brokerage Agreements.
(a) Debtor shall, if any of the shares, securities, moneys or
property previously held by a Person other than Debtor pursuant to a Brokerage
Agreement are received by Debtor, forthwith transfer and deliver to Secured
Party such shares, securities, moneys or property so received by Debtor
(together with the certificates for any such shares and securities duly
endorsed in blank or accompanied by undated stock powers duly executed in
blank), all of which thereafter shall be held by Secured Party, pursuant to the
terms of this Agreement, as part of the Collateral; provided, that if no Event
of Default exists, Debtor may receive cash distributions and dividends (not
consisting of a distribution of or return of capital) declared and paid with
respect to any securities.
(b) (i) For the better perfection of Secured Party's Rights in and
to the Brokerage Agreements or any part thereof and to facilitate
implementation of such Rights, Debtor shall, insofar as possible, if an
Event of Default exists and upon the request of Secured Party (if
Secured Party deems such action necessary to the perfection or priority
of the Liens in the Collateral), cause the Brokerage Agreements to be
transferred, registered or otherwise put into the name or names of such
nominee or nominees of Secured Party as Secured Party shall from time to
time direct.
(ii) So long as no Event of Default exists (and after any Event
of Default until, by notice to Debtor, Secured Party elects while the
Event of Default is continuing to exercise the right to vote or
consent), Debtor shall retain the right to exercise all voting,
consensual and other power of ownership pertaining to the Brokerage
Agreements owned by it for all purposes not inconsistent with the terms
of this Agreement or any other Loan Paper; and Secured Party shall
execute and deliver to Debtor or cause to be executed and delivered to
Debtor all such proxies, powers of attorney, dividend and other orders,
and all such instruments, without recourse, as Debtor may reasonably
request for the purpose of enabling Debtor to exercise the rights and
powers which it is entitled to exercise pursuant to this Section 3.6.
(iii) If any Event of Default exists, and whether or not Secured
Party exercises any available Right to declare any Obligations due and
payable or seeks or
13
<PAGE> 18
pursues any other relief or remedy available under applicable Laws or
under any agreement relating to such Obligations, all distributions and
dividends on any securities and payments and distributions in respect of
each Brokerage Agreement shall be paid directly to Secured Party and
retained by it as part of the Collateral subject to the terms of this
Agreement, and, if Secured Party shall so request, Debtor agrees to
execute and deliver to Secured Party appropriate additional dividend,
distribution and other orders and documents to that end.
3.7 Rights to Dividends and Distributions. With respect to any
certificates, bonds, or other instruments or securities (including but not
limited to any certificate or participation issued in any proceeding under any
Debtor Relief Law) constituting a part of the Collateral, Secured Party shall
have authority if an Event of Default exists, without notice to Debtor, either
to have the same registered in Secured Party's name or in the name of a
nominee, and, with or without such registration, to demand of the issuer
thereof, and to receive and receipt for, any and all distributions (including
any stock or similar dividend or distribution) payable in respect thereof,
whether they be ordinary or extraordinary. Except for any property maintained
in a Brokerage Account, if Debtor shall become entitled to receive or shall
receive any interest in or certificate (including, without limitation, any
interest in or certificate representing a distribution in connection with any
reclassification, increase, or reduction of capital, or issued in connection
with any reorganization), or any option or rights arising from or relating to
any of the Collateral, whether as an addition to, in substitution of, as a
conversion of, or in exchange for any of the Collateral, or otherwise, Debtor
agrees to accept the same as Secured Party's agent and to hold the same in
trust on behalf of and for the benefit of Secured Party, and to deliver the
same immediately to Secured Party in the exact form received, with appropriate
undated stock or similar powers, duly executed in blank, to be held by Secured
Party, subject to the terms hereof, as Collateral. Unless an Event of Default
is in existence, Debtor shall be entitled to receive all cash dividends paid in
respect of any of the Collateral (subject to the restrictions of any other Loan
Paper).
3.8 Right of Secured Party to Notify Issuers. If an Event of Default
exists and at such other times as Secured Party is entitled to receive
dividends or distributions and other property in respect of or consisting of
Instruments and securities, Secured Party may notify each party to a Brokerage
Agreement and issuers of the Instruments and securities to make payments of all
dividends and distributions directly to Secured Party and Secured Party may
take control of all proceeds of any Instruments and securities. Until Secured
Party elects to exercise such Rights, during the continuance of an Event of
Default, Debtor, as agent of Secured Party, shall collect and segregate all
dividends and distributions and other amounts paid or distributed with respect
to the Instruments and securities.
3.9 Secured Party Appointed Attorney-in-Fact. Debtor hereby
irrevocably appoints Secured Party Debtor's attorney-in-fact, with full
authority in the place and stead of Debtor and in the name of Debtor or
otherwise to take any action and to execute any instrument which
14
<PAGE> 19
Secured Party may deem necessary or advisable to accomplish the purposes of
this Agreement, including, without limitation (provided that the actions listed
in each clause below other than the obtainment of insurance may only be taken
or exercised if an Event of Default exists):
(a) to obtain and adjust insurance required to be paid to Secured
Party pursuant to Section 3.3,
(b) to ask, demand, collect, sue for, recover, compromise, receive
and give acquittance and receipts for moneys due and to become due under or in
connection with the Collateral,
(c) to receive, indorse, and collect any drafts or other Instruments,
documents and Chattel Paper, in connection therewith, and
(d) to file any claims or take any action or institute any
proceedings which Secured Party may deem necessary or desirable for the
collection of any of the Collateral or otherwise to enforce compliance with the
terms and conditions of any Collateral or the rights of Secured Party with
respect to any of the Collateral. DEBTOR HEREBY IRREVOCABLY GRANTS TO SECURED
PARTY DEBTOR'S PROXY (EXERCISABLE IF AN EVENT OF DEFAULT EXISTS) TO VOTE ANY
SECURITIES COLLATERAL AND APPOINTS SECURED PARTY DEBTOR'S ATTORNEY-IN-FACT TO
PERFORM ALL OBLIGATIONS OF DEBTOR UNDER THIS AGREEMENT AND TO EXERCISE ALL OF
SECURED PARTY'S RIGHTS HEREUNDER. THE PROXY AND EACH POWER OF ATTORNEY HEREIN
GRANTED, AND EACH STOCK POWER AND SIMILAR POWER NOW OR THEREAFTER GRANTED
(INCLUDING ANY EVIDENCED BY A SEPARATE WRITING), ARE COUPLED WITH AN INTEREST
AND ARE IRREVOCABLE PRIOR TO FINAL PAYMENT IN FULL OF THE OBLIGATIONS.
ARTICLE IV. RIGHTS AND POWERS OF SECURED PARTY
4.1 Secured Party May Perform. If Debtor fails to perform any
agreement contained herein, Secured Party may itself perform, or cause
performance of, such agreement, and the expenses of Secured Party incurred in
connection therewith shall be payable by Debtor under Section 4.5.
4.2 Secured Party's Duties. The powers conferred on Secured Party
hereunder are solely to protect its interest in the Collateral and shall not
impose any duty upon it or any Secured Party to exercise any such powers.
Except for the safe custody of any Collateral in its possession and the
accounting for moneys actually received by it hereunder, Secured Party shall
have no duty as to any Collateral, as to ascertaining or taking action with
respect to calls, conversions, exchanges, maturities, tenders or other matters
relative to any Collateral, whether
15
<PAGE> 20
or not Secured Party has or is deemed to have knowledge of such matters, or as
to the taking of any necessary steps to preserve rights against prior parties
or any other rights pertaining to any reasonable care in the custody and
preservation of any Collateral in its possession if such Collateral is accorded
treatment substantially equal to that which Secured Party accords its own
property. Except as provided in this Section 4.2, Secured Party shall not have
any duty or liability to protect or preserve any Collateral or to preserve
rights pertaining thereto. Nothing contained in this Agreement shall be
construed as requiring or obligating Secured Party, and Secured Party shall not
be required or obligated, to (a) present or file any claim or notice or take
any action, with respect to any Collateral or in connection therewith or (b)
notify Debtor of any decline in the value of any Collateral.
4.3 Remedies. If any Event of Default exists:
(a) Secured Party may exercise in respect of the Collateral, in
addition to other rights and remedies provided for herein or otherwise
available to it, all the rights and remedies of a secured party on default
under the Uniform Commercial Code in effect in the State of Texas at that time
(the "UCC") (whether or not the Uniform Commercial Code applies to the affected
Collateral), and also may (i) require Debtor to, and Debtor hereby agrees that
it will at its expense and upon request of Secured Party forthwith, assemble
all or part of the Collateral as directed by Secured Party and make it
available to Secured Party at a place to be designated by Secured Party which
is reasonably convenient to both parties at public or private sale, at any of
Secured Party's offices or elsewhere, for cash, on credit or for future
delivery, and upon such other terms as Secured Party may deem commercially
reasonable. Debtor agrees that, to the extent notice of sale shall be required
by Law, ten days' notice to Debtor of the time and place of any public sale or
the time after which any private sale is to be made shall constitute reasonable
notification. Secured Party shall not be obligated to make any sale of
Collateral regardless of notice of sale having been given. Secured Party may
adjourn any public or private sale from time to time by announcement at the
time and place fixed therefor, and such sale may, without further notice, be
made at the time and place to which it was so adjourned.
(b) All cash proceeds received by Secured Party upon any sale of,
collection of, or other realization upon, all or any part of the Collateral
shall be applied as follows:
First: To the payment of all out-of-pocket costs and expenses incurred
in connection with the sale of, collection of or other realization upon
Collateral, including reasonable attorneys' fees and disbursements;
Second: To the payment of the Obligations in such order and in such
manner consistent with applicable Laws as Secured Party in its
discretion shall decide (with Debtor remaining liable for any
deficiency); and
16
<PAGE> 21
Third: To the extent of the balance (if any) of such proceeds, to
Debtor or other Person legally entitled thereto.
(c) All payments received by Debtor under or in connection with any
Collateral shall be received in trust for the benefit of Secured Party, shall
be segregated from other funds of Debtor and shall be forthwith paid over to
Secured Party in the same form as so received (with any necessary indorsement).
(d) Because of the FDA Act, the Securities Act of 1933, as amended
("Securities Act") and other Laws, including without limitation state blue sky
Laws, or contractual restrictions or agreements imposed by any licensor or
licensee of certain Rights, there may be legal restrictions or limitations
affecting Secured Party in any attempts to dispose of the Collateral and the
enforcement of its Rights hereunder. For these reasons, Secured Party is
hereby authorized by Debtor, but not obligated, if any Event of Default exists,
to sell or otherwise dispose of any of the Collateral at private sale, subject
to an investment letter, or in any other manner which will be in compliance
with the FDA Act, will not require the Collateral, or any part thereof, to be
registered in accordance with the Securities Act, and the rules and regulations
promulgated under the foregoing, and each other Law applicable to the
Collateral. Secured Party is also hereby authorized by Debtor, but not
obligated, to take such actions, give such notices, obtain such consents, and
do such other things as Secured Party may deem required or appropriate under
the FDA Act, Securities Act or other Laws or contractual restrictions or
agreements in the event of a sale or disposition of any Collateral. Debtor
clearly understands that Secured Party may in its discretion approach a
restricted number of potential purchasers and that a sale under such
circumstances may yield a lower price for the Collateral than would otherwise
be obtainable if same were registered and sold in the open market. No sale so
made in good faith by Secured Party shall be deemed to be not "commercially
reasonable" because so made. Debtor agrees that in the event Secured Party
shall, if an Event of Default exists, sell the Collateral or any portion
thereof at any private sale or sales, Secured Party shall have the right to
rely upon the advice and opinion of appraisers and other Persons, which
appraisers and other Persons are acceptable to Secured Party, as to the best
price reasonably obtainable upon such a private sale thereof. In the absence
of fraud, such reliance shall be conclusive evidence that Secured Party handled
such matter in a commercially reasonable manner under applicable Law.
4.4 Further Approvals Required.
(a) In connection with the exercise by Secured Party of its Rights
hereunder that effects the disposition of or use of any Collateral, it may be
necessary to obtain the prior consent or approval of Tribunals and other
Persons to a transfer or assignment of Collateral, including, without
limitation, the FDA.
(b) Debtor hereby agrees, if an Event of Default exists, to execute,
deliver, and file, and hereby appoints (to the extent permitted under
applicable Law) Secured Party as its attorney-
17
<PAGE> 22
in-fact, if an Event of Default exists, to execute, deliver, and file on
Debtor's behalf and in Debtor's name, all applications, certificates, filings,
instruments, and other documents (including without limitation any application
for an assignment or transfer of control or ownership) that may be necessary or
appropriate, in Secured Party's opinion, to obtain such consents, waivers, or
approvals. Debtor further agrees to use its best efforts to obtain the
foregoing consents, waivers, and approvals, including receipt of consents,
waivers, and approvals under applicable agreements prior to a Default or Event
of Default. Debtor acknowledges that there is no adequate remedy at Law for
failure by it to comply with the provisions of this Section 4.4(b) and that
such failure would not be adequately compensable in damages, and therefore
agrees that this Section 4.4(b) may be specifically enforced.
4.5 INDEMNITY AND EXPENSES. (A) DEBTOR AGREES TO INDEMNIFY SECURED
PARTY FROM AND AGAINST ANY AND ALL CLAIMS, LOSSES AND LIABILITIES (INCLUDING
REASONABLE ATTORNEYS' FEES) GROWING OUT OF OR RESULTING FROM THIS AGREEMENT
(INCLUDING, WITHOUT LIMITATION, ENFORCEMENT OF THIS AGREEMENT), EXCEPT CLAIMS,
LOSSES OR LIABILITIES RESULTING FROM SECURED PARTY'S GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT.
(b) Debtor will upon demand pay to Secured Party the amount of any
and all reasonable expenses, including the reasonable fees and expenses of its
counsel and of any experts and agents, which Secured Party may incur in
connection with (i) the administration of this Agreement, (ii) the custody,
preservation, use or operation of, or the sale of, collection from, or other
realization upon, any of the Collateral, (iii) the exercise or enforcement of
any of the Rights of Secured Party hereunder or (iv) the failure by Debtor to
perform or observe any of the provisions hereof. Any payments so made shall be
a part of the Obligation, shall be payable upon demand, and shall bear interest
(i) if no Event of Default exists, at the Prime Base Rate, and (ii) if an Event
of Default exists, at the lesser of (A) the Prime Base Rate plus 3% and (B) the
Highest Lawful Rate.
ARTICLE V. MISCELLANEOUS
5.1 Cumulative Rights. All Rights of Secured Party under the Loan
Papers are cumulative of each other and of every other Right which Secured
Party may otherwise have at Law or in equity or under any other contract or
other writing for the enforcement of the security interest herein or the
collection of the Obligations. The exercise of one or more Rights shall not
prejudice or impair the concurrent or subsequent exercise of other Rights.
5.2 Modifications; Amendments; Schedules; Etc. No amendment or
waiver of any provision of this Agreement, and no consent to any departure by
Debtor here from, shall in any event be effective unless the same shall be in
writing and signed by Secured Party, and then such
18
<PAGE> 23
waiver or consent shall be effective only in the specific instance and for the
specific purpose for which given. Upon any change in any material information
disclosed on any schedule, Debtor shall promptly prepare and deliver to Secured
Party a replacement schedule, indicating its effective date, in form and
substance satisfactory to Secured Party and amendments to and additional
financing statements as Secured Party may require to preserve and perfect a
first priority security interest in the Collateral.
5.3 Continuing Security Interest. This Agreement shall create a
continuing security interest in the Collateral and shall (a) remain in full
force and effect until the later of (i) the final payment in full of the
Obligations and all amounts payable under this Agreement and (ii) the
expiration or termination of the obligations of Secured Party to extend credit
to Debtor, (b) be binding upon Debtor, its successors and assigns, and (c)
inure to the benefit of, and be enforceable by, Secured Party and its
successors, transferees and assigns. Upon any such termination, Secured Party
will, at Debtor's expense, execute and deliver to Debtor such documents as such
Debtor shall reasonably request to evidence such termination.
5.4 MANDATORY ARBITRATION. (A) ANY CONTROVERSY OR CLAIM BETWEEN OR
AMONG THE PARTIES HERETO INCLUDING BUT NOT LIMITED TO THOSE ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR ANY RELATED AGREEMENTS OR INSTRUMENTS, INCLUDING
ANY CLAIM BASED ON OR ARISING FROM AN ALLEGED TORT, SHALL BE DETERMINED BY
BINDING ARBITRATION IN ACCORDANCE WITH THE FEDERAL ARBITRATION ACT (OR IF NOT
APPLICABLE, THE APPLICABLE STATE LAW), THE RULES OF PRACTICE AND PROCEDURE FOR
THE ARBITRATION OF COMMERCIAL DISPUTES OF JUDICIAL ARBITRATION AND MEDIATION
SERVICES, INC. ("JAMS"), AND THE "SPECIAL RULES" SET FORTH BELOW. IN THE EVENT
OF ANY INCONSISTENCY, THE SPECIAL RULES SHALL CONTROL. JUDGMENT UPON ANY
ARBITRATION AWARD MAY BE ENTERED IN ANY COURT HAVING JURISDICTION. ANY PARTY
TO THIS AGREEMENT MAY BRING AN ACTION, INCLUDING A SUMMARY OR EXPEDITED
PROCEEDING, TO COMPEL ARBITRATION OF ANY CONTROVERSY OR CLAIM TO WHICH THIS
AGREEMENT APPLIES IN ANY COURT HAVING JURISDICTION OVER SUCH ACTION.
(b) Special Rules. The arbitration shall be conducted in Dallas,
Texas and administered by JAMS who will appoint an arbitrator; if JAMS is
unable or legally precluded from administering the arbitration, then the
American Arbitration Association will serve. All arbitration hearings will be
commenced within ninety days of the demand for arbitration; further, the
arbitrator shall only, upon a showing of cause, be permitted to extend the
commencement of such hearing for up to an additional sixty days.
19
<PAGE> 24
(c) Reservations of Rights. Nothing in this Agreement or any other
Loan Paper shall be deemed to (i) limit the applicability of any otherwise
applicable statutes of limitation or repose and any waivers contained in this
Agreement; or (ii) be a waiver by Secured Party of the protection afforded to
it by 12 U.S.C. Section 91 or any substantially equivalent state law; or (iii)
limit the right of Secured Party hereto (A) to exercise self help remedies such
as (but not limited to) setoff, or (B) to foreclose against any real or
personal property collateral, or (C) to obtain from a court provisional or
ancillary remedies such as (but not limited to) injunctive relief or the
appointment of a receiver. Secured Party may exercise such self help rights,
foreclose upon such property, or obtain such provisional or ancillary remedies
before, during or after the pendency of any arbitration proceeding brought
pursuant to this Agreement. At Secured Party's option, foreclosure under a
deed of trust or mortgage may be accomplished by any of the following: the
exercise of a power of sale under the deed of trust or mortgage, or by judicial
sale under the deed of trust or mortgage, or by judicial foreclosure. Neither
this exercise of self help remedies nor the institution or maintenance of an
action for foreclosure or provisional or ancillary remedies shall constitute a
waiver of the right of any party, including the claimant in any such action, to
arbitrate the merits of the controversy or claim occasioning resort to such
remedies.
5.5 GOVERNING LAW; TERMS. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS, EXCEPT TO THE
EXTENT THAT THE VALIDITY OR PERFECTION OF THE SECURITY INTEREST HEREUNDER, OR
REMEDIES HEREUNDER, IN RESPECT OF ANY PARTICULAR COLLATERAL ARE GOVERNED BY THE
LAWS OF A JURISDICTION OTHER THAN THE STATE OF TEXAS. UNLESS OTHERWISE DEFINED
HEREIN OR IN THE CREDIT AGREEMENT, TERMS USED IN ARTICLE 9 OF THE UCC ARE USED
HEREIN AS THEREIN DEFINED.
5.6 WAIVER OF JURY TRIAL. SECURED PARTY AND DEBTOR HEREBY WAIVE
TRIAL BY JURY IN ANY JUDICIAL PROCEEDINGS INVOLVING, DIRECTLY OR INDIRECTLY,
ANY MATTER (WHETHER IN TORT, CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF,
RELATED TO, OR CONNECTED WITH THIS AGREEMENT OR THE RELATIONSHIP ESTABLISHED
HEREUNDER.
5.7 Secured Party's Right to Use Agents. Secured Party may exercise
its Rights under this Agreement through an agent or other designee.
5.8 No Interference, Compensation or Expense. Secured Party may
exercise its Rights under this Agreement without payment of any rent, license
fee or compensation of any kind to Debtor.
5.9 Waivers of Rights Inhibiting Enforcement. Debtor waives (a) any
claim that, as to any part of the Collateral, a public sale, should the Secured
Party elect so to proceed, is, in and
20
<PAGE> 25
of itself, not a commercially reasonable method of sale for such Collateral,
(b) except as otherwise provided in this Agreement, TO THE EXTENT PERMITTED BY
APPLICABLE LAW, NOTICE OR JUDICIAL HEARING IN CONNECTION WITH SECURED PARTY'S
DISPOSITION OF ANY OF THE COLLATERAL INCLUDING ANY AND ALL PRIOR NOTICE AND
HEARING FOR ANY PREJUDGMENT REMEDY OR REMEDIES AND ANY SUCH RIGHT THAT DEBTOR
WOULD OTHERWISE HAVE UNDER THE CONSTITUTION OR ANY STATUTE OF THE UNITED STATES
OR OF ANY STATE, AND ALL OTHER REQUIREMENTS AS TO THE TIME, PLACE AND TERMS OF
SALE OR OTHER REQUIREMENTS WITH RESPECT TO THE ENFORCEMENT OF SECURED PARTY'S
RIGHTS HEREUNDER and (c) all rights of redemption, appraisal or valuation.
5.10 Notices and Deliveries.
(a) Manner of Delivery. All notices, communications and materials to
be given or delivered pursuant to this Agreement shall, except in those cases
where giving notice by telephone is expressly permitted, be given or delivered
in writing. All written notices, communications and materials shall be sent by
registered or certified mail, postage prepaid, return receipt requested, by
telecopier, or delivered by hand. In the event of a discrepancy between any
telephonic notice and any written confirmation thereof, such written
confirmation shall be deemed the effective notice except to the extent Secured
Party or Debtor has acted in reliance on such telephonic notice.
(b) Addresses. All notices, communications and materials to be given
or delivered pursuant to this Agreement shall be given or delivered at the
following respective addresses and telecopier and telephone numbers and to the
attention of the following individuals or departments:
(i) if to Debtor, to it at:
Advanced Neuromodulation Systems, Inc.
c/o Quest Medical, Inc.
One Allentown Parkway
Allen, Texas 75002
Telecopier No.: (972) 390-9687
Telephone No.: (972) 390-9800
Attention: F. Robert Merrill III
21
<PAGE> 26
(ii) if to Secured Party, to it at:
NationsBank of Texas, N.A.
NationsBank Plaza
901 Main Street
7th Floor
Dallas, Texas 75202
Telecopier No.: (214) 508-3140
Telephone No.: (214) 508-2825
Attention: Commercial Banking
or at such other address or, telecopier or telephone number or to the attention
of such other individual or department as the party to which such information
pertains may hereafter specify for the purpose in a notice to the other
specifically captioned "Notice of Change of Address".
(c) Effectiveness. Each notice, communication and any material to be
given or delivered to Secured Party or Debtor pursuant to this Agreement shall
be effective or deemed delivered or furnished (i) if sent by certified mail,
return receipt requested, on the fifth Business Day after such notice,
communication or material is deposited in the mail, addressed as above
provided, (ii) if sent by telecopier, when such notice, communication or
material is transmitted to the appropriate number determined as above provided
in this Section 5.10 and the appropriate receipt is received or otherwise
acknowledged, (iii) if sent by hand delivery or overnight courier, when left at
the address of the addressee addressed as above provided, and (iv) if given by
telephone, when communicated to the individual or any member of the department
specified as the individual or department to whose attention notices,
communications and materials are to be given or delivered except that notices
of a change of address, telecopier or telephone number or individual or
department to whose attention notices, communications and materials are to be
given or delivered shall not be effective until received.
5.11 Successors and Assigns. All of the provisions of this Agreement
shall be binding and inure to the benefit of the parties thereto and their
respective successors and assigns.
5.12 Loan Paper. This Agreement is a Loan Paper executed pursuant to
the Credit Agreement and shall (unless otherwise expressly indicated herein) be
construed, administered and applied in accordance with the terms and provisions
thereof.
5.13 Definitions. Capitalized terms not otherwise defined herein have
the meaning specified in the Credit Agreement and, to the extent of any
conflict, terms as defined in the Credit Agreement shall control (provided,
that a more expansive or explanatory definition shall not be deemed a
conflict).
22
<PAGE> 27
5.14 Severability. If any provision of any Loan Paper is held to be
illegal, invalid, or unenforceable under present or future Laws during the term
thereof, such provision shall be fully severable, the appropriate Loan Paper
shall be construed and enforced as if such illegal, invalid, or unenforceable
provision had never comprised a part thereof, and the remaining provisions
thereof shall remain in full force and effect and shall not be affected by the
illegal, invalid, or unenforceable provision or by its severance therefrom.
Furthermore, in lieu of such illegal, invalid, or unenforceable provision there
shall be added automatically as a part of such Loan Paper a legal, valid, and
enforceable provision as similar in terms to the illegal, invalid, or
unenforceable provision as may be possible.
5.15 Obligations Not Affected. To the fullest extent permitted by
applicable Law, the obligations of Debtor under this Agreement shall remain in
full force and effect without regard to, and shall not be impaired or affected
by:
(a) any amendment or modification or addition or supplement to any
Loan Paper, any instrument delivered in connection therewith or any assignment
or transfer thereof;
(b) any exercise, non-exercise, or waiver by Secured Party of any
Right, remedy, power or privilege under or in respect of, or any release of any
guaranty, any collateral or the Collateral or any part thereof provided
pursuant to, this Agreement or any Loan Paper;
(c) any waiver, consent, extension, indulgence or other action or
inaction in respect of this Agreement or any Loan Paper or any assignment or
transfer of any thereof; or
(d) any bankruptcy, insolvency, reorganization, arrangement,
readjustment, composition, liquidation or the like of Debtor, or any other
Person, whether or not Debtor shall have notice or knowledge of any of the
foregoing.
5.16 Prior Security Agreements. This Agreement restates in their
entirety each of the Facility A Security Agreement and the Existing Security
Agreement.
5.17 Counterparts. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be deemed an
original, but all such counterparts together shall constitute but one and the
same instrument.
5.18 ENTIRE AGREEMENT. THIS WRITTEN AGREEMENT, TOGETHER WITH THE
OTHER LOAN PAPERS, REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY
NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE
PARTIES.
23
<PAGE> 28
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
24
<PAGE> 29
IN WITNESS WHEREOF, Debtor and Secured Party have caused this Agreement
to be duly executed and delivered as of the date first above written.
DEBTOR:
ADVANCED NEUROMODULATION
SYSTEMS, INC.
By: /s/ F. ROBERT MERRILL III
------------------------------------
F. Robert Merrill III,
Vice President
SECURED PARTY:
NATIONSBANK OF TEXAS, N.A.
By: /s/ BRIAN K. SCHNEIDER
------------------------------------
Brian K. Schneider,
Vice President
25
<PAGE> 1
EXHIBIT 10.20
================================================================================
FIRST AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY
AGREEMENT AND ASSIGNMENT
dated as of March 3, 1997
Between
QUEST MEDICAL, INC.
as Debtor
and
NATIONSBANK OF TEXAS, N.A.
as Secured Party
================================================================================
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
ARTICLE I. ASSIGNMENT AND GRANT OF SECURITY INTEREST
1.1 Assignment and Grant of Security Interest . . . . . . . . . 2
1.2 Security for Obligations . . . . . . . . . . . . . . . . . . 2
1.3 Validity and Priority of Security Interest . . . . . . . . . 2
1.4 Maintenance of Status of Security Interest, Collateral
and Rights . . . . . . . . . . . . . . . . . . . . . . . . . 2
(a) Required Action . . . . . . . . . . . . . . . . . . . 2
(b) Protection of Collateral . . . . . . . . . . . . . . 3
(c) Authorized Action . . . . . . . . . . . . . . . . . . 3
(d) State Registrations . . . . . . . . . . . . . . . . . 3
1.5 Debtor Remains Obligated; Secured Party Not Obligated . . . 3
1.6 Termination . . . . . . . . . . . . . . . . . . . . . . . . 3
1.7 Security Interest Absolute . . . . . . . . . . . . . . . . . 4
ARTICLE II. REPRESENTATIONS AND WARRANTIES
2.1 Organization; Power . . . . . . . . . . . . . . . . . . . . 4
2.2 Authorization; Enforceability; Required Consents; Absence of
Conflicts . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.3 Accuracy of Questionnaire . . . . . . . . . . . . . . . . . 5
2.4 Rights of Debtor . . . . . . . . . . . . . . . . . . . . . . 5
2.5 Perfection . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.6 State Registrations . . . . . . . . . . . . . . . . . . . . 5
ARTICLE III. COVENANTS
3.1 Certain Matters Relating to Preservation of Status of Security
Interest . . . . . . . . . . . . . . . . . . . . . . . . . . 5
(a) Chief Executive Office . . . . . . . . . . . . . . . 5
(b) Change of Name, Identity, etc. . . . . . . . . . . . 5
3.2 Preservation of Existence and Preservation of Enforceability 5
3.3 Requested Information . . . . . . . . . . . . . . . . . . . 6
3.4 No Disposition of Collateral . . . . . . . . . . . . . . . . 6
3.5 Additional Property . . . . . . . . . . . . . . . . . . . . 6
ARTICLE IV. EVENT OF DEFAULT
4.1 Application of Proceeds . . . . . . . . . . . . . . . . . . 7
4.2 Remedies . . . . . . . . . . . . . . . . . . . . . . . . . . 7
(a) Power of Sale . . . . . . . . . . . . . . . . . . . . 7
(b) Receiver . . . . . . . . . . . . . . . . . . . . . . 8
</TABLE>
- i -
<PAGE> 3
<TABLE>
<S> <C> <C>
(c) Enforcement by Secured Party . . . . . . . . . . . . 8
(d) Other Loan Papers; Laws . . . . . . . . . . . . . . . 8
(e) Sale Restrictions . . . . . . . . . . . . . . . . . . 8
4.3 INDEMNITY AND EXPENSES . . . . . . . . . . . . . . . . . . . 8
ARTICLE V. INTERPRETATION
5.1 Definitional Provision . . . . . . . . . . . . . . . . . . . 9
(a) Certain Terms Defined by Reference . . . . . . . . . 9
(b) Other Defined Terms . . . . . . . . . . . . . . . . . 9
(c) Other Definitional Provisions . . . . . . . . . . . . 12
5.2 Power of Attorney . . . . . . . . . . . . . . . . . . . . . 12
ARTICLE VI. MISCELLANEOUS
6.1 Expenses of Debtor's Agreements and Duties . . . . . . . . . 12
6.2 Secured Party's Right to Perform on Debtor's Behalf . . . . 12
6.3 Secured Party's Right to Use Agents . . . . . . . . . . . . 13
6.4 No Interference, Compensation or Expense . . . . . . . . . . 13
6.5 Limitation of Secured Party's Obligations With Respect to
Collateral . . . . . . . . . . . . . . . . . . . . . . . . . 13
6.6 Rights of Secured Party under UCC and Applicable Law . . . . 13
6.7 Waivers of Rights Inhibiting Enforcement . . . . . . . . . . 13
6.8 Notices and Deliveries . . . . . . . . . . . . . . . . . . . 14
(a) Manner of Delivery . . . . . . . . . . . . . . . . . 14
(b) Addresses . . . . . . . . . . . . . . . . . . . . . . 14
(c) Effectiveness . . . . . . . . . . . . . . . . . . . . 15
(d) Designation of Notice . . . . . . . . . . . . . . . . 15
6.9 Rights and Remedies Cumulative . . . . . . . . . . . . . . . 15
6.10 Amendments; Waivers . . . . . . . . . . . . . . . . . . . . 15
6.11 Assignments . . . . . . . . . . . . . . . . . . . . . . . . 15
6.12 MANDATORY ARBITRATION . . . . . . . . . . . . . . . . . . . 16
6.13 GOVERNING LAW . . . . . . . . . . . . . . . . . . . . . . . 17
6.14 WAIVER OF JURY TRIAL . . . . . . . . . . . . . . . . . . . . 17
6.15 Consent to Jurisdiction; Waiver of Immunities . . . . . . . 17
6.16 Severability of Provisions . . . . . . . . . . . . . . . . . 17
6.17 Counterparts . . . . . . . . . . . . . . . . . . . . . . . . 18
6.18 Successors and Assigns . . . . . . . . . . . . . . . . . . . 18
6.19 Loan Papers . . . . . . . . . . . . . . . . . . . . . . . . 18
6.20 Obligations Not Affected . . . . . . . . . . . . . . . . . . 18
6.21 ENTIRE AGREEMENT . . . . . . . . . . . . . . . . . . . . . . 18
</TABLE>
- ii -
<PAGE> 4
FIRST AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT AND
ASSIGNMENT
FIRST AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT AND
ASSIGNMENT, dated as of March 3, 1997, between Quest Medical, Inc., a Texas
corporation ("Debtor"), and NationsBank of Texas, N.A., a national banking
association ("Secured Party").
BACKGROUND.
(1) Secured Party and Debtor have entered into the First Amended and
Restated Credit Agreement dated as of March 31, 1995 (such agreement, together
with all amendments and restatements thereof, being the "1995 Credit
Agreement").
(2) Secured Party and Debtor have entered into the Second Amended and
Restated Credit Agreement dated as of February 9, 1996 (such agreement,
together with all amendments and restatements thereof, the "Existing Credit
Agreement") which restates in its entirety the 1995 Credit Agreement.
(3) Secured Party and Debtor have entered into the Third Amended and
Restated Credit Agreement dated as of March 3, 1997 (such agreement, together
with all amendments and restatements thereof, the "Credit Agreement") which
restates in its entirety the Existing Credit Agreement.
(4) It is the intention of the parties hereto that this Agreement
create a first priority security interest securing the payment of the
obligations set forth in Section 1.2.
(5) It is a condition precedent to the effectiveness of the Credit
Agreement that Debtor shall have executed and delivered this Agreement.
AGREEMENT.
NOW, THEREFORE, in consideration of the premises set forth herein and
for other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, and in order to induce Secured Party to make Advances
under the Credit Agreement, Debtor hereby agrees with Secured Party as follows:
<PAGE> 5
ARTICLE I. ASSIGNMENT AND GRANT OF SECURITY INTEREST
1.1 Assignment and Grant of Security Interest. Debtor hereby
assigns, pledges and grants to Secured Party a security interest in the entire
right, title and interest of Debtor in and to the Collateral. Debtor is
assigning the marks in the above identified applications as part of the entire
business or portion thereof to which the marks pertain as required by 15 U.S.C.
Section 1060.
1.2 Security for Obligations. This Agreement creates a first priority
security interest securing the payment and performance of any and all
obligations now or hereafter existing of Debtor and each other Obligor under
the Credit Agreement and the other Loan Papers, including any extensions,
modifications, substitutions, amendments and renewals thereof, whether for
principal, interest, fees, expenses, indemnification or otherwise (all such
obligations of Debtor and each other Obligor being the "Obligations"). Without
limiting the generality of the foregoing, this Agreement secures the payment,
of all amounts which constitute part of the Obligations and would be owed by
Debtor or any other Obligor to Secured Party under any Loan Papers, but for the
fact that they are unenforceable or not allowable due to the existence of a
bankruptcy, reorganization or similar proceeding involving Debtor or any other
Obligor (including all interest accruing after, or that would have accrued but
for, the filing of any petition in bankruptcy, or the commencement of any
insolvency, reorganization or like proceeding of Debtor or any other Obligor).
1.3 Validity and Priority of Security Interest. Debtor agrees that
the Security Interest shall at all times be valid, perfected, continuing and
binding and enforceable against Debtor and all other Persons, in accordance
with the terms hereof, as security for the Obligations, and that the Collateral
shall not at any time be subject to any Lien, except as provided in the Loan
Papers.
1.4 Maintenance of Status of Security Interest, Collateral and
Rights.
(a) Required Action. Debtor shall take all action that may be
necessary or that Secured Party may reasonably request, so as at all times (i)
to maintain the validity, perfection, enforceability and priority of the
Security Interest in the Collateral in conformity with the requirements of
Section 1.3, and (ii) to protect and preserve, and to enable the exercise or
enforcement of, the rights of Secured Party hereunder, including (A)
immediately discharging all Liens, (B) executing and delivering the notice in
the form of Schedule 1.04(a)(ii)(B)-A, (C) executing and delivering the notice
in the form of Schedule 1.04(a)(ii)(B)-B, (D) executing and delivering the
notice in the form of Schedule 1.04(a)(ii)(B)-C and (E) executing and
delivering financing or continuation statements, instruments of pledge, notices
and instructions in each case in form and substance reasonably satisfactory to
Secured Party.
- 2 -
<PAGE> 6
(b) Protection of Collateral. Debtor shall protect, preserve, renew
and maintain, in each case in a manner consistent with reasonably responsible
business and legal practices all rights of Debtor in the Collateral, including
the duty to prosecute and/or defend against any and all suits concerning
infringement or dilution of the Collateral, any suits against Debtor asserting
the invalidity of the Collateral and any suits claiming injury to the goodwill
associated with any of the Collateral. Any expenses incurred in protecting,
preserving, renewing and maintaining the Collateral shall be borne by Debtor.
To the maximum extent permitted by Laws, if a Default or Event of Default
exists, Secured Party shall have the right, without taking title to any
Collateral, to bring suit to enforce any or all Collateral or its Security
Interest in any or all of the Collateral, in which event Debtor shall, at the
request of Secured Party, do any and all lawful acts and execute any and all
proper documents required by Secured Party in aid of such enforcement. All
costs, expenses and other moneys advanced by Secured Party in connection with
the foregoing shall, whether or not there are then outstanding any amounts
under the Credit Agreement, be treated as Obligations, but the making of any
advances by Secured Party shall not relieve Debtor of any default hereunder.
(c) Authorized Action. Secured Party is hereby authorized to file
one or more financing or continuation statements or amendments thereto and
instruments of pledge, notices and instructions without the signature of or in
the name of Debtor. A carbon, photographic or other reproduction of this
Agreement or of any financing statement filed in connection with this Agreement
shall be sufficient as a financing statement.
(d) State Registrations. Debtor shall renew or maintain, as
specified in any applicable Law and shall make any filings necessary to renew
or maintain each registration described in Section 2.6.
1.5 Debtor Remains Obligated; Secured Party Not Obligated. The grant
by Debtor to Secured Party of the Security Interest shall not relieve Debtor
from the performance of any term, covenant, condition or agreement on its part
to be performed or observed (including by virtue of the exercise by Secured
Party of any of its Rights hereunder), or from any liability to any Person,
under or in respect of any of the Collateral or impose any obligation on
Secured Party or impose any liability on Secured Party for any act or omission
on the part of Debtor relative thereto.
1.6 Termination.
(a) In the event that (i) the License Agreement shall have been
terminated pursuant to a written termination by Secured Party delivered to
Debtor, and (ii) the Obligations shall have been finally paid in full, and all
commitments by Secured Party to extend credit shall have been terminated and
Secured Party shall have delivered to Debtor a written termination agreement,
then this Agreement shall also terminate and be of no further force and effect
(except as provided in Section 1.6(b)).
- 3 -
<PAGE> 7
(b) Debtor agrees that, if at any time all or any part of any payment
theretofore applied by Secured Party to any of the Obligations is or must be
rescinded or returned by any Person for any reason whatsoever (including the
insolvency, bankruptcy or reorganization of Debtor or any other Person), such
Obligations shall, for the purposes of this Agreement, to the extent that such
payment is or must be rescinded or returned, be deemed to have continued in
existence, notwithstanding such application by Secured Party, and the Security
Interest granted hereunder shall continue to be effective or be reinstated, as
the case may be, as to such Obligations, all as though such application by
Secured Party had not been made.
1.7 Security Interest Absolute. All Rights of Secured Party and the
Security Interest granted to Secured Party hereunder, and all obligations of
Debtor hereunder, shall, to the extent permitted by Laws, be absolute and
unconditional, irrespective of
(a) any lack of validity or enforceability of any Loan Papers;
(b) any change in the time, manner or place of payment or performance
of, or in any other term of, all or any of the Obligations or any other
amendment to or waiver of or any consent to departure from any Loan Papers;
(c) any exchange, release or non-perfection of any collateral
(including the Collateral or any part thereof), or any release of or amendment
to or waiver of or consent to departure from any guaranty, for all or any of
the Obligations; or
(d) any other circumstances which might otherwise constitute a
defense available to, or a discharge of, Debtor, any other Obligor or any other
Person.
ARTICLE II. REPRESENTATIONS AND WARRANTIES
Debtor represents and warrants as follows:
2.1 Organization; Power. Debtor is a corporation duly organized,
validly existing and in good standing under the laws of Texas and has the
corporate power and authority to own its property and to carry on its business
as now being and hereafter proposed to be conducted.
2.2 Authorization; Enforceability; Required Consents; Absence of
Conflicts. Debtor has the power, and has taken all necessary action (including
any necessary corporate action) to authorize it, to execute, deliver and
perform in accordance with its terms this Agreement and to execute and deliver
all financing statements and other filings contemplated hereby. This Agreement
has been duly executed and delivered by Debtor and is the legal, valid and
binding obligation of Debtor, enforceable in accordance with its terms. The
execution, delivery and performance in accordance with its terms by Debtor of
this Agreement does not and (absent any change in any Law) will not (a) require
any Governmental Approval or any other consent or approval, including any
consent or
- 4 -
<PAGE> 8
approval of any partner of Debtor, other than those Governmental Approvals,
consents and approvals listed on Schedule 2.02 hereto which have been duly
obtained and remain in full force and effect, or (b) violate or conflict with,
result in a breach of, constitute a default under, or result in or require the
creation of any Lien (other than the Security Interest) upon any assets of
Debtor under any such contract or agreement or applicable Laws.
2.3 Accuracy of Questionnaire. The Questionnaire is, as of the date
hereof, complete and correct in all respects.
2.4 Rights of Debtor. Debtor is the legal and beneficial owner of
the Collateral free and clear of any Lien or other charge or encumbrance,
including, without limitation, pledges, assignments, licenses, shop rights and
covenants by Debtor not to sue any Person, except for the security interests
and assignment created by this Agreement. No effective financing statement or
other instrument similar in effect naming Debtor as "debtor" covering all or
any part of the Collateral is on file in any recording office, except such as
may have been filed in favor of Secured Party relating to this Agreement.
2.5 Perfection. This Agreement will create in favor of Secured Party
valid and perfected security interests in the Collateral upon making the filing
of Schedules 1.04(a)(ii)(B)-A,-B and-C and the financing statements described
on Schedule 2.02 and such security interests will be a first priority security
interest.
2.6 State Registrations. Schedule 2.06 lists each and all
registrations and applications of Debtor with the applicable authority of each
indicated state with respect to any Trademarks, Goodwill, Patents, Copyrights
and Trade Secrets.
ARTICLE III. COVENANTS
3.1 Certain Matters Relating to Preservation of Status of Security
Interest.
(a) Chief Executive Office. Debtor shall maintain its chief
executive office and the office where the books and records relating to the
Collateral are kept only at One Allentown Parkway, Allen, Texas 75002.
(b) Change of Name, Identity, etc. Debtor shall not change its name
without (i) giving Secured Party thirty days' prior written notice thereof and
(ii) performing all acts required by Secured Party to preserve the Liens herein
granted and the priority and perfection thereof.
3.2 Preservation of Existence and Preservation of Enforceability.
Debtor shall, so long as any of the Obligations remain outstanding, (a)
preserve and maintain its corporate existence and (b) take all action and
obtain all consents and Government Approvals required so
- 5 -
<PAGE> 9
that its obligations under this Agreement will at all times be legal, valid and
binding and enforceable in accordance with its terms.
3.3 Requested Information. In addition to such other Information as
shall be specifically provided for herein, Debtor shall furnish to Secured
Party such other Information with respect to the Collateral as Secured Party
may reasonably request from time to time in connection with the Collateral, or
the protection, preservation, maintenance or enforcement of the Security
Interest or the Collateral including, without limitation, all documents and
things in Debtor's possession, or subject to its demand for possession, related
to the production and sale by Debtor, or any subsidiary, licensee or
subcontractor thereof, of products or services sold by or under the authority
of Debtor in connection with the Collateral, including by way of example,
without limiting the interest granted by this Agreement: (i) all lists and
ancillary documents which identify and describe any of Debtor's customers, or
licensees, for products sold or services rendered under or in connection with
the Collateral, including without limitation, such existing lists and ancillary
documents which contain each customer's full name and address, the full name
and address of all of its warehouses and branches, the identity of the Person
or Persons having the principal responsibility on each customer's behalf for
ordering products or services of the kind supplied by Debtor, the credit,
payment, discount, delivery and other sale terms applicable to such customer,
together with detailed information setting forth the total purchases, by brand,
product, style and size, and the patterns of such purchases; (ii) all product
and service specification documents and production and quality of services sold
under or in connection with the Collateral; (iii) all documents which reveal
the names and addresses of all sources of supply, and all terms of purchase and
delivery, for all materials and components used in the production or products
or provision of services, sold under or in connection with the Collateral; and
(iv) all documents constituting or concerning the then current or proposed
advertising and promotion by Debtor, licensees or subcontractors of products or
services sold under or in connection with the Collateral, including, by way of
example and not in limitation, all documents which reveal the media used or to
be used and the cost for all such advertising conducted within the described
period or planned for such products or services. In connection with its
enforcement of the Security Interest, Secured Party may use such Information or
transfer it to any assignee or sublicensee permitted hereunder for such
assignee's or sublicensee's use.
3.4 No Disposition of Collateral. Debtor shall not sell, transfer or
otherwise dispose of any of the Collateral or any interest therein, or grant
any license thereunder except for and as permitted by the License Agreement.
3.5 Additional Property. Prior to the application for, use or
acquisition or any interest in any property which is within the definition of
"Collateral" or modification, reformulation or other alteration to any such
interest (and, with respect to Collateral with respect to which Debtor's sole
interest is as a licensee, if allowed by the applicable license agreement),
Debtor shall execute and deliver to Secured Party all documents and instruments
Secured Party may require to grant to Secured Party a perfected first priority
Lien therein and to subject to all of such interest to this Agreement,
including but not limited to any new, supplementary or
- 6 -
<PAGE> 10
additional filings in the form of Schedule 1.04(a)(ii)(B)-A,-B,or -C. Debtor
shall execute and deliver to Secured Party such license agreements and
amendments thereto as Secured Party may require.
ARTICLE IV. EVENT OF DEFAULT
Upon the occurrence and during the continuance of an Event of Default:
4.1 Application of Proceeds. All cash proceeds received by Secured
Party upon any sale of, collection of, or other realization upon, all or any
part of the Collateral shall be applied as follows:
First: To the payment of all out-of-pocket costs and expenses incurred
in connection with the sale of, collection of or other realization upon
Collateral, including attorneys' fees and disbursements;
Second: To the payment of the Obligations as provided in the Credit
Agreement (with Debtor remaining liable for any deficiency); and
Third: To the extent of the balance (if any) of such proceeds, to the
payment to Debtor or other Person entitled thereto.
4.2 Remedies.
(a) Power of Sale. Secured Party (i) may sell the Collateral at
public or private sale, at any of its offices or elsewhere, for cash (including
for this purpose, should Secured Party be the successful purchaser at any such
sale, the cancellation of any of the Obligations) or on credit or for future
delivery, and at such price or prices and upon such other terms as it may deem
commercially reasonable, (ii) shall not be obligated to make any sale of
Collateral regardless of notice of sale having been given, and (iii) may
adjourn any public or private sale from time to time by announcement at the
time and place fixed therefor, and such sale may, without further notice, be
made at the time and place to which it was so adjourned; provided, however,
that, if any item of the Collateral constituting a Trademark is assigned or
sold, rather than licensed, it shall be assigned or sold only as an entirety.
Secured Party may be the purchaser at any sale of the Collateral and may pay
all or any part of the purchase price thereof by canceling part or all of the
Obligations. To the fullest extent permitted by applicable Law, Debtor hereby
waives the right to object to the manner of sufficiency of advertising,
refurbishing of the Collateral, or solicitation of bids in connection with any
sales or other disposition of the Collateral. Debtor hereby expressly waives
and releases, to the fullest extent permitted by applicable Law, any right of
redemption on the part of Debtor. If any notification of intended disposition
of any of the Collateral is required by law, such notification, if mailed,
shall be deemed reasonably and properly given if mailed at least ten days
before such disposition, postage prepaid, addressed to
- 7 -
<PAGE> 11
Debtor either at the address shown below, or at any other address of Debtor
appearing on the records of Secured Party.
(b) Receiver. Secured Party may obtain the appointment of a receiver
of the Collateral.
(c) Enforcement by Secured Party. Secured Party may without notice
to Debtor (except that if no Event of Default exists Secured Party shall give
at least 10 days' notice) and at such time or times as Secured Party in its
sole discretion may determine, exercise any or all of Debtor's rights in, to
and under, or in any way connected with or related to, any or all of the
Collateral, including (i) enforcing the performance of, and exercising any or
all of Debtor's rights with respect to the Collateral, in each case by legal
proceedings or otherwise and (ii) settling, adjusting, compromising, extending,
renewing, discharging and releasing any or all of, and any legal proceedings
brought with respect to any or all of, Debtor's rights with respect to the
Collateral.
(d) Other Loan Papers; Laws. Secured Party may exercise any other
right or remedy available under any other Loan Paper or Laws.
(e) Sale Restrictions. Debtor agrees that, in any sale of any of the
Collateral, Secured Party is authorized to comply with any limitation or
restriction in connection with such sale as counsel may advise Secured Party is
necessary in order to avoid any violation of applicable Law (including
compliance with such procedures as may restrict the number of prospective
bidders or purchasers, require that such prospective bidders and purchasers
have certain qualifications, and restrict such prospective bidders and
purchasers to Persons who will represent and agree that they are purchasing for
their own account or investment and not with a view to the distribution or
resale of such Collateral), or in order to obtain any required approval of the
sale or of the purchase by any governmental or regulatory authority or
official, and Debtor further agrees that such compliance shall not result in
such sale being considered or deemed not to have been made in a commercially
reasonable manner, nor shall Secured Party be liable or accountable to Debtor
for any discount allowed by reason of the fact that such Collateral was sold in
compliance with any such limitation or restriction.
4.3 INDEMNITY AND EXPENSES.
(a) DEBTOR AGREES TO INDEMNIFY (WHICH SHALL BE PAYABLE FROM TIME TO
TIME ON DEMAND) SECURED PARTY FROM AND AGAINST ANY AND ALL CLAIMS, LOSSES AND
LIABILITIES GROWING OUT OF OR RESULTING FROM THIS AGREEMENT (INCLUDING
ENFORCEMENT OF THIS AGREEMENT), EXPRESSLY INCLUDING SUCH CLAIMS, LOSSES, OR
LIABILITIES ARISING OUT OF MERE NEGLIGENCE OF SECURED PARTY, EXCEPT CLAIMS,
LOSSES OR LIABILITIES RESULTING FROM SECURED PARTY'S GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT.
- 8 -
<PAGE> 12
(b) Debtor will upon demand pay to Secured Party the amount of any
and all reasonable expenses, including the reasonable fees and disbursements of
its counsel and of any experts and agents, which Secured Party may incur in
connection with (i) the administration of this Agreement, (ii) the custody,
preservation, use or operation of, or the sale of, collection from, or other
realization upon, any of the Collateral, (iii) the exercise or enforcement of
any of the Rights of Secured Party hereunder, or (iv) the failure by Debtor to
perform or observe any of the provisions hereof.
ARTICLE V. INTERPRETATION
5.1 Definitional Provision.
(a) Certain Terms Defined by Reference. The terms "collateral",
"inventory", "rights", and "security interest" shall have the meanings ascribed
thereto in the UCC, or, when capitalized, the meanings specified in subsection
(b) below.
(b) Other Defined Terms. For purposes of this Agreement:
"Agreement" means this Agreement, including all schedules, annexes and
exhibits hereto.
"Bankruptcy Code" means 11 U.S.C.Sections 101-1330 (1995), as amended,
or any successor statute.
"Collateral" means Debtor's rights, title and interests (whatever they
may be), in each of the following, in each case whether now or hereafter
existing or now owned or hereafter acquired by Debtor and whether or not the
same is subject to Article 9 of the UCC, and wherever the same may be located:
i) the Trademarks and Goodwill;
ii) the Copyrights;
iii) the Patents;
iv) the Trade Secrets;
v) each state registration and application listed on Schedule
2.06;
vi) any renewal, reissue, re-examination certificate,
extension or the like with respect to the Trademarks, Patents,
Copyrights and Trade Secrets (as applicable);
- 9 -
<PAGE> 13
vii) all rights to use the Trademarks as trade names or assumed
names in all aspects of its business; and
viii) all proceeds and products of the foregoing together with
any license in favor of or from Debtor of any of the foregoing in
whatever form. The inclusion of "proceeds" of Collateral in the
definition of "Collateral" shall not be deemed a consent by Secured
Party to any sale or other disposition of any Collateral not otherwise
specifically permitted by the terms hereof.
"Copyright" means any copyright, copyright registration and applications
for such registration, including but not limited to the copyrights listed on
Annex C-1 attached hereto, all subject matter related to such copyrights, in
any and all forms, and all copyrights and applications for copyrights related
to such copyrights, including those copyrights and applications listed in Annex
C-2 attached hereto.
"Credit Agreement" is defined in the Background.
"Event of Default" means (i) those events described as a "Default" or an
"Event of Default" in the Credit Agreement, or (ii) the Rejection of the
License Agreement.
"Goodwill" means the goodwill of the businesses connected with the use
of (or associated with) and symbolized by the Trademarks, but not any other
goodwill.
"Governmental Approval" means any authorization, consent, approval,
license or exemption of, registration or filing with, or report or notice to,
any Tribunal.
"Information" means data, certificates, reports, statements (including
financial statements), documents and other information in form (including
electronic media) acceptable to Secured Party.
"License Agreement" means the License Agreement dated March 31, 1995
between Debtor and Secured Party, including any renewal, extension,
modification or restatement thereof.
"Lien" means, with respect to any property or asset (or any income or
profits therefrom) of any Person (in each case whether the same is consensual
or nonconsensual or arises by contract, operation of law, legal process or
otherwise) (i) any mortgage, lien, pledge, attachment, levy, priority or other
security interest or encumbrance of any kind thereupon or in respect thereof
and (ii) any arrangement, express or implied, under which the same is
subordinated, transferred, sequestered or otherwise identified so as to subject
the same, or make the same available for, the payment or performance of any
obligation in priority to the payment of the ordinary, unsecured creditors of
such Person.
- 10 -
<PAGE> 14
"Loan Papers" means the Credit Agreement and each agreement, certificate
and other documents delivered to any Person pursuant to the Credit Agreement.
"Obligations" is defined in Section 1.2.
"Patents" means all patents, all inventions and subject matter related
to such patents, in any and all forms, and all patents and applications for
patents related to such patents, including but not limited to the patents
listed on Annex A-1 attached hereto, all inventions and all subject matter
related to such patents, in any and all forms, and all patents and applications
for patents related to such patents, including those patents and applications
listed on Annex A-2 attached hereto.
"Person" means an individual, firm, corporation, partnership,
association, joint venture, trust or any other entity or organization or
Tribunal.
"Questionnaire" means the Questionnaire in the form attached hereto as
Schedule 5.01 executed and delivered by Debtor to Secured Party in connection
with this Agreement.
"Rejection" means, with respect to the License Agreement in respect of
any item of Collateral, the entry of an order in any proceeding authorizing the
rejection by Debtor (or a trustee for Debtor or Debtor as debtor-in-possession)
of the License Agreement or any analogous event in any proceeding under the
laws of any jurisdiction; provided, however, that nothing contained in this
Agreement shall be deemed to be an acknowledgment or an agreement by any party
hereto that the License Agreement may be rejected under any Debtor Relief Law
or subject to any analogous event under any similar law of any jurisdiction
other than the United States.
"Security Interest" means the continuing security interest of Secured
Party and assignment to Secured Party in the Collateral intended to be effected
by the terms of this Agreement or any financing and continuation statements or
other filings contemplated hereby.
"Trade Secrets" means those general intangibles (sometimes known as
"trade secrets").
"Trademarks" means all trademarks, all designs and logotypes related to
such trademarks, in any and all forms, and all trademark registrations and
applications for registration related to such trademarks, including but not
limited to the trademarks listed on Annex B-1 attached hereto, all designs and
logotypes related to such trademarks, in any and all forms, and all trademark
registrations and applications for registration related to such trademarks,
including those registrations and applications listed on Annex B-2 attached
hereto.
"UCC" means Chapter 9 of the Texas Business and Commerce Code as in
effect from time to time in the State of Texas.
- 11 -
<PAGE> 15
(c) Other Definitional Provisions.
i) Except as otherwise specified herein, all references
herein (A) to any Person shall be deemed to include such Person's
successors and assigns, (B) to any applicable Law referred to herein
shall be deemed references to such applicable Law as the same may have
been or may be amended or supplemented from time to time and (C) to this
Agreement or other agreement defined or referred to herein shall be
deemed a reference to this Agreement or other agreement as the terms
thereof may have been or may be amended, supplemented, waived or
otherwise modified from time to time.
ii) Whenever the context so requires, the neuter gender
includes the masculine or feminine, the masculine gender includes the
feminine, and the singular number includes the plural, and vice versa.
iii) Except as otherwise indicated, any reference herein to the
"Collateral", the "Obligations" or any other collective or plural term
shall be deemed to be a reference to each and every item included within
the category described by such collective or plural term, so that a
reference to the "Collateral" or the "Obligations" shall be deemed a
reference to any or all of the Collateral or the Obligations, as the
case may be.
iv) Capitalized Terms not otherwise defined herein have the
meaning specified in the Credit Agreement, and, to the extent of any
conflict, terms as defined in the Credit Agreement shall control
(provided, that a more expansive or explanatory definition shall not be
deemed a conflict).
5.2 Power of Attorney. Each power of attorney, license and other
authorization in favor of Secured Party or any other Person granted by or
pursuant to this Agreement shall be deemed to be irrevocable and coupled with
an interest.
ARTICLE VI. MISCELLANEOUS
6.1 Expenses of Debtor's Agreements and Duties. Secured Party shall
not be liable for the costs and expenses of Debtor arising out of Debtor's
performance or observance of the terms, conditions, covenants and agreements to
be observed or performed by Debtor under this Agreement.
6.2 Secured Party's Right to Perform on Debtor's Behalf. If Debtor
shall fail to observe or perform any of the terms, conditions, covenants and
agreements to be observed or performed by it under this Agreement, Secured
Party may (but shall not be obligated to) do the same or cause it to be done or
performed or observed, either in its name or in the name and on behalf of
Debtor, and in the event that Debtor shall have failed to observe or perform
any of the terms, conditions, covenants and agreements to be observed or
performed by it under this Agreement, then Debtor hereby authorizes Secured
Party to do so, and Debtor hereby appoints
- 12 -
<PAGE> 16
Secured Party, and any other Person Secured Party may designate, as Debtor's
attorney-in-fact to do, or cause to be done, in the name, place and stead of
Debtor in any way in which Debtor itself could do, or cause to be done, any or
all things necessary to observe or perform the terms, conditions, covenants and
agreements to be observed or performed by Debtor under this Agreement. In
addition, Debtor hereby irrevocably appoints Secured Party as Debtor's
attorney-in-fact to execute and deliver in Debtor's name and stead to any
purchaser at any sale held under Section 4.2 any and all documents and
instruments of assignment, transfer and conveyance necessary or appropriate to
transfer to such purchaser the Collateral sold at such sale.
6.3 Secured Party's Right to Use Agents. Secured Party may exercise
its rights under this Agreement through an agent or other designee.
6.4 No Interference, Compensation or Expense. Secured Party may
exercise its rights under this Agreement (a) without resistance or interference
by Debtor and (b) without payment of any rent, license fee or compensation of
any kind to Debtor.
6.5 Limitation of Secured Party's Obligations With Respect to
Collateral.
(a) Except as provided in the License Agreement, Secured Party shall
not have any duty or liability to protect or preserve any Collateral or to
preserve rights pertaining thereto.
(b) Nothing contained in this Agreement shall be construed as
requiring or obligating Secured Party, and Secured Party shall not be required
or obligated, to (i) present or file any claim or notice or take any action,
with respect to any Collateral or in connection therewith or (ii) notify Debtor
of any decline in the value of any Collateral.
6.6 Rights of Secured Party under UCC and Applicable Law. Secured
Party shall have, with respect to the Collateral, in addition to all of its
rights under this Agreement, (a) the rights of a secured party under the UCC,
whether or not the UCC would otherwise apply to the collateral in question, and
(b) the rights of a secured party under all other applicable Laws.
6.7 Waivers of Rights Inhibiting Enforcement. Debtor waives (a) any
claim that, as to any part of the Collateral, a public sale, should Secured
Party elect so to proceed, is, in and of itself, not a commercially reasonable
method of sale for such Collateral, (b) except as otherwise provided in this
Agreement, TO THE EXTENT PERMITTED BY APPLICABLE LAW, NOTICE OR JUDICIAL
HEARING IN CONNECTION WITH SECURED PARTY'S DISPOSITION OF ANY OF THE COLLATERAL
INCLUDING ANY AND ALL PRIOR NOTICE AND HEARING FOR ANY PREJUDGMENT REMEDY OR
REMEDIES AND ANY SUCH RIGHT THAT DEBTOR WOULD OTHERWISE HAVE UNDER THE
CONSTITUTION OR ANY STATUTE OF THE UNITED STATES OR OF ANY STATE, AND ALL OTHER
REQUIREMENTS AS TO THE TIME, PLACE AND TERMS OF SALE OR OTHER REQUIREMENTS WITH
RESPECT TO THE ENFORCEMENT OF
- 13 -
<PAGE> 17
SECURED PARTY'S RIGHTS HEREUNDER and (c) all rights of redemption, appraisement
or valuation.
6.8 Notices and Deliveries.
(a) Manner of Delivery. All notices, communications and materials
(including all Information) to be given or delivered pursuant to this Agreement
shall, except in those cases where giving notice by telephone is expressly
permitted, be given or delivered in writing. All written notices,
communications and materials shall be sent by registered or certified mail,
postage prepaid, return receipt requested, by telecopier, or delivered by hand.
In the event of a discrepancy between any telephonic notice and any written
confirmation thereof, such written confirmation shall be deemed the effective
notice except to the extent Secured Party or Debtor has acted in reliance on
such telephonic notice.
(b) Addresses. All notices, communications and materials to be given
or delivered pursuant to this Agreement shall be given or delivered at the
following respective addresses and telecopier and telephone numbers and to the
attention of the following individuals or departments:
(i) if to Debtor, to it at:
Quest Medical, Inc.
One Allentown Parkway
Allen, Texas 75002
Telephone No: (214) 390-9800
Telecopier No: (214) 390-9687
Attention: F. Robert Merrill III
(ii) if to Secured Party, to it at:
NationsBank of Texas, N.A.
NationsBank Plaza
901 Main Street
7th Floor
Dallas, Texas 75202
Telephone No: (214) 508-2825
Telecopier No: (214) 508-3140
Attention: Commercial Banking
- 14 -
<PAGE> 18
or at such other address, telecopier or telephone number or to the attention of
such other individual or department as the party to which such information
pertains may hereafter specify for the purpose in a notice to the other
specifically captioned "Notice of Change of Address".
(c) Effectiveness. Each notice, communication and any material to be
given or delivered to Secured Party or Debtor pursuant to this Agreement shall
be effective or deemed delivered or furnished (i) if sent by mail, on the fifth
Business Day after such notice, communication or material is deposited in the
mail, addressed as above provided, (ii) if sent by telecopier, when such
notice, communication or material is transmitted to the appropriate number
determined as above provided in this Section 6.8 and the appropriate receipt is
received or acknowledged, (iii) if sent by hand delivery or overnight courier,
when left at the address of the addressee addressed as above provided and the
appropriate receipt is received or acknowledged, and (iv) if given by
telephone, when communicated to the individual or any member of the department
specified as the individual or department to whose attention notices,
communications and materials are to be given or delivered except that notices
of a change of address, telecopier or telephone number or individual or
department to whose attention notices, communications and materials are to be
given or delivered shall not be effective until received.
(d) Designation of Notice. No notice shall be effective under
Section 3.1(a) or (b) unless it is specifically designated and, in the case of
a notice under Section 3.1(a), "Notice of Change of Executive Office and Books
and Records."
6.9 Rights and Remedies Cumulative. Each of Secured Party's rights
and remedies under this Agreement shall be in addition to all of its other
rights and remedies under this Agreement and applicable Law, and nothing herein
shall be construed as limiting any such rights or remedies.
6.10 Amendments; Waivers. Any term, covenant, agreement or condition
of this Agreement may be amended, and any right under this Agreement may be
waived, if, but only if, such amendment or waiver is in writing and is signed
by Secured Party and, in the case of an amendment, by Debtor. Unless otherwise
specified in such waiver, a waiver of any right under this Agreement shall be
effective only in the specific instance and for the specific purpose for which
given. No election not to exercise, failure to exercise or delay in exercising
any right, nor any course of dealing or performance, shall operate as a waiver
of any right of the Secured Party under this Agreement or applicable Law, nor
shall any single or partial exercise of any such right preclude any other or
further exercise thereof or the exercise of any other right of Secured Party
under this Agreement or applicable Law.
6.11 Assignments.
(a) Debtor may not assign any of its rights or obligations under this
Agreement without the prior written consent of Secured Party.
- 15 -
<PAGE> 19
(b) Secured Party may, in connection with any assignment under and in
accordance with the License Agreement to any Person of any or all of the
licensee's rights and obligations under such License Agreement, assign to such
Person, or any agent(s) or representative(s) on behalf of such licensee and its
sublicenses, any or all of Secured Party's rights and obligations under this
Agreement and any other document or instrument, including financing and
continuation statements and other filings, contemplated hereby and with respect
to the Collateral without the consent of Debtor. In addition, Secured Party
may assign or otherwise transfer (in whole or in part) to any other Person all
of its rights and obligations under any Loan Papers (including this Agreement)
or otherwise.
6.12 MANDATORY ARBITRATION.
(a) ANY CONTROVERSY OR CLAIM BETWEEN OR AMONG THE PARTIES HERETO
INCLUDING BUT NOT LIMITED TO THOSE ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR ANY RELATED AGREEMENTS OR INSTRUMENTS, INCLUDING ANY CLAIM BASED ON OR
ARISING FROM AN ALLEGED TORT, SHALL BE DETERMINED BY BINDING ARBITRATION IN
ACCORDANCE WITH THE FEDERAL ARBITRATION ACT (OR IF NOT APPLICABLE, THE
APPLICABLE STATE LAW), THE RULES OF PRACTICE AND PROCEDURE FOR THE ARBITRATION
OF COMMERCIAL DISPUTES OF JUDICIAL ARBITRATION AND MEDIATION SERVICES, INC.
("JAMS"), AND THE "SPECIAL RULES" SET FORTH BELOW. IN THE EVENT OF ANY
INCONSISTENCY, THE SPECIAL RULES SHALL CONTROL. JUDGMENT UPON ANY ARBITRATION
AWARD MAY BE ENTERED IN ANY COURT HAVING JURISDICTION. ANY PARTY TO THIS
AGREEMENT MAY BRING AN ACTION, INCLUDING A SUMMARY OR EXPEDITED PROCEEDING, TO
COMPEL ARBITRATION OF ANY CONTROVERSY OR CLAIM TO WHICH THIS AGREEMENT APPLIES
IN ANY COURT HAVING JURISDICTION OVER SUCH ACTION.
(b) Special Rules. The arbitration shall be conducted in Dallas,
Texas and administered by JAMS who will appoint an arbitrator; if JAMS is
unable or legally precluded from administering the arbitration, then the
American Arbitration Association will serve. All arbitration hearings will be
commenced within ninety days of the demand for arbitration; further, the
arbitrator shall only, upon a showing of cause, be permitted to extend the
commencement of such hearing for up to an additional sixty days.
(c) Reservations of Rights. Nothing in this Agreement or any other
Loan Paper shall be deemed to (i) limit the applicability of any otherwise
applicable statutes of limitation or repose and any waivers contained in this
Agreement; or (ii) be a waiver by Secured Party of the protection afforded to
it by 12 U.S.C. Section 91 or any substantially equivalent state law; or (iii)
limit the right of Secured Party hereto (A) to exercise self help remedies such
as (but not limited to) setoff, or (B) to foreclose against any real or
personal property collateral, or (C) to obtain from a
- 16 -
<PAGE> 20
court provisional or ancillary remedies such as (but not limited to) injunctive
relief or the appointment of a receiver. Secured Party may exercise such self
help rights, foreclose upon such property, or obtain such provisional or
ancillary remedies before, during or after the pendency of any arbitration
proceeding brought pursuant to this Agreement. At Secured Party's option,
foreclosure under a deed of trust or mortgage may be accomplished by any of the
following: the exercise of a power of sale under the deed of trust or
mortgage, or by judicial sale under the deed of trust or mortgage, or by
judicial foreclosure. Neither this exercise of self help remedies nor the
institution or maintenance of an action for foreclosure or provisional or
ancillary remedies shall constitute a waiver of the right of any party,
including the claimant in any such action, to arbitrate the merits of the
controversy or claim occasioning resort to such remedies.
6.13 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF TEXAS (WITHOUT REFERENCE
TO PRINCIPALS OF CONFLICTS OF LAWS), EXCEPT TO THE EXTENT THAT THE VALIDITY OR
PERFECTION OF THE SECURITY INTEREST HEREUNDER, OR REMEDIES HEREUNDER, IN
RESPECT OF ANY PARTICULAR COLLATERAL ARE REQUIRED TO GOVERNED BY THE LAWS OF A
JURISDICTION OTHER THAN THE STATE OF TEXAS.
6.14 WAIVER OF JURY TRIAL. SECURED PARTY AND DEBTOR HEREBY WAIVE
TRIAL BY JURY IN ANY JUDICIAL PROCEEDINGS INVOLVING, DIRECTLY OR INDIRECTLY,
ANY MATTER (WHETHER IN TORT, CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF,
RELATED TO, OR CONNECTED WITH THIS AGREEMENT OR THE RELATIONSHIP ESTABLISHED
HEREUNDER.
6.15 Consent to Jurisdiction; Waiver of Immunities.
(a) Debtor hereby irrevocably submits to the non-exclusive
jurisdiction of any United States Federal or Texas State courts sitting in
Dallas County in any action or proceeding arising out of or relating to this
Agreement, and Debtor hereby irrevocably waives any objection it may now or
hereafter have as to the venue of any such suit, action or proceeding brought
in such court or that such court is an inconvenient forum.
(b) Nothing in this section shall limit the right of Secured Party to
bring any action or proceeding against Debtor or its property in the courts of
any other jurisdictions.
(c) Any judicial proceeding by Debtor against Secured Party
involving, directly or indirectly, any matter in any way arising out of,
related to, or connected with this Agreement shall be brought only in a court
in Dallas County, Texas to the extent that jurisdiction may be effected against
such Person in Dallas County, Texas.
6.16 Severability of Provisions. Any provision of this Agreement that
is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such
- 17 -
<PAGE> 21
prohibition or unenforceability without invalidating the remaining provisions
hereof in that jurisdiction or affecting the validity or enforceability of such
provision in any other jurisdiction. In the event that any change in
applicable Law would render invalid or unenforceable any provision of this
Agreement, Debtor agrees to enter into such amendments or modifications to this
Agreement to provide Secured Party with benefits intended to be granted by such
provision.
6.17 Counterparts. This Agreement may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if
the signatures thereto were upon the same instrument.
6.18 Successors and Assigns. All of the provisions of this Agreement
shall be binding and inure to the benefit of the parties thereto and their
respective successors and assigns; provided, Debtor may not assign its rights
or obligations under this Agreement.
6.19 Loan Papers. This Agreement is a Loan Papers executed pursuant
to the Credit Agreement and shall (unless otherwise expressly indicated herein)
be construed, administered and applied in accordance with the terms and
provisions thereof.
6.20 Obligations Not Affected. To the fullest extent permitted by
applicable Law, the obligations of Debtor under this Agreement shall remain in
full force and effect without regard to, and shall not be impaired or affected
by:
(a) any amendment or modification or addition or supplement to any
Loan Papers or any instrument delivered in connection therewith or any
assignment or transfer thereof;
(b) any exercise, non-exercise, or waiver by Secured Party of any
right, remedy, power or privilege under or in respect of, or any release of any
guaranty or the Collateral or any part thereof provided pursuant to, this
Agreement or any Loan Papers;
(c) any waiver, consent, extension, indulgence or other action or
inaction in respect of this Agreement, any Loan Papers or any assignment or
transfer of any thereof; or
(d) any bankruptcy, insolvency, reorganization, arrangement,
readjustment, composition, liquidation or the like of Debtor or any other
Person, whether or not Debtor shall have notice or knowledge of any of the
foregoing.
6.21 ENTIRE AGREEMENT. THIS WRITTEN AGREEMENT, TOGETHER WITH THE
OTHER LOAN PAPERS, REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY
NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE
PARTIES.
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
- 18 -
<PAGE> 22
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized officers all as of the date first above
written.
DEBTOR:
QUEST MEDICAL, INC.
By: /s/ F. ROBERT MERRILL III
---------------------------------
F. Robert Merrill III,
Vice President
SECURED PARTY:
NATIONSBANK OF TEXAS, N.A.
By: /s/ BRIAN K. SCHNEIDER
---------------------------------
Brian K. Schneider, Vice
President
- 19 -
<PAGE> 1
EXHIBIT 10.21
================================================================================
FIRST AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY
AGREEMENT AND ASSIGNMENT
dated as of March 3, 1997
Between
ADVANCED NEUROMODULATION SYSTEMS, INC.
as Debtor and Successor by Merger and
Successor in Interest to Neuromed, Inc.
and
NATIONSBANK OF TEXAS, N.A.
as Secured Party
================================================================================
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
ARTICLE I. ASSIGNMENT AND GRANT OF SECURITY INTEREST
1.1 Assignment and Grant of Security Interest . . . . . . . . . 2
1.2 Security for Obligations . . . . . . . . . . . . . . . . . . 2
1.3 Validity and Priority of Security Interest . . . . . . . . . 2
1.4 Maintenance of Status of Security Interest,
Collateral and Rights . . . . . . . . . . . . . . . . . . . 2
(a) Required Action . . . . . . . . . . . . . . . . . . . 2
(b) Protection of Collateral . . . . . . . . . . . . . . 3
(c) Authorized Action . . . . . . . . . . . . . . . . . . 3
(d) State Registrations . . . . . . . . . . . . . . . . . 3
1.5 Debtor Remains Obligated; Secured Party Not Obligated . . . 3
1.6 Termination . . . . . . . . . . . . . . . . . . . . . . . . 4
1.7 Security Interest Absolute . . . . . . . . . . . . . . . . . 4
ARTICLE II. REPRESENTATIONS AND WARRANTIES
2.1 Organization; Power . . . . . . . . . . . . . . . . . . . . 4
2.2 Authorization; Enforceability; Required Consents;
Absence of Conflicts . . . . . . . . . . . . . . . . . . . . 5
2.3 Accuracy of Questionnaire . . . . . . . . . . . . . . . . . 5
2.4 Rights of Debtor . . . . . . . . . . . . . . . . . . . . . . 5
2.5 Perfection . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.6 State Registrations . . . . . . . . . . . . . . . . . . . . 5
ARTICLE III. COVENANTS
3.1 Certain Matters Relating to Preservation of Status of
Security Interest . . . . . . . . . . . . . . . . . . . . . 5
(a) Chief Executive Office . . . . . . . . . . . . . . . 5
(b) Change of Name, Identity, etc. . . . . . . . . . . . 6
3.2 Preservation of Existence and Preservation of
Enforceability . . . . . . . . . . . . . . . . . . . . . . . 6
3.3 Requested Information . . . . . . . . . . . . . . . . . . . 6
3.4 No Disposition of Collateral . . . . . . . . . . . . . . . . 6
3.5 Additional Property . . . . . . . . . . . . . . . . . . . . 7
ARTICLE IV. EVENT OF DEFAULT
4.1 Application of Proceeds . . . . . . . . . . . . . . . . . . 7
4.2 Remedies . . . . . . . . . . . . . . . . . . . . . . . . . . 7
(a) Power of Sale . . . . . . . . . . . . . . . . . . . . 7
(b) Receiver . . . . . . . . . . . . . . . . . . . . . . 8
</TABLE>
- i -
<PAGE> 3
<TABLE>
<S> <C> <C>
(c) Enforcement by Secured Party . . . . . . . . . . . . 8
(d) Other Loan Papers; Laws . . . . . . . . . . . . . . . 8
(e) Sale Restrictions . . . . . . . . . . . . . . . . . . 8
4.3 INDEMNITY AND EXPENSES . . . . . . . . . . . . . . . . . . . 9
ARTICLE V. INTERPRETATION
5.1 Definitional Provision . . . . . . . . . . . . . . . . . . . 9
(a) Certain Terms Defined by Reference . . . . . . . . . 9
(b) Other Defined Terms . . . . . . . . . . . . . . . . . 9
(c) Other Definitional Provisions . . . . . . . . . . . . 12
5.2 Power of Attorney . . . . . . . . . . . . . . . . . . . . . 12
ARTICLE VI. MISCELLANEOUS
6.1 Expenses of Debtor's Agreements and Duties . . . . . . . . . 12
6.2 Secured Party's Right to Perform on Debtor's Behalf . . . . 13
6.3 Secured Party's Right to Use Agents . . . . . . . . . . . . 13
6.4 No Interference, Compensation or Expense . . . . . . . . . . 13
6.5 Limitation of Secured Party's Obligations With
Respect to Collateral . . . . . . . . . . . . . . . . . . . 13
6.6 Rights of Secured Party under UCC and Applicable Law . . . . 13
6.7 Waivers of Rights Inhibiting Enforcement . . . . . . . . . . 13
6.8 Notices and Deliveries . . . . . . . . . . . . . . . . . . . 14
(a) Manner of Delivery . . . . . . . . . . . . . . . . . 14
(b) Addresses . . . . . . . . . . . . . . . . . . . . . . 14
(c) Effectiveness . . . . . . . . . . . . . . . . . . . . 15
(d) Designation of Notice . . . . . . . . . . . . . . . . 15
6.9 Rights and Remedies Cumulative . . . . . . . . . . . . . . . 15
6.10 Amendments; Waivers . . . . . . . . . . . . . . . . . . . . 15
6.11 Assignments . . . . . . . . . . . . . . . . . . . . . . . . 16
6.12 MANDATORY ARBITRATION . . . . . . . . . . . . . . . . . . . 16
6.13 GOVERNING LAW . . . . . . . . . . . . . . . . . . . . . . . 17
6.14 WAIVER OF JURY TRIAL . . . . . . . . . . . . . . . . . . . . 17
6.15 Consent to Jurisdiction; Waiver of Immunities . . . . . . . 17
6.16 Severability of Provisions . . . . . . . . . . . . . . . . . 18
6.17 Counterparts . . . . . . . . . . . . . . . . . . . . . . . . 18
6.18 Successors and Assigns . . . . . . . . . . . . . . . . . . . 18
6.19 Loan Papers . . . . . . . . . . . . . . . . . . . . . . . . 18
6.20 Obligations Not Affected . . . . . . . . . . . . . . . . . . 18
6.21 ENTIRE AGREEMENT . . . . . . . . . . . . . . . . . . . . . . 19
</TABLE>
- ii -
<PAGE> 4
FIRST AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT AND
ASSIGNMENT
FIRST AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT AND
ASSIGNMENT, dated as of March 3, 1997, between Advanced Neuromodulation
Systems, Inc., a Texas corporation ("Debtor") and successor by merger and
successor in interest to Neuromed, Inc., formerly a Florida corporation, and
NationsBank of Texas, N.A., a national banking association ("Secured Party").
BACKGROUND.
(1) Secured Party and Quest Medical, Inc., a Texas corporation
("Borrower"), have entered into the First Amended and Restated Credit Agreement
dated as of March 31, 1995 (such agreement, together with all amendments and
restatements thereof, being the "1995 Credit Agreement").
(2) In connection with the 1995 Credit Agreement, Neuromed, Inc.,
formerly a Florida corporation, executed an Intellectual Property Security
Agreement and Assignment dated as of March 31, 1995, as amended, restated and
modified from time to time, (the "Original Agreement")
(3) Secured Party and Borrower have entered into the Second Amended
and Restated Credit Agreement dated as of February 9, 1996 (such agreement,
together with all amendments and restatements thereof, the "Existing Credit
Agreement") which restates in its entirety the 1995 Credit Agreement.
(4) In October 1996, Neuromed, Inc. merged into Debtor, and Debtor
assumed all obligations of Neuromed, Inc., including but not limited to the
obligations under the Original Agreement, and Debtor succeeded to all the
assets, including, but not limited to the intellectual property assets of
Neuromed, Inc.
(5) Secured Party and Borrower have entered into the Third Amended
and Restated Credit Agreement dated as of March 3, 1997 (such agreement,
together with all amendments and restatements thereof, the "Credit Agreement")
which restates in its entirety the Existing Credit Agreement.
(6) It is the intention of the parties hereto that this Agreement
create a first priority security interest securing the payment of the
obligations set forth in Section 1.2.
(7) It is a condition precedent to the effectiveness of the Credit
Agreement that Debtor shall have executed and delivered this Agreement,
expressly succeeding to the obligations of Neuromed, Inc. in connection with
the Original Agreement.
<PAGE> 5
AGREEMENT.
NOW, THEREFORE, in consideration of the premises set forth herein and
for other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, and in order to induce Secured Party to make Advances
under the Credit Agreement, Debtor hereby agrees with Secured Party as follows:
ARTICLE I. ASSIGNMENT AND GRANT OF SECURITY INTEREST
1.1 Assignment and Grant of Security Interest. Debtor hereby
assigns, pledges and grants to Secured Party a security interest in the entire
right, title and interest of Debtor in and to the Collateral. Debtor is
assigning the marks in the above identified applications as part of the entire
business or portion thereof to which the marks pertain as required by 15 U.S.C.
Section 1060.
1.2 Security for Obligations. This Agreement creates a first priority
security interest securing the payment and performance of any and all
obligations now or hereafter existing of Debtor and each other Obligor under
the Credit Agreement and the other Loan Papers, including any extensions,
modifications, substitutions, amendments and renewals thereof, whether for
principal, interest, fees, expenses, indemnification or otherwise (all such
obligations of Debtor and each other Obligor being the "Obligations"). Without
limiting the generality of the foregoing, this Agreement secures the payment,
of all amounts which constitute part of the Obligations and would be owed by
Debtor or any other Obligor to Secured Party under any Loan Papers, but for the
fact that they are unenforceable or not allowable due to the existence of a
bankruptcy, reorganization or similar proceeding involving Debtor or any other
Obligor (including all interest accruing after, or that would have accrued but
for, the filing of any petition in bankruptcy, or the commencement of any
insolvency, reorganization or like proceeding of Debtor or any other Obligor).
1.3 Validity and Priority of Security Interest. Debtor agrees that
the Security Interest shall at all times be valid, perfected, continuing and
binding and enforceable against Debtor and all other Persons, in accordance
with the terms hereof, as security for the Obligations, and that the Collateral
shall not at any time be subject to any Lien, except as provided in the Loan
Papers.
1.4 Maintenance of Status of Security Interest, Collateral and
Rights.
(a) Required Action. Debtor shall take all action that may be
necessary or that Secured Party may reasonably request, so as at all times (i)
to maintain the validity, perfection, enforceability and priority of the
Security Interest in the Collateral in conformity with the requirements of
Section 1.3, and (ii) to protect and preserve, and to enable the exercise or
- 2 -
<PAGE> 6
enforcement of, the rights of Secured Party hereunder, including (A)
immediately discharging all Liens, (B) executing and delivering the notice in
the form of Schedule 1.04(a)(ii)(B)-A, (C) executing and delivering the notice
in the form of Schedule 1.04(a)(ii)(B)-B, (D) executing and delivering the
notice in the form of Schedule 1.04(a)(ii)(B)-C and (E) executing and
delivering financing or continuation statements, instruments of pledge, notices
and instructions in each case in form and substance reasonably satisfactory to
Secured Party.
(b) Protection of Collateral. Debtor shall protect, preserve, renew
and maintain, in each case in a manner consistent with reasonably responsible
business and legal practices all rights of Debtor in the Collateral, including
the duty to prosecute and/or defend against any and all suits concerning
infringement or dilution of the Collateral, any suits against Debtor asserting
the invalidity of the Collateral and any suits claiming injury to the goodwill
associated with any of the Collateral. Any expenses incurred in protecting,
preserving, renewing and maintaining the Collateral shall be borne by Debtor.
To the maximum extent permitted by Laws, if a Default or Event of Default
exists, Secured Party shall have the right, without taking title to any
Collateral, to bring suit to enforce any or all Collateral or its Security
Interest in any or all of the Collateral, in which event Debtor shall, at the
request of Secured Party, do any and all lawful acts and execute any and all
proper documents required by Secured Party in aid of such enforcement. All
costs, expenses and other moneys advanced by Secured Party in connection with
the foregoing shall, whether or not there are then outstanding any amounts
under the Credit Agreement, be treated as Obligations, but the making of any
advances by Secured Party shall not relieve Debtor of any default hereunder.
(c) Authorized Action. Secured Party is hereby authorized to file
one or more financing or continuation statements or amendments thereto and
instruments of pledge, notices and instructions without the signature of or in
the name of Debtor. A carbon, photographic or other reproduction of this
Agreement or of any financing statement filed in connection with this Agreement
shall be sufficient as a financing statement.
(d) State Registrations. Debtor shall renew or maintain, as
specified in any applicable Law and shall make any filings necessary to renew
or maintain each registration described in Section 2.6.
1.5 Debtor Remains Obligated; Secured Party Not Obligated. The grant
by Debtor to Secured Party of the Security Interest shall not relieve Debtor
from the performance of any term, covenant, condition or agreement on its part
to be performed or observed (including by virtue of the exercise by Secured
Party of any of its Rights hereunder), or from any liability to any Person,
under or in respect of any of the Collateral or impose any obligation on
Secured Party or impose any liability on Secured Party for any act or omission
on the part of Debtor relative thereto.
- 3 -
<PAGE> 7
1.6 Termination.
(a) In the event that (i) the License Agreement shall have been
terminated pursuant to a written termination by Secured Party delivered to
Debtor, and (ii) the Obligations shall have been finally paid in full, and all
commitments by Secured Party to extend credit shall have been terminated and
Secured Party shall have delivered to Debtor a written termination agreement,
then this Agreement shall also terminate and be of no further force and effect
(except as provided in Section 1.6(b)).
(b) Debtor agrees that, if at any time all or any part of any payment
theretofore applied by Secured Party to any of the Obligations is or must be
rescinded or returned by any Person for any reason whatsoever (including the
insolvency, bankruptcy or reorganization of Debtor or any other Person), such
Obligations shall, for the purposes of this Agreement, to the extent that such
payment is or must be rescinded or returned, be deemed to have continued in
existence, notwithstanding such application by Secured Party, and the Security
Interest granted hereunder shall continue to be effective or be reinstated, as
the case may be, as to such Obligations, all as though such application by
Secured Party had not been made.
1.7 Security Interest Absolute. All Rights of Secured Party and the
Security Interest granted to Secured Party hereunder, and all obligations of
Debtor hereunder, shall, to the extent permitted by Laws, be absolute and
unconditional, irrespective of
(a) any lack of validity or enforceability of any Loan Papers;
(b) any change in the time, manner or place of payment or performance
of, or in any other term of, all or any of the Obligations or any other
amendment to or waiver of or any consent to departure from any Loan Papers;
(c) any exchange, release or non-perfection of any collateral
(including the Collateral or any part thereof), or any release of or amendment
to or waiver of or consent to departure from any guaranty, for all or any of
the Obligations; or
(d) any other circumstances which might otherwise constitute a
defense available to, or a discharge of, Debtor, any other Obligor or any other
Person.
ARTICLE II. REPRESENTATIONS AND WARRANTIES
Debtor represents and warrants as follows:
2.1 Organization; Power. Debtor is a corporation duly organized,
validly existing and in good standing under the laws of Texas and has the
corporate power and authority to own its property and to carry on its business
as now being and hereafter proposed to be conducted.
- 4 -
<PAGE> 8
2.2 Authorization; Enforceability; Required Consents; Absence of
Conflicts. Debtor has the power, and has taken all necessary action (including
any necessary corporate action) to authorize it, to execute, deliver and
perform in accordance with its terms this Agreement and to execute and deliver
all financing statements and other filings contemplated hereby. This Agreement
has been duly executed and delivered by Debtor and is the legal, valid and
binding obligation of Debtor, enforceable in accordance with its terms. The
execution, delivery and performance in accordance with its terms by Debtor of
this Agreement does not and (absent any change in any Law) will not (a) require
any Governmental Approval or any other consent or approval, including any
consent or approval of any partner of Debtor, other than those Governmental
Approvals, consents and approvals listed on Schedule 2.02 hereto which have
been duly obtained and remain in full force and effect, or (b) violate or
conflict with, result in a breach of, constitute a default under, or result in
or require the creation of any Lien (other than the Security Interest) upon any
assets of Debtor under any such contract or agreement or applicable Laws.
2.3 Accuracy of Questionnaire. The Questionnaire is, as of the date
hereof, complete and correct in all respects.
2.4 Rights of Debtor. Debtor is the legal and beneficial owner of
the Collateral free and clear of any Lien or other charge or encumbrance,
including, without limitation, pledges, assignments, licenses, shop rights and
covenants by Debtor not to sue any Person, except for the security interests
and assignment created by this Agreement. No effective financing statement or
other instrument similar in effect naming Debtor as "debtor" covering all or
any part of the Collateral is on file in any recording office, except such as
may have been filed in favor of Secured Party relating to this Agreement.
2.5 Perfection. This Agreement will create in favor of Secured Party
valid and perfected security interests in the Collateral upon making the filing
of Schedules 1.04(a)(ii)(B)-A,-B and-C and the financing statements described
on Schedule 2.02 and such security interests will be a first priority security
interest.
2.6 State Registrations. Schedule 2.06 lists each and all
registrations and applications of Debtor with the applicable authority of each
indicated state with respect to any Trademarks, Goodwill, Patents, Copyrights
and Trade Secrets.
ARTICLE III. COVENANTS
3.1 Certain Matters Relating to Preservation of Status of Security
Interest.
(a) Chief Executive Office. Debtor shall maintain its chief
executive office and the office where the books and records relating to the
Collateral are kept only at One Allentown Parkway, Allen, Texas 75002.
- 5 -
<PAGE> 9
(b) Change of Name, Identity, etc. Debtor shall not change its name
without (i) giving Secured Party thirty days' prior written notice thereof and
(ii) performing all acts required by Secured Party to preserve the Liens herein
granted and the priority and perfection thereof.
3.2 Preservation of Existence and Preservation of Enforceability.
Debtor shall, so long as any of the Obligations remain outstanding, (a)
preserve and maintain its corporate existence and (b) take all action and
obtain all consents and Government Approvals required so that its obligations
under this Agreement will at all times be legal, valid and binding and
enforceable in accordance with its terms.
3.3 Requested Information. In addition to such other Information as
shall be specifically provided for herein, Debtor shall furnish to Secured
Party such other Information with respect to the Collateral as Secured Party
may reasonably request from time to time in connection with the Collateral, or
the protection, preservation, maintenance or enforcement of the Security
Interest or the Collateral including, without limitation, all documents and
things in Debtor's possession, or subject to its demand for possession, related
to the production and sale by Debtor, or any subsidiary, licensee or
subcontractor thereof, of products or services sold by or under the authority
of Debtor in connection with the Collateral, including by way of example,
without limiting the interest granted by this Agreement: (i) all lists and
ancillary documents which identify and describe any of Debtor's customers, or
licensees, for products sold or services rendered under or in connection with
the Collateral, including without limitation, such existing lists and ancillary
documents which contain each customer's full name and address, the full name
and address of all of its warehouses and branches, the identity of the Person
or Persons having the principal responsibility on each customer's behalf for
ordering products or services of the kind supplied by Debtor, the credit,
payment, discount, delivery and other sale terms applicable to such customer,
together with detailed information setting forth the total purchases, by brand,
product, style and size, and the patterns of such purchases; (ii) all product
and service specification documents and production and quality of services sold
under or in connection with the Collateral; (iii) all documents which reveal
the names and addresses of all sources of supply, and all terms of purchase and
delivery, for all materials and components used in the production or products
or provision of services, sold under or in connection with the Collateral; and
(iv) all documents constituting or concerning the then current or proposed
advertising and promotion by Debtor, licensees or subcontractors of products or
services sold under or in connection with the Collateral, including, by way of
example and not in limitation, all documents which reveal the media used or to
be used and the cost for all such advertising conducted within the described
period or planned for such products or services. In connection with its
enforcement of the Security Interest, Secured Party may use such Information or
transfer it to any assignee or sublicensee permitted hereunder for such
assignee's or sublicensee's use.
3.4 No Disposition of Collateral. Debtor shall not sell, transfer or
otherwise dispose of any of the Collateral or any interest therein, or grant
any license thereunder except for and as permitted by the License Agreement.
- 6 -
<PAGE> 10
3.5 Additional Property. Prior to the application for, use or
acquisition or any interest in any property which is within the definition of
"Collateral" or modification, reformulation or other alteration to any such
interest (and, with respect to Collateral with respect to which Debtor's sole
interest is as a licensee, if allowed by the applicable license agreement),
Debtor shall execute and deliver to Secured Party all documents and instruments
Secured Party may require to grant to Secured Party a perfected first priority
Lien therein and to subject to all of such interest to this Agreement,
including but not limited to any new, supplementary or additional filings in
the form of Schedule 1.04(a)(ii)(B)-A,-B,or -C. Debtor shall execute and
deliver to Secured Party such license agreements and amendments thereto as
Secured Party may require.
ARTICLE IV. EVENT OF DEFAULT
Upon the occurrence and during the continuance of an Event of Default:
4.1 Application of Proceeds. All cash proceeds received by Secured
Party upon any sale of, collection of, or other realization upon, all or any
part of the Collateral shall be applied as follows:
First: To the payment of all out-of-pocket costs and expenses incurred
in connection with the sale of, collection of or other realization upon
Collateral, including attorneys' fees and disbursements;
Second: To the payment of the Obligations as provided in the Credit
Agreement (with Debtor remaining liable for any deficiency); and
Third: To the extent of the balance (if any) of such proceeds, to the
payment to Debtor or other Person entitled thereto.
4.2 Remedies.
(a) Power of Sale. Secured Party (i) may sell the Collateral at
public or private sale, at any of its offices or elsewhere, for cash (including
for this purpose, should Secured Party be the successful purchaser at any such
sale, the cancellation of any of the Obligations) or on credit or for future
delivery, and at such price or prices and upon such other terms as it may deem
commercially reasonable, (ii) shall not be obligated to make any sale of
Collateral regardless of notice of sale having been given, and (iii) may
adjourn any public or private sale from time to time by announcement at the
time and place fixed therefor, and such sale may, without further notice, be
made at the time and place to which it was so adjourned; provided, however,
that, if any item of the Collateral constituting a Trademark is assigned or
sold, rather than licensed, it shall be assigned or sold only as an entirety.
Secured Party may be the purchaser at any sale of the Collateral and may pay
all or any part of the purchase price thereof by canceling part or all
- 7 -
<PAGE> 11
of the Obligations. To the fullest extent permitted by applicable Law, Debtor
hereby waives the right to object to the manner of sufficiency of advertising,
refurbishing of the Collateral, or solicitation of bids in connection with any
sales or other disposition of the Collateral. Debtor hereby expressly waives
and releases, to the fullest extent permitted by applicable Law, any right of
redemption on the part of Debtor. If any notification of intended disposition
of any of the Collateral is required by law, such notification, if mailed,
shall be deemed reasonably and properly given if mailed at least ten days
before such disposition, postage prepaid, addressed to Debtor either at the
address shown below, or at any other address of Debtor appearing on the records
of Secured Party.
(b) Receiver. Secured Party may obtain the appointment of a receiver
of the Collateral.
(c) Enforcement by Secured Party. Secured Party may without notice
to Debtor (except that if no Event of Default exists Secured Party shall give
at least 10 days' notice) and at such time or times as Secured Party in its
sole discretion may determine, exercise any or all of Debtor's rights in, to
and under, or in any way connected with or related to, any or all of the
Collateral, including (i) enforcing the performance of, and exercising any or
all of Debtor's rights with respect to the Collateral, in each case by legal
proceedings or otherwise and (ii) settling, adjusting, compromising, extending,
renewing, discharging and releasing any or all of, and any legal proceedings
brought with respect to any or all of, Debtor's rights with respect to the
Collateral.
(d) Other Loan Papers; Laws. Secured Party may exercise any other
right or remedy available under any other Loan Paper or Laws.
(e) Sale Restrictions. Debtor agrees that, in any sale of any of the
Collateral, Secured Party is authorized to comply with any limitation or
restriction in connection with such sale as counsel may advise Secured Party is
necessary in order to avoid any violation of applicable Law (including
compliance with such procedures as may restrict the number of prospective
bidders or purchasers, require that such prospective bidders and purchasers
have certain qualifications, and restrict such prospective bidders and
purchasers to Persons who will represent and agree that they are purchasing for
their own account or investment and not with a view to the distribution or
resale of such Collateral), or in order to obtain any required approval of the
sale or of the purchase by any governmental or regulatory authority or
official, and Debtor further agrees that such compliance shall not result in
such sale being considered or deemed not to have been made in a commercially
reasonable manner, nor shall Secured Party be liable or accountable to Debtor
for any discount allowed by reason of the fact that such Collateral was sold in
compliance with any such limitation or restriction.
- 8 -
<PAGE> 12
4.3 INDEMNITY AND EXPENSES.
(a) DEBTOR AGREES TO INDEMNIFY (WHICH SHALL BE PAYABLE FROM TIME TO
TIME ON DEMAND) SECURED PARTY FROM AND AGAINST ANY AND ALL CLAIMS, LOSSES AND
LIABILITIES GROWING OUT OF OR RESULTING FROM THIS AGREEMENT (INCLUDING
ENFORCEMENT OF THIS AGREEMENT), EXPRESSLY INCLUDING SUCH CLAIMS, LOSSES, OR
LIABILITIES ARISING OUT OF MERE NEGLIGENCE OF SECURED PARTY, EXCEPT CLAIMS,
LOSSES OR LIABILITIES RESULTING FROM SECURED PARTY'S GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT.
(b) Debtor will upon demand pay to Secured Party the amount of any
and all reasonable expenses, including the reasonable fees and disbursements of
its counsel and of any experts and agents, which Secured Party may incur in
connection with (i) the administration of this Agreement, (ii) the custody,
preservation, use or operation of, or the sale of, collection from, or other
realization upon, any of the Collateral, (iii) the exercise or enforcement of
any of the Rights of Secured Party hereunder, or (iv) the failure by Debtor to
perform or observe any of the provisions hereof.
ARTICLE V. INTERPRETATION
5.1 Definitional Provision.
(a) Certain Terms Defined by Reference. The terms "collateral",
"inventory", "rights", and "security interest" shall have the meanings ascribed
thereto in the UCC, or, when capitalized, the meanings specified in subsection
(b) below.
(b) Other Defined Terms. For purposes of this Agreement:
"Agreement" means this Agreement, including all schedules, annexes and
exhibits hereto.
"Bankruptcy Code" means 11 U.S.C.Sections 101-1330 (1995), as amended,
or any successor statute.
"Collateral" means Debtor's rights, title and interests (whatever they
may be), in each of the following, in each case whether now or hereafter
existing or now owned or hereafter acquired by Debtor and whether or not the
same is subject to Article 9 of the UCC, and wherever the same may be located:
i) the Trademarks and Goodwill;
ii) the Copyrights;
iii) the Patents;
- 9 -
<PAGE> 13
iv) the Trade Secrets;
v) each state registration and application listed on Schedule
2.06;
vi) any renewal, reissue, re-examination certificate,
extension or the like with respect to the Trademarks, Patents,
Copyrights and Trade Secrets (as applicable);
vii) all rights to use the Trademarks as trade names or assumed
names in all aspects of its business; and
viii) all proceeds and products of the foregoing together with
any license in favor of or from Debtor of any of the foregoing in
whatever form. The inclusion of "proceeds" of Collateral in the
definition of "Collateral" shall not be deemed a consent by Secured
Party to any sale or other disposition of any Collateral not otherwise
specifically permitted by the terms hereof.
"Copyright" means any copyright, copyright registration and applications
for such registration, including but not limited to the copyrights listed on
Annex C-1 attached hereto, all subject matter related to such copyrights, in
any and all forms, and all copyrights and applications for copyrights related
to such copyrights, including those copyrights and applications listed in Annex
C-2 attached hereto.
"Credit Agreement" is defined in the Background.
"Event of Default" means (i) those events described as a "Default" or an
"Event of Default" in the Credit Agreement, or (ii) the Rejection of the
License Agreement.
"Goodwill" means the goodwill of the businesses connected with the use
of (or associated with) and symbolized by the Trademarks, but not any other
goodwill.
"Governmental Approval" means any authorization, consent, approval,
license or exemption of, registration or filing with, or report or notice to,
any Tribunal.
"Information" means data, certificates, reports, statements (including
financial statements), documents and other information in form (including
electronic media) acceptable to Secured Party.
"License Agreement" means the License Agreement dated March 31, 1995
between Debtor and Secured Party, including any renewal, extension,
modification or restatement thereof.
- 10 -
<PAGE> 14
"Lien" means, with respect to any property or asset (or any income or
profits therefrom) of any Person (in each case whether the same is consensual
or nonconsensual or arises by contract, operation of law, legal process or
otherwise) (i) any mortgage, lien, pledge, attachment, levy, priority or other
security interest or encumbrance of any kind thereupon or in respect thereof
and (ii) any arrangement, express or implied, under which the same is
subordinated, transferred, sequestered or otherwise identified so as to subject
the same, or make the same available for, the payment or performance of any
obligation in priority to the payment of the ordinary, unsecured creditors of
such Person.
"Loan Papers" means the Credit Agreement and each agreement, certificate
and other documents delivered to any Person pursuant to the Credit Agreement.
"Obligations" is defined in Section 1.2.
"Patents" means all patents, all inventions and subject matter related
to such patents, in any and all forms, and all patents and applications for
patents related to such patents, including but not limited to the patents
listed on Annex A-1 attached hereto, all inventions and all subject matter
related to such patents, in any and all forms, and all patents and applications
for patents related to such patents, including those patents and applications
listed on Annex A-2 attached hereto.
"Person" means an individual, firm, corporation, partnership,
association, joint venture, trust or any other entity or organization or
Tribunal.
"Questionnaire" means the Questionnaire in the form attached hereto as
Schedule 5.01 executed and delivered by Debtor to Secured Party in connection
with this Agreement.
"Rejection" means, with respect to the License Agreement in respect of
any item of Collateral, the entry of an order in any proceeding authorizing the
rejection by Debtor (or a trustee for Debtor or Debtor as debtor-in-possession)
of the License Agreement or any analogous event in any proceeding under the
laws of any jurisdiction; provided, however, that nothing contained in this
Agreement shall be deemed to be an acknowledgment or an agreement by any party
hereto that the License Agreement may be rejected under any Debtor Relief Law
or subject to any analogous event under any similar law of any jurisdiction
other than the United States.
"Security Interest" means the continuing security interest of Secured
Party and assignment to Secured Party in the Collateral intended to be effected
by the terms of this Agreement or any financing and continuation statements or
other filings contemplated hereby.
"Trade Secrets" means those general intangibles (sometimes known as
"trade secrets").
"Trademarks" means all trademarks, all designs and logotypes related to
such trademarks, in any and all forms, and all trademark registrations and
applications for registration
- 11 -
<PAGE> 15
related to such trademarks, including but not limited to the trademarks listed
on Annex B-1 attached hereto, all designs and logotypes related to such
trademarks, in any and all forms, and all trademark registrations and
applications for registration related to such trademarks, including those
registrations and applications listed on Annex B-2 attached hereto.
"UCC" means Chapter 9 of the Texas Business and Commerce Code as in
effect from time to time in the State of Texas.
(c) Other Definitional Provisions.
i) Except as otherwise specified herein, all references
herein (A) to any Person shall be deemed to include such Person's
successors and assigns, (B) to any applicable Law referred to herein
shall be deemed references to such applicable Law as the same may have
been or may be amended or supplemented from time to time and (C) to this
Agreement or other agreement defined or referred to herein shall be
deemed a reference to this Agreement or other agreement as the terms
thereof may have been or may be amended, supplemented, waived or
otherwise modified from time to time.
ii) Whenever the context so requires, the neuter gender
includes the masculine or feminine, the masculine gender includes the
feminine, and the singular number includes the plural, and vice versa.
iii) Except as otherwise indicated, any reference herein to the
"Collateral", the "Obligations" or any other collective or plural term
shall be deemed to be a reference to each and every item included within
the category described by such collective or plural term, so that a
reference to the "Collateral" or the "Obligations" shall be deemed a
reference to any or all of the Collateral or the Obligations, as the
case may be.
iv) Capitalized Terms not otherwise defined herein have the
meaning specified in the Credit Agreement, and, to the extent of any
conflict, terms as defined in the Credit Agreement shall control
(provided, that a more expansive or explanatory definition shall not be
deemed a conflict).
5.2 Power of Attorney. Each power of attorney, license and other
authorization in favor of Secured Party or any other Person granted by or
pursuant to this Agreement shall be deemed to be irrevocable and coupled with
an interest.
ARTICLE VI. MISCELLANEOUS
6.1 Expenses of Debtor's Agreements and Duties. Secured Party shall
not be liable for the costs and expenses of Debtor arising out of Debtor's
performance or observance of the
- 12 -
<PAGE> 16
terms, conditions, covenants and agreements to be observed or performed by
Debtor under this Agreement.
6.2 Secured Party's Right to Perform on Debtor's Behalf. If Debtor
shall fail to observe or perform any of the terms, conditions, covenants and
agreements to be observed or performed by it under this Agreement, Secured
Party may (but shall not be obligated to) do the same or cause it to be done or
performed or observed, either in its name or in the name and on behalf of
Debtor, and in the event that Debtor shall have failed to observe or perform
any of the terms, conditions, covenants and agreements to be observed or
performed by it under this Agreement, then Debtor hereby authorizes Secured
Party to do so, and Debtor hereby appoints Secured Party, and any other Person
Secured Party may designate, as Debtor's attorney-in-fact to do, or cause to be
done, in the name, place and stead of Debtor in any way in which Debtor itself
could do, or cause to be done, any or all things necessary to observe or
perform the terms, conditions, covenants and agreements to be observed or
performed by Debtor under this Agreement. In addition, Debtor hereby
irrevocably appoints Secured Party as Debtor's attorney-in-fact to execute and
deliver in Debtor's name and stead to any purchaser at any sale held under
Section 4.2 any and all documents and instruments of assignment, transfer and
conveyance necessary or appropriate to transfer to such purchaser the
Collateral sold at such sale.
6.3 Secured Party's Right to Use Agents. Secured Party may exercise
its rights under this Agreement through an agent or other designee.
6.4 No Interference, Compensation or Expense. Secured Party may
exercise its rights under this Agreement (a) without resistance or interference
by Debtor and (b) without payment of any rent, license fee or compensation of
any kind to Debtor.
6.5 Limitation of Secured Party's Obligations With Respect to
Collateral.
(a) Except as provided in the License Agreement, Secured Party shall
not have any duty or liability to protect or preserve any Collateral or to
preserve rights pertaining thereto.
(b) Nothing contained in this Agreement shall be construed as
requiring or obligating Secured Party, and Secured Party shall not be required
or obligated, to (i) present or file any claim or notice or take any action,
with respect to any Collateral or in connection therewith or (ii) notify Debtor
of any decline in the value of any Collateral.
6.6 Rights of Secured Party under UCC and Applicable Law. Secured
Party shall have, with respect to the Collateral, in addition to all of its
rights under this Agreement, (a) the rights of a secured party under the UCC,
whether or not the UCC would otherwise apply to the collateral in question, and
(b) the rights of a secured party under all other applicable Laws.
6.7 Waivers of Rights Inhibiting Enforcement. Debtor waives (a) any
claim that, as to any part of the Collateral, a public sale, should Secured
Party elect so to proceed, is, in and of
- 13 -
<PAGE> 17
itself, not a commercially reasonable method of sale for such Collateral, (b)
except as otherwise provided in this Agreement, TO THE EXTENT PERMITTED BY
APPLICABLE LAW, NOTICE OR JUDICIAL HEARING IN CONNECTION WITH SECURED PARTY'S
DISPOSITION OF ANY OF THE COLLATERAL INCLUDING ANY AND ALL PRIOR NOTICE AND
HEARING FOR ANY PREJUDGMENT REMEDY OR REMEDIES AND ANY SUCH RIGHT THAT DEBTOR
WOULD OTHERWISE HAVE UNDER THE CONSTITUTION OR ANY STATUTE OF THE UNITED STATES
OR OF ANY STATE, AND ALL OTHER REQUIREMENTS AS TO THE TIME, PLACE AND TERMS OF
SALE OR OTHER REQUIREMENTS WITH RESPECT TO THE ENFORCEMENT OF SECURED PARTY'S
RIGHTS HEREUNDER and (c) all rights of redemption, appraisement or valuation.
6.8 Notices and Deliveries.
(a) Manner of Delivery. All notices, communications and materials
(including all Information) to be given or delivered pursuant to this Agreement
shall, except in those cases where giving notice by telephone is expressly
permitted, be given or delivered in writing. All written notices,
communications and materials shall be sent by registered or certified mail,
postage prepaid, return receipt requested, by telecopier, or delivered by hand.
In the event of a discrepancy between any telephonic notice and any written
confirmation thereof, such written confirmation shall be deemed the effective
notice except to the extent Secured Party or Debtor has acted in reliance on
such telephonic notice.
(b) Addresses. All notices, communications and materials to be given
or delivered pursuant to this Agreement shall be given or delivered at the
following respective addresses and telecopier and telephone numbers and to the
attention of the following individuals or departments:
(i) if to Debtor, to it at:
Advanced Neuromodulation Systems, Inc.
c/o Quest Medical, Inc.
One Allentown Parkway
Allen, Texas 75002
Telephone No: (214) 390-9800
Telecopier No: (214) 390-9687
Attention: F. Robert Merrill III
- 14 -
<PAGE> 18
(ii) if to Secured Party, to it at:
NationsBank of Texas, N.A.
NationsBank Plaza
901 Main Street
7th Floor
Dallas, Texas 75202
Telephone No: (214) 508-2825
Telecopier No: (214) 508-3140
Attention: Commercial Banking
or at such other address, telecopier or telephone number or to the attention of
such other individual or department as the party to which such information
pertains may hereafter specify for the purpose in a notice to the other
specifically captioned "Notice of Change of Address".
(c) Effectiveness. Each notice, communication and any material to be
given or delivered to Secured Party or Debtor pursuant to this Agreement shall
be effective or deemed delivered or furnished (i) if sent by mail, on the fifth
Business Day after such notice, communication or material is deposited in the
mail, addressed as above provided, (ii) if sent by telecopier, when such
notice, communication or material is transmitted to the appropriate number
determined as above provided in this Section 6.8 and the appropriate receipt is
received or acknowledged, (iii) if sent by hand delivery or overnight courier,
when left at the address of the addressee addressed as above provided and the
appropriate receipt is received or acknowledged, and (iv) if given by
telephone, when communicated to the individual or any member of the department
specified as the individual or department to whose attention notices,
communications and materials are to be given or delivered except that notices
of a change of address, telecopier or telephone number or individual or
department to whose attention notices, communications and materials are to be
given or delivered shall not be effective until received.
(d) Designation of Notice. No notice shall be effective under
Section 3.1(a) or (b) unless it is specifically designated and, in the case of
a notice under Section 3.1(a), "Notice of Change of Executive Office and Books
and Records."
6.9 Rights and Remedies Cumulative. Each of Secured Party's rights
and remedies under this Agreement shall be in addition to all of its other
rights and remedies under this Agreement and applicable Law, and nothing herein
shall be construed as limiting any such rights or remedies.
6.10 Amendments; Waivers. Any term, covenant, agreement or condition
of this Agreement may be amended, and any right under this Agreement may be
waived, if, but only if, such amendment or waiver is in writing and is signed
by Secured Party and, in the case of an
- 15 -
<PAGE> 19
amendment, by Debtor. Unless otherwise specified in such waiver, a waiver of
any right under this Agreement shall be effective only in the specific instance
and for the specific purpose for which given. No election not to exercise,
failure to exercise or delay in exercising any right, nor any course of dealing
or performance, shall operate as a waiver of any right of the Secured Party
under this Agreement or applicable Law, nor shall any single or partial
exercise of any such right preclude any other or further exercise thereof or
the exercise of any other right of Secured Party under this Agreement or
applicable Law.
6.11 Assignments.
(a) Debtor may not assign any of its rights or obligations under this
Agreement without the prior written consent of Secured Party.
(b) Secured Party may, in connection with any assignment under and in
accordance with the License Agreement to any Person of any or all of the
licensee's rights and obligations under such License Agreement, assign to such
Person, or any agent(s) or representative(s) on behalf of such licensee and its
sublicenses, any or all of Secured Party's rights and obligations under this
Agreement and any other document or instrument, including financing and
continuation statements and other filings, contemplated hereby and with respect
to the Collateral without the consent of Debtor. In addition, Secured Party
may assign or otherwise transfer (in whole or in part) to any other Person all
of its rights and obligations under any Loan Papers (including this Agreement)
or otherwise.
6.12 MANDATORY ARBITRATION.
(a) ANY CONTROVERSY OR CLAIM BETWEEN OR AMONG THE PARTIES HERETO
INCLUDING BUT NOT LIMITED TO THOSE ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR ANY RELATED AGREEMENTS OR INSTRUMENTS, INCLUDING ANY CLAIM BASED ON OR
ARISING FROM AN ALLEGED TORT, SHALL BE DETERMINED BY BINDING ARBITRATION IN
ACCORDANCE WITH THE FEDERAL ARBITRATION ACT (OR IF NOT APPLICABLE, THE
APPLICABLE STATE LAW), THE RULES OF PRACTICE AND PROCEDURE FOR THE ARBITRATION
OF COMMERCIAL DISPUTES OF JUDICIAL ARBITRATION AND MEDIATION SERVICES, INC.
("JAMS"), AND THE "SPECIAL RULES" SET FORTH BELOW. IN THE EVENT OF ANY
INCONSISTENCY, THE SPECIAL RULES SHALL CONTROL. JUDGMENT UPON ANY ARBITRATION
AWARD MAY BE ENTERED IN ANY COURT HAVING JURISDICTION. ANY PARTY TO THIS
AGREEMENT MAY BRING AN ACTION, INCLUDING A SUMMARY OR EXPEDITED PROCEEDING, TO
COMPEL ARBITRATION OF ANY CONTROVERSY OR CLAIM TO WHICH THIS AGREEMENT APPLIES
IN ANY COURT HAVING JURISDICTION OVER SUCH ACTION.
- 16 -
<PAGE> 20
(b) Special Rules. The arbitration shall be conducted in Dallas,
Texas and administered by JAMS who will appoint an arbitrator; if JAMS is
unable or legally precluded from administering the arbitration, then the
American Arbitration Association will serve. All arbitration hearings will be
commenced within ninety days of the demand for arbitration; further, the
arbitrator shall only, upon a showing of cause, be permitted to extend the
commencement of such hearing for up to an additional sixty days.
(c) Reservations of Rights. Nothing in this Agreement or any other
Loan Paper shall be deemed to (i) limit the applicability of any otherwise
applicable statutes of limitation or repose and any waivers contained in this
Agreement; or (ii) be a waiver by Secured Party of the protection afforded to
it by 12 U.S.C. Section 91 or any substantially equivalent state law; or (iii)
limit the right of Secured Party hereto (A) to exercise self help remedies such
as (but not limited to) setoff, or (B) to foreclose against any real or
personal property collateral, or (C) to obtain from a court provisional or
ancillary remedies such as (but not limited to) injunctive relief or the
appointment of a receiver. Secured Party may exercise such self help rights,
foreclose upon such property, or obtain such provisional or ancillary remedies
before, during or after the pendency of any arbitration proceeding brought
pursuant to this Agreement. At Secured Party's option, foreclosure under a
deed of trust or mortgage may be accomplished by any of the following: the
exercise of a power of sale under the deed of trust or mortgage, or by judicial
sale under the deed of trust or mortgage, or by judicial foreclosure. Neither
this exercise of self help remedies nor the institution or maintenance of an
action for foreclosure or provisional or ancillary remedies shall constitute a
waiver of the right of any party, including the claimant in any such action, to
arbitrate the merits of the controversy or claim occasioning resort to such
remedies.
6.13 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF TEXAS (WITHOUT REFERENCE
TO PRINCIPALS OF CONFLICTS OF LAWS), EXCEPT TO THE EXTENT THAT THE VALIDITY OR
PERFECTION OF THE SECURITY INTEREST HEREUNDER, OR REMEDIES HEREUNDER, IN
RESPECT OF ANY PARTICULAR COLLATERAL ARE REQUIRED TO GOVERNED BY THE LAWS OF A
JURISDICTION OTHER THAN THE STATE OF TEXAS.
6.14 WAIVER OF JURY TRIAL. SECURED PARTY AND DEBTOR HEREBY WAIVE
TRIAL BY JURY IN ANY JUDICIAL PROCEEDINGS INVOLVING, DIRECTLY OR INDIRECTLY,
ANY MATTER (WHETHER IN TORT, CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF,
RELATED TO, OR CONNECTED WITH THIS AGREEMENT OR THE RELATIONSHIP ESTABLISHED
HEREUNDER.
6.15 Consent to Jurisdiction; Waiver of Immunities.
(a) Debtor hereby irrevocably submits to the non-exclusive
jurisdiction of any United States Federal or Texas State courts sitting in
Dallas County in any action or proceeding arising out of or relating to this
Agreement, and Debtor hereby irrevocably waives any objection it may
- 17 -
<PAGE> 21
now or hereafter have as to the venue of any such suit, action or proceeding
brought in such court or that such court is an inconvenient forum.
(b) Nothing in this section shall limit the right of Secured Party to
bring any action or proceeding against Debtor or its property in the courts of
any other jurisdictions.
(c) Any judicial proceeding by Debtor against Secured Party
involving, directly or indirectly, any matter in any way arising out of,
related to, or connected with this Agreement shall be brought only in a court
in Dallas County, Texas to the extent that jurisdiction may be effected against
such Person in Dallas County, Texas.
6.16 Severability of Provisions. Any provision of this Agreement that
is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or
unenforceability without invalidating the remaining provisions hereof in that
jurisdiction or affecting the validity or enforceability of such provision in
any other jurisdiction. In the event that any change in applicable Law would
render invalid or unenforceable any provision of this Agreement, Debtor agrees
to enter into such amendments or modifications to this Agreement to provide
Secured Party with benefits intended to be granted by such provision.
6.17 Counterparts. This Agreement may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if
the signatures thereto were upon the same instrument.
6.18 Successors and Assigns. All of the provisions of this Agreement
shall be binding and inure to the benefit of the parties thereto and their
respective successors and assigns; provided, Debtor may not assign its rights
or obligations under this Agreement.
6.19 Loan Papers. This Agreement is a Loan Papers executed pursuant
to the Credit Agreement and shall (unless otherwise expressly indicated herein)
be construed, administered and applied in accordance with the terms and
provisions thereof.
6.20 Obligations Not Affected. To the fullest extent permitted by
applicable Law, the obligations of Debtor under this Agreement shall remain in
full force and effect without regard to, and shall not be impaired or affected
by:
(a) any amendment or modification or addition or supplement to any
Loan Papers or any instrument delivered in connection therewith or any
assignment or transfer thereof;
(b) any exercise, non-exercise, or waiver by Secured Party of any
right, remedy, power or privilege under or in respect of, or any release of any
guaranty or the Collateral or any part thereof provided pursuant to, this
Agreement or any Loan Papers;
- 18 -
<PAGE> 22
(c) any waiver, consent, extension, indulgence or other action or
inaction in respect of this Agreement, any Loan Papers or any assignment or
transfer of any thereof; or
(d) any bankruptcy, insolvency, reorganization, arrangement,
readjustment, composition, liquidation or the like of Debtor or any other
Person, whether or not Debtor shall have notice or knowledge of any of the
foregoing.
6.21 ENTIRE AGREEMENT. THIS WRITTEN AGREEMENT, TOGETHER WITH THE
OTHER LOAN PAPERS, REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY
NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE
PARTIES.
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
- 19 -
<PAGE> 23
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized officers all as of the date first above
written.
DEBTOR:
ADVANCED NEUROMODULATION SYSTEMS,
INC., as Debtor and successor by
merger and successor in interest of
Neuromed, Inc.
By: /s/ F. ROBERT MERRILL III
------------------------------
F. Robert Merrill III,
Vice President
SECURED PARTY:
NATIONSBANK OF TEXAS, N.A.
By: /s/ BRIAN K. SCHNEIDER
------------------------------
Brian K. Schneider,
Vice President
- 20 -
<PAGE> 1
EXHIBIT 10.22
================================================================================
FIRST AMENDED AND RESTATED LICENSE AGREEMENT
Dated as of March 3, 1997
Between
QUEST MEDICAL, INC.
as Licensor
and
NATIONSBANK OF TEXAS, NATIONAL ASSOCIATION
as Licensee
================================================================================
<PAGE> 2
FIRST AMENDED AND RESTATED LICENSE AGREEMENT
FIRST AMENDED AND RESTATED LICENSE AGREEMENT, dated March 3, 1997, by
and between Quest Medical, Inc., a Texas corporation ("Licensor") and
NationsBank of Texas, National Association, a national banking association
("Licensee").
W I T N E S S E T H:
WHEREAS, Licensor presently owns and will hereafter acquire right,
title, and interest (including rights and interests pursuant to licenses)
throughout the world in various Trademarks, Patents, Copyrights and Trade
Secrets (hereinafter, collectively, the "Intellectual Property");
WHEREAS, Licensee and Licensor have entered into the First Amended and
Restated Credit Agreement dated as of March 31, 1995 (such agreement, together
with all amendments and restatements thereof, being the "1995 Credit
Agreement");
WHEREAS, Licensee and Licensor have entered into the Second Amended and
Restated Credit Agreement dated as of February 9, 1996 (such agreement,
together with all amendments and restatements thereof, the "Existing Credit
Agreement") which restates in its entirety the 1995 Credit Agreement.
WHEREAS, Licensee and Licensor have entered into the Third Amended and
Restated Credit Agreement dated as of March 3, 1997 (such agreement, together
with all amendments and restatements thereof, the "Credit Agreement") which
restates in its entirety the Existing Credit Agreement.
WHEREAS, as security for the payment and performance of the Obligations
which are owed by Licensor and each other Obligor to Licensee pursuant to the
Loan Papers, Licensor has agreed to grant or cause to be granted to Licensee,
security interests in, and pledges and assignments of, all assets of Licensor,
including all cash, Inventory, Receivables, Equipment, Permits and the
Intellectual Property, a license to use the Intellectual Property and Permits
and certain other collateral, to secure the Obligations;
WHEREAS, Licensee desires a license to use the Intellectual Property and
Permits in all countries of the world solely if an Event of Default exists to
enable Licensee to exercise its rights and remedies with respect to the
Collateral under the Security Agreement;
WHEREAS, Licensor desires to grant Licensee the foregoing license to so
use the Intellectual Property and Permits; and
WHEREAS, the parties acknowledge the excellent reputation for quality of
products sold under the Intellectual Property and Permits, and desire to
safeguard, promote and enhance that
<PAGE> 3
reputation by ensuring the future quality of materials, workmanship, and
performance of the Inventory with respect to which Licensee has been granted a
security interest, pledge and assignment and may exercise its rights and
remedies under the Security Agreement and Intellectual Property Agreement, if
an Event of Default exists.
AGREEMENT.
NOW, THEREFORE, in consideration of the above premises and of the mutual
covenants herein contained, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, and intending to be
legally bound, the parties hereto agree as follows:
ARTICLE I. DEFINITIONS
1.1 "Collateral" has the same definition provided in the Security
Agreement.
1.2 "Effective Date" means March 3, 1997.
1.3 "Equipment" has the same definition provided in the Security
Agreement.
1.4 "Intellectual Property Agreement" means the Amended and Restated
Intellectual Property Security Agreement and Assignment dated
March 3, 1997 between Licensor and Licensee.
1.5 "Inventory" has the same definition provided in the Security
Agreement.
1.6 "Permits" means all licenses, permits and other similar rights
now or hereafter owned by Licensor (including but not limited to
all licenses, permits and similar rights issued by the FDA) and
necessary to the operation of its business, including but not
limited to all licenses, permits and other rights listed on
Schedule 2.
1.7 "Receivables" has the same definition provided in the Security
Agreement.
1.8 "Security Agreement" means the Amended and Restated Security
Agreement dated March 3, 1997 between Licensor and Licensee.
1.9 Unless otherwise defined in this Agreement, all capitalized terms
herein shall have the same definition provided in the Credit
Agreement, the Intellectual Property Agreement and the Security
Agreement.
-2-
<PAGE> 4
ARTICLE II. GRANTS TO LICENSEE AND RELATED MATTERS
2.1 Licensor hereby grants to Licensee an irrevocable, non-exclusive
royalty-free right and license to use the Intellectual Property and Permits
worldwide including, without limitation, the Intellectual Property identified
in Schedule 1 and Permits identified on Schedule 2, if an Event of Default
exists, and to enable Licensee to exercise its rights and remedies under the
Security Agreement and Intellectual Property Agreement with respect to
Collateral, including, without limitation, the right to use the Intellectual
Property and Permits on or in connection with the operation and disposition of
any Collateral and the disposition, maintenance or further production,
manufacturing or processing of the Inventory, the operation and maintenance of
the Equipment and the collection of Receivables as Licensee reasonably deems
necessary or appropriate in the exercise of its rights and remedies under the
Security Agreement and Intellectual Property Agreement with respect to
Collateral.
The parties acknowledge and agree that the Intellectual Property and
Permits are the sole and exclusive property of Licensor, subject to the terms
and conditions stated in this Agreement, the Security Agreement and the
Intellectual Property Agreement. Other than in connection with any security
interest in the Intellectual Property and Permits that Licensor has granted to
Licensee pursuant to the Security Agreement and the Intellectual Property
Agreement or any rights and remedies of Licensee under the Security Agreement
or the Intellectual Property Agreement, Licensee shall not challenge Licensor's
ownership of the Intellectual Property and Permits. Licensor expressly retains
all rights to license third parties to use the Intellectual Property and
Permits for any purpose whatsoever not in violation of the Loan Papers and
which are not exclusive as to prevent Licensee from using any of the
Intellectual Property and Permits as provided in the Security Agreement and
Intellectual Property Agreement.
2.2 The license granted to Licensee hereunder shall include the right
of Licensee to grant sublicenses to others to use the Intellectual Property and
Permits if an Event of Default exists, and to enable such sublicensees to
exercise any rights and remedies of Licensee under the Security Agreement and
the Intellectual Property Agreement with respect to Collateral, including,
without limitation, the right to grant sublicenses to others to use the
Intellectual Property and Permits on or in connection with the operation and
disposition of any Collateral, the disposition, maintenance or further
production, manufacturing or processing of Inventory, the operation and
maintenance of the Equipment and the collection of Receivables as Licensee
reasonably deems necessary or appropriate in the exercise of the rights and
remedies of Licensee under the Security Agreement and the Intellectual Property
Agreement. In any country where sublicenses are incapable of registration or
where registration of a sublicense will not satisfactorily protect the rights
of Licensor and Licensee, Licensee shall also have the right to designate other
parties as direct licensees of Licensor to use the Intellectual Property and
Permits if an Event of Default exists and to enable such direct licensees to
exercise any rights and remedies of Licensee under the Security Agreement and
the Intellectual Property Agreement including, without limitation, the right to
use the Intellectual Property and Permits on or in connection with the
operation and disposition of any Collateral, the disposition, maintenance or
further production, manufacturing or processing of Inventory, the operation and
maintenance of the Equipment and the collection of Receivables as such
licensees reasonably deem necessary or
-3-
<PAGE> 5
appropriate and Licensor agrees to enter into direct written licenses with the
parties as designated on the same terms as would be applicable to a sublicense,
and any such direct license may, depending on the relevant local requirements,
be either (a) in lieu of a sublicense or (b) supplemental to a sublicense. In
either case, the parties hereto shall cooperate to determine what shall be
necessary or appropriate in the circumstances. For each sublicense to a
sublicensee and direct license to a licensee, Licensor appoints Licensee its
agent for the purpose of exercising quality control over the sublicensee.
Licensor shall execute this Agreement in any form, content and language
suitable for recordation, notice and/or registration in all available and
appropriate agencies of foreign countries as Licensee may require.
2.3 In connection with the assignment or other transfer (in whole or
in part) of its obligations under the Security Agreement and the Intellectual
Property Agreement to any other Person, Licensee may assign the license granted
herein without Licensor's consent and upon such assignment or transfer such
other Person shall thereupon become vested with all rights and benefits in
respect thereof granted to Licensee under this Agreement.
2.4 The parties hereto shall take reasonable action to preserve the
confidentiality of the Intellectual Property and Permits which is not otherwise
public information; provided, that Licensee shall not have any liability to any
Person for any disclosure of the Intellectual Property or Permits upon and
after any realization upon Collateral under the Security Agreement or the
Intellectual Property Agreement or otherwise as part of Licensee's enforcement
of remedies under the Loan Papers.
ARTICLE III. QUALITY CONTROL
3.1 Licensor shall refrain from using the Intellectual Property and
Permits in a form and manner or for a subject matter as to (a) reduce the value
of the Intellectual Property or Permits or (b) cause injury to Licensor's
business, reputation or goodwill.
3.2 If an Event of Default exists and Licensee exercises its rights
or remedies under the license granted herein:
(a) Licensee may use the Trademarks licensed hereby in such form and
manner as previously used by Licensor, and shall need not notify Licensor of
any change in the form or substance of the display of a Trademark licensed
hereby. Licensee shall take reasonable action to apply trademark notice or
other marking as may be required under applicable Law of each territory and
country where each Trademark is used, or as otherwise appropriate, in
connection with use of each of the Trademarks licensed hereunder. Licensee
shall have the right to register any and all Trademarks in any and all
countries on and after the Effective Date.
(b) Licensee may dispose of any Inventory and any other manufactured
products under any of the Intellectual Property or Permits licensed hereby,
provided the Inventory and any
-4-
<PAGE> 6
other manufactured products so disposed of by it or any other Person acting on
behalf of Licensee shall comply in any material respect with (i) quality
standards and specifications, including labelling specifications, employed by
Licensor in commerce prior to the Effective Date, or, where no such standards
and specifications exist, a level of quality comparable to the quality
standards generally accepted for other leading competitive brands of the same
item of Inventory in the same markets from time to time; or (ii) a level of
quality comparable to that which may be adopted by Licensor for its or its
other licensees' products. Licensee shall maintain quality control
commensurate with the quality standards of Licensor at the Effective Date or,
if quality control improves after the Effective Date, commensurate with such
improved quality standards.
ARTICLE IV. TERM AND TERMINATION
4.1 This Agreement is effective as of the Effective Date and, unless
sooner terminated under the provisions set forth in this Article IV, is
perpetual and irrevocable.
4.2 The license granted in Article II with respect to any
Intellectual Property and Permits may be terminated only upon the event that
the Obligations which are owed by Licensor and each other Obligor to Licensee,
and which are secured in part by the Collateral of Licensor under the Security
Agreement and the Intellectual Property Agreement and by the license granted
herein, are finally and fully satisfied and paid in accordance with all terms
and conditions of the Loan Papers at the time of such termination. If after
termination of this Agreement, there occurs a rescission of payment of any of
the Obligations or the restoration of such payments by Licensee or any other
Person upon the insolvency, bankruptcy or reorganization of Licensor or any
other Person, this Agreement shall be reinstated as though such payment had not
been made and remain in full force and effect in accordance with the terms of
the preceding sentence.
4.3 Upon termination of this Agreement, Licensee shall, and shall
cause any sublicensee, to cease all use of any and all of the Intellectual
Property and Permits and not thereafter use any of them in any other manner
whatsoever, subject to reinstatement under Section 4.2.
4.4 Upon termination (or reinstatement) of this Agreement, the
parties shall perform all other acts which may be necessary or useful to render
effective the termination (or reinstatement) of the interest of Licensee in the
Intellectual Property and Permits, including but not limited to the
cancellation of any registration or recordation (or the reinstatement by
registration or recordation) of this Agreement, or any summary thereof.
-5-
<PAGE> 7
ARTICLE V. RECORDATION OF AGREEMENT
5.1 The parties shall cooperate to determine what may or shall be
required to satisfy the laws or regulations throughout the world with respect
to the recordation and validation of this Agreement, or otherwise to render
this Agreement and the Intellectual Property and Permits effective, and shall
execute all documents which may be necessary or desirable to implement this
Section 5.1, including registered user statements or other documents suitable
for filing with the appropriate government authorities of any country.
ARTICLE VI. REPRESENTATION AND WARRANTIES
6.1 Licensor represents and warrants that it is the owner of the
Intellectual Property identified in Schedule 1 and Permits identified on
Schedule 2 and has the right to grant the rights and license granted herein.
ARTICLE VII. PRODUCT LIABILITY INSURANCE
7.1 Licensor shall maintain product liability insurance covering
liabilities for its activities pursuant to this Agreement, of at least such
amounts as is required by the Loan Papers.
ARTICLE VIII. MISCELLANEOUS
8.1 Failure of either party to insist upon strict performance of the
terms, conditions, and provisions of this Agreement shall not be deemed a
waiver of such terms, conditions or provisions or a waiver of future compliance
therewith. No waiver of any terms, conditions, or provisions hereof shall be
deemed to have been made unless expressed in writing and signed by the waiving
party.
8.2 Any sale, transfer or other disposition of ownership of any
Intellectual Property or Permits by Licensor shall be subject to this Agreement
and the Intellectual Property Agreement and any purchaser or transferee shall
specifically state in writing that it is assuming this Agreement and that it
will be bound by all of the terms and conditions of this Agreement and the
Intellectual Property Agreement (this sentence is not a consent by Licensee to
any sale, transfer or other disposition (other than the grant of a license
permitted pursuant to Section 2.1) of any interest in Intellectual Property or
Permits). After giving effect to such sale, transfer or other disposition,
this Agreement and the Intellectual Property Agreement shall be valid, binding,
and enforceable in accordance with its terms against such purchaser or
transferee. A sale, transfer or other disposition of any shares of the capital
stock of Licensor shall not be deemed to be a sale, transfer or other
disposition of ownership of any Intellectual Property or Permits.
-6-
<PAGE> 8
8.3 Except as otherwise may be expressly provided in this Agreement
or any other Loan Paper, Licensee shall not be construed to be and shall not
represent itself as an agent of Licensor.
8.4 (a) All notices, communications and materials to be given or
delivered pursuant to this Agreement shall, except in those cases where giving
notice by telephone is expressly permitted, be given or delivered in writing.
All written notices, communications and materials shall be sent by registered
or certified mail, postage prepaid, return receipt requested, by telecopier, or
delivered by hand. In the event of a discrepancy between any telephonic notice
and any written confirmation thereof, such written confirmation shall be deemed
the effective notice except to the extent Licensor or Licensee has acted in
reliance on such telephonic notice.
(b) All notices, communications and materials to be given or
delivered pursuant to this Agreement shall be given or delivered at the
following respective addresses and telecopier and telephone numbers and to the
attention of the following individuals or departments:
To Licensor: Quest Medical, Inc.
One Allentown Parkway
Allen, Texas 75002
U.S.A.
Attention: F. Robert Merrill III
To Licensee: NationsBank of Texas, National Association
NationsBank Plaza
901 Main Street, 7th Floor
Dallas, Texas 75202
U.S.A.
Attention: Commercial Banking
8.5 This Agreement shall be governed by and construed in accordance
with the internal laws of the State of Texas, U.S.A.
8.6 (a) Licensor hereby irrevocably submits to the non-exclusive
jurisdiction of any United States Federal or Texas State court sitting in
Dallas County, Texas, U.S.A. in any action or proceeding arising out of or
relating to this Agreement, and Licensor hereby irrevocably agrees that all
claims in respect of such action or proceeding may be heard or determined in
any such court and hereby irrevocably waives any objection it may now or
hereafter have as to the venue of any such suit, action or proceeding brought
in such court or that such court is an inconvenient forum.
-7-
<PAGE> 9
(b) Nothing in this Section 8.6 shall limit the right of
Licensee to bring any action or proceeding against Licensor or its property in
the courts of any other jurisdiction or any party's rights under Section 8.10
of the Credit Agreement.
(c) Any judicial proceeding by Licensor against Licensee
involving, directly or indirectly, any matter in any way arising out of,
related to, or connected with this Agreement shall be brought only in a court
in Dallas County, Texas, U.S.A.
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
-8-
<PAGE> 10
IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their respective duly authorized officers as of the date written
above.
QUEST MEDICAL, INC.
- ----------------------------
Witness
By: /s/ F. ROBERT MERRILL III
---------------------------------
F. Robert Merrill III,
Vice President
- ----------------------------
Witness
NATIONSBANK OF TEXAS, NATIONAL
ASSOCIATION
- ----------------------------
Witness
By: /s/ BRIAN K. SCHNEIDER
---------------------------------
Brian K. Schneider,
Vice President
- ----------------------------
Witness
-9-
<PAGE> 1
EXHIBIT 10.23
================================================================================
FIRST AMENDED AND RESTATED LICENSE AGREEMENT
Dated as of March 3, 1997
Between
ADVANCED NEUROMODULATION SYSTEMS, INC.
as Licensor and Successor by Merger and
Successor in Interest to Neuromed, Inc.
and
NATIONSBANK OF TEXAS, NATIONAL ASSOCIATION
as Licensee
================================================================================
<PAGE> 2
FIRST AMENDED AND RESTATED LICENSE AGREEMENT
FIRST AMENDED AND RESTATED LICENSE AGREEMENT, dated March 3, 1997, by
and between Advanced Neuromodulation Systems, Inc., a Texas corporation
("Licensor") as successor by merger and successor in interest to the assets of
Neuromed, Inc., and NationsBank of Texas, National Association, a national
banking association ("Licensee").
W I T N E S S E T H:
WHEREAS, Licensor presently owns and will hereafter acquire right,
title, and interest (including rights and interests pursuant to licenses)
throughout the world in various Trademarks, Patents, Copyrights and Trade
Secrets (hereinafter, collectively, the "Intellectual Property");
WHEREAS, Licensee and Quest Medical, Inc., a Texas corporation
("Borrower"), have entered into the First Amended and Restated Credit Agreement
dated as of March 31, 1995 (such agreement, together with all amendments and
restatements thereof, being the "1995 Credit Agreement") pursuant to which
Neuromed, Inc. entered into a license agreement (the "Original Agreement");
WHEREAS, Borrower has entered into the Second Amended and Restated
Credit Agreement dated as of February 9, 1996 (such agreement, together with
all amendments and restatements thereof, the "Existing Credit Agreement") which
restates in its entirety the 1995 Credit Agreement.
WHEREAS, in October 1996, Neuromed, Inc. merged into Licensor, and
Licensor assumed all obligations of Neuromed, Inc., including but not limited
to the obligations under the Original Agreement, and Licensor succeeded to all
the assets, including, but not limited to the intellectual property assets of
Neuromed, Inc.
WHEREAS, Licensee and Borrower have entered into the Third Amended and
Restated Credit Agreement dated as of March 3, 1997 (such agreement, together
with all amendments and restatements thereof, the "Credit Agreement") which
restates in its entirety the Existing Credit Agreement.
WHEREAS, Licensor is a wholly-owned subsidiary of Borrower;
WHEREAS, as security for the payment and performance of the Obligations
which are owed by Licensor and each other Obligor to Licensee pursuant to the
Loan Papers, Licensor has agreed to grant or cause to be granted to Licensee,
security interests in, and pledges and assignments of, all assets of Licensor,
including all cash, Inventory, Receivables, Equipment, Permits and the
Intellectual Property, a license to use the Intellectual Property and Permits
and certain other collateral, to secure the Obligations;
<PAGE> 3
WHEREAS, Licensee desires a license to use the Intellectual Property and
Permits in all countries of the world solely if an Event of Default exists to
enable Licensee to exercise its rights and remedies with respect to the
Collateral under the Security Agreement;
WHEREAS, Licensor desires to grant Licensee the foregoing license to so
use the Intellectual Property and Permits; and
WHEREAS, the parties acknowledge the excellent reputation for quality of
products sold under the Intellectual Property and Permits, and desire to
safeguard, promote and enhance that reputation by ensuring the future quality
of materials, workmanship, and performance of the Inventory with respect to
which Licensee has been granted a security interest, pledge and assignment and
may exercise its rights and remedies under the Security Agreement and
Intellectual Property Agreement, if an Event of Default exists.
AGREEMENT.
NOW, THEREFORE, in consideration of the above premises and of the mutual
covenants herein contained, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, and intending to be
legally bound, the parties hereto agree as follows:
ARTICLE I. DEFINITIONS
1.1 "Collateral" has the same definition provided in the Security
Agreement.
1.2 "Effective Date" means March 3, 1997.
1.3 "Equipment" has the same definition provided in the Security
Agreement.
1.4 "Intellectual Property Agreement" means the Amended and Restated
Intellectual Property Security Agreement and Assignment dated
March 3, 1997 between Licensor and Licensee.
1.5 "Inventory" has the same definition provided in the Security
Agreement.
1.6 "Permits" means all licenses, permits and other similar rights
now or hereafter owned by Licensor (including but not limited to
all licenses, permits and similar rights issued by the FDA) and
necessary to the operation of its business, including but not
limited to all licenses, permits and other rights listed on
Schedule 2.
1.7 "Receivables" has the same definition provided in the Security
Agreement.
-2-
<PAGE> 4
1.8 "Security Agreement" means the Amended and Restated Security
Agreement dated March 3, 1997 between Licensor and Licensee.
1.9 Unless otherwise defined in this Agreement, all capitalized terms
herein shall have the same definition provided in the Credit
Agreement, the Intellectual Property Agreement and the Security
Agreement.
ARTICLE II. GRANTS TO LICENSEE AND RELATED MATTERS
2.1 Licensor hereby grants to Licensee an irrevocable, non-exclusive
royalty-free right and license to use the Intellectual Property and Permits
worldwide including, without limitation, the Intellectual Property identified
in Schedule 1 and Permits identified on Schedule 2, if an Event of Default
exists, and to enable Licensee to exercise its rights and remedies under the
Security Agreement and Intellectual Property Agreement with respect to
Collateral, including, without limitation, the right to use the Intellectual
Property and Permits on or in connection with the operation and disposition of
any Collateral and the disposition, maintenance or further production,
manufacturing or processing of the Inventory, the operation and maintenance of
the Equipment and the collection of Receivables as Licensee reasonably deems
necessary or appropriate in the exercise of its rights and remedies under the
Security Agreement and Intellectual Property Agreement with respect to
Collateral.
The parties acknowledge and agree that the Intellectual Property and
Permits are the sole and exclusive property of Licensor, subject to the terms
and conditions stated in this Agreement, the Security Agreement and the
Intellectual Property Agreement. Other than in connection with any security
interest in the Intellectual Property and Permits that Licensor has granted to
Licensee pursuant to the Security Agreement and the Intellectual Property
Agreement or any rights and remedies of Licensee under the Security Agreement
or the Intellectual Property Agreement, Licensee shall not challenge Licensor's
ownership of the Intellectual Property and Permits. Licensor expressly retains
all rights to license third parties to use the Intellectual Property and
Permits for any purpose whatsoever not in violation of the Loan Papers and
which are not exclusive as to prevent Licensee from using any of the
Intellectual Property and Permits as provided in the Security Agreement and
Intellectual Property Agreement.
2.2 The license granted to Licensee hereunder shall include the right
of Licensee to grant sublicenses to others to use the Intellectual Property and
Permits if an Event of Default exists, and to enable such sublicensees to
exercise any rights and remedies of Licensee under the Security Agreement and
the Intellectual Property Agreement with respect to Collateral, including,
without limitation, the right to grant sublicenses to others to use the
Intellectual Property and Permits on or in connection with the operation and
disposition of any Collateral, the disposition, maintenance or further
production, manufacturing or processing of Inventory, the operation and
maintenance of the Equipment and the collection of Receivables as Licensee
reasonably deems necessary or appropriate in the exercise of the rights and
remedies of Licensee
-3-
<PAGE> 5
under the Security Agreement and the Intellectual Property Agreement. In any
country where sublicenses are incapable of registration or where registration
of a sublicense will not satisfactorily protect the rights of Licensor and
Licensee, Licensee shall also have the right to designate other parties as
direct licensees of Licensor to use the Intellectual Property and Permits if an
Event of Default exists and to enable such direct licensees to exercise any
rights and remedies of Licensee under the Security Agreement and the
Intellectual Property Agreement including, without limitation, the right to use
the Intellectual Property and Permits on or in connection with the operation
and disposition of any Collateral, the disposition, maintenance or further
production, manufacturing or processing of Inventory, the operation and
maintenance of the Equipment and the collection of Receivables as such
licensees reasonably deem necessary or appropriate and Licensor agrees to enter
into direct written licenses with the parties as designated on the same terms
as would be applicable to a sublicense, and any such direct license may,
depending on the relevant local requirements, be either (a) in lieu of a
sublicense or (b) supplemental to a sublicense. In either case, the parties
hereto shall cooperate to determine what shall be necessary or appropriate in
the circumstances. For each sublicense to a sublicensee and direct license to
a licensee, Licensor appoints Licensee its agent for the purpose of exercising
quality control over the sublicensee. Licensor shall execute this Agreement in
any form, content and language suitable for recordation, notice and/or
registration in all available and appropriate agencies of foreign countries as
Licensee may require.
2.3 In connection with the assignment or other transfer (in whole or
in part) of its obligations under the Security Agreement and the Intellectual
Property Agreement to any other Person, Licensee may assign the license granted
herein without Licensor's consent and upon such assignment or transfer such
other Person shall thereupon become vested with all rights and benefits in
respect thereof granted to Licensee under this Agreement.
2.4 The parties hereto shall take reasonable action to preserve the
confidentiality of the Intellectual Property and Permits which is not otherwise
public information; provided, that Licensee shall not have any liability to any
Person for any disclosure of the Intellectual Property or Permits upon and
after any realization upon Collateral under the Security Agreement or the
Intellectual Property Agreement or otherwise as part of Licensee's enforcement
of remedies under the Loan Papers.
ARTICLE III. QUALITY CONTROL
3.1 Licensor shall refrain from using the Intellectual Property and
Permits in a form and manner or for a subject matter as to (a) reduce the value
of the Intellectual Property or Permits or (b) cause injury to Licensor's
business, reputation or goodwill.
3.2 If an Event of Default exists and Licensee exercises its rights
or remedies under the license granted herein:
-4-
<PAGE> 6
(a) Licensee may use the Trademarks licensed hereby in such form and
manner as previously used by Licensor, and shall need not notify Licensor of
any change in the form or substance of the display of a Trademark licensed
hereby. Licensee shall take reasonable action to apply trademark notice or
other marking as may be required under applicable Law of each territory and
country where each Trademark is used, or as otherwise appropriate, in
connection with use of each of the Trademarks licensed hereunder. Licensee
shall have the right to register any and all Trademarks in any and all
countries on and after the Effective Date.
(b) Licensee may dispose of any Inventory and any other manufactured
products under any of the Intellectual Property or Permits licensed hereby,
provided the Inventory and any other manufactured products so disposed of by it
or any other Person acting on behalf of Licensee shall comply in any material
respect with (i) quality standards and specifications, including labelling
specifications, employed by Licensor in commerce prior to the Effective Date,
or, where no such standards and specifications exist, a level of quality
comparable to the quality standards generally accepted for other leading
competitive brands of the same item of Inventory in the same markets from time
to time; or (ii) a level of quality comparable to that which may be adopted by
Licensor for its or its other licensees' products. Licensee shall maintain
quality control commensurate with the quality standards of Licensor at the
Effective Date or, if quality control improves after the Effective Date,
commensurate with such improved quality standards.
ARTICLE IV. TERM AND TERMINATION
4.1 This Agreement is effective as of the Effective Date and, unless
sooner terminated under the provisions set forth in this Article IV, is
perpetual and irrevocable.
4.2 The license granted in Article II with respect to any
Intellectual Property and Permits may be terminated only upon the event that
the Obligations which are owed by Licensor and each other Obligor to Licensee,
and which are secured in part by the Collateral of Licensor under the Security
Agreement and the Intellectual Property Agreement and by the license granted
herein, are finally and fully satisfied and paid in accordance with all terms
and conditions of the Loan Papers at the time of such termination. If after
termination of this Agreement, there occurs a rescission of payment of any of
the Obligations or the restoration of such payments by Licensee or any other
Person upon the insolvency, bankruptcy or reorganization of Licensor or any
other Person, this Agreement shall be reinstated as though such payment had not
been made and remain in full force and effect in accordance with the terms of
the preceding sentence.
4.3 Upon termination of this Agreement, Licensee shall, and shall
cause any sublicensee, to cease all use of any and all of the Intellectual
Property and Permits and not thereafter use any of them in any other manner
whatsoever, subject to reinstatement under Section 4.2.
-5-
<PAGE> 7
4.4 Upon termination (or reinstatement) of this Agreement, the
parties shall perform all other acts which may be necessary or useful to render
effective the termination (or reinstatement) of the interest of Licensee in the
Intellectual Property and Permits, including but not limited to the
cancellation of any registration or recordation (or the reinstatement by
registration or recordation) of this Agreement, or any summary thereof.
ARTICLE V. RECORDATION OF AGREEMENT
5.1 The parties shall cooperate to determine what may or shall be
required to satisfy the laws or regulations throughout the world with respect
to the recordation and validation of this Agreement, or otherwise to render
this Agreement and the Intellectual Property and Permits effective, and shall
execute all documents which may be necessary or desirable to implement this
Section 5.1, including registered user statements or other documents suitable
for filing with the appropriate government authorities of any country.
ARTICLE VI. REPRESENTATION AND WARRANTIES
6.1 Licensor represents and warrants that it is the owner of the
Intellectual Property identified in Schedule 1 and Permits identified on
Schedule 2 and has the right to grant the rights and license granted herein.
ARTICLE VII. PRODUCT LIABILITY INSURANCE
7.1 Licensor shall maintain product liability insurance covering
liabilities for its activities pursuant to this Agreement, of at least such
amounts as is required by the Loan Papers.
ARTICLE VIII. MISCELLANEOUS
8.1 Failure of either party to insist upon strict performance of the
terms, conditions, and provisions of this Agreement shall not be deemed a
waiver of such terms, conditions or provisions or a waiver of future compliance
therewith. No waiver of any terms, conditions, or provisions hereof shall be
deemed to have been made unless expressed in writing and signed by the waiving
party.
8.2 Any sale, transfer or other disposition of ownership of any
Intellectual Property or Permits by Licensor shall be subject to this Agreement
and the Intellectual Property Agreement and any purchaser or transferee shall
specifically state in writing that it is assuming this Agreement and that it
will be bound by all of the terms and conditions of this Agreement and the
Intellectual Property Agreement (this sentence is not a consent by Licensee to
any sale,
-6-
<PAGE> 8
transfer or other disposition (other than the grant of a license permitted
pursuant to Section 2.1) of any interest in Intellectual Property or Permits).
After giving effect to such sale, transfer or other disposition, this Agreement
and the Intellectual Property Agreement shall be valid, binding, and
enforceable in accordance with its terms against such purchaser or transferee.
A sale, transfer or other disposition of any shares of the capital stock of
Licensor shall not be deemed to be a sale, transfer or other disposition of
ownership of any Intellectual Property or Permits.
8.3 Except as otherwise may be expressly provided in this Agreement
or any other Loan Paper, Licensee shall not be construed to be and shall not
represent itself as an agent of Licensor.
8.4 (a) All notices, communications and materials to be given or
delivered pursuant to this Agreement shall, except in those cases where giving
notice by telephone is expressly permitted, be given or delivered in writing.
All written notices, communications and materials shall be sent by registered
or certified mail, postage prepaid, return receipt requested, by telecopier, or
delivered by hand. In the event of a discrepancy between any telephonic notice
and any written confirmation thereof, such written confirmation shall be deemed
the effective notice except to the extent Licensor or Licensee has acted in
reliance on such telephonic notice.
(b) All notices, communications and materials to be given or
delivered pursuant to this Agreement shall be given or delivered at the
following respective addresses and telecopier and telephone numbers and to the
attention of the following individuals or departments:
To Licensor: Advanced Neuromodulation Systems, Inc.
c/o Quest Medical, Inc.
One Allentown Parkway
Allen, Texas 75002
U.S.A.
Attention: F. Robert Merrill III
To Licensee: NationsBank of Texas, National Association
NationsBank Plaza
901 Main Street, 7th Floor
Dallas, Texas 75202
U.S.A.
Attention: Commercial Banking
8.5 This Agreement shall be governed by and construed in accordance
with the internal laws of the State of Texas, U.S.A.
-7-
<PAGE> 9
8.6 (a) Licensor hereby irrevocably submits to the non-exclusive
jurisdiction of any United States Federal or Texas State court sitting in
Dallas County, Texas, U.S.A. in any action or proceeding arising out of or
relating to this Agreement, and Licensor hereby irrevocably agrees that all
claims in respect of such action or proceeding may be heard or determined in
any such court and hereby irrevocably waives any objection it may now or
hereafter have as to the venue of any such suit, action or proceeding brought
in such court or that such court is an inconvenient forum.
(b) Nothing in this Section 8.6 shall limit the right of
Licensee to bring any action or proceeding against Licensor or its property in
the courts of any other jurisdiction or any party's rights under Section 8.10
of the Credit Agreement.
(c) Any judicial proceeding by Licensor against Licensee
involving, directly or indirectly, any matter in any way arising out of,
related to, or connected with this Agreement shall be brought only in a court
in Dallas County, Texas, U.S.A.
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
-8-
<PAGE> 10
IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their respective duly authorized officers as of the date written
above.
ADVANCED NEUROMODULATION SYSTEMS,
INC., as successor by merger and
successor in interest to the assets
of Neuromed, Inc.
- --------------------------------
Witness
By: /s/ F. ROBERT MERRILL III
---------------------------------
F. Robert Merrill III, Vice
President
- --------------------------------
Witness
NATIONSBANK OF TEXAS, NATIONAL
ASSOCIATION
- --------------------------------
Witness
By: /s/ BRIAN K. SCHNEIDER
---------------------------------
Brian K. Schneider, Vice
President
- --------------------------------
Witness
-9-
<PAGE> 1
EXHIBIT 10.24
GUARANTY
THIS GUARANTY is entered into as of this 3rd day of March, 1997 by
Advanced Neuromodulation Systems, Inc., a Texas corporation, SPAC Acquisition
Corp., a Delaware corporation, Hug Centers of America I., Inc., a Delaware
corporation and Quest Acquisition Corporation, a Delaware corporation
(collectively, the "Guarantor"), in favor of NationsBank of Texas, N.A.
("Lender") under the Third Amended and Restated Credit Agreement dated as of
March 3rd, 1997 (such agreement, together with all amendments and restatements
thereof, the "Credit Agreement") between Quest Medical, Inc. ("Borrower") and
Lender.
RECITALS:
Pursuant to the Credit Agreement and the other Loan Papers, Borrower
may from time to time be indebted to Lender; and
Lender is not willing to make Advances under the Credit Agreement or
otherwise extend credit to Borrower unless Guarantor unconditionally guarantees
payment of all present and future indebtedness and obligations of Borrower to
Lender; and
Guarantors are wholly-owned subsidiaries of Borrower and will directly
benefit from Lender's making loans to Borrower.
AGREEMENT:
NOW, THEREFORE, as an inducement to Lender to enter into the Credit
Agreement and to make loans to Borrower thereunder, and to extend such
additional credit as Lender may from time to time agree to extend, and for
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties do hereby agree as follows:
Guarantor hereby unconditionally guarantees to Lender the prompt
payment at the time provided in Section 5 of this Guaranty, at maturity (by
acceleration or otherwise), and at all times thereafter, of the Guaranteed
Indebtedness (hereinafter defined), this guaranty being upon the following
terms and conditions:
1. Definitions. Unless defined herein, all capitalized terms
have the meanings ascribed to such terms in the Credit Agreement. As used
herein, the following terms are defined as follows:
"Borrower" includes, without limitation, Borrower, Borrower as a
debtor-in-possession, and any receiver, trustee, liquidator,
conservator, custodian, or similar party appointed for Borrower or all
or substantially all of its assets pursuant to any Debtor Relief Law.
<PAGE> 2
"Guaranteed Indebtedness" means any and all obligations now or
hereafter existing of Borrower, each other Obligor and any other
Person under the Credit Agreement and the other Loan Papers, including
any extensions, modifications, substitutions, amendments and renewals
thereof, whether for principal, interest, fees, premium, expenses,
indemnification or otherwise (all such obligations of Borrower and
each other Obligor being the "Obligations"), together with all amounts
which constitute part of the Obligations and would be owed by Borrower
or any other Person to Lender under any Loan Paper, but for the fact
that they are unenforceable or not allowable due to the existence of a
bankruptcy, reorganization or similar proceeding involving Borrower,
each other Obligor or any other Person (including all such amounts
which would become due but for the operation of the automatic stay
under Section 362(a) of the United States Bankruptcy Code, 11 U.S.C.
Section 362(a), and the operation of Sections 502(b) and 506(b) of the
United States Bankruptcy Code, 11 U.S.C. Section 502(b) and Section
506(b) or any analogous stay under any foreign Law), and any and all
costs, attorneys' fees, and expenses incurred by Lender by reason of
Borrower's, Guarantor's or any other Person's default in payment of
any of the foregoing indebtedness.
"Maximum Guaranteed Indebtedness" means, with respect to Guarantor as
of the date of determination, the lesser of (a) the Guaranteed
Indebtedness, and (b) the maximum amount for which Guarantor may be
liable under this Guaranty without such amount and Guarantor's
obligations under this Guaranty with respect to such amount being
deemed a fraudulent transfer, as determined by a bankruptcy or similar
court.
2. Maximum Guaranteed Indebtedness. Notwithstanding any contrary
provision herein or in any other Loan Paper, Guarantor's maximum liability
hereunder shall not exceed the Maximum Guaranteed Indebtedness. Guarantor
agrees that the Guaranteed Indebtedness may at any time exceed the aggregate
Maximum Guaranteed Indebtedness of all Obligors (excluding Borrower) on all or
any part of the Guaranteed Indebtedness, without affecting or impairing the
obligation of Guarantor.
3. Continuing Guaranty. This instrument shall be an absolute and
continuing guaranty of payment, and the circumstances that at any time or from
time to time the Guaranteed Indebtedness may be paid in full shall not affect
the obligation of Guarantor with respect to indebtedness or obligations of
Borrower to Lender thereafter incurred pursuant to the Credit Agreement, any
other Loan Paper, or otherwise.
4. Other Debt. If Guarantor becomes liable for any indebtedness
owing by Borrower to Lender by endorsement or otherwise, other than this
Guaranty, such liability shall not be in any manner impaired or affected
hereby, and the Rights of Lender hereunder shall be cumulative of any and all
other Rights which Lender may ever have against Guarantor. The
-2-
<PAGE> 3
exercise by Lender of any Right or remedy hereunder or under any other
instrument shall not preclude the concurrent or subsequent exercise of any
other Right or remedy.
5. Payment. If an Event of Default exists, Guarantor shall, on
demand by Lender and without further notice of dishonor, without any notice
having been given to Guarantor previous to such demand of acceptance by Lender
of this Guaranty, and without any notice having been given to Guarantor
previous to such demand of the creating or incurring of the Guaranteed
Indebtedness, pay the entire amount of the Guaranteed Indebtedness to Lender at
the Principal Office of Lender, and it shall not be necessary for Lender, in
order to enforce such payment by Guarantor, first to institute suit or exhaust
its remedies against Borrower, or other Person liable for the Guaranteed
Indebtedness, or to enforce its Rights against any security which shall ever
have been given to secure the Guaranteed Indebtedness, this Guaranty being a
guaranty of payment and not of collection, and in no way conditional or
contingent. Guarantor hereby irrevocably and unconditionally covenants and
agrees that it is liable for the Guaranteed Indebtedness as primary obligor.
6. Obligation Not Impaired. Guarantor hereby agrees that its
obligations under the terms of this Guaranty shall not be released, diminished,
impaired, reduced, or affected by the occurrence of any one or more of the
following events: (a) the taking or accepting of any other security or
guaranty for any or all of the Guaranteed Indebtedness; (b) any release,
surrender, exchange, subordination, or loss of any security at any time
existing in connection with any or all of the Guaranteed Indebtedness; (c) the
modification of, amendment to, or waiver of compliance with any terms of the
Credit Agreement or any other Loan Paper without the notification of Guarantor
(the right to such notification being herein specifically waived by Guarantor);
(d) the insolvency, bankruptcy, or lack of corporate or other power of Borrower
or any other Person at any time liable for the payment of any or all of the
Guaranteed Indebtedness, whether now existing or hereafter occurring; (e) any
renewal, extension, and/or rearrangement of the payment of any or all of the
Guaranteed Indebtedness, either with or without notice to or consent of
Guarantor, or any adjustment, indulgence, forbearance, or compromise that may
be granted or given by Lender to Borrower, Guarantor or any Person at any time
liable for the payment of any or all of the Guaranteed Indebtedness; (f) any
neglect, delay, omission, failure, or refusal of Lender to take or prosecute
any action for the collection of any of the Guaranteed Indebtedness or to
foreclose or take or prosecute any action in connection with any instrument or
agreement evidencing or securing all or any part of the Guaranteed
Indebtedness; (g) any failure of Lender to notify Guarantor of any renewal,
extension, or assignment of the Guaranteed Indebtedness or any part thereof, or
the release of any security, or of any other action taken or refrained from
being taken by Lender, it being understood that Lender shall not be required to
give Guarantor any notice of any kind under any circumstances whatsoever with
respect to or in connection with the Guaranteed Indebtedness; (h) the
unenforceability of all or any part of the Guaranteed Indebtedness against
Borrower or any Person at any time liable for the payment of any or all of the
Guaranteed Indebtedness by reason of the fact that the Guaranteed Indebtedness,
and/or the interest paid or payable with respect thereto, exceeds the amount
permitted by Law, the act of creating the Guaranteed Indebtedness, or any part
thereof, is ultra vires, or the officers creating same acted in excess of their
authority, or for any other reason; or (i) any payment by
-3-
<PAGE> 4
Borrower to Lender is held to constitute a preference under any Debtor Relief
Law or if for any other reason Lender is required to refund such payment or pay
the amount thereof to another Person.
7. Waivers. Guarantor hereby waives all Rights by which it might
be entitled to require suit on an accrued right of action in respect of any of
the Guaranteed Indebtedness or require suit against Borrower or others, whether
arising pursuant to Section 34.02 of the Texas Business and Commerce Code, as
amended, Section 17.001 of the Texas Civil Practice and Remedies Code, as
amended, and Rule 31 of the Texas Rules of Civil Procedure, as amended, or
otherwise.
8. Guarantor Insolvency. Should Guarantor become insolvent, fail
to pay its debts generally as they become due, voluntarily seek, consent to, or
acquiesce in the benefits of any Debtor Relief Law or become a party to or be
made the subject of any proceeding provided for by any Debtor Relief Law (other
than as a creditor or claimant) that could suspend or otherwise adversely
affect the Rights of Lender granted hereunder, then, the Guaranteed
Indebtedness shall be, as between Guarantor and Lender, a fully matured, due,
and payable obligation of Guarantor to Lender (without regard to whether
Borrower is then in default under the Credit Agreement or any other Loan Paper
or whether any part of the Obligation is then due and owing by Borrower to
Lender), payable in full by Guarantor to Lender upon demand, which shall be the
estimated amount owing in respect of the contingent claim created hereunder.
9. Representations and Warranties. Guarantor represents and
warrants to Lender that:
(a) Guarantor is a corporation duly organized and validly
existing under the Laws of the State of Texas or Delaware, as the case
may be;
(b) Guarantor is qualified to do business in all
jurisdictions where the nature of its business or properties require
such qualification;
(c) the board of directors of Guarantor has duly
authorized the execution, delivery, and performance of this Guaranty
and the other Loan Papers to be executed by Guarantor and no consent
of any shareholder of Guarantor is required to authorize such
execution, delivery or performance;
(d) Guarantor has full legal right, power, and authority
to execute, deliver, and perform under this Guaranty and the Loan
Papers to be executed and delivered by it;
(e) this Guaranty and the other Loan Papers to be
executed by Guarantor constitute the legal, valid, and binding
obligations of Guarantor enforceable in accordance with their terms
(subject as to enforcement of remedies to any applicable Debtor Relief
Laws);
-4-
<PAGE> 5
(f) the execution or delivery of any Loan Papers to be
executed by Guarantor and performance thereunder, does not conflict
with, or result in a breach of the terms, conditions, or provisions
of, or constitute a default under, or result in any violation of, or
result in the creation of any Lien upon any properties of Guarantor
(other than rights of setoff in favor of Lender) under, or require any
consent (other than consents already obtained), approval, or other
action by, notice to, or filing with any Tribunal or Person pursuant
to, the corporate governance documents of Guarantor, any award of any
arbitrator, or any agreement, instrument, or Law to which Guarantor or
any of its properties is subject;
(g) the financial statements of Guarantor and its
subsidiaries dated December 31, 1996 delivered to Lender fairly
present its financial condition and the results of operations as of
the dates and for the periods shown, all in accordance with GAAP
(subject to audit adjustments) and such financial statements reflect
all material liabilities, direct and contingent, of Guarantor that are
required to be disclosed in accordance with GAAP (subject to audit
adjustments);
(h) as of the date of such financial statements, there
were no contingent liabilities, liabilities for Taxes currently due
and payable, forward or long-term commitments, or unrealized or
anticipated losses from any unfavorable commitments that are
substantial in amount and that are not reflected on such financial
statements or otherwise disclosed in writing to Lender;
(i) Guarantor is Solvent;
(j) there is no pending or, to Guarantor's best
knowledge, threatened Litigation or any claim related to the release
of any toxic or hazardous waste or substance or alleged violation of
any federal, state or local environmental, health or safety law
against Guarantor that could constitute a Material Adverse Change as
to Guarantor;
(k) the value of the consideration received and to be
received by Guarantor is reasonably worth at least as much as the
liability and obligation of Guarantor hereunder, and such liability
and obligation may reasonably be expected to benefit Guarantor
directly or indirectly;
(l) Guarantor is familiar with, and has independently
reviewed books and records regarding, the financial condition of
Borrower and is familiar with the value of any and all collateral
intended to be created as security for the payment of the Guaranteed
Indebtedness; and
(m) neither Lender nor any of its officers or agents has
made any representation, warranty or statement to Guarantor in order
to induce Guarantor to execute this Guaranty.
-5-
<PAGE> 6
10. Affirmative Covenants. So long as any of the Facility A
Commitment or the Facility B Commitment or any Advance under the Credit
Agreement or any portion of the Obligation is outstanding, or Borrower owes any
amount under any Loan Paper, Guarantor:
(a) shall furnish to Lender:
(i) As soon as available and in any
event within 45 days after the end of each of Guarantor's
fiscal quarters, consolidated and consolidating balance sheets
of Guarantor as of the end of such quarter, and consolidated
and consolidating statements of income, and a consolidated
statement of changes in cash flow of Guarantor and its
subsidiaries for such quarter and for the portion of the
fiscal year ending with such quarter, setting forth, in
comparative form, figures for the corresponding periods in the
previous fiscal year, all in reasonable detail, and certified
by an authorized officer of Guarantor as prepared in
accordance with GAAP, and fairly presenting the financial
condition and results of operations of Guarantor and its
subsidiaries;
(ii) As soon as available and in any
event within 90 days after the end of each fiscal year of
Guarantor, a consolidated balance sheet of Guarantor and its
subsidiaries as at the end of such fiscal year, and
consolidated statements of income and changes in cash flow of
Guarantor and its subsidiaries for such fiscal year, all in
reasonable detail, prepared in accordance with GAAP, and
accompanied by an unqualified opinion of the auditor, which
opinion shall state that said financial statements were
prepared in accordance with GAAP, that the examination by the
auditor in connection with such financial statements was made
in accordance with generally accepted auditing standards, and
that said financial statements present fairly the financial
condition and results of operations of Guarantor and its
subsidiaries;
(iii) Promptly upon becoming aware,
written notice of any actual or potential contingent
liabilities, including Litigation, against Guarantor involving
liability in an amount which must be disclosed in either
Borrower's or Guarantor's financial statements or filings with
the Securities and Exchange Commission;
(iv) Promptly after filing or receipt
thereof by an officer of Guarantor, copies of all reports and
notices that Guarantor or any of its Subsidiaries furnishes to
or receives from any holders of any Debt or Contingent
Liability, if any information or dispute referred to therein
could result in a Default or an Event of Default;
(v) As soon as possible and in any event
within 10 days after Guarantor knows that any Reportable Event
has occurred with respect to any Plan of Guarantor, a
statement, signed by an authorized officer, describing said
-6-
<PAGE> 7
Reportable Event and the action which Guarantor proposes to
take with respect thereto;
(vi) As soon as possible, and in any
event within 10 days after receipt by Guarantor, a copy of (A)
any notice or claim to the effect that Guarantor or any of its
subsidiaries is or may be liable to any Person as a result of
the release by Guarantor, any of its subsidiaries or any other
Person of any toxic or hazardous waste or substance into the
environment, and (B) any notice alleging any violation of any
federal, state or local environmental, health or safety law or
regulation by Guarantor or any of its subsidiaries, which
could, in either case, cause a Material Adverse Change as to
Guarantor; and
(vii) Promptly upon request, such other
information concerning the condition or operations of any of
Guarantor, its subsidiaries, and its Affiliates, financial or
otherwise, as Lender may from time to time reasonably request.
(b) (i) shall cause to be done all things
necessary to preserve and keep in full force and effect
Guarantor's existence as a corporation;
(ii) shall comply with the requirements
of all applicable Laws and orders (including but not limited
to the FDA Act, ERISA and environmental laws) of Tribunals or
other governmental authorizations necessary to the ownership
of Guarantor's properties or to the conduct of its business if
the result of failure to so comply would have a Material
Adverse Effect as to Guarantor; and
(iii) will, on request of Lender, promptly
correct any defect, error or omission which may be discovered
in the contents of any of the Loan Papers to which it is a
party or in the execution or acknowledgment thereof, and will
execute, acknowledge and deliver such further instruments and
do such further acts as may be necessary or as may be
requested by Lender to carry out more effectively the purposes
of this Guaranty and the Loan Papers to which it is a party.
11. Setoff. Guarantor grants to Lender a right of setoff and Lien
upon each deposit account (time, demand, special and other) of Guarantor
maintained with Lender and any of its Affiliates to secure performance of
Guarantor's obligations hereunder. If an Event of Default exists, Lender may
setoff and otherwise apply any and all amounts in any such deposit account to
all amounts due hereunder.
12. Benefit; Binding Obligation. This Guaranty is for the benefit
of Lender and its successors and assigns, and in the event of an assignment of
the Guaranteed Indebtedness, or any part thereof, the Rights and benefits
hereunder, to the extent applicable to the Guaranteed
-7-
<PAGE> 8
Indebtedness so assigned, may be transferred with such indebtedness. This
Guaranty is binding not only on Guarantor, but on its successors and assigns.
13. Defenses. The Guaranteed Indebtedness shall not be reduced,
discharged, or released because or by reason of any existing or future offset,
claim or defense of Borrower or any other Person against Lender or against
payment of the Guaranteed Indebtedness, whether such offset, claim, or defense
arises in connection with the Guaranteed Indebtedness or otherwise.
14. Change of Borrower Status. Should the status of Borrower
change through merger, consolidation, or otherwise, this Guaranty shall
continue and shall cover Guaranteed Indebtedness under the new status.
15. Fees. Guarantor agrees to pay reasonable attorneys' fees and
collection costs if this Guaranty is placed in the hands of an attorney for
collection.
16. Governing Law. This Guaranty shall be governed by and
construed according to the substantive Laws of the State of Texas. The
unenforceability or invalidity, as determined by a court of competent
jurisdiction, of any provision of this Guaranty shall not render unenforceable
or invalid any other provision of this Guaranty.
17. Waiver of Subrogation. Guarantor shall not assert, enforce,
or otherwise exercise (i) any right of subrogation to any of the rights or
liens of Lender or any other beneficiary of any Lien against Borrower or any
other obligor on the Guaranteed Indebtedness or any collateral or other
security, or (ii) any right of recourse, reimbursement, contribution,
indemnification, or similar right against Borrower or any other obligor on all
or any part of the Guaranteed Indebtedness or any guarantor thereof, and
Guarantor hereby waives any and all of the foregoing rights and the benefit of,
and any right to participate in, any collateral or other security given to
Lender or any other beneficiary of any Lien to secure payment of the Guaranteed
Indebtedness. The provisions of this Section 17 shall survive the termination
of this Guaranty, and any satisfaction and discharge of Borrower by virtue of
any payment, court order, or Law.
18. LOAN PAPERS. THIS GUARANTY AND THE OTHER LOAN PAPERS
REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED
BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE
PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.
REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
-8-
<PAGE> 9
EXECUTED as of March 3rd, 1997.
ADVANCED NEUROMODULATION
SYSTEMS, INC.
By: /s/F. Robert Merrill III
---------------------------------------
F. Robert Merrill III, Vice President
SPAC ACQUISITION CORP.
HUG CENTERS OF AMERICA I., INC.
QUEST ACQUISITION CORPORATION
By: /s/F. Robert Merrill III
---------------------------------------
F. Robert Merrill III, Secretary of
each corporation
-9-
<PAGE> 1
EXHIBIT 11.1
QUEST MEDICAL, INC.
COMPUTATION OF EARNINGS PER SHARE
YEARS ENDED DECEMBER 31
<TABLE>
<CAPTION>
1996 1995 1994
---------- ------------ -----------
<S> <C> <C> <C>
Primary and fully diluted:
Weighted average common shares outstanding........ 8,259,129 6,267,439 5,256,683
Stock options and warrants(1) -- based on the
treasury stock method using average market
price (which was higher than the year end
price)......................................... 272,370 374,643 --
---------- ------------ -----------
Primary weighted average common and common
equivalent shares outstanding.................. 8,531,499 6,642,082 5,256,683
========== ============ ===========
Loss before extraordinary item.................... $ (412,157) $(10,104,998) $(1,719,193)
---------- ------------ -----------
Extraordinary item -- loss on early extinguishment
of debt........................................ $ -- $ (269,045) $ --
---------- ------------ -----------
Net loss.......................................... $ (412,157) $(10,374,043) $(1,719,193)
========== ============ ===========
Loss before extraordinary item per share.......... $ (.05) $ (1.52) $ (.33)
---------- ------------ -----------
Extraordinary item per share...................... $ -- $ (.04) $ --
---------- ------------ -----------
Net loss per share................................ $ (.05) $ (1.56) $ (.33)
========== ============ ===========
</TABLE>
- ---------------
(1) The effect of stock options and warrants was included in the quarterly
calculations in those quarters where the effect was dilutive. Weighted
average common and common equivalent shares for the full year represent the
average of the quarterly computations.
<PAGE> 1
EXHIBIT 21.1
SUBSIDIARIES
Advanced Neuromodulation Systems, Inc......................................Texas
<PAGE> 1
EXHIBIT 23.1
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in the Registration Statements
(Form S-8 -- Nos. 2-82414, 2-91410, 33-235312, and 33-00967) pertaining to the
Quest Medical, Inc. 1979 Amended and Restated Employees' Stock Option Plan; the
Quest Medical, Inc. Directors' Stock Option Plan; the Quest Medical, Inc. 1987
Employees' Stock Option Plan; and the Quest Medical, Inc. 1995 Stock Option
Plan, the Quest Medical, Inc. Sales and Marketing Employees Stock Option Plan,
and the Heaton Stock Option Plan and the related Prospectuses of our report
dated March 14, 1997, with respect to the consolidated financial statements of
Quest Medical, Inc. and subsidiaries, included in the Annual Report (Form 10-K)
for the year ended December 31, 1996.
/s/ ERNST & YOUNG LLP
------------------------------------
Ernst & Young LLP
Dallas, Texas
March 26, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> DEC-31-1996
<CASH> 696,196
<SECURITIES> 1,366,089
<RECEIVABLES> 5,181,039
<ALLOWANCES> 174,337
<INVENTORY> 8,364,594
<CURRENT-ASSETS> 16,553,827
<PP&E> 16,016,998
<DEPRECIATION> 4,832,468
<TOTAL-ASSETS> 48,992,455
<CURRENT-LIABILITIES> 5,466,305
<BONDS> 0
0
0
<COMMON> 416,926
<OTHER-SE> 30,576,557
<TOTAL-LIABILITY-AND-EQUITY> 48,992,455
<SALES> 26,073,808
<TOTAL-REVENUES> 26,073,808
<CGS> 11,005,260
<TOTAL-COSTS> 14,968,358
<OTHER-EXPENSES> 429,472
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 766,769
<INCOME-PRETAX> (329,282)
<INCOME-TAX> 82,875
<INCOME-CONTINUING> (412,157)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (412,157)
<EPS-PRIMARY> (.05)
<EPS-DILUTED> (.05)
</TABLE>
